<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Aripiprazole versus other atypical antipsychotics for schizophrenia - Khanna, P - 2014 | Cochrane Library</title> <meta content="Aripiprazole versus other atypical antipsychotics for schizophrenia - Khanna, P - 2014 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006569.pub5/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Aripiprazole versus other atypical antipsychotics for schizophrenia - Khanna, P - 2014 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006569.pub5/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD006569.pub5" name="dc.identifier" scheme="DOI"/> <meta content="Aripiprazole versus other atypical antipsychotics for schizophrenia" name="citation_title"/> <meta content="Priya Khanna" name="citation_author"/> <meta content="Northumberland, Tyne and Wear NHS Foundation Trust" name="citation_author_institution"/> <meta content="Tao Suo" name="citation_author"/> <meta content="Zhongshan Hospital, Fudan University" name="citation_author_institution"/> <meta content="simonsuo@aliyun.com" name="citation_author_email"/> <meta content="Katja Komossa" name="citation_author"/> <meta content="University Hospital of Zurich" name="citation_author_institution"/> <meta content="Huaixing Ma" name="citation_author"/> <meta content="Zhongshan Hospital, Fudan University" name="citation_author_institution"/> <meta content="Christine Rummel‐Kluge" name="citation_author"/> <meta content="University of Leipzig" name="citation_author_institution"/> <meta content="Hany G El‐Sayeh" name="citation_author"/> <meta content="Tees, Esk &amp; Wear Valleys NHS Foundation Trust" name="citation_author_institution"/> <meta content="Stefan Leucht" name="citation_author"/> <meta content="Technische Universität München Klinikum rechts der Isar" name="citation_author_institution"/> <meta content="Jun Xia" name="citation_author"/> <meta content="The University of Nottingham" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="1" name="citation_issue"/> <meta content="10.1002/14651858.CD006569.pub5" name="citation_doi"/> <meta content="2014" name="citation_date"/> <meta content="2014/01/02" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006569.pub5/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006569.pub5/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006569.pub5/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Antipsychotic Agents [*therapeutic use]; Aripiprazole; Benzodiazepines [therapeutic use]; Piperazines [*therapeutic use]; Quinolones [*therapeutic use]; Randomized Controlled Trials as Topic; Schizophrenia [*drug therapy]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006569.pub5&amp;doi=10.1002/14651858.CD006569.pub5&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006569.pub5&amp;doi=10.1002/14651858.CD006569.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006569.pub5&amp;doi=10.1002/14651858.CD006569.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006569.pub5&amp;doi=10.1002/14651858.CD006569.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006569.pub5&amp;doi=10.1002/14651858.CD006569.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006569.pub5&amp;doi=10.1002/14651858.CD006569.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006569.pub5&amp;doi=10.1002/14651858.CD006569.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006569.pub5&amp;doi=10.1002/14651858.CD006569.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006569.pub5&amp;doi=10.1002/14651858.CD006569.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006569.pub5&amp;doi=10.1002/14651858.CD006569.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006569.pub5&amp;doi=10.1002/14651858.CD006569.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006569.pub5&amp;doi=10.1002/14651858.CD006569.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006569.pub5&amp;doi=10.1002/14651858.CD006569.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006569.pub5&amp;doi=10.1002/14651858.CD006569.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006569.pub5&amp;doi=10.1002/14651858.CD006569.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006569.pub5&amp;doi=10.1002/14651858.CD006569.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006569.pub5&amp;doi=10.1002/14651858.CD006569.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006569.pub5&amp;doi=10.1002/14651858.CD006569.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006569.pub5&amp;doi=10.1002/14651858.CD006569.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006569.pub5&amp;doi=10.1002/14651858.CD006569.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006569.pub5&amp;doi=10.1002/14651858.CD006569.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006569.pub5&amp;doi=10.1002/14651858.CD006569.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006569.pub5&amp;doi=10.1002/14651858.CD006569.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="IYhCEbRn";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD006569\x2epub5\x26doi\x3d10\x2e1002\x2f14651858\x2eCD006569\x2epub5\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006569\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006569\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","hr","pl","fr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD006569.pub5",title:"Aripiprazole versus other atypical antipsychotics for schizophrenia",firstPublishedDate:"Jan 2, 2014 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Schizophrenia Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=IYhCEbRn&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006569.pub5&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD006569.pub5';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD006569.pub5/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD006569.pub5/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006569.pub5%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD006569.PUB5" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD006569.pub5/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD006569.PUB5" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD006569.pub5/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD006569.pub5/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>7003 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD006569.pub5" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006569.pub5/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006569.pub5/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006569.pub5/full#CD006569-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006569.pub5/full#CD006569-sec-0439"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006569.pub5/full#CD006569-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006569.pub5/full#CD006569-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006569.pub5/full#CD006569-sec-0028"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006569.pub5/full#CD006569-sec-0029"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006569.pub5/full#CD006569-sec-0099"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006569.pub5/full#CD006569-sec-0424"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006569.pub5/appendices#CD006569-sec-0451"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/table_n/CD006569StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/table_n/CD006569StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006569.pub5/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006569.pub5/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006569.pub5/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD006569.pub5/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD006569.pub5/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD006569.pub5/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2016 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Aripiprazole versus other atypical antipsychotics for schizophrenia</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006569.pub5/information#CD006569-cr-0002">Priya Khanna</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006569.pub5/information#CD006569-cr-0003"><i class="icon corresponding-author fa fa-envelope"></i>Tao Suo</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006569.pub5/information#CD006569-cr-0004">Katja Komossa</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006569.pub5/information#CD006569-cr-0005">Huaixing Ma</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006569.pub5/information#CD006569-cr-0006">Christine Rummel‐Kluge</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006569.pub5/information#CD006569-cr-0007">Hany G El‐Sayeh</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006569.pub5/information#CD006569-cr-0008">Stefan Leucht</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006569.pub5/information#CD006569-cr-0009">Jun Xia</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/information/en#CD006569-sec-0487">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 02 January 2014 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD006569.pub5">https://doi.org/10.1002/14651858.CD006569.pub5</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD006569-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD006569-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD006569-abs-0007">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD006569-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD006569-abs-0002">Français</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD006569-abs-0001" lang="en"> <section id="CD006569-sec-0001"> <h3 class="title" id="CD006569-sec-0001">Background</h3> <p>In most western industrialised countries, second generation (atypical) antipsychotics are recommended as first‐line drug treatments for people with schizophrenia. In this review, we specifically examine how the efficacy and tolerability of one such agent ‐ aripiprazole ‐ differs from that of other comparable second generation antipsychotics. </p> </section> <section id="CD006569-sec-0002"> <h3 class="title" id="CD006569-sec-0002">Objectives</h3> <p>To review the effects of aripiprazole compared with other atypical antipsychotics for people with schizophrenia and schizophrenia‐like psychoses. </p> </section> <section id="CD006569-sec-0003"> <h3 class="title" id="CD006569-sec-0003">Search methods</h3> <p>We searched the Cochrane Schizophrenia Group Trials Register (November 2012), inspected references of all identified studies for further trials and contacted relevant pharmaceutical companies, drug approval agencies and authors of trials for additional information. </p> </section> <section id="CD006569-sec-0004"> <h3 class="title" id="CD006569-sec-0004">Selection criteria</h3> <p>We included all randomised clinical trials (RCTs) comparing aripiprazole (oral) with oral and parenteral forms of amisulpride, clozapine, olanzapine, quetiapine, risperidone, sertindole, ziprasidone or zotepine for people with schizophrenia or schizophrenia‐like psychoses. </p> </section> <section id="CD006569-sec-0005"> <h3 class="title" id="CD006569-sec-0005">Data collection and analysis</h3> <p>We extracted data independently. For dichotomous data we calculated risk ratios (RR) and their 95% confidence intervals (CI) on an intention‐to‐treat basis based on a random‐effects model. Where possible, we calculated illustrative comparative risks for primary outcomes. For continuous data, we calculated mean differences (MD), again based on a random‐effects model. We assessed risk of bias for each included study and used GRADE approach to rate quality of evidence. </p> </section> <section id="CD006569-sec-0006"> <h3 class="title" id="CD006569-sec-0006">Main results</h3> <p>We now have included 174 trials involving 17,244 participants. Aripiprazole was compared with clozapine, quetiapine, risperidone, ziprasidone and olanzapine. The overall number of participants leaving studies early was 30% to 40%, limiting validity (no differences between groups). </p> <p>When compared with clozapine, there were no significant differences for global state (no clinically significant response, n = 2132, 29 RCTs, <i>low quality evidence</i> ); mental state (BPRS, n = 426, 5 RCTs, <i>very low quality evidence</i> ); or leaving the study early for any reason (n = 240, 3 RCTs, <i>very low quality evidence</i> ). Quality of life score using the WHO‐QOL‐100 scale demonstrated significant difference, favouring aripiprazole (n = 132, 2 RCTs, RR 2.59 CI 1.43 to 3.74, <i>very low quality evidence</i> ). General extrapyramidal symptoms (EPS) were no different between groups (n = 520, 8 RCTs,<i>very low quality evidence</i>). No study reported general functioning or service use. </p> <p>When compared with quetiapine, there were no significant differences for global state (n = 991, 12 RCTs, <i>low quality evidence</i> ); mental state (PANSS positive symptoms, n = 583, 7 RCTs, <i>very low quality evidence</i> ); leaving the study early for any reason (n = 168, 2 RCTs, <i>very low quality evidence</i> ), or general EPS symptoms (n = 348, 4 RCTs, <i>very low quality evidence</i> ). Results were significantly in favour of aripiprazole for quality of life (WHO‐QOL‐100 total score, n = 100, 1 RCT, MD 2.60 CI 1.31 to 3.89, <i>very low quality evidence</i>). No study reported general functioning or service use. </p> <p>When compared with risperidone, there were no significant differences for global state (n = 6381, 80 RCTs, <i>low quality evidence</i> ); or leaving the study early for any reason (n = 1239, 12 RCTs, <i>very low quality evidence</i> ). Data were significantly in favour of aripiprazole for improvement in mental state using the BPRS (n = 570, 5 RCTs, MD 1.33 CI 2.24 to 0.42, <i>very low quality evidence</i> ); with higher adverse effects seen in participants receiving risperidone of general EPS symptoms (n = 2605, 31 RCTs, RR 0.39 CI 0.31 to 0.50, <i>low quality evidence</i>). No study reported general functioning, quality of life or service use. </p> <p>When compared with ziprasidone, there were no significant differences for global state (n = 442, 6 RCTs, <i>very low quality evidence</i> ); mental state using the BPRS (n = 247, 1 RCT, <i>very low quality evidence</i> ); or leaving the study early for any reason (n = 316, 2 RCTs, <i>very low quality evidence</i> ). Weight gain was significantly greater in people receiving aripiprazole (n = 232, 3 RCTs, RR 4.01 CI 1.10 to 14.60, <i>very low quality evidence</i>). No study reported general functioning, quality of life or service use. </p> <p>When compared with olanzapine, there were no significant differences for global state (n = 1739, 11 RCTs, <i>very low quality evidence</i> ); mental state using PANSS (n = 1500, 11 RCTs, <i>very low quality evidence</i> ); or quality of life using the GQOLI‐74 scale (n = 68, 1 RCT, <i>very low quality of evidence</i> ). Significantly more people receiving aripiprazole left the study early due to any reason (n = 2331, 9 RCTs, RR 1.15 CI 1.05 to 1.25, <i>low quality evidence</i> ) and significantly more people receiving olanzapine gained weight (n = 1538, 9 RCTs, RR 0.25 CI 0.15 to 0.43, <i>very low quality evidence</i>). None of the included studies provided outcome data for the comparisons of 'service use' or 'general functioning'. </p> </section> <section id="CD006569-sec-0007"> <h3 class="title" id="CD006569-sec-0007">Authors' conclusions</h3> <p>Information on all comparisons is of limited quality, is incomplete and problematic to apply clinically. The quality of the evidence is all low or very low. Aripiprazole is an antipsychotic drug with an important adverse effect profile. Long‐term data are sparse and there is considerable scope for another update of this review as new data emerge from ongoing larger, independent pragmatic trials. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD006569-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD006569-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD006569-abs-0008">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD006569-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD006569-abs-0006">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD006569-abs-0004">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/pl#CD006569-abs-0005">Polski</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD006569-abs-0003" lang="en"> <h3>Aripiprazole versus other atypical antipsychotics</h3> <p>In many countries in the industrialised world there has been a huge growth in the prescription of medication for people with mental health problems, taken orally as a tablet or by injection. Atypical and second generation antipsychotic drugs have become ever more popular, because they are thought to help people with mental health problems who do not respond quite so well to initial treatment. These newer drugs hold the promise of both reducing symptoms, such as hearing voices or seeing things, and reducing problematic side effects, such as sleepiness, weight gain, and shaking. </p> <p>However, there is little research and comparison of the ways in which drugs differ from one another. This review examines the effectiveness of aripiprazole with other new antipsychotics.<br/> <br/> Originally the review included 12 research trials. After an update search carried out in November 2012, 162 trials were added. Most of these trials were from China and although new data were added to the review, overall conclusions did not change. The review now has five comparisons with aripiprazole being compared with clozapine, olanzapine, quetiapine, risperidone and ziprasidone. </p> <p>For people with schizophrenia it may be important to know that aripiprazole may not be as good or effective as olanzapine but that it has less side effects. Aripiprazole is similar in effectiveness to risperidone and somewhat better than ziprasidone. Aripiprazole had less side‐ effects than olanzapine and risperidone (such as weight gain, sleepiness, heart problems, shaking and increased cholesterol levels). Aripiprazole was not as good as ziprasidone for dealing with restlessness or people’s inability to sit still. Comparison with other antipsychotic drugs as a group showed that people preferred taking aripiprazole. However, people with schizophrenia as well as mental health professionals and policy makers should know that the evidence is limited and mostly of low or very low quality. More trials and research is required, including on outcomes such as: quality of life; the views of service users and carers; and patient preference. </p> <p>This plain language summary has been written by a consumer from Rethink Mental Illness, Benjamin Gray. Email: <a class="__cf_email__" data-cfemail="7a181f14541d081b033a081f0e121314115415081d" href="/cdn-cgi/l/email-protection">[email protected]</a> </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD006569-sec-0439" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD006569-sec-0439"></div> <h3 class="title" id="CD006569-sec-0440">Implications for practice</h3> <section id="CD006569-sec-0440"> <section id="CD006569-sec-0441"> <h5 class="title">1. For people with schizophrenia</h5> <p>For people with schizophrenia, it may be important to know that aripiprazole may be slightly less effective than olanzapine, but is less associated with adverse effects such as weight gain, cholesterol and prolactin increase and sedation. Aripiprazole's efficacy seems to be similar to that of risperidone, but certain movement disorders, cholesterol and prolactin increase may occur less frequently when taking aripiprazole. Aripiprazole may also be slightly better than ziprasidone with no clear differences apparent in adverse effects. When compared to other atypical antipsychotics as a group, people allocated to aripiprazole preferred its use. However, effects on quality of life were similar and carers found the two groups to be similar. </p> </section> <section id="CD006569-sec-0442"> <h5 class="title">2. For clinicians</h5> <p>Clinicians should know that randomised evidence of the effects of aripiprazole compared with other second generation antipsychotic drugs is only available for a few drugs. Aripiprazole does not seem dogged by the problems of weight gain and raised prolactin. As with many antipsychotic drugs, it may, however, cause some extrapyramidal effects. More studies are needed to clarify the role of aripiprazole compared to other second generation antipsychotic drugs. </p> </section> <section id="CD006569-sec-0443"> <h5 class="title">3. For managers/policy makers</h5> <p>Data that are relevant for policy makers such as service utilisation, functioning in society or costs are not available. We therefore find it difficult to make recommendations for decision makers. </p> </section> </section> <h3 class="title" id="CD006569-sec-0444">Implications for research</h3> <section id="CD006569-sec-0444"> <section id="CD006569-sec-0445"> <h5 class="title">1. General</h5> <p>Outcome reporting remains insufficient in antipsychotic drug trials. Strict adherence to the <a href="http://www.consortstatement.org" target="_blank">CONSORT</a> statement (<a href="./references#CD006569-bbs2-0319" title="MoherD , SchulzKF , AltmanD . The CONSORT Statement: revised recommendations for improving the quality of reports of parallel‐ group randomized trials. JAMA2001;285:1987‐1. ">Moher 2001</a>) would make such studies much more informative. Making all data available would set this compound far ahead of its competitors (<a href="http://alltrials.net" target="_blank">ALLTRIALS</a>). Increasingly healthcare sub‐specialities are gaining universal agreement on core outcomes to be reported within all trials (<a href="http://www.comet-initiative.org/" target="_blank">COMET</a>). This would greatly reduce disaggregation of data and add to the power of reviews such as this. </p> </section> <section id="CD006569-sec-0446"> <h5 class="title">2. Specific</h5> <section id="CD006569-sec-0447"> <h6 class="title">2.1 Reviews</h6> <p>Many interesting and potentially informative trials have had to be excluded as they are not of direct relevance to this review. Suggestions for their use within reviews are given in <a href="#CD006569-tbl-0006">Table 1</a>. </p> <div class="table" id="CD006569-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Titles for reviews suggested by excluded studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Suggested title/ongoing title</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Excluded study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Reference to relevant ongoing Cochrane title*</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Alpha‐receptor agonists for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006569-bbs2-0179" title="BergmanM , FriedmanJI , StawarzK , BowmanA , SieverL , CavagnaM , et al. A double blind placebo controlled study of guanfacine adjunctive treatment to atypical antipsychotics for cognitive dysfunction in schizophrenia. http://www.clinicaltrials.gov2007. ">Bergman 2007</a>   </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Currently no review.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Antidepressant augmentation of antipsychotic drugs for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006569-bbs2-0190" title="FawziM , FawziMJr . Aripiprazole, olanzapine and olanzapine‐clomipramine combination in schizophrenia with obsessive‐compulsive symptoms. World Psychiatry2009;8(Suppl 1):NRS5.4. ">Fawzi 2009</a>   </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006569-bbs2-0334" title="WhiteheadC , MossS , CardnoA , LewisG . Antidepressants for people with both schizophrenia and depression. Cochrane Database of Systematic Reviews2002, Issue 2. [DOI: 10.1002/14651858.CD002305; PUBMED: 12076447] ">Whitehead 2002</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole augmentation of other antipsychotics for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006569-bbs2-0180" title="Bristol‐MyersSquibb , Otsuka AmericaPharmaceutical . A multicenter, randomized, double‐blind, placebo‐controlled, 16 week study of aripiprazole used as dual therapy in the treatment of patients with chronic stable schizophrenia or schizoaffective disorder demonstrating an inadequate response to quetiapine or risperidone monotherapy. http://www.clinicaltrials.gov2006. ">Bristol‐Myers 2006</a>, <a href="./references#CD006569-bbs2-0231" title="ShimJC , KellyDL , JungDU , SeoYS , KimYH , ConleyRR . Adjunctive treatment with a dopamine partial agonist, aripiprazole for antipsychotic induced hyperprolactinemia. European Neuropsychopharmacology2006;16(Suppl 4):S405. ">Shim 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006569-bbs2-0314" title="MaayanN , Soares‐WeiserK , XiaJ , AdamsCE . Antipsychotic combinations for schizophrenia. Cochrane Database of Systematic Reviews2011, Issue 2. [DOI: 10.1002/14651858.CD009005] ">Maayan 2011</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole for people with metabolic syndrome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006569-bbs2-0188" title="ColomboGL , CaruggiM , DiMatteoS , RossiA . An economic evaluation of aripiprazole vs olanzapine adapted to the Italian setting using outcomes of metabolic syndrome and risk for diabetes in patients with schizophrenia. Neuropsychiatric Disease and Treatment2008;4(5):967‐76. ">Colombo 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006569-bbs2-0320" title="MukundanA , FaulknerG , CohnT , RemingtonG . Antipsychotic switching for people with schizophrenia who have neuroleptic‐induced weight or metabolic problems. Cochrane Database of Systematic Reviews2010, Issue 12. [DOI: 10.1002/14651858.CD006629.pub2; CD006629] ">Mukundan 2010</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole versus first generation antipsychotics for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006569-bbs2-0181" title="CarsonWH , KaneJM , AliM , DunbarGC , IngenitoG . Efficacy of aripiprazole in psychotic disorders: comparison with haloperidol and placebo. European Neuropsychopharmacology2000;10(Suppl 3):S309. ">Carson 2000</a>, <a href="./references#CD006569-bbs2-0221" title="MossnerR , SchuhmacherA , KuhnKU , CvetanovskaG , RujescuD , ZillP , et al. Functional serotonin 1A receptor variant influences treatment response to atypical antipsychotics in schizophrenia. Pharmacogenetics and Genomics2009;19(1):91‐4. [MEDLINE: 18849890] ">Mossner 2009</a>, <a href="./references#CD006569-bbs2-0235" title="TalbottS , BuckleyP , EudiconeJ , McQuadeR , Van‐TranQ . Akathisia in schizophrenia patients treated with aripiprazole, haloperidol, or olanzapine‐analyses of the first 12 weeks of three double‐blind, long‐term trials. Proceedings of the 11th International Congress on Schizophrenia Research; 2007 Mar 28‐Apr 1; Colorado Springs, Colorado, USA2007. ">Talbott 2007</a>, <a href="./references#CD006569-bbs2-0236" title="TaylorD . Haloperidol, olanzapine and risperidone reduce treatment failure compared to aripiprazole, quetiapine and ziprasidone in acute schizophrenia. Evidence‐Based Mental Health2007;10(3):76. [MEDLINE: 17652558] ">Taylor 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006569-bbs2-0279" title="BhattacharjeeJ , El‐Sayeh Hany GeorgeG . Aripiprazole versus typical antipsychotic drugs for schizophrenia. Cochrane Database of Systematic Reviews2008, Issue 3. [DOI: 10.1002/14651858.CD006617.pub3] ">Bhattacharjee 2008</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole versus placebo for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006569-bbs2-0181" title="CarsonWH , KaneJM , AliM , DunbarGC , IngenitoG . Efficacy of aripiprazole in psychotic disorders: comparison with haloperidol and placebo. European Neuropsychopharmacology2000;10(Suppl 3):S309. ">Carson 2000</a>, <a href="./references#CD006569-bbs2-0196" title="HendersonDC , FanX , CopelandPM , BorbaCP , FreudenreichO , EvinsAE , et al. Aripiprazole added to overweight and obese olanzapine‐treated schizophrenia patients. Journal of Clinical Psychopharmacology2009;29(2):165‐9. RousselJJ , MachonDA , HendersonDC . A placebo‐controlled, cross‐over trial of aripiprazole added to obese olanzapine‐treated patients with schizophrenia. http://www.clinicaltrials.gov2006. ">Henderson 2009</a>, <a href="./references#CD006569-bbs2-0220" title="MortimerAMP . Aripiprazole is effective for relapse prevention in people with chronic stable schizophrenia. Evidence‐Based Mental Health2004;7(2):41. [MEDLINE: 15107337] ">Mortimer 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006569-bbs2-0278" title="Belgamwar RavindraB , El‐Sayeh Hany GeorgeG . Aripiprazole versus placebo for schizophrenia. Cochrane Database of Systematic Reviews2011, Issue 8. [DOI: 10.1002/14651858.CD006622.pub2] ">Belgamwar 2011</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Augmentation of clozapine for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006569-bbs2-0191" title="FleischhackerW , HeikkinenME , OlieJP , DewaeleP , McQuadeR , HennickenD , et al. Long‐term effect on weight of aripiprazole‐clozapine in schizophrenia patients with suboptimal response on clozapine. European Neuropsychopharmacology2008;18:S447. MarkovicO . A multicenter, comparative, randomized, double‐blind, placebo controlled study on the effect on weight of adjunctive treatment with aripiprazole in patients with schizophrenia. http://www.clinicaltrials.gov2006. ">Fleischhacker 2008a</a>, <a href="./references#CD006569-bbs2-0201" title="KimYS . A double‐blind randomized placebo controlled study of aripiprazole augmentation for clozapine‐treated patients with refractory schizophrenia. http://www.clinicaltrials.gov2006. ">Kim 2006</a>, <a href="./references#CD006569-bbs2-0216" title="MaQ , LianH‐T , LiL‐X . A study of aripiprazole combined with clozapine in refractory schizophrenia [阿 立 哌 唑 合 并 氯 氮 平 治 疗 难 治 性 精 神 分 裂 症]. Medical Journal of Chinese People's Health [中 国 民 康 医 学 ]2007;19(12):1046, 1048. ">Ma 2007</a>, <a href="./references#CD006569-bbs2-0219" title="MillarH , FelterC , LandsbergW . The effects of aripiprazole in combination with clozapine: patient functioning results from a double‐blind, 16‐week study in patients with schizophrenia (CN138‐170). Journal of Psychopharmacology2008;22(5):A17. ">Millar 2008</a>, <a href="./references#CD006569-bbs2-0222" title="NameyLB , HendersonDC . Aripiprazole for clozapine associated medical morbidity. http://www.clinicaltrials.gov2006. ">Namey 2006</a>, <a href="./references#CD006569-bbs2-0228" title="RemingtonG . Refractory schizophrenia: Adding aripiprazole to clozapine reduces negative but not overall symptoms. Evidence‐Based Mental Health2009;12(2):51. ">Remington 2009</a>     </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006569-bbs2-0285" title="CiprianiA , BosoM , BarbuiC . Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia. Cochrane Database of Systematic Reviews2009, Issue 3. [DOI: 10.1002/14651858.CD006324.pub2] ">Cipriani 2009</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Psychosocial intervention for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006569-bbs2-0177" title="Anon . Effectiveness of antipsychotic combination with psychosocial intervention on outcome of patients with schizophrenia. http://www.clinicaltrials.gov2008. ">Anon 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear which of the many reviews would be relevant.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Switching from other antipsychotics to aripiprazole for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006569-bbs2-0198" title="JanssenF . A comparative, randomized, open‐label, multicenter study on the efficacy and safety of switch treatment with aripiprazole in schizophrenic out‐patients who are experiencing insufficient efficacy with risperidone and/or safety and tolerability issues, while on risperidone. http://www.clinicaltrials.gov2005. ">Janssen 2005</a>, <a href="./references#CD006569-bbs2-0203" title="LanT , ChiuH , HuT , HuangH , WuB , TuanY . Prolactin level as an indicator to clinical psychopathological severity in aripiprazole treated schizophrenia. European Neuropsychopharmacology2008;18:S440. ">Lan 2008</a>, <a href="./references#CD006569-bbs2-0226" title="PaeCU , SerrettiA , ChiesaA , MandelliL , LeeC , KimJ , et al. Immediate versus gradual suspension of previous treatments during switch to aripiprazole: results of a randomized, open label study. European Neuropsychopharmacology2009;19(8):562‐70. ">Pae 2009a</a>, <a href="./references#CD006569-bbs2-0229" title="SchreinerA , DeArceR , EdingE , Marques‐TeixeiraJ , MilanovaV , RancansE , et al. Descriptive analyses of the aripiprazole arm in the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Proceedings of the 9th World Congress of Biological Psychiatry; 2009 Jun 28‐Jul 2; Paris, France. 2009. ">Schreiner 2009</a>, <a href="./references#CD006569-bbs2-0234" title="TakeuchiH , SuzukiT , UchidaH , NakajimaS , NomuraK , KikuchiT , et al. A randomized, open‐label comparison of 2 switching strategies to aripiprazole treatment in patients with schizophrenia: add‐on, wait, and tapering of previous antipsychotics versus add‐on and simultaneous tapering. Journal of Clinical Psychopharmacology2008;28(5):540‐3. ">Takeuchi 2008</a>   </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006569-bbs2-0320" title="MukundanA , FaulknerG , CohnT , RemingtonG . Antipsychotic switching for people with schizophrenia who have neuroleptic‐induced weight or metabolic problems. Cochrane Database of Systematic Reviews2010, Issue 12. [DOI: 10.1002/14651858.CD006629.pub2; CD006629] ">Mukundan 2010</a> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>* It is possible that these studies could also contribute to other titles not referenced in this column. </p> </div> </div> </section> <section id="CD006569-sec-0448"> <h6 class="title">2.2 Trials</h6> <p>There is much room for further, better, randomised trials comparing aripiprazole with other second generation antipsychotic drugs. Comparisons with amisulpride, sertindole and zotepine are currently missing. We present a suggestion in <a href="#CD006569-tbl-0007">Table 2</a> recognising that much goes into design and conduct of such a large study that cannot be captured in a table. </p> <div class="table" id="CD006569-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Suggested design of future study</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Methods</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Allocation: randomised ‐ clearly described generation of sequence and concealment of allocation.<br/> Blindness: double ‐ described and tested.<br/> Duration: six months minimum. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diagnosis: schizophrenia (operational criteria).<br/> N = 2700.*<br/> Age: any.<br/> Gender: both.<br/> History: any. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1. Aripiprazole: dose ˜ 10‐30 mg/day. N = 300.<br/> 2. Amisulpride: dose ˜ 400‐800 mg/day. N = 300.<br/> 3. Clozapine: dose ˜ 300‐800 mg/day. N = 300.<br/> 4. Olanzapine: dose ˜ 10‐20 mg/day. N = 300.<br/> 5. Quetiapine: dose ˜300‐800 mg/day. N = 300.<br/> 6. Risperidone: dose ˜ 4‐8 mg/day. N = 300.<br/> 7. Sertindole: dose ˜ 12‐24 mg/day. N = 300.<br/> 8. Ziprasidone: dose ˜ 120‐160 mg/day. N = 300.<br/> 9. Zotepine: dose ˜ 100‐300 mg/day. N = 300. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Leaving study early (any reason, adverse events, inefficacy).<br/> Service outcomes: hospitalised, time in hospital, attending out patient clinics.<br/> Global impression: CGI**, relapse.<br/> Mental state: PANSS.<br/> Adverse events/effects: UKU, major adverse event/effect.<br/> Employment, living independently, family satisfaction, patient satisfaction. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>* power calculation suggested 300/group would allow good chance of showing a 10% difference between groups for primary outcome.<br/> <br/> ** Primary outcome<br/> CGI: Clinical Global Impression Scale<br/> PANSS: Positive and Negative Syndrome Scale<br/> UKU: Udvalg for kliniske ndersogelser Side Effect Rating Scale ‐side effect rating scale </p> </div> </div> </section> </section> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD006569-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD006569-sec-0022"></div> <div class="table" id="CD006569-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">COMPARISON 1. ARIPIPRAZOLE versus CLOZAPINE for schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>COMPARISON 1. ARIPIPRAZOLE versus CLOZAPINE for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with schizophrenia<br/> <b>Settings:</b> inpatient and outpatient<br/> <b>Intervention:</b> COMPARISON 1. ARIPIPRAZOLE versus CLOZAPINE </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> COMPARISON 1. ARIPIPRAZOLE versus CLOZAPINE</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Global state: No clinically significant response</b> <br/> Follow‐up: up to 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Low<sup>1</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>RR 1.05</b> <br/> (0.87 to 1.27) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>2132<br/> (29 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"></td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>105 per 1000</b> <br/> (87 to 127) </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>150 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>157 per 1000</b> <br/> (131 to 190) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>200 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>210 per 1000</b> <br/> (174 to 254) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state: as measured by BPRS</b> <br/> BPRS (high score = poor) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean mental state: as measured by BPRS in the intervention groups was<br/> <b>0.22 lower</b> <br/> (1.44 lower to 1 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>426<br/> (5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,3,4,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Leaving the study early ‐ Any reason</b> <br/> Follow‐up: up to 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Low<sup>1</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>RR 1.41</b> <br/> (0.46 to 4.29) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>240<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> <br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>50 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>70 per 1000</b> <br/> (23 to 214) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>141 per 1000</b> <br/> (46 to 429) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life: as measured by WHO‐QOL‐100</b> <br/> WHO‐QOL‐100 (low score = poor)<br/> Follow‐up: up to 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean quality of life: as measured by WHO‐QOL‐100 in the intervention groups was<br/> <b>2.59 higher</b> <br/> (1.43 to 3.74 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>132<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Adverse effects: extrapyramidal effects</b> <br/> Follow‐up: up to 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Low<sup>1</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>RR 1.91</b> <br/> (0.75 to 4.85) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>520<br/> (8 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,3,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> <br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>50 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>96 per 1000</b> <br/> (38 to 242) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>191 per 1000</b> <br/> (75 to 485) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>General functioning</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study measured or reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Service use</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study measured or reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Risk: moderate risk approximately equates to that of the control group risk in the study population.<br/> <sup>2</sup> Risk of bias: rated 'serious' ‐ majority of the included studies had inadequate study design ‐ unclear randomisation, allocation concealment and blinding. Some also had selective reporting concerns.<br/> <sup>3</sup> Imprecision: rated 'serious' ‐ most of these included studies are of small samples with small effect size and wide confidence interval. The combined effect was not statistically significant.<br/> <sup>4</sup> Imprecision: rated 'serious' ‐ we were unable to obtain direct binary measure of mental state, thus used BPRS score as an indicator.<br/> <sup>5</sup> Publication bias: rated 'strongly suspected' ‐ only a small number of studies favouring intervention group were identified.<br/> <sup>6</sup> Indirectness: rated 'serious' ‐ we were unable to obtain direct binary measure of quality of life, thus employed WHO‐QOL‐100 rating score as an indicator. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD006569-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">COMPARISON 2. ARIPIPRAZOLE versus QUETIAPINE for schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>COMPARISON 2. ARIPIPRAZOLE versus QUETIAPINE for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with schizophrenia<br/> <b>Settings:</b> inpatient and outpatient<br/> <b>Intervention:</b> COMPARISON 2. ARIPIPRAZOLE versus QUETIAPINE </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> COMPARISON 2. ARIPIPRAZOLE versus QUETIAPINE</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Global state: No clinically significant response (as defined by original studies)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Low<sup>1</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>RR 0.92</b> <br/> (0.64 to 1.32) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>991<br/> (12 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"></td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>50 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>46 per 1000</b> <br/> (32 to 66) </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>92 per 1000</b> <br/> (64 to 132) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>150 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>138 per 1000</b> <br/> (96 to 198) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state: as assessed by PANSS positive symptom scale score</b> <br/> PANSS positive symptom subscale (high score = poor)<br/> Follow‐up: up to 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean mental state: as assessed by PANSS positive symptom scale score in the intervention groups was<br/> <b>0.97 lower</b> <br/> (2.34 lower to 0.41 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>583<br/> (7 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>4,5,6,7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Leaving the study early</b> <br/> Follow‐up: up to 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Low<sup>1</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>RR 0.8</b> <br/> (0.22 to 2.87) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>168<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,8</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> <br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>50 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>40 per 1000</b> <br/> (11 to 143) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>80 per 1000</b> <br/> (22 to 287) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life: as measured by WHO‐QOL‐100</b> <br/> Follow‐up: up to 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean quality of life: as measured by WHO‐QOL‐100 in the intervention groups was<br/> <b>2.6 higher</b> <br/> (1.31 to 3.89 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>8,9,10,11</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Adverse effects: extrapyramidal symptoms</b> <br/> Follow‐up: up to 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Low<sup>1</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>RR 2.8</b> <br/> (0.64 to 12.31) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>348<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,7,12,13</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> <br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>50 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>140 per 1000</b> <br/> (32 to 616) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>280 per 1000</b> <br/> (64 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>General functioning</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study measured or reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Service use</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study measured or reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Risk: moderate risk approximately equates to that of the control group risk in the study population.<br/> <sup>2</sup> Risk of bias: rated 'serious' – majority of the included studies had inadequate study design ‐ unclear randomisation, allocation concealment and blinding. A large proportion of them also had selective reporting concerns.<br/> <sup>3</sup> Imprecision: rated 'serious' – most of these included studies are of small samples with small effect size and wide confidence interval. The 95% confidence interval of the combined estimated effect was not statistically significant.<br/> <sup>4</sup> Imprecision and risk of bias: rated 'serious' ‐ most of the studies included are of small sample size, the overall pooled estimate of effect is not significant.<br/> <sup>5</sup> Inconsistency: rated 'serious' ‐ unexplained heterogeneity is high (70%).<br/> <sup>6</sup> Indirectness: rated 'serious' ‐ we were unable to obtain direct binary measure of mental state, thus used the best approximate measure available as an indicator.<br/> <sup>7</sup> Publication bias: rated 'strongly suspected' ‐ only small number of studies were identified ‐ publication bias likely.<br/> <sup>8</sup> Imprecision and publication bias: rated 'serious' ‐ only small number of studies with poor methodological design favouring intervention group were identified ‐ publication bias likely<br/> <sup>9</sup> Risk of bias: rated 'serious' – the only included study has unclear study design (randomisation, allocation concealment, blinding were unclear) and concerns of selective reporting.<br/> <sup>10</sup> Indirectness: rated 'serious' ‐ we are unable to obtain a direct binary measure of quality of life, thus used the best available proximate measure of WHO‐QOL‐100 as an indicator.<br/> <sup>11</sup> Imprecision: rated 'very serious' ‐ only one study is available on this outcome. The sample size is small and the CI of effect estimate is wide.<br/> <sup>12</sup> Inconsistency: rated 'serious' ‐ unexplained heterogeneity is around 53%.<br/> <sup>13</sup> Imprecision: rated 'serious' ‐ overall event rate is small (&lt;300). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD006569-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE for schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with schizophrenia<br/> <b>Settings:</b> inpatient and outpatient<br/> <b>Intervention:</b> COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Global state: No clinically significant response (as defined by the original studies)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Low<sup>1</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>RR 1.08</b> <br/> (0.96 to 1.21) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>6381<br/> (80 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"></td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>50 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>54 per 1000</b> <br/> (48 to 61) </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>108 per 1000</b> <br/> (96 to 121) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>150 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>162 per 1000</b> <br/> (144 to 182) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state: as measured by BPRS</b> <br/> BPRS (high score = poor)<br/> Follow‐up: up to 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean mental state: as measured by BPRS in the intervention groups was<br/> <b>1.33 lower</b> <br/> (2.24 to 0.42 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>570<br/> (5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>4,5,6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Leaving the study early</b> <br/> Follow‐up: up to 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Low<sup>1</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>RR 1.02</b> <br/> (0.79 to 1.32) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>1239<br/> (12 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>6,7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> <br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>102 per 1000</b> <br/> (79 to 132) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>150 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>153 per 1000</b> <br/> (119 to 198) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study measured or reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Adverse effects: extrapyramidal symptoms</b> <br/> Follow‐up: up to 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Low<sup>1</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>RR 0.39</b> <br/> (0.31 to 0.5) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>2605<br/> (31 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,8</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>39 per 1000</b> <br/> (31 to 50) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>300 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>117 per 1000</b> <br/> (93 to 150) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>400 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>156 per 1000</b> <br/> (124 to 200) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>General functioning</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study measured or reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Service use</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study measured or reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Risk: moderate risk approximately equates to that of the control group risk of the study population.<br/> <sup>2</sup> Risk of bias: rated 'serious' ‐ majority of the included studies had inadequate study design ‐ unclear randomisation, allocation concealment and blinding. A large proportion of them also had selective reporting concerns.<br/> <sup>3</sup> Imprecision: rated 'serious' ‐ 95% CI around the pool estimate of effect was not statistically significant.<br/> <sup>4</sup> Risk of bias: rated 'serious' ‐ only a small number of publications with poor methodological design favouring intervention group were identified ‐ publication bias likely.<br/> <sup>5</sup> Indirectness: rated 'serious' ‐ we were unable to find direct binary measure of mental state, thus used the best available data as an indicator.<br/> <sup>6</sup> Publication bias: rated 'strongly suspected' ‐ overall event number is small (&lt;300) and the pooled effect estimate is not statistically significant.<br/> <sup>7</sup> Imprecision: rated 'serious' ‐ overall event number is small (&lt;300).<br/> <sup>8</sup> Publication bias: rated 'strongly suspected' ‐ most of the studies identified were of poor methodological quality favouring intervention group ‐ publication bias likely. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD006569-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">COMPARISON 4. ARIPIPRAZOLE versus ZIPRASIDONE for schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>COMPARISON 4. ARIPIPRAZOLE versus ZIPRASIDONE for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with schizophrenia<br/> <b>Settings:</b> inpatient and outpatient<br/> <b>Intervention:</b> COMPARISON 4. ARIPIPRAZOLE versus ZIPRASIDONE </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> COMPARISON 4. ARIPIPRAZOLE versus ZIPRASIDONE</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Global state: No clinically significant response (as defined by the original studies)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Low<sup>1</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>RR 0.97</b> <br/> (0.62 to 1.52) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>442<br/> (6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"></td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>97 per 1000</b> <br/> (62 to 152) </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>150 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>146 per 1000</b> <br/> (93 to 228) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>200 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>194 per 1000</b> <br/> (124 to 304) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state: as measured with BPRS</b> <br/> BPRS (high score = poor)<br/> Follow‐up: up to 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean mental state: as measured with BPRS in the intervention groups was<br/> <b>2.2 lower</b> <br/> (4.97 lower to 0.57 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>247<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>5,6,7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Leaving the study early</b> <br/> Follow‐up: up to 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Low<sup>1</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>RR 0.94</b> <br/> (0.66 to 1.34) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>316<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>150 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>141 per 1000</b> <br/> (99 to 201) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>250 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>235 per 1000</b> <br/> (165 to 335) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>350 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>329 per 1000</b> <br/> (231 to 469) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study measured or reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Adverse effects: weight gain</b> <br/> Follow‐up: up to 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Low<sup>1</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>RR 4.01</b> <br/> (1.1 to 14.6) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>232<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,3,8</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> <br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>40 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>160 per 1000</b> <br/> (44 to 584) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>401 per 1000</b> <br/> (110 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>General functioning</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study measured or reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Service use</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study measured or reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Risk: moderate risk approximately equates to that of the control group risk in the study population.<br/> <sup>2</sup> Risk of bias: rated 'serious' ‐ majority of the included studies had inadequate study design ‐ unclear randomisation, allocation concealment and blinding. A large proportion of them also had selective reporting concerns.<br/> <sup>3</sup> Imprecision: rated 'serious' ‐ the total event number is small (&lt;300) and that the 95% CI of the pooled best estimate of effect is not statistically significant.<br/> <sup>4</sup> Publication bias: rated 'strongly suspected' ‐ only a small number of trials with small sample size were identified. It is likely that these trials with low methodological quality would have exaggerated intervention effect.<br/> <sup>5</sup> Risk of bias: rated 'serious' ‐ the only included study has serious concern with selective reporting and unclear allocation concealment and incomplete outcome.<br/> <sup>6</sup> Indirectness: rated 'serious' ‐ we were unable to find direct binary measure of mental state, thus used BPRS score as an indicator.<br/> <sup>7</sup> Imprecision: rated 'serious' ‐ only one study is identified, the estimate of effect is not statistically significant.<br/> <sup>8</sup> Publication bias: rated 'strongly suspected' ‐ only small number of trials with poor methodological quality were identified ‐ publication bias likely. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD006569-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">COMPARISON 5. ARIPIPRAZOLE versus OLANZAPINE for schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>COMPARISON 5. ARIPIPRAZOLE versus OLANZAPINE for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with schizophrenia<br/> <b>Settings:</b> inpatient and outpatient<br/> <b>Intervention:</b> COMPARISON 5. ARIPIPRAZOLE versus OLANZAPINE </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> COMPARISON 5. ARIPIPRAZOLE versus OLANZAPINE</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Global state: No clinically significant response</b> <br/> Follow‐up: up to 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Low<sup>1</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>RR 1.06</b> <br/> (0.96 to 1.17) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>1739<br/> (11 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"></td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>200 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>212 per 1000</b> <br/> (192 to 234) </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>350 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>371 per 1000</b> <br/> (336 to 409) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>500 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>530 per 1000</b> <br/> (480 to 585) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state: as measured with PANSS</b> <br/> PANSS (high score = poor)<br/> Follow‐up: up to 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean mental state: as measured with PANSS in the intervention groups was<br/> <b>0.61 higher</b> <br/> (0.23 lower to 1.46 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1500<br/> (11 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,5,6,7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Leaving the study early</b> <br/> Follow‐up: up to 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Low<sup>1</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>RR 1.15</b> <br/> (1.05 to 1.25) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>2331<br/> (9 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>200 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>230 per 1000</b> <br/> (210 to 250) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>350 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>402 per 1000</b> <br/> (367 to 438) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>500 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>575 per 1000</b> <br/> (525 to 625) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life: as measured with GQOLI‐74</b> <br/> GQOLI‐74 (low score = poor) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean quality of life: as measured with gqoli‐74 in the intervention groups was<br/> <b>1.26 lower</b> <br/> (6.37 lower to 3.85 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>7,8,9,10</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Adverse effects: weight gain</b> <br/> Follow‐up: up to 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Low<sup>1</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>RR 0.25</b> <br/> (0.15 to 0.43) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>1538<br/> (9 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,3,7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>25 per 1000</b> <br/> (15 to 43) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>200 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>50 per 1000</b> <br/> (30 to 86) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>300 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>75 per 1000</b> <br/> (45 to 129) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>General functioning</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study measured or reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Service use</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study measured or reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Risk: moderate risk approximately equates to that of the control group risk of the study population.<br/> <sup>2</sup> Risk of bias: rated 'serious' ‐ majority of the included studies had inadequate study design ‐ unclear randomisation, allocation concealment and blinding. Some of them also had selective reporting concerns.<br/> <sup>3</sup> Imprecision: rated 'serious' ‐ total number of events is small (&lt;300) and that the 95% CI of pooled estimate of effect is not statistically significant.<br/> <sup>4</sup> Publication bias: rated 'strongly suspected' ‐ only small number of trials with small sample size were identified. It is likely that these small studies with poor methodological quality have negatively affected on the estimate of treatment effect.<br/> <sup>5</sup> Indirectness: rated 'serious' ‐ we are unable to find direct binary measure of mental state, thus used PANSS score as an indicator.<br/> <sup>6</sup> Imprecision: rated 'serious' ‐ the overall pooled estimate of effect was not statistically significant and with wide confidence interval.<br/> <sup>7</sup> Publication bias: rated 'strongly suspected' ‐ only a small number of studies with poor methodological deign were identified ‐ publication bias likely.<br/> <sup>8</sup> Risk of bias: rated 'serious' ‐ unclear randomisation, allocation concealment, blinding and serious concern with selective reporting.<br/> <sup>9</sup> Indirectness: rated 'serious' ‐ we are unable to find direct binary measure of quality of life, thus used GQOLI‐74 score as an indicator.<br/> <sup>10</sup> Imprecision: rated 'very serious' ‐ only one study with serious methodological concerns was identified and the estimate of effect is not significant. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD006569-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD006569-sec-0023"></div> <section id="CD006569-sec-0024"> <h3 class="title" id="CD006569-sec-0024">Description of the condition</h3> <p>Schizophrenia is usually a chronic and disabling psychiatric disorder, which afflicts approximately one per cent of the population worldwide, affecting  male and female patients in similar proportions. The annual incidence of schizophrenia averages 15 per 100,000 population  and the risk of developing the illness over one's lifetime averages 0.7% (<a href="./references#CD006569-bbs2-0330" title='TandonR , KeshavanMS , NasralllahHA . Schizophrenia, "just the facts"What we know in 2008.2. Epidemiology and etiology. Schizophrenia Research2008;102:1‐18. '>Tandon 2008</a>). Its typical manifestations include  'positive' symptoms such as fixed, false beliefs (delusions) and perceptions without cause (hallucinations), 'negative' symptoms such as apathy and lack of drive, disorganisation of behaviour and thought, and catatonic symptoms such as mannerisms and bizarre posturing (<a href="./references#CD006569-bbs2-0283" title="CarpenterWTJr , BuchananRW . Schizophrenia. New England Journal of Medicine1994;330:681‐90. ">Carpenter 1994</a>). The degree of suffering and disability is considerable with 80% to 90% of those affected not working (<a href="./references#CD006569-bbs2-0317" title="MarvahaS , JohnsonS . Schizophrenia and employment ‐ a review. Social Psychiatry and Psychiatric Epidemiology2004;39:337‐49. ">Marvaha 2004</a>) and up to 10% dying prematurely (<a href="./references#CD006569-bbs2-0332" title="TsuangMT . Suicide in schizophrenics, manics, depressives, and surgical controls: a comparison with general population suicide mortality. Archives of General Psychiatry1978;35:153‐5. ">Tsuang 1978</a>). In the age group of 15 to 44 years, schizophrenia is among the top 10 leading causes of disease‐related disability in the world (<a href="./references#CD006569-bbs2-0335" title="WHO . The World Health Report 2001 ‐ Mental Health: New Understanding, New Hope. Geneva: World Health Organization, 2001. ">WHO 2001</a>). Conventional antipsychotic drugs, such as chlorpromazine and haloperidol, have traditionally been used as first line antipsychotics for people with schizophrenia (<a href="./references#CD006569-bbs2-0306" title="KaneJM . Treatment programme and long‐term outcome in chronic schizophrenia. Acta Psychiatrica Scandinavica1993;46:585‐93. ">Kane 1993</a>). The introduction and subsequent use of clozapine in the United States of America identified that clozapine seemed to be more effective, and was associated with fewer movement disorders than existing agents such as chlorpromazine (<a href="./references#CD006569-bbs2-0305" title="KaneJM , HonigfeldG , SingerJ , MeltzerH , Clozaril Collaborative Study Group. Clozapine for the treatment of treatment‐resistant schizophrenia: a double‐blind comparison with chlorpromazine. Archives of General Psychiatry1988;45:789‐96. ">Kane 1988</a>). These results boosted the development and marketing of new/second/atypical generation antipsychotics (SGAs). </p> </section> <section id="CD006569-sec-0025"> <h3 class="title" id="CD006569-sec-0025">Description of the intervention</h3> <p>There is no good definition of what constitutes an atypical/second generation antipsychotic, but they were initially said to differ from older generation drugs in that they did not cause movement disorders (catalepsy) in rats at clinically effective doses (<a href="./references#CD006569-bbs2-0276" title="ArntJ , SkarsfeldtT . Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology1998;18:63‐101. ">Arnt 1998</a>). The terms new or second generation to describe clozapine, a very old drug, are equally poor descriptors. According to treatment guidelines (<a href="./references#CD006569-bbs2-0275" title="American Psychiatric Association. Practice guidelines for the treatment of patients with schizophrenia. American Journal of Psychiatry. 2nd Edition. American Psychiatric Publishing, Inc, 2004:1‐114. ">APA 2004</a>; <a href="./references#CD006569-bbs2-0295" title="GaebelW , FalkaiP , WeinmannS , WobrockT . Treatment guidelines for schizophrenia [Behandlungsleitlinie Schizophrenie]. Steinkopf2006. ">Gaebel 2006</a>), SGAs include drugs such as amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, risperidone, sertindole, ziprasidone and zotepine. It is unclear whether some old and inexpensive compounds such as sulpiride, perazine or even low‐dose chlorpromazine, have similar properties (<a href="./references#CD006569-bbs2-0321" title="MöllerHJ . New assessment of atypical antipsychotics [Aktuelle bewertung neuer/atypischer neuroleptika]. Nervenarzt2000;71:329‐44. ">Möller 2000</a>). High expectations were raised for these SGAs as regards their alleged superiority in a number of areas such as compliance, cognitive functioning, negative symptoms, movement disorders, quality of life and efficacy in treatment‐resistant schizophrenia. </p> </section> <section id="CD006569-sec-0026"> <h3 class="title" id="CD006569-sec-0026">How the intervention might work</h3> <p>Aripiprazole is said to be the prototype of a new and third generation of antipsychotics; the so called dopamine‐serotonin system stabilisers. It is reported to exert its antipsychotic effects by acting as a partial agonist at D2 dopamine and 5‐HT1a serotonin receptors and as an agonist at 5‐HT2 serotonin receptors. It has been postulated that through the above receptor site actions, and hence dopamine and serotonin system stabilisation, a partial D2 agonist would be able to act as an antagonist in pathways where an abundance of dopamine was producing psychosis, yet it would stimulate receptors as an agonist at sites in which low dopaminergic tone would produce adverse effects (e.g. areas mediating motor movement and prolactin release (<a href="./references#CD006569-bbs2-0325" title="Rivas‐VasquezRA . Aripiprazole: A novel antipsychotic with dopamine stabilising properties. Professional Psychology2003;34(1):108‐11. ">Rivas‐Vasquez 2003</a>)). Aripiprazole, however, also has an affinity to other receptors including D3, D4, 5‐HT2c, 5HT7, alpha‐1 adrenergic and histamine receptors. This may explain adverse effects associated with this compound such as somnolence, headache, gastrointestinal upset and light headedness (<a href="./references#CD006569-bbs2-0293" title="U. S. Federal Drug Administration CDER. Abilify (aripiprazole) tablets, medical review. www.fda.gov/cder/foi/nda/2002/21‐436_Abilify.htm 2002 (accessed 18 August 2006). ">FDA 2002</a>). The recommended target dose for aripiprazole is 10‐15 mg per day (dose range 10‐30 mg/day). Phase III trials were initially conducted in Japan in 1995 and the drug was granted Approved Status by the FDA (USA) on the 15 November 2002 for the treatment of schizophrenia. Aripiprazole has since been licensed in most countries worldwide. </p> </section> <section id="CD006569-sec-0027"> <h3 class="title" id="CD006569-sec-0027">Why it is important to do this review</h3> <p>The debate as to how far the second generation antipsychotic drugs improve these outcomes compared to conventional antipsychotics continues (<a href="./references#CD006569-bbs2-0289" title="DugganL , DardennesR , El‐DosokyA , FentonM , IndranS , RathboneJ . Olanzapine for schizophrenia. Cochrane Database of Systematic Reviews2005, Issue 2. [DOI: 10.1002/14651858.CD001359.pub2] ">Duggan 2005</a>) and results from recent studies were sobering (<a href="./references#CD006569-bbs2-0304" title="JonesPB , BarnesTRE , DaviesL , DunnG , LloydH , HayhurstKP , et al. Randomized controlled trial of the effect on quality of life. Archives of General Psychiatry2006;63:1079‐6. ">Jones 2006</a>; <a href="./references#CD006569-bbs2-0313" title="LiebermannJA , StroupTS , McEvoyJP , SwartzMS , RosenheckRA , PerkinsDO , et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine2005;353:1209‐23. ">Lieberman 2005</a>). Nevertheless, in some parts of the world, particularly  in western industrialised countries, SGAs have become the mainstay of treatment. Second generation antipsychotics also differ in terms of their costs. Amisulpride and risperidone, for example, are already generic in many countries. Therefore, the question as to whether they differ from each other in their clinical efficacy becomes increasingly important. In this review we aim to summarise evidence from randomised controlled trials comparing aripiprazole with other SGAs. This  acts as a continuum to the comparisons previously published by <a href="./references#CD006569-bbs2-0291" title="El‐SayehHG , MorgantiC . Aripiprazole for schizophrenia. Cochrane Database of Systematic Reviews2006, Issue 2. [DOI: 10.1002/14651858.CD004578.pub3] ">EL‐Sayeh 2006</a>, <a href="./references#CD006569-bbs2-0312" title="LeuchtS , KomossaK , Rummel‐KlugeC , CorvesC , HungerH , SchmidF , et al. A meta‐analysis of head‐to‐head comparisons of second‐generation antipsychotics in the treatment of schizophrenia. American Journal of Psychiatry2009;166(2):152‐63. [DOI: 10.1176/appi.ajp.2008.08030368] ">Leucht 2008</a> and  <a href="./references#CD006569-bbs2-0339" title="KomossaK , Rummel‐KlugeC , SchmidF , HungerH , SchwarzS , El‐SayehHG , et al. Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews2009, Issue 4. [DOI: 10.1002/14651858.CD006569.pub3; PUBMED: 19821375] ">Komossa 2009</a>. </p> <p>This review was published in early 2013 with a vast number of Chinese studies in awaiting classification, thus we have updated it again in June 2013. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD006569-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD006569-sec-0028"></div> <p>To review the effects of aripiprazole compared with other second generation/atypical antipsychotics for people with schizophrenia. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD006569-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD006569-sec-0029"></div> <section id="CD006569-sec-0030"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD006569-sec-0031"> <h4 class="title">Types of studies</h4> <p>We included both open and double‐blinded, randomised controlled trials. We included open trials as we felt that important data that could potentially have an impact on the results might otherwise be overlooked. Where a trial was described as "double‐blind" but it was only implied that the study was randomised, we included these trials in a sensitivity analysis. If there was no substantive difference within primary outcomes (see <a href="#CD006569-sec-0036">Types of outcome measures</a>) when these 'implied randomisation' studies were added, then we included these in the final analysis. If there was a substantive difference, we only used clearly randomised trials and described the results of the sensitivity analysis in the text. We excluded quasi‐randomised studies, such as those allocating by using alternate days of the week. </p> </section> <section id="CD006569-sec-0032"> <h4 class="title">Types of participants</h4> <p>We included people with schizophrenia and other types of schizophrenia‐like psychosis (e.g. schizophreniform and schizoaffective disorders), irrespective of the diagnostic criteria used. There is no clear evidence that the schizophrenia‐like psychoses are caused by fundamentally different disease processes or require different treatment approaches (<a href="./references#CD006569-bbs2-0283" title="CarpenterWTJr , BuchananRW . Schizophrenia. New England Journal of Medicine1994;330:681‐90. ">Carpenter 1994</a>). </p> </section> <section id="CD006569-sec-0033"> <h4 class="title">Types of interventions</h4> <section id="CD006569-sec-0034"> <h5 class="title">1. Aripiprazole</h5> <p>Any oral form of application, any dose.</p> </section> <section id="CD006569-sec-0035"> <h5 class="title">2. Other new/atypical antipsychotic drugs</h5> <p>These include amisulpride, clozapine, olanzapine, quetiapine, risperidone, sertindole, ziprasidone, zotepine: any oral or parenteral form of application, any dose. </p> </section> </section> <section id="CD006569-sec-0036"> <h4 class="title">Types of outcome measures</h4> <p>We grouped outcomes into the short term (up to 12 weeks), medium term (13‐26 weeks) and long term (over 26 weeks). </p> <section id="CD006569-sec-0037"> <h5 class="title">Primary outcomes</h5> <section id="CD006569-sec-0038"> <h6 class="title">1. Global state</h6> <p>No clinically important response ‐ as defined by the individual studies (e.g. global impression less than much improved or less than 50% reduction on a rating scale) ‐ medium term </p> </section> <section id="CD006569-sec-0039"> <h6 class="title">2. General functioning</h6> <p>No clinically important change in general functioning ‐ medium term</p> </section> <section id="CD006569-sec-0040"> <h6 class="title">3. Adverse effects</h6> <p>Clinically important specific adverse effects ‐ medium term</p> </section> </section> <section id="CD006569-sec-0041"> <h5 class="title">Secondary outcomes</h5> <p><b>1. Global state</b> </p> <p>1.1 No clinically important change in global state (as defined by individual studies)<br/> 1.2 Relapse (as defined by the individual studies) </p> <p><b>2. Mental state</b> </p> <p>2.1 No clinically important change in general mental state score<br/> 2.2 Average endpoint general mental score<br/> 2.3 Average change in general mental state score<br/> 2.4 No clinically important change in specific symptoms (positive symptoms of schizophrenia, negative symptoms of schizophrenia)<br/> 2.5 Average endpoint specific symptom score<br/> 2.6 Average change in specific symptom score </p> <p><b>3. Leaving the studies early</b> </p> <p>3.1 Any reason, adverse events, inefficacy of treatment</p> <p><b>4. Quality of life/satisfaction with treatment</b> </p> <p>4.1 No clinically important change in general quality of life<br/> 4.2 Average endpoint general quality of life score<br/> 4.3 Average change in general quality of life score </p> <p><b>5. General functioning</b> </p> <p>5.1 No clinically important change in general functioning,‐ short and long term<br/> 5.2 Average endpoint general functioning score<br/> 5.3 Average change in general functioning score </p> <section id="CD006569-sec-0042"> <h6 class="title">6. Cognitive functioning</h6> <p>6.1 No clinically important change in overall cognitive functioning<br/> 6.2 Average endpoint of overall cognitive functioning score<br/> 6.3 Average change of overall cognitive functioning score </p> </section> <section id="CD006569-sec-0043"> <h6 class="title">7. Service use</h6> <p>7.1 Number of patients hospitalised</p> </section> <section id="CD006569-sec-0044"> <h6 class="title">8. Adverse effects</h6> <p>8.1 Number of participants with at least one adverse effect<br/> 8.2 Clinically important specific adverse effects (cardiac effects, death, movement disorders, prolactin increase and associated effects, weight gain, effects on white blood cell count), short and long term<br/> 8.3 Average endpoint in specific adverse effects<br/> 8.4 Average change in specific adverse effects </p> </section> <section id="CD006569-sec-0045"> <h6 class="title">9. 'Summary of findings' table</h6> <p>We used the GRADE approach to interpret findings (<a href="./references#CD006569-bbs2-0327" title="SchünemannHJ , OxmanAD , VistGE , HigginsJPT , DeeksJJ , GlasziouP , et al. Chapter 12: Interpreting results and drawing conclusions. In: HigginsJPT , GreenS editor(s). Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration, 2008:359‐83. ">Schünemann 2008</a>) and used the GRADE profiler to import data from Review Manager (RevMan) to create 'Summary of findings' tables. These tables provide outcome‐specific information concerning the overall quality of evidence from each included study in the comparison, the magnitude of effect of the interventions examined, and the sum of available data on all outcomes we rated as important to patient‐care and decision making. We selected the following main outcomes for inclusion in the 'Summary of findings' tables. </p> <p> <ol id="CD006569-list-0001"> <li> <p>Global state</p> </li> <li> <p>Mental state</p> </li> <li> <p>Leaving the study early</p> </li> <li> <p>Quality of Life</p> </li> <li> <p>Adverse effects</p> </li> <li> <p>General functioning</p> </li> <li> <p>Service use</p> </li> </ol> </p> </section> </section> </section> </section> <section id="CD006569-sec-0046"> <h3 class="title">Search methods for identification of studies</h3> <p>No language restriction was applied within the limitations of the search tools.</p> <section id="CD006569-sec-0047"> <h4 class="title">Electronic searches</h4> <section id="CD006569-sec-0048"> <h5 class="title">1. Update search</h5> <p>We searched the Cochrane Schizophrenia Group Trials Register (5 November 2012) using the phrase: </p> <p>[ ( (aripiprazol* AND (amisulprid* OR clozapin* OR olanzapin* OR quetiapin* OR risperidon* OR sertindol* OR ziprasidon* OR zotepin*)) in title, abstract or index terms of REFERENCE) or ( (aripiprazol* AND (amisulprid* OR clozapin* OR olanzapin* OR quetiapin* OR risperidon* OR sertindol* OR ziprasidon* OR zotepin*)) in interventions of STUDY)] </p> <p>The Cochrane Schizophrenia Group’s Trials Register is compiled by systematic searches of major databases, handsearches of journals and conference proceedings (see <a href="http://szg.cochrane.org/cszg-specialised-register" target="_blank">Group Module</a>). Incoming trials are assigned to relevant existing or new review titles. </p> </section> <section id="CD006569-sec-0049"> <h5 class="title">2. Previous electronic search</h5> <p>Please see <a href="./appendices#CD006569-sec-0452">Appendix 1</a>. </p> </section> </section> <section id="CD006569-sec-0050"> <h4 class="title">Searching other resources</h4> <section id="CD006569-sec-0051"> <h5 class="title">1. Reference searching</h5> <p>We inspected the reference lists of all studies identified in the search for more trials. </p> </section> <section id="CD006569-sec-0052"> <h5 class="title">2. Personal contact</h5> <p>Where possible, we contacted the first author of each included study for missing information.</p> </section> <section id="CD006569-sec-0053"> <h5 class="title">3. Drug companies</h5> <p>We contacted the manufacturers of all atypical antipsychotics included for additional data in the 2011 update. </p> </section> </section> </section> <section id="CD006569-sec-0054"> <h3 class="title" id="CD006569-sec-0054">Data collection and analysis</h3> <p>For previous data collection and analysis methods please see <a href="./appendices#CD006569-sec-0453">Appendix 2</a>. </p> <section id="CD006569-sec-0055"> <h4 class="title">Selection of studies</h4> <p>Review author TS inspected the reports for this update. TS resolved any doubts by discussion with other review authors, and where there was still doubt, TS acquired the full article for further inspection. Once the full articles were obtained, TS decided whether the studies met the review criteria. Twenty per cent of the references were randomly checked by HXM for reliability. Any disagreements were resolved by discussion. For any persistent disagreement, TS sought further information from authors of studies and added these trials to the list of those awaiting assessment. (See also <a href="#CD006569-fig-0001">Figure 1</a>, <a href="#CD006569-fig-0002">Figure 2</a> and <a href="#CD006569-fig-0003">Figure 3</a> for detailed flow chart of the selection process). </p> <div class="figure" id="CD006569-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram: original search" data-id="CD006569-fig-0001" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram: original search</p> </div> </div> </div> <div class="figure" id="CD006569-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Study flow diagram: update 2011" data-id="CD006569-fig-0002" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram: update 2011</p> </div> </div> </div> <div class="figure" id="CD006569-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Study flow diagram: update 2012" data-id="CD006569-fig-0003" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram: update 2012</p> </div> </div> </div> </section> <section id="CD006569-sec-0056"> <h4 class="title">Data extraction and management</h4> <section id="CD006569-sec-0057"> <h5 class="title">1. Extraction</h5> <p>For this update, TS and HXM extracted data from included studies. If data were presented only in graphs and figures, TS and HXM extracted data whenever possible. When further information was necessary, TS contacted authors of studies in order to obtain missing data or for clarification. If studies were multicentre, where possible, TS extracted data relevant to each component centre separately. </p> </section> <section id="CD006569-sec-0058"> <h5 class="title">2. Management</h5> <section id="CD006569-sec-0059"> <h6 class="title">2.1 Forms</h6> <p>We extracted data onto standard, simple forms.</p> </section> <section id="CD006569-sec-0060"> <h6 class="title">2.2 Scale‐derived data</h6> <p>We included continuous data from rating scales only if:<br/> a. the psychometric properties of the measuring instrument have been described in a peer‐reviewed journal (<a href="./references#CD006569-bbs2-0315" title="MarshallM , LockwoodA , AdamsC , BradleyC , JoyC , FentonM . Unpublished rating scales ‐ a major source of bias in randomised controlled trials of treatments for schizophrenia?. British Journal of Psychiatry2000;176:249‐52. ">Marshall 2000</a>); and<br/> b. the measuring instrument has not been written or modified by one of the trialists for that particular trial. </p> <p>Ideally, the measuring instrument should either be i. a self‐report or ii. completed by an independent rater or relative (not the therapist). We realise that this is not often reported clearly; we have noted whether or not this is the case in <a href="#CD006569-sec-0100">Description of studies</a>. </p> </section> <section id="CD006569-sec-0061"> <h6 class="title">2.3 Endpoint versus change data</h6> <p>There are advantages of both endpoint and change data. Change data can remove a component of between‐person variability from the analysis. On the other hand, calculation of change needs two assessments (baseline and endpoint), which can be difficult in unstable and difficult to measure conditions such as schizophrenia. We decided primarily to use endpoint data, and only use change data if the former were not available. We combined endpoint and change data in the analysis as we used mean differences (MD) rather than standardised mean differences (SMD) throughout (<a href="./references#CD006569-bbs2-0301" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org2011. ">Higgins 2011</a>, Chapter 9.4.5.2). </p> </section> <section id="CD006569-sec-0062"> <h6 class="title">2.4 Skewed data</h6> <p>Continuous data on clinical and social outcomes are often not normally distributed. To avoid the pitfall of applying parametric tests to non‐parametric data, we aimed to apply the following standards to all data before inclusion: </p> <p>a) standard deviations (SDs) and means are reported in the paper or obtainable from the authors; </p> <p>b) when a scale starts from the finite number zero, the SD, when multiplied by two, is less than the mean (as otherwise the mean is unlikely to be an appropriate measure of the centre of the distribution (<a href="./references#CD006569-bbs2-0274" title="AltmanDG , BlandJM . Detecting skewness from summary information. BMJ1996;313:1200. ">Altman 1996</a>)); </p> <p>c) if a scale started from a positive value (such as the Positive and Negative Syndrome Scale (PANSS, (<a href="./references#CD006569-bbs2-0307" title="KaySR , OplerLA , FiszbeinA . Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda (NY): Multi‐Health Systems, 1986. ">Kay 1986</a>)), which can have values from 30 to 210), we modified the calculation described above to take the scale starting point into account. In these cases skew is present if 2 SD &gt; (S‐S min), where S is the mean score and S min is the minimum score. </p> <p>Endpoint scores on scales often have a finite start and end point and these rules can be applied. We entered skewed endpoint data from studies of fewer than 200 participants in as other data within the data and analyses tables rather than into an analysis. Skewed data pose less of a problem when looking at mean if the sample size is large; we entered such endpoint data into syntheses. </p> <p>When continuous data are presented on a scale that includes a possibility of negative values (such as change data), it is difficult to tell whether data are skewed or not; we entered skewed change data into analyses regardless of the size of study. </p> </section> <section id="CD006569-sec-0063"> <h6 class="title">2.5 Common measure</h6> <p>To facilitate comparison between trials, we intended to convert variables that can be reported in different metrics, such as days in hospital (mean days per year, per week or per month) to a common metric (e.g. mean days per month). </p> </section> <section id="CD006569-sec-0064"> <h6 class="title">2.6 Conversion of continuous to binary</h6> <p>Where possible, we made efforts to convert outcome measures to dichotomous data. This can be done by identifying cut‐off points on rating scales and dividing participants accordingly into 'clinically improved' or 'not clinically improved'. It is generally assumed that if there is a 50% reduction in a scale‐derived score such as the Brief Psychiatric Rating Scale (BPRS, <a href="./references#CD006569-bbs2-0323" title="OverallJE , GorhamDR . The brief psychiatric rating scale. Psychological Reports1962;10:799‐812. ">Overall 1962</a>) or the PANSS (<a href="./references#CD006569-bbs2-0307" title="KaySR , OplerLA , FiszbeinA . Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda (NY): Multi‐Health Systems, 1986. ">Kay 1986</a>), this could be considered as a clinically significant response (<a href="./references#CD006569-bbs2-0310" title="LeuchtS , KaneJM , KisslingW , HamannJ , EtschelE , EngelR . Clinical implications of brief psychiatric rating scale scores. British Journal of Psychiatry2005;187:366‐71. [PUBMED: 16199797] ">Leucht 2005a</a>; <a href="./references#CD006569-bbs2-0309" title="LeuchtS , KaneJM , KisslingW , HamannJ , EtschelE , EngelR . What does the PANSS mean?. Schizophrenia Research2005;79:231‐8. ">Leucht 2005</a>). If data based on these thresholds were not available, we used the primary cut‐off presented by the original authors. </p> </section> <section id="CD006569-sec-0065"> <h6 class="title">2.7 Direction of graphs</h6> <p>Where possible, we entered data in such a way that the area to the left of the line of no effect indicated a favourable outcome for aripiprazole. </p> </section> </section> </section> <section id="CD006569-sec-0066"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>For this update, review author TS worked independently by using criteria described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD006569-bbs2-0301" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org2011. ">Higgins 2011</a>) to assess trial quality. This new set of criteria is based on evidence of associations between overestimate of effect and high risk of bias of the article such as sequence generation, allocation concealment, blinding, incomplete outcome data and selective reporting. </p> <p>Where inadequate details of randomisation and other characteristics of trials were provided we contacted the authors of the studies in order to obtain additional information. </p> <p>We have noted the level of risk of bias in both the text of the review and in the <a href="./full#CD006569-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./full#CD006569-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD006569-tbl-0003">summary of findings Table 3</a>; <a href="./full#CD006569-tbl-0004">summary of findings Table 4</a>; <a href="./full#CD006569-tbl-0005">summary of findings Table 5</a>. </p> </section> <section id="CD006569-sec-0067"> <h4 class="title">Measures of treatment effect</h4> <section id="CD006569-sec-0068"> <h5 class="title">1. Binary data</h5> <p>For binary outcomes, we calculated a standard estimation of the risk ratio (RR) and its 95% confidence interval (CI). It has been shown that RR is more intuitive (<a href="./references#CD006569-bbs2-0282" title="BoisselJP , CucheratM , LiW , ChatellierG , GueyffierF , BuyseM , BoutitieF , et al. The problem of therapeutic efficacy indices.3. Comparison of the indices and their use. Therapie1999;54(4):405‐11. ">Boissel 1999</a>) than odds ratios and that odds ratios tend to be interpreted as RR by clinicians (<a href="./references#CD006569-bbs2-0286" title="DeeksJ . Issues in the selection for meta‐analyses of binary data. Proceeding of the 8th International Cochrane Colloquium; 2000 Oct 25‐28th; Cape Town, South Africa. Cape Town: Cochrane Collaboration, 2000. ">Deeks 2000</a>). The Number Needed to Treat/Harm (NNT/H) statistic with its CI is intuitively attractive to clinicians but is problematic both in its accurate calculation in meta‐analyses and interpretation (<a href="./references#CD006569-bbs2-0302" title="HuttonJL . Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials. British Journal of Haematology2009;146(1):27‐30. ">Hutton 2009</a>). For binary data presented in the 'Summary of findings' tables, where possible, we calculated illustrative comparative risks. </p> </section> <section id="CD006569-sec-0069"> <h5 class="title">2. Continuous data</h5> <p>For continuous outcomes, we estimated the mean difference (MD) between groups. We would prefer not to calculate effect size measures (standardised mean difference (SMD). However, if scales of very considerable similarity were used, we presumed there was a small difference in measurement, and we calculated effect size and transformed the effect back to the units of one or more of the specific instruments. </p> </section> </section> <section id="CD006569-sec-0070"> <h4 class="title">Unit of analysis issues</h4> <section id="CD006569-sec-0071"> <h5 class="title">1. Cluster trials</h5> <p>Studies increasingly employ 'cluster randomisation' (such as randomisation by clinician or practice), but analysis and pooling of clustered data poses problems. Authors often fail to account for intra‐class correlation in clustered studies, leading to a 'unit of analysis' error (<a href="./references#CD006569-bbs2-0287" title="DivineGW , BrownJT , FrazerLM . The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine1992;7:623‐9. ">Divine 1992</a>) whereby P values are spuriously low, CIs unduly narrow and statistical significance overestimated. This causes type I errors (<a href="./references#CD006569-bbs2-0280" title="BlandJM , KerrySM . Statistics notes. Trials randomised in clusters. BMJ1997;315:600. ">Bland 1997</a>; <a href="./references#CD006569-bbs2-0296" title="GullifordMC , UkoumunneOC , ChinnS . Components of variance and intraclass correlations for the design of community‐based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology1999;149:876‐83. ">Gulliford 1999</a>). </p> <p>No cluster‐randomised trials were identified in our search; however, if reviews in the future include such trials, where clustering is not accounted for in primary studies, we will present data in a table, with a (*) symbol to indicate the presence of a probable unit of analysis error. In subsequent versions of this review, we will seek to contact first authors of such studies to obtain intra‐class correlation coefficients (ICCs) for their clustered data and to adjust for this by using accepted methods (<a href="./references#CD006569-bbs2-0296" title="GullifordMC , UkoumunneOC , ChinnS . Components of variance and intraclass correlations for the design of community‐based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology1999;149:876‐83. ">Gulliford 1999</a>). Where clustering is been incorporated into the analysis of primary studies, we will present these data as if from a non cluster‐randomised study, but adjust for the clustering effect. </p> <p>We have sought statistical advice and have been advised that the binary data as presented in a report should be divided by a 'design effect'. This is calculated using the mean number of participants per cluster (m) and the ICC [Design effect = 1+(m‐1)*ICC] (<a href="./references#CD006569-bbs2-0288" title="DonnerA , KlarN . Issues in the meta‐analysis of cluster randomized trials. Statistics in Medicine2002;21:2971‐80. ">Donner 2002</a>). If the ICC was not reported it was assumed to be 0.1 (<a href="./references#CD006569-bbs2-0333" title="UkoumunneOC , GullifordMC , ChinnS , SterneJAC , BurneyPGJ . Methods for evaluating area‐wide and organisation‐based interventions in health and health care: a systematic review. Health Technology Assessment1999;3(5):iii‐92. ">Ukoumunne 1999</a>). </p> <p>If, in future updates of this review cluster trials are identified, cluster studies will be appropriately analysed taking into account ICCs and relevant data documented in the report, synthesis with other studies would be possible using the generic inverse variance technique. </p> </section> <section id="CD006569-sec-0072"> <h5 class="title">2. Cross‐over trials</h5> <p>A major concern of cross‐over trials is the carry‐over effect. It occurs if an effect (e.g. pharmacological, physiological or psychological) of the treatment in the first phase is carried over to the second phase. As a consequence, on entry to the second phase the participants can differ systematically from their initial state despite a wash‐out phase. For the same reason cross‐over trials are not appropriate if the condition of interest is unstable (<a href="./references#CD006569-bbs2-0292" title="ElbourneD , AltmanDG , HigginsJPT , CurtinaF , WorthingtondHV , VaileA . Meta‐analyses involving cross‐over trials: methodological issues. International Journal of Epidemiology2002;31(1):140‐9. ">Elbourne 2002</a>). As both effects are very likely in severe mental illness, if we encountered such trials, we planned only to use data of the first phase of cross‐over studies. </p> </section> <section id="CD006569-sec-0073"> <h5 class="title">3. Studies with multiple treatment groups</h5> <p>Where a study involves more than two treatment arms, if relevant, we presented the additional treatment arms in comparisons. If data were binary, we simply added these and combined them within the two‐by‐two table. If data were continuous, we combined data following the formula in section 7.7.3.8 (Combining groups) of the <i>Cochrane Handbook for Systemic reviews of Interventions</i> (<a href="./references#CD006569-bbs2-0301" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org2011. ">Higgins 2011</a>). Where the additional treatment arms were not relevant, we did not reproduce these data. </p> </section> </section> <section id="CD006569-sec-0074"> <h4 class="title">Dealing with missing data</h4> <section id="CD006569-sec-0075"> <h5 class="title">1. Overall loss of credibility</h5> <p>At some degree of loss of follow‐up, data must lose credibility (<a href="./references#CD006569-bbs2-0337" title="XiaJ , AdamsCE , BhagatN , BhagatV , BhoopathiP , El‐SayehH , et al. Loss to outcomes stakeholder survey: the LOSS study. Psychiatric Bulletin2009;33(7):254‐7. ">Xia 2009</a>). Although high rates of premature discontinuation are a major problem in this field, we felt that it was unclear which degree of attrition leads to a high degree of bias. We, therefore, did not exclude outcomes on the basis of the percentage of participants completing them. However, we addressed the attrition problem in all parts of the review, including the abstract. For this purpose, we calculated, presented and commented on frequency statistics (overall rates of leaving the studies early in all studies and comparators pooled and their ranges). We assumed that the people who discontinued the studies for any reason did not show any response to the treatment. </p> </section> <section id="CD006569-sec-0076"> <h5 class="title">2. Binary</h5> <p>We presented data on a 'once‐randomised‐always‐analyse' basis (an intention‐to‐treat (ITT) analysis). We undertook a sensitivity analysis to test how prone the primary outcomes are to change when data only from people who complete the study to that point are compared with the ITTanalysis using the above assumptions. </p> </section> <section id="CD006569-sec-0077"> <h5 class="title">3. Continuous</h5> <section id="CD006569-sec-0078"> <h6 class="title">3.1 Attrition</h6> <p>In the case of continuous outcomes, we preferred to use ITT results, but if not available we used completer data. </p> </section> <section id="CD006569-sec-0079"> <h6 class="title">3.2 Standard deviations</h6> <p>If SDs were not reported, we first tried to obtain the missing values from the authors. If not available, where there are missing measures of variance for continuous data, but an exact standard error (SE) and CIs available for group means, and either a P value or T value available for differences in mean, we can calculate them according to the rules described in the <i>Cochrane Handbook for Systemic reviews of Interventions</i> (<a href="./references#CD006569-bbs2-0301" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org2011. ">Higgins 2011</a>): When only the SE is reported, SDs are calculated by the formula SD = SE* square root (n). Chapters 7.7.3 and 16.1.3 of the <i>Cochrane Handbook for Systemic reviews of Interventions</i> (<a href="./references#CD006569-bbs2-0301" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org2011. ">Higgins 2011</a>) present detailed formulae for estimating SDs from P values, T or F values, CIs, ranges or other statistics. If these formulae do not apply, we would have calculated the SDs according to a validated imputation method, which is based on the SDs of the other included studies (<a href="./references#CD006569-bbs2-0294" title="FurukawaTA , BarbuiC , CiprianiA , BrambillaP , WatanabeN . Imputing missing standard deviations in meta‐analyses can provide accurate results. Journal of Clinical Epidemiology2006;59:7‐10. ">Furukawa 2006</a>). Although some of these imputation strategies can introduce error, the alternative would be to exclude a given study’s outcome and thus to lose information. We nevertheless would have examined the validity of the imputations in a sensitivity analysis excluding imputed values, had we imputed any values. </p> </section> <section id="CD006569-sec-0080"> <h6 class="title">3.3 Last observation carried forward</h6> <p>We anticipated that in many studies the method of last observation carried forward (LOCF) would be employed within the study report. As with all methods of imputation to deal with missing data, LOCF introduces uncertainty about the reliability of the results (<a href="./references#CD006569-bbs2-0311" title="LeuchtS , EngelRR , BaumlJ , DavisJM . Is the superior efficacy of new generation antipsychotics an artifact of LOCF?. Schizophrenia Bulletin2007;33(1):183‐91. [PUBMED: 16905632] ">Leucht 2007</a>). We nevertheless used LOCF data being aware that many results are the product of LOCF assumptions. </p> </section> </section> </section> <section id="CD006569-sec-0081"> <h4 class="title">Assessment of heterogeneity</h4> <section id="CD006569-sec-0082"> <h5 class="title">1. Clinical heterogeneity</h5> <p>We considered all included studies initially, without seeing comparison data, to judge clinical heterogeneity. We simply inspected all studies for clearly outlying people or situations which we had not predicted would arise. When such situations or participant groups arose, we discussed these fully. </p> </section> <section id="CD006569-sec-0083"> <h5 class="title">2. Methodological heterogeneity</h5> <p>We considered all included studies initially, without seeing comparison data, to judge methodological heterogeneity. We simply inspected all studies for clearly outlying methods which we had not predicted would arise. When such methodological outliers arose, we discussed these fully. </p> </section> <section id="CD006569-sec-0084"> <h5 class="title">3. Statistical heterogeneity</h5> <section id="CD006569-sec-0085"> <h6 class="title">3.1 Visual inspection</h6> <p>We visually inspected graphs to investigate the possibility of statistical heterogeneity.</p> </section> <section id="CD006569-sec-0086"> <h6 class="title">3.2 Employing the I<sup>2</sup> statistic </h6> <p>We investigated heterogeneity between studies by considering the I<sup>2</sup> method alongside the ChI<sup>2</sup> P value. The I<sup>2</sup> provides an estimate of the percentage of inconsistency thought to be due to chance (<a href="./references#CD006569-bbs2-0300" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327:557‐60. ">Higgins 2003</a>). The importance of the observed value of I<sup>2</sup> depends on i. magnitude and direction of effects and ii. strength of evidence for heterogeneity (e.g. P value from ChI<sup>2</sup> test, or a confidence interval for I<sup>2</sup>). An I<sup>2</sup> estimate greater than or equal to around 50% accompanied by a statistically significant ChI<sup>2</sup> statistic was interpreted as evidence of substantial levels of heterogeneity (<a href="./references#CD006569-bbs2-0301" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org2011. ">Higgins 2011</a>). When substantial levels of heterogeneity were found in the primary outcome, we explored reasons for heterogeneity (<a href="#CD006569-sec-0089">Subgroup analysis and investigation of heterogeneity</a>). </p> </section> </section> </section> <section id="CD006569-sec-0087"> <h4 class="title">Assessment of reporting biases</h4> <p>Reporting biases arise when the dissemination of research findings is influenced by the nature and direction of results (<a href="./references#CD006569-bbs2-0290" title="EggerM , Davey‐SmithG , SchneiderM , MinderCSO . Bias in meta‐analysis detected by a simple, graphical test. BMJ1997;13:629‐34. ">Egger 1997</a>). These are described in Section 10 of the <i>Handbook</i> (<a href="./references#CD006569-bbs2-0301" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org2011. ">Higgins 2011</a>). We are aware that funnel plots may be useful in investigating reporting biases but are of limited power to detect small‐study effects. We did not use funnel plots for outcomes where there were 10 or fewer studies, or where all studies were of similar sizes. In other cases, where funnel plots were possible, we sought statistical advice in their interpretation. </p> </section> <section id="CD006569-sec-0088"> <h4 class="title">Data synthesis</h4> <p>We understand that there is no closed argument for preference for use of fixed‐effect or random‐effects models. The random‐effects method incorporates an assumption that the different studies are estimating different, yet related, intervention effects. This often seems to be true to us and the random‐effects model takes into account differences between studies even if there is no statistically significant heterogeneity. There is, however, a disadvantage to the random‐effects model: it puts added weight onto small studies, which often are the most biased ones. Depending on the direction of effect, these studies can either inflate or deflate the effect size. Where possible, for both dichotomous and continuous data we used the random‐effects model for data synthesis. </p> </section> <section id="CD006569-sec-0089"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <section id="CD006569-sec-0090"> <h5 class="title">1. Subgroup analyses ‐ only primary outcomes</h5> <p>We did not anticipate any subgroup analyses.</p> </section> <section id="CD006569-sec-0091"> <h5 class="title">2. Investigation of heterogeneity</h5> <p>If inconsistency was high, we reported this. First, we investigated whether data had been entered correctly. Second, if data were correct, we visually inspected the graph and successively removed outlying studies to see if homogeneity was restored. For this review we decided that should this occur with data contributing to the summary finding of no more than around 10% of the total weighting, we would present data. If not, then we did not pool data and discussed relevant issues. We know of no supporting research for this 10% cut‐off, but we used prediction intervals as an alternative to this unsatisfactory state.<br/> <br/> When unanticipated clinical or methodological heterogeneity was obvious, we simply stated hypotheses regarding these for future reviews or versions of this review. We did not anticipate undertaking analyses relating to these. </p> </section> </section> <section id="CD006569-sec-0092"> <h4 class="title">Sensitivity analysis</h4> <section id="CD006569-sec-0093"> <h5 class="title">1. Implication of randomisation</h5> <p>We aimed to include trials in a sensitivity analysis if they were described in some way so as to imply randomisation. For the primary outcomes, we included these studies and, if there was no substantive difference when the implied randomised studies were added to those with better description of randomisation, then we entered all data from these studies. </p> </section> <section id="CD006569-sec-0094"> <h5 class="title">2. Assumptions for lost binary data</h5> <p>Where assumptions had to be made regarding people lost to follow‐up (see <a href="#CD006569-sec-0074">Dealing with missing data</a>), we compared the findings of the primary outcomes when we used our assumptions and when we used data only from people who completed the study to that point. If there was a substantial difference, we reported results and discussed them, but continued to employ our assumption. </p> <p>Where assumptions had to be made regarding missing SDs data (see <a href="#CD006569-sec-0074">Dealing with missing data</a>), we compared the findings of the primary outcomes when we used our assumptions and when we used data only from people who completed the study to that point. A sensitivity analysis was undertaken to test how prone results were to change when completer‐only data only were compared to the imputed data using the above assumption. If there was a substantial difference, we reported results and discussed them, but continued to employ our assumption. </p> </section> <section id="CD006569-sec-0095"> <h5 class="title">3. Risk of bias</h5> <p>We analysed the effects of excluding trials that were judged to be at high risk of bias across one or more of the domains of randomisation (implied as randomised with no further details available): allocation concealment, blinding and outcome reporting for the meta‐analysis of the primary outcome. If the exclusion of trials at high risk of bias did not substantially alter the direction of effect or the precision of the effect estimates, then we included data from these trials in the analysis. </p> </section> <section id="CD006569-sec-0096"> <h5 class="title">4. Imputed values</h5> <p>We planned to undertake a sensitivity analysis to assess the effects of including data from trials where we used imputed values for ICC in calculating the design effect in cluster randomised trials. However, no cluster‐randomised trials were identified for this update. </p> <p>In future updates, if cluster randomised trials are included we will undertake sensitivity analyses. If we note substantial differences in the direction or precision of effect estimates in any of the sensitivity analyses listed above, we will not pool data from the excluded trials with the other trials contributing to the outcome, but present them separately. </p> </section> <section id="CD006569-sec-0097"> <h5 class="title">5. Skewed data</h5> <p>We planned sensitivity analyses a priori for examining the change in the robustness of the sensitivity to including studies with potentially skewed data. </p> </section> <section id="CD006569-sec-0098"> <h5 class="title">6. Comparator dose</h5> <p>A recent report showed that some of the comparisons of atypical antipsychotics may have been biased by using inappropriate comparator doses (<a href="./references#CD006569-bbs2-0299" title="HeresS , DavisJ , MainoK , JetzingerE , KisslingW , LeuchtS . Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine. American Journal of Psychiatry2006;163:185‐94. ">Heres 2006</a>). We, therefore, also analysed whether the exclusion of studies with inappropriate comparator doses changed the results of the primary outcome and the general mental state. </p> <p>Comparator doses were considered inappropriate where they exceeded BNF and Martindale recommended maximum doses (<a href="./references#CD006569-bbs2-0281" title="British National Formulary (BNF). http://www.bnf.org/bnf/index.htmaccessed June/July 2013. ">BNF 2013</a>; <a href="./references#CD006569-bbs2-0316" title="Martindale: the complete drug reference. http://www.medicinescomplete.com/mc/martindale/current/accessed June/ July 2013. ">Martindale 2013</a>). </p> <p> <ul id="CD006569-list-0002"> <li> <p>Aripiprazole: usual maintenance dose of 15 mg daily; range 10 to 15 mg once daily; maximum dose 30 mg daily. </p> </li> <li> <p>Clozapine: usual dose 200 to 450 mg daily; maximum dose 900 mg daily.</p> </li> <li> <p>Quetiapine: usual range 300 to 450 mg daily in two divided doses; maximum dose 750 mg daily. </p> </li> <li> <p>Risperidone: usual dose 4 mg daily; maximum dose 50 mg every two weeks.</p> </li> <li> <p>Ziprasidone: (oral) 20 mg twice daily, increased if necessary up to maximum 80 mg twice daily; usual maintenance dose 20 mg twice daily; (intramuscular (IM) for acute agitation) 10 to 20 mg as required; maximum dose 40 mg daily for three consecutive days (to switch to oral therapy as soon as possible). </p> </li> <li> <p>Olanzapine: usual range 5 to 20 mg daily; maximum dose 20 mg daily.</p> </li> </ul> </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD006569-sec-0099" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD006569-sec-0099"></div> <section id="CD006569-sec-0100"> <h3 class="title">Description of studies</h3> <p>For a substantive description of studies please see <a href="./references#CD006569-sec-0493" title="">Characteristics of included studies</a> and <a href="./references#CD006569-sec-0494" title="">Characteristics of excluded studies</a> tables. </p> <section id="CD006569-sec-0101"> <h4 class="title">Results of the search</h4> <section id="CD006569-sec-0102"> <h5 class="title">1. Original search (2005/2007)</h5> <p>The first search yielded 3620 reports of which 28 were closely inspected. After excluding 22 studies, six publications on four trials and two comparisons could be included: aripiprazole versus olanzapine (two) and aripiprazole versus risperidone (two) (<a href="./references#CD006569-bbs2-0339" title="KomossaK , Rummel‐KlugeC , SchmidF , HungerH , SchwarzS , El‐SayehHG , et al. Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews2009, Issue 4. [DOI: 10.1002/14651858.CD006569.pub3; PUBMED: 19821375] ">Komossa 2009</a>) (<a href="#CD006569-fig-0001">Figure 1</a>). </p> </section> <section id="CD006569-sec-0103"> <h5 class="title">2. Updated search (November 2011)</h5> <p>The search we undertook for the first update of the review (<a href="./references#CD006569-bbs2-0338" title="KhannaP , KomossaK , Rummel‐KlugeC , HungerH , SchwarzS , El‐SayehHG , et al. Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews2013, Issue 2. [DOI: 10.1002/14651858.CD006569.pub4] ">Khanna 2013</a>) identified 618 further results and, after close inspection, we included eight more studies; making a total of 12 studies altogether. We excluded 38 trials, added 216 trials to 'Studies awaiting classification' (due to the need for translation or data extraction) and 16 trials to 'Ongoing studies' category (<a href="./references#CD006569-bbs2-0338" title="KhannaP , KomossaK , Rummel‐KlugeC , HungerH , SchwarzS , El‐SayehHG , et al. Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews2013, Issue 2. [DOI: 10.1002/14651858.CD006569.pub4] ">Khanna 2013</a>) (<a href="#CD006569-fig-0002">Figure 2</a>). </p> </section> <section id="CD006569-sec-0104"> <h5 class="title">3. Updated search (November 2012)</h5> <p>The 2012 updated search for this current version of the review yielded 215 new citations; 209 full‐text articles were assessed for eligibility, and ultimately 162 studies (from 167 references) were included. The total amount of included studies in this current review is 174 (<a href="#CD006569-fig-0003">Figure 3</a>). </p> </section> </section> <section id="CD006569-sec-0105"> <h4 class="title">Included studies</h4> <p>The 174 included studies randomised 17,244 participants with the diagnosis of schizophrenia or schizoaffective disorder. All studies were described as randomised. We included both double blind and open label studies. Many were sponsored by pharmaceutical companies with some pecuniary interest in the result. </p> <section id="CD006569-sec-0106"> <h5 class="title">1. Length of studies</h5> <p>One trial was only five days long. The vast majority were short term with a duration of three to eight weeks. Seven medium‐term studies ranged from 20 to 26 weeks, and long‐term studies from 28 weeks to two years. </p> </section> <section id="CD006569-sec-0107"> <h5 class="title">2. Setting</h5> <p>Studies reported inpatient and outpatient settings; the vast majority of studies were undertaken in China, where, it seems, aripiprazole is being heavily marketed. </p> </section> <section id="CD006569-sec-0108"> <h5 class="title">3. Participants</h5> <p>Participants were diagnosed with varying diagnostic criteria; Diagnostic Statistical Manual version 4 (DSM‐IV); clinical diagnosis (or no mention). The vast majority of participants in included studies were diagnosed using the Chinese Classification of Mental Disorders (CCMD‐3). Participants were usually relatively chronically ill with mean ages in the late thirties. </p> </section> <section id="CD006569-sec-0109"> <h5 class="title">4. Study size</h5> <p>The sample size varied from n = 40 (<a href="./references#CD006569-bbs2-0157" title="张胜利 , 盛民生 , 李永强 , 李振宇 . Comparison of the efficacy of aripiprazole and risperidone in the treatment of schizophrenia [阿立哌唑与利培酮治疗精神分裂症的疗效比较]. Medical Journal of Chinese People's Health [中国民康医学]2008;20(20):2386, 2435. ">Zhang 2008b</a>) to n = 1599 (<a href="./references#CD006569-bbs2-0097" title="RieraL , HuR , StockE , NyilasM , TorbeynsA , BorianF , et al. Broad effectiveness trial with aripiprazole. Schizophrenia Research2004;67(1):157. TandonR , MarcusRN , StockEG , RieraLC , KosticD , PansM , et al. A prospective, multicenter, randomized, parallel‐group, open‐label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad Effectiveness Trial With aripiprazole (BETA). Schizophrenia Research2006;84(1):77‐89. ">Tandon 2006</a>) people. </p> </section> <section id="CD006569-sec-0110"> <h5 class="title">5. Interventions</h5> <section id="CD006569-sec-0111"> <h6 class="title">5.1 Aripiprazole</h6> <p>Doses ranged between 2.5 to 30 mg/day.</p> </section> <section id="CD006569-sec-0112"> <h6 class="title">5.2 Control drugs</h6> <p>Other atypical drugs, namely olanzapine, risperidone, ziprasidone and quetiapine were used as controls. As some studies did not elucidate doses it can only be presumed that therapeutic doses were employed. </p> </section> </section> <section id="CD006569-sec-0113"> <h5 class="title">6. Outcomes</h5> <section id="CD006569-sec-0114"> <h6 class="title">6.1 Leaving the study early</h6> <p>Thirty‐five studies reported on participants leaving the study early due to any reason.</p> </section> <section id="CD006569-sec-0115"> <h6 class="title">6.2 Rating scales</h6> <p>Details of scales that provided usable data are shown below. Reasons for exclusion of data from other instruments are given under 'Outcomes' in the <a href="./references#CD006569-sec-0493" title="">Characteristics of included studies</a>. </p> <section id="CD006569-sec-0116"> <p><b>6.2.1 Global state scales</b></p> <p>6.2.1.1 Clinical Global Impression Scale ‐ CGI Scale (<a href="./references#CD006569-bbs2-0297" title="GuyU . ECDEU assessment manual for psychopharmacology. National Institute of Mental Health, 1976. ">Guy 1976</a>)<br/> This is used to assess both severity of illness and clinical improvement, by comparing the conditions of the person standardised against other people with the same diagnosis. A seven‐point scoring system is used with low scores showing decreased severity and/or overall improvement. </p> <p>6.2.1.2 Investigator's Assessment Questionnaire ‐ IAQ (<a href="./references#CD006569-bbs2-0329" title="TandonR , DevellisRF , HanJ , LiH , FrangouS , DursunS , et al. Validation of the investigator's assessment questionnaire, a new clinical tool for relative assessment of response to antipsychotics in patients with schizophrenia and schizoaffective disorder. Psychiatry Research2005;136(2‐3):211‐21. [PUBMED: 16115690] ">Tandon 2005</a>)<br/> The IAQ is a quantifiable clinical tool that can provide detailed information regarding common safety, efficacy and tolerability concerns that patients experience while taking antipsychotics. It has been shown to highly correlate with time to study discontinuation which is a common measure of effectiveness. </p> <p>6.2.1.3 Arizona Sexual Experience Scale ‐ ASEX (<a href="./references#CD006569-bbs2-0318" title="McGahueyCA , GelenbergAJ , LaukesCA , MorenoFA , DelgadoPL , McKnightKM , et al. The Arizona Sexual Experience Scale (ASEX): reliability and validity. Journal of Sex &amp; Marital Therapy2000;26(1):25‐40. [PUBMED: 10693114] ">McGahuey 2000</a>)<br/> This is a brief scale for self‐rating of sexual function. It has five items and is rated in five steps. Possible scores range from five to 30 with higher scores indicating more sexual dysfunction. </p> </section> <section id="CD006569-sec-0117"> <p><b>6.2.2 Mental state scales</b></p> <p>6.2.2.1 Positive and Negative Syndrome Scale ‐ PANSS (<a href="./references#CD006569-bbs2-0307" title="KaySR , OplerLA , FiszbeinA . Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda (NY): Multi‐Health Systems, 1986. ">Kay 1986</a>)<br/> This schizophrenia scale has 30 items, each of which can be defined on a seven‐point scoring system varying from one ‐ absent to seven ‐ extreme. It can be divided into three sub scales for measuring the severity of general psychopathology, positive symptoms (PANSS‐P), and negative symptoms (PANSS‐N). A low score indicates lesser severity. </p> <p>6.2.2.2 Positive and Negative Syndrome Scale‐Excited Component ‐ PANSS‐EC (<a href="./references#CD006569-bbs2-0284" title="ChaichanW . Evaluation of the use of the positive and negative syndrome scale‐excited component as a criterion for administration of p. r. n. medication. Journal of Psychiatric Practice2008;14(2):105‐13. [PUBMED: 18360196] ">Chaichan 2008</a>)<br/> The PANSS‐EC scale is derived as a sub scale of PANSS and is a simple scale used to measure the degree of agitation. The scale consists of five items (poor impulse control, tension, hostility, uncooperativeness, excitement), each being ranked from one to seven giving a potential maximum score of 35 points. </p> <p>6.2.2.3 Brief Psychiatric Rating Scale – BPRS (<a href="./references#CD006569-bbs2-0323" title="OverallJE , GorhamDR . The brief psychiatric rating scale. Psychological Reports1962;10:799‐812. ">Overall 1962</a>)<br/> This consists of 18 to 24 items (depending on the version) each rated on a scale from one (absent) to seven (extreme). </p> </section> <section id="CD006569-sec-0118"> <p><b>6.2.3 Adverse effects scales</b></p> <p>6.2.3.1 Abnormal Involuntary Movement Scale ‐ AIMS (<a href="./references#CD006569-bbs2-0297" title="GuyU . ECDEU assessment manual for psychopharmacology. National Institute of Mental Health, 1976. ">Guy 1976</a>)<br/> This scale has been used to assess tardive dyskinesia, a long‐term, drug‐induced movement disorder and short‐term movement disorders such as tremor. </p> <p>6.2.3.2 Simpson Angus Scale ‐ SAS (<a href="./references#CD006569-bbs2-0328" title="SimpsonEN , AngusJWF . A rating scale for extrapyramidal adverse effects. Acta Psychiatrica Scandinavica Supplementum1970;212:11‐9. ">Simpson 1970</a>)<br/> This 10‐item scale (with a scoring system of zero to four on each item) measures drug‐induced parkinsonism, a short‐term drug‐induced movement disorder. A low score indicates low levels of parkinsonism. </p> <p>6.2.3.3 Barnes Akathisia Scale ‐ BAS (<a href="./references#CD006569-bbs2-0277" title="BarnesTR . A rating scale for drug‐induced akathisia. British Journal of Psychiatry1989;154:672‐6. ">Barnes 1989</a>)<br/> The scale comprises items rating the observable, restless movements that characterise akathisia, a subjective awareness of restlessness, and any distress associated with the condition. These items are rated from zero (normal) to three (severe). In addition, there is an item for rating global severity (from zero (absent) to five (severe)). A low score indicates low levels of akathisia. </p> </section> <section id="CD006569-sec-0119"> <p><b>6.2.4 Quality of Life</b></p> <p>6.2.4.1 Euro‐QoL‐5D ‐ EQ‐5D (<a href="./references#CD006569-bbs2-0303" title="JelsmaJ , MhundwaK , DeWeerdtW , DeCockP , ChimeraJ , ChivauraV . The reliability of the Shona version of the EQ‐5D. Central African Journal of Medicine2001;47(1):8‐13. [PUBMED: 11961858] ">Jelsma 2001</a>)<br/> The EuroQoL‐5D is a generic preference based measure of health‐related quality of life. It has five domains which are mobility, self‐care, usual activities, pain/ discomfort and anxiety/ depression, each having three short questions. The EQ‐5D Utility score assesses all five items on a scale of zero to one, where zero represents worst possible health and one represents perfect health. The EQ‐5D Health Dimension Scale assesses each item on three possible scores where one is the best and three the worst score. </p> <p>6.2.4.2 Quality of Life Scale – QLS (<a href="./references#CD006569-bbs2-0298" title="HeinrichsDW , HanlonTE , CarpenterWTJr . The quality of life scale: An instrument for rating the schizophrenic deficit syndrome. Schizophrenia Bulletin1984;10(3):388‐98. [PUBMED: 6474101] ">Heinrichs 1984</a>)<br/> Quality of Life Scale (QLS), a 21‐item scale divided into four domains including Interpersonal relations, Instrumental role, Intrapsychic foundations and common objects/activities scored on a seven‐point scale with lowest score indicating severe dysfunction. </p> <p>6.2.4.3 Impact of Weight on Quality of Life ‐ IwQOL‐Lite (<a href="./references#CD006569-bbs2-0308" title="KolotkinRL , CrosbyRD . Psychometric evaluation of the impact of weight on quality of life‐lite questionnaire (IWQOL‐lite) in a community sample. Quality of Life Research2002;11(2):157‐71. [PUBMED: 12018739] ">Kolotkin 2002</a>)<br/> This is a survey instrument that is used to quantitatively assess an individual's perception of how their weight affects their day‐to‐day life. This instrument is especially valuable to obesity researchers, clinicians, psychologists, medical device and/or pharmaceutical companies seeking to validate the effectiveness of their treatments for obesity using metrics that go beyond the physical measurements of weight loss. </p> <p>6.2.4.4 World Health Organisation Quality of Life Scale (WHOQoL‐Bref, <a href="./references#CD006569-bbs2-0322" title="O'CarrollRE , SmithK , CoustonM , CossarJA , HayesPC . A comparison of the WHOQOL‐100 and the WHOQOL‐BREF in detecting change in quality of life following liver transplantation. Quality of Life Research2000;9:121‐4. ">O'Carroll 2000</a>)<br/> The WHOQoL‐Bref is a 26‐item self‐report comprising satisfaction with health, psychological functioning, social relationships and environmental opportunities. Each item is scored on a five‐point scale from one (poor) to five (worse). The Chinese version of the WHOQoL scale, the generic quality of life inventory (GQOLI‐74), was also used in included Chinese studies. </p> </section> <section id="CD006569-sec-0120"> <p><b>6.2.1 Global state scales</b></p> <p>6.2.1.1 Clinical Global Impression Scale ‐ CGI Scale (<a href="./references#CD006569-bbs2-0297" title="GuyU . ECDEU assessment manual for psychopharmacology. National Institute of Mental Health, 1976. ">Guy 1976</a>)<br/> This is used to assess both severity of illness and clinical improvement, by comparing the conditions of the person standardised against other people with the same diagnosis. A seven‐point scoring system is used with low scores showing decreased severity and/or overall improvement. </p> <p>6.2.1.2 Investigator's Assessment Questionnaire ‐ IAQ (<a href="./references#CD006569-bbs2-0329" title="TandonR , DevellisRF , HanJ , LiH , FrangouS , DursunS , et al. Validation of the investigator's assessment questionnaire, a new clinical tool for relative assessment of response to antipsychotics in patients with schizophrenia and schizoaffective disorder. Psychiatry Research2005;136(2‐3):211‐21. [PUBMED: 16115690] ">Tandon 2005</a>)<br/> The IAQ is a quantifiable clinical tool that can provide detailed information regarding common safety, efficacy and tolerability concerns that patients experience while taking antipsychotics. It has been shown to highly correlate with time to study discontinuation which is a common measure of effectiveness. </p> <p>6.2.1.3 Arizona Sexual Experience Scale ‐ ASEX (<a href="./references#CD006569-bbs2-0318" title="McGahueyCA , GelenbergAJ , LaukesCA , MorenoFA , DelgadoPL , McKnightKM , et al. The Arizona Sexual Experience Scale (ASEX): reliability and validity. Journal of Sex &amp; Marital Therapy2000;26(1):25‐40. [PUBMED: 10693114] ">McGahuey 2000</a>)<br/> This is a brief scale for self‐rating of sexual function. It has five items and is rated in five steps. Possible scores range from five to 30 with higher scores indicating more sexual dysfunction. </p> </section> <section id="CD006569-sec-0121"> <p><b>6.2.2 Mental state scales</b></p> <p>6.2.2.1 Positive and Negative Syndrome Scale ‐ PANSS (<a href="./references#CD006569-bbs2-0307" title="KaySR , OplerLA , FiszbeinA . Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda (NY): Multi‐Health Systems, 1986. ">Kay 1986</a>)<br/> This schizophrenia scale has 30 items, each of which can be defined on a seven‐point scoring system varying from one ‐ absent to seven ‐ extreme. It can be divided into three sub scale for measuring the severity of general psychopathology, positive symptoms (PANSS‐P), and negative symptoms (PANSS‐N). A low score indicates lesser severity. </p> <p>6.2.2.2 Positive and Negative Syndrome Scale‐Excited Component ‐ PANSS‐EC (<a href="./references#CD006569-bbs2-0284" title="ChaichanW . Evaluation of the use of the positive and negative syndrome scale‐excited component as a criterion for administration of p. r. n. medication. Journal of Psychiatric Practice2008;14(2):105‐13. [PUBMED: 18360196] ">Chaichan 2008</a>)<br/> The PANSS‐EC scale is derived as a sub scale of PANSS and is a simple scale used to measure the degree of agitation. The scale consists of five items (poor impulse control, tension, hostility, uncooperativeness, excitement) each being ranked from one to seven giving a potential maximum score of 35 points. </p> <p>6.2.2.3 Brief Psychiatric Rating Scale – BPRS (<a href="./references#CD006569-bbs2-0323" title="OverallJE , GorhamDR . The brief psychiatric rating scale. Psychological Reports1962;10:799‐812. ">Overall 1962</a>)<br/> This consists of 18 to 24 items (depending on the version) each rated on a scale from one (absent) to seven (extreme). </p> </section> <section id="CD006569-sec-0122"> <p><b>6.2.3 Adverse effects scales</b></p> <p>6.2.3.1 Abnormal Involuntary Movement Scale ‐ AIMS (<a href="./references#CD006569-bbs2-0297" title="GuyU . ECDEU assessment manual for psychopharmacology. National Institute of Mental Health, 1976. ">Guy 1976</a>)<br/> This scale has been used to assess tardive dyskinesia, a long‐term, drug‐induced movement disorder and short‐term movement disorders such as tremor. </p> <p>6.2.3.2 Simpson Angus Scale ‐ SAS (<a href="./references#CD006569-bbs2-0328" title="SimpsonEN , AngusJWF . A rating scale for extrapyramidal adverse effects. Acta Psychiatrica Scandinavica Supplementum1970;212:11‐9. ">Simpson 1970</a>)<br/> This 10‐item scale (with a scoring system of zero to four on each item) measures drug‐induced parkinsonism, a short‐term drug‐induced movement disorder. A low score indicates low levels of parkinsonism. </p> <p>6.2.3.3 Barnes Akathisia Scale ‐ BAS (<a href="./references#CD006569-bbs2-0277" title="BarnesTR . A rating scale for drug‐induced akathisia. British Journal of Psychiatry1989;154:672‐6. ">Barnes 1989</a>)<br/> The scale comprises items rating the observable, restless movements that characterise akathisia, a subjective awareness of restlessness, and any distress associated with the condition. These items are rated from zero (normal) to three (severe). In addition, there is an item for rating global severity (from zero (absent) to five (severe)). A low score indicates low levels of akathisia. </p> </section> <section id="CD006569-sec-0123"> <p><b>6.2.4 Quality of Life</b></p> <p>6.2.4.1 Euro‐QoL‐5D ‐ EQ‐5D (<a href="./references#CD006569-bbs2-0303" title="JelsmaJ , MhundwaK , DeWeerdtW , DeCockP , ChimeraJ , ChivauraV . The reliability of the Shona version of the EQ‐5D. Central African Journal of Medicine2001;47(1):8‐13. [PUBMED: 11961858] ">Jelsma 2001</a>)<br/> The EuroQoL‐5D is a generic preference based measure of health‐related quality of life. It has five domains which are mobility, self‐care, usual activities, pain/ discomfort and anxiety/ depression, each having three short questions. The EQ‐5D Utility score assesses all five items on a scale of zero to one, where zero represents worst possible health and one represents perfect health. The EQ‐5D Health Dimension Scale assesses each item on three possible scores where one is the best and three the worst score. </p> <p>6.2.4.2 Quality of Life Scale – QLS (<a href="./references#CD006569-bbs2-0298" title="HeinrichsDW , HanlonTE , CarpenterWTJr . The quality of life scale: An instrument for rating the schizophrenic deficit syndrome. Schizophrenia Bulletin1984;10(3):388‐98. [PUBMED: 6474101] ">Heinrichs 1984</a>)<br/> Quality of Life Scale (QLS), a 21‐item scale divided into four domains including Interpersonal relations, Instrumental role, Intrapsychic foundations and common objects/activities scored on a seven‐point scale with lowest score indicating severe dysfunction. </p> <p>6.2.4.3 Impact of Wieght on Quality of Life ‐ IwQOL‐Lite (<a href="./references#CD006569-bbs2-0308" title="KolotkinRL , CrosbyRD . Psychometric evaluation of the impact of weight on quality of life‐lite questionnaire (IWQOL‐lite) in a community sample. Quality of Life Research2002;11(2):157‐71. [PUBMED: 12018739] ">Kolotkin 2002</a>)<br/> This is a survey instrument that is used to quantitatively assess an individual's perception of how their weight affects their day‐to‐day life. This instrument is especially valuable to obesity researchers, clinicians, psychologists, medical device and/or pharmaceutical companies seeking to validate the effectiveness of their treatments for obesity using metrics that go beyond the physical measurements of weight loss. </p> <p>6.2.4.4 World Health Organization Quality of Life Scale (WHOQoL‐Bref, <a href="./references#CD006569-bbs2-0322" title="O'CarrollRE , SmithK , CoustonM , CossarJA , HayesPC . A comparison of the WHOQOL‐100 and the WHOQOL‐BREF in detecting change in quality of life following liver transplantation. Quality of Life Research2000;9:121‐4. ">O'Carroll 2000</a>) </p> <p>The WHOQoL‐Bref is a 26‐item self‐report comprising satisfaction with health, psychological functioning, social relationships and environmental opportunities. Each item is scored on a five‐point scale from one (poor) to five (worse). The Chinese version of the WHOQoL scale, the generic quality of life inventory (GQOLI‐74), was also used in included Chinese studies. </p> </section> </section> <section id="CD006569-sec-0124"> <h6 class="title">6.3 Adverse effects</h6> <p>Adverse effects were mainly recorded in open interviews. In addition, continuous data were provided for weight, QTc time and cholesterol levels. </p> </section> <section id="CD006569-sec-0125"> <h6 class="title">6.4 Missing outcomes</h6> <p>No information was provided on the number of people hospitalised or global functioning. This can be an important and useful measure of the efficacy of medications being used. Also, not one study reported on functional outcomes, such as living skills, ability to live independently or employment. These trials clearly are more explanatory than pragmatic, focusing on whether in ideal circumstances aripiprazole has an effect rather than whether it would be useful in everyday routine care (<a href="./references#CD006569-bbs2-0331" title="ThorpeKE , ZwarensteinM , OxmanAD , TreweekS , FurbergCD , AltmanDG , et al. A pragmatic‐explanatory continuum indicator summary (PRECIS): a tool to help trial designers. Journal of Clinical Epidemiology2009;62(5):464‐75. [PUBMED: 19348971] ">Thorpe 2009</a>). </p> </section> </section> </section> <section id="CD006569-sec-0126"> <h4 class="title">Excluded studies</h4> <p>There are a total of 79 excluded studies in this 2012 update. The most common reason for exclusion was because of lack of randomisation (see <a href="./references#CD006569-sec-0494" title="">Characteristics of excluded studies</a>). </p> <section id="CD006569-sec-0127"> <h5 class="title">Awaiting classification</h5> <p>Four studies are awaiting assessment (<a href="./references#CD006569-bbs2-0254" title="WangH , WangY , LuL . A comparative study between aripiprazole and risperidone in the treatment of chronic schizophrenia [阿立哌唑与利培酮治疗慢性精神分裂症的对照研究]. Chinese Journal of Health Psychology [中国健康心理学杂志]2006;14(6):650‐1. ">Wang 2006f</a>; <a href="./references#CD006569-bbs2-0255" title="ZhaoL , WangM , WangB . A controlled study of aripiprazole versus quetiapine in the treatment of first‐episode schizophrenia [阿立哌唑与奎的平治疗首发精神分裂症对照研究]. Chinese Journal of Health Psychology [中国健康心理学杂志]2006;14(6):663‐4. ">Zhao 2006a</a>; <a href="./references#CD006569-bbs2-0256" title="郑孝荣 . Aripiprazole in the treatment of schizophrenia, efficacy and safety analysis [阿立哌唑治疗精神分裂症的疗效与安全性分析]. Modern Practical Medicine2008;20(6):457‐8. ">Zheng XR 2008</a>; <a href="./references#CD006569-bbs2-0257" title="陶建青 , 梁佳 , 曾强 , 康红 . A controlled study on compliance of schizophrenia treated with aripiprazole and risperidone. Proceedings of the 8th National Academic Congress of CSP with the Regional Meeting of the WPA; 2007 Sep 20‐23; Shanghai. 2007:334. ">陶建青, 2007</a>). Three of these were because of inconsistent reporting of denominators. Since we were unable to get clarification from the authors, we decided to leave these trials in <a href="./references#CD006569-bbs1-0003" title="">Studies awaiting classification</a> until further information becomes available. Please refer to <a href="./references#CD006569-sec-0495" title="">Characteristics of studies awaiting classification</a> for further details. </p> </section> <section id="CD006569-sec-0128"> <h5 class="title">Ongoing studies</h5> <p>There are 16 studies in this category (see <a href="./references#CD006569-sec-0496" title="">Characteristics of ongoing studies</a>). There appeared to be much ongoing research activity in 2005 but completed studies have not yet been identified. We have contacted authors for current information but have received no updates. </p> </section> </section> </section> <section id="CD006569-sec-0129"> <h3 class="title">Risk of bias in included studies</h3> <p>For details please refer to the 'Risk of bias' table for each study and <a href="#CD006569-fig-0004">Figure 4</a> and <a href="#CD006569-fig-0005">Figure 5</a> for the graphic overview. </p> <div class="figure" id="CD006569-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD006569-fig-0004" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD006569-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD006569-fig-0005" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD006569-sec-0130"> <h4 class="title">Allocation</h4> <p>The vast majority of included studies were rated as an 'unclear' risk of bias. Eighteen trials were rated as a 'low' risk of bias and described randomisation methods in some detail (<a href="#CD006569-fig-0005">Figure 5</a>). Three of these used computer‐generated voice recognition systems. It remained unclear whether there was a risk of bias. Only one study described the method of allocation concealment ‐ by means of a sealed envelope (<a href="./references#CD006569-bbs2-0118" title="WeiS‐Z , TangQ‐S , XuZ‐N , RuanX‐J , LuB . A randomized, double blind, double dummy parallel controlled study in the female first‐episode schizophrenia treated with aripiprazole and quetiapine [阿立哌唑与奎硫平治疗女性首发精神分裂症的随机、双盲、双模拟平行对照研究]. Chinese Journal of Nervous and Mental Diseases2006;32(6):511‐7. 韩树华 . Aripiprazole and quetiapine in the treatment of schizophrenia control study of women] Google Translate [阿立哌唑与奎硫平治疗女性首发精神分裂症的对照研究]. Medical Journal of Chinese People's Health [中国民康医学]2010; Vol. 22, issue 5:511‐6. ">Wei 2006</a>). </p> </section> <section id="CD006569-sec-0131"> <h4 class="title">Blinding</h4> <p>Only 11 included studies were described as double blind (<a href="./references#CD006569-bbs2-0008" title="陈飞 , 王红艳 , 李德咏 , 周保卫 , 程夫英 . Aripiprazole, quetiapine treatment of female episode schizophrenia [阿立哌唑、喹硫平治疗女性首发精神分裂症对照研究]. Shandong Archives of Psychiatry [山东精神医学]2007; Vol. 20, issue 6:381‐3. ">Chen 2007a</a>; <a href="./references#CD006569-bbs2-0021" title="DuB , ZhaoS‐M , TianG‐Q . Study on effects of aripiprazole on serum prolactin level and body weight [阿立哌唑对精神分裂症患者血清催乳素及体重的影响]. Chinese General Practice [中国全科医学]2006;9(13):1065‐6. ">Du 2006</a>; <a href="./references#CD006569-bbs2-0024" title="FengY , YanX , ZhaoZ . The clinical study on aripiprazole and risperidone in trea tment of first‐onset schizophrenia [阿立哌唑与利培酮治疗首发精神分裂症患者疗效的对照研究]. Chinese Journal of Health Psychology [中国健康心理学杂志]2006;14(4):418‐9. ">Feng 2006</a>; <a href="./references#CD006569-bbs2-0025" title="BMS . A multicenter, double‐blind, randomized, comparative study of aripiprazole and olanzapine in the treatment of patients with acute schizophrenia. Clinical Study Report CN1380032005. ">Fleischhacker 2008</a>; <a href="./references#CD006569-bbs2-0029" title="GuoX‐F , ChenJ‐D , ZhaoJ‐P . A randomized and double‐blind controlled clinical trial of aripiprazole in the treatment of schizophrenia [阿立哌唑治療精神分裂癥的隨機雙盲對照試驗]. Journal of Clinical Research2006;23(5):716‐8. ">Guo 2006</a>; <a href="./references#CD006569-bbs2-0038" title="Ascher‐SvanumH , StenslandMD , PengX , FariesDE , StaufferVL , OsuntokunOO , et al. Cost‐effectiveness of olanzapine vs. aripiprazole in the treatment of schizophrenia. Current Medical Research and Opinion2011;27(1):115‐22. KaneJM , OsuntokunO , KryzhanovskayaLA , XuW , StaufferV , WatsonSB . A 28‐week, randomized, double‐blind study of olanzapine versus aripiprazole in the treatment of schizophrenia. Biological Psychiatry2008;63(7 Suppl):289S. KaneJM , OsuntokunO , KryzhanovskayaLA , XuW , StaufferV , WatsonSB . A 28‐week, randomized, double‐blind study of olanzapine versus aripiprazole in the treatment of schizophrenia. Proceedings of the 63rd Annual Convention of the Society of Biological Psychiatry. 2008. KaneJM , OsuntokunO , KryzhanovskayaLA , XuW , StaufferVL , WatsonSB , et al. A 28‐week, randomized, double‐blind study of olanzapine versus aripiprazole in the treatment of schizophrenia. Journal of Clinical Psychiatry2009;70(4):572‐81. [MEDLINE: 19323965] OsuntokunO , KaneJM , KryzhanovskayaLA , XuW , StaufferV , WatsonSB . A 28‐week, randomized, double‐blind study of olanzapine versus aripiprazole in the treatment of schizophrenia. International Journal of Neuropsychopharmacology2008;11(Suppl 1):153. WatsonSB , KaneJM , OsuntokunO , KryzhanovskayaLA , XuW , StaufferV . A 28‐week, randomized, double‐blind study of olanzapine versus aripiprazole in the treatment of schizophrenia. Proceedings of the 161st Annual Meeting of the American Psychiatric Association; 2008 May 3‐8; Washington DC, USA. 2008. ">Kane 2009</a>; <a href="./references#CD006569-bbs2-0041" title="EliLilly , Company . Olanzapine versus aripiprazole in the treatment of acutely ill patients with schizophrenia. Eli Lilly and Company Clinical Trial Registry2004. KinonBJ , StaufferVL , Kollack‐WalkerS , ChenL , SniadeckiJ . Olanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophrenia. Journal of Clinical Psychopharmacology2008;28(6):601‐7. [MEDLINE: 19011427] StaufferV , KinonB , Kollack‐WalkerS , ChenL , SniadeckiJ . Olanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophrenia. Proceedings of the 161st Annual Meeting of the American Psychiatric Association; 2008 May 3‐8; Washington DC, USA. 2008. ">Kinon 2004</a>; <a href="./references#CD006569-bbs2-0076" title="Abou GharbiaN , McQuadeR , JodyD , KujawaM , CarsonW , IwamotoT , et al. Comparative study of the long‐term effects of aripiprazole and olanzapine treatment on body weight. Proceedings of the Thematic Conference of the World Psychiatric Association on &quot;Treatments in Psychiatry: An Update&quot;; 2004 Nov 10‐13; Florence, Italy. 2004. BlondeL , RayS , Corey‐LislePK , CisloPR , L'ItalienG . The risk of new‐onset type 2 diabetes and coronary heart disease in chronic schizophrenic patients treated with aripiprazole and olanzapine. Journal of the European College of Neuropsychopharmacology2004;14(Suppl 3):S275. JodyD , McQuadeRD , KujawaM , CarsonW , IwamotoT , ArchibaldD , et al. Long‐term weight effects of aripiprazole versus olanzapine. Schizophrenia Research2004;67(1):187. McQuadeRD , JodyD , KujawaMJ , CarsonWH , IwamotoT , ArchibaldDG , et al. Long‐term weight effects of aripiprazole versus olanzapine. Proceedings of the 156th Annual Meeting of the American Psychiatric Association; 2003 May 17‐22; San Francisco, California, USA. 2003. McQuadeRD , KujawaM , SahaAR , IngenitoGG , AliMW , LuoX , et al. Aripiprazole for long‐term maintenance treatment of schizophrenia. Schizophrenia Research2003;60(1):295. McQuadeRD , StockE , MarcusR , JodyD , GharbiaNA , VanveggelS , et al. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double‐blind study. Journal of Clinical Psychiatry2004;65(Suppl 18):47‐56. [MEDLINE: 15600384] McQuadeRD , StockE , MarcusR , JodyD , GharbiaNA , VanveggelS , et al. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double‐blind study. Journal of Clinical Psychiatry2004;65(Suppl 18):47‐56. MeyerJM , RosenblattLC , KimE , BakerRA , WhiteheadR . The moderating impact of ethnicity on metabolic outcomes during treatment with olanzapine and aripiprazole in patients with schizophrenia. Journal of Clinical Psychiatry2009;70(3):318‐25. [MEDLINE: 19192469] ">McQuade 2004</a>; <a href="./references#CD006569-bbs2-0082" title="PotkinSG , KujawaM , CarsonWH , SahaAR , AliM , IngenitoG . Aripiprazole and risperidone versus placebo in schizophrenia and schizoaffective disorder. Schizophrenia Research2003;60:300. PotkinSG , SahaAR , KujawaMJ , CarsonWH , AliM , StockE , et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Archives of General Psychiatry2003;60(7):681‐90. ">Potkin 2003</a>; <a href="./references#CD006569-bbs2-0130" title="徐筠 , 李朝 , 王慧芳 , 李华芳 . Aripiprazole and risperidone in the treatment of schizophrenia randomized double‐blind controlled study] Google Translate [阿立哌唑与利培酮治疗精神分裂症随机双盲对照研究 []. Linchuang Jingshen Yixue Zazhi [临床精神医学杂志]2010; Vol. 20, issue 1:35‐7. ">Xu 2010</a>; <a href="./references#CD006569-bbs2-0173" title="Pfizer . A study comparing the efficacy and safety of ziprasidone and aripiprazole for the treatment of schizophrenia or schizoaffective disorder in hospitalized patients. http://www.clinicaltrials.gov2008. ZimbroffD , WarringtonL , LoebelA , YangR , SiuC . Comparison of ziprasidone and aripiprazole in acutely ill patients with schizophrenia or schizoaffective disorder: A randomized, double‐blind, 4‐week study. International Clinical Psychopharmacology2007;22(6):363‐70. [MEDLINE: 17917555] ">Zimbroff 2007</a>). <a href="./references#CD006569-bbs2-0005" title="ChanHY , LinWW , LinSK , HwangTJ , SuTP , ChiangSC , et al. Efficacy and safety of aripiprazole in the acute treatment of schizophrenia in Chinese patients with risperidone as an active control: A randomized trial. Journal of Clinical Psychiatry2007;68(1):29‐36. HwangTJ , ChanHY , LinWW , LinSK , HwuHG , ChengMY , et al. Aripiprazole versus risperidone in the treatment of acutely relapsed patients with schizophrenia in Taiwan: a randomized controlled trial. Journal of the European College of Neuropsychopharmacology2005;14(Suppl 3):S497. ">Chan 2007</a> and <a href="./references#CD006569-bbs2-0082" title="PotkinSG , KujawaM , CarsonWH , SahaAR , AliM , IngenitoG . Aripiprazole and risperidone versus placebo in schizophrenia and schizoaffective disorder. Schizophrenia Research2003;60:300. PotkinSG , SahaAR , KujawaMJ , CarsonWH , AliM , StockE , et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Archives of General Psychiatry2003;60(7):681‐90. ">Potkin 2003</a> described using identical capsules for blinding. <a href="./references#CD006569-bbs2-0173" title="Pfizer . A study comparing the efficacy and safety of ziprasidone and aripiprazole for the treatment of schizophrenia or schizoaffective disorder in hospitalized patients. http://www.clinicaltrials.gov2008. ZimbroffD , WarringtonL , LoebelA , YangR , SiuC . Comparison of ziprasidone and aripiprazole in acutely ill patients with schizophrenia or schizoaffective disorder: A randomized, double‐blind, 4‐week study. International Clinical Psychopharmacology2007;22(6):363‐70. [MEDLINE: 17917555] ">Zimbroff 2007</a> used double dummy administration of medication. The other studies did not provide any information on the blinding procedure. No study examined whether blinding was effective. Six studies were open label (<a href="./references#CD006569-bbs2-0010" title="陈红英 , 张郦 , 付迎春 , 季海峰 , 费玥 , 黄雅南 . Aripiprazole and quetiapine in the treatment of schizophrenia] Google Translate [阿立哌唑和喹硫平治疗精神分裂症的对照研究]. Shandong Archives of Psychiatry [山东精神医学]2009;22(1):53‐4. ">Chen 2009</a>; <a href="./references#CD006569-bbs2-0039" title="KernRS , GreenMF , CornblattBA , OwenJR , McQuadeRD , CarsonWH , et al. The neurocognitive effects of aripiprazole: an open‐label comparison with olanzapine. Psychopharmacology2006;187(3):312‐20. ">Kern 2006</a>; <a href="./references#CD006569-bbs2-0040" title="BeuzenJN , L'ItalienG , HanssensL , MarcusRN , McQuadeRD , CarsonWH . Changes in prolactin levels and arizona sexual experience scale (ASEX) scores among patients switched from risperidone to aripiprazole in the schizophrenia trial of aripiprazole (STAR) study. Schizophrenia Bulletin2007;33(2):421‐2. BlondeL , KanHJ , GuttermanEM , L'ItalienGJ , KimMS , HanssensL , et al. Predicted risk of diabetes and coronary heart disease in patients with schizophrenia: aripiprazole versus standard of care. Journal of Clinical Psychiatry2008;69(5):741‐8. [MEDLINE: 18435564] HanssensL , L'ItalienG , MarcusRN , McQuadeRD , CarsonWH , BeuzenJN . Reasons for switching from previous therapy and preference of medication in the large, randomized, naturalistic schizophrenia trial of aripiprazole (STAR). Schizophrenia Bulletin2007;33(2):432. HanssensL , L’ ItalienG , McQuadeR , IwamotoT , PansM . Evaluation of quality of life in community‐treated schizophrenic patients: a naturalistic, open‐label study comparing aripiprazole to standard‐of‐care (Schizophrenia Trial of aripiprazole: STAR study). European Psychiatry2006;21(Suppl 1):S99. KerwinR , MilletB , HermanE , BankiCM , LublinH , PansM , et al. A multi centre, randomized, naturalistic, open‐label study between aripiprazole and standard of care in the management of community‐treated schizophrenic patients Schizophrenia Trial of aripiprazole: (STAR) study. European Psychiatry2007;22(7):433‐43. [MEDLINE: 17555947] KerwinR , MilletB , HermanE , BankiCM , LublinH , PansM , et al. A multi centre, randomized, naturalistic, open‐label study between aripiprazole and standard of care in the management of community‐treated schizophrenic patients. Schizophrenic Trial of aripiprazole: (STAR) study. Wiadomosci Psychiatryczne2008;11(2):105‐19. KingD , KnappM , ThomasP , RazzoukD , LozeJY , KanHJ , et al. Cost‐effectiveness analysis of aripiprazole vs standard‐of‐care in the management of community‐treated patients with schizophrenia: Star study. Current Medical Research and Opinion2011;27(2):365‐74. KolotkinRL , Corey‐LislePK , CrosbyRD , KanHJ , McQuadeRD . Changes in weight and weight‐related quality of life in a multi centre, randomized trial of aripiprazole versus standard of care. European Psychiatry2008;23(8):561‐6. [MEDLINE: 18374544] L'ItalienG , HanssensL , KanHJ , BakerRA , MarcusRN , McQuadeRD , et al. Metabolic effects of aripiprazole versus olanzapine, quetiapine, or risperidone (the STAR trial). Schizophrenia Bulletin2007;33(2):439. L'ItalienGJ , BlondeL , HanssensL , McQuadeR . Prevalence of diabetes/cardiovascular risk factors among schizophrenia patients treated with atypical antipsychotics in a multicenter, randomized, naturalistic, open‐label study (Schizophrenia Trial of aripiprazole: STAR study). Diabetes2006;55(Suppl 1):A538. L'ltalienGJ , HanssensL , MarcusRN , McQuadeRD . Evidence of antipsychotic treatment selection based on metabolic risk factors among community‐based schizophrenia patients (The STAR Trial). Proceedings of the 160th Annual Meeting of the American Psychiatric Association; 2007 May 19‐24; San Diego, CA2007. MilletB . A multicenter, randomized, naturalistic, open‐label study between aripiprazole and standard of care in the management of community‐treated schizophrenic patients (Schizophrenia Trial of aripiprazole ‐ STAR). http://www.clinicaltrials.gov2005. TaylorD , HanssensL , LozeJ‐Y , PansM , L'ItalienG , MarcusRN . Preference of medicine and patient‐reported quality of life in community‐treated schizophrenic patients receiving aripiprazole vs standard of care: results from the STAR study. European Psychiatry2008;23(5):336‐43. ">Kerwin 2007</a>; <a href="./references#CD006569-bbs2-0097" title="RieraL , HuR , StockE , NyilasM , TorbeynsA , BorianF , et al. Broad effectiveness trial with aripiprazole. Schizophrenia Research2004;67(1):157. TandonR , MarcusRN , StockEG , RieraLC , KosticD , PansM , et al. A prospective, multicenter, randomized, parallel‐group, open‐label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad Effectiveness Trial With aripiprazole (BETA). Schizophrenia Research2006;84(1):77‐89. ">Tandon 2006</a>; <a href="./references#CD006569-bbs2-0123" title="SanchezR , KosticD , StockE , TorbeynsAF , KerselaersW , NyilasM , et al. Aripiprazole vs olanzapine in patients with acutely relapsing or chronic, stable schizophrenia: A 52‐week open‐label extension study. Proceedings of the 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4‐10; Davos, Switzerland. 2006. WlodzimierzCK , MarcusRN , TorbeynsA , NyilasM , McQuadeRD . Effectiveness of long‐term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52‐week, open‐label comparison with olanzapine. Psychopharmacology2006;189(2):259‐66. ">Wlodzmierz 2006</a>; <a href="./references#CD006569-bbs2-0124" title="BeuzenJ‐N , PansM , ModellS , HagensP , McQuadeR , IwamatoT , et al. Broad effectiveness trial with aripiprazole in Europe Eu‐Beta. Proceedings of the 13th Congress of the Association of European Psychiatrists; 2005 Apr 2‐6; Munich, Germany. 2005. BeuzenJ‐N , PansM , ModellS , HagensP , McQuadeR , IwamotoT , et al. Naturalistic study of aripiprazole treatment. Proceedings of the XIII World Congress of Psychiatry; 2005 Sep 10‐15; Cairo, Egypt. 2005. BeuzenJ‐N , SchirrK , PansM , HagensP , KosticD , CarsonW , et al. Effectiveness of aripiprazole in a naturalistic setting: a European multicenter study. Proceedings of the 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4‐10; Davos, Switzerland. 2006. WolfJ , JanssenF , LublinH , SalokangasRKR , AllainH , SmeraldiE , et al. A prospective, multi centre, open‐label study of aripiprazole in the management of patients with schizophrenia in psychiatric practice in Europe: Broad Effectiveness Trial with aripiprazole in Europe (EU‐BETA). Current Medical Research and Opinion2007;23(10):2313‐23. [MEDLINE: 17706003] ">Wolf 2007</a>), and two described single‐blinding (<a href="./references#CD006569-bbs2-0159" title="张东卫 , 甘景梨 , 高存友 , 段惠峰 . Aripiprazole and risperidone on glucose and lipid] Google Translate [阿立哌唑与利培酮对血糖、血脂的影响]. Linchuang Jingshen Yixue Zazhi [临床精神医学杂志]2009;19(5):343‐5. ">Zhang 2009a</a>; <a href="./references#CD006569-bbs2-0170" title="ZhuP‐J , ChengZ‐E , ZhangJ , ZhuP‐L , ZhanX‐M . Clinical study of therapeutic effects of aripiprazole in treatment of patients with schizophrenia. Chinese Journal of Clinical Pharmacology and Therapeutics2005;10(10):1194‐7. ZhuP‐L , ZhuP‐J , ChenZ‐E , ZhangJ , ZhanX‐M , LiQ‐Z . Treatment of 40 cases of schizophrenia with aripiprazole [阿立哌唑治疗精神分裂症40例]. Herald of Medicine [医药导报] [醫藥導報]2006;25(6):536‐8. ">Zhu 2005</a>). We found that the adverse effect profiles of examined compounds are quite different which may have made blinding difficult. We therefore conclude that the risk of bias for objective outcomes (e.g. death or laboratory values) was low but there was considerable risk of bias for subjective outcomes. </p> </section> <section id="CD006569-sec-0132"> <h4 class="title">Incomplete outcome data</h4> <p>In two studies the rates of participants leaving the study early were higher than 30% (<a href="./references#CD006569-bbs2-0076" title="Abou GharbiaN , McQuadeR , JodyD , KujawaM , CarsonW , IwamotoT , et al. Comparative study of the long‐term effects of aripiprazole and olanzapine treatment on body weight. Proceedings of the Thematic Conference of the World Psychiatric Association on &quot;Treatments in Psychiatry: An Update&quot;; 2004 Nov 10‐13; Florence, Italy. 2004. BlondeL , RayS , Corey‐LislePK , CisloPR , L'ItalienG . The risk of new‐onset type 2 diabetes and coronary heart disease in chronic schizophrenic patients treated with aripiprazole and olanzapine. Journal of the European College of Neuropsychopharmacology2004;14(Suppl 3):S275. JodyD , McQuadeRD , KujawaM , CarsonW , IwamotoT , ArchibaldD , et al. Long‐term weight effects of aripiprazole versus olanzapine. Schizophrenia Research2004;67(1):187. McQuadeRD , JodyD , KujawaMJ , CarsonWH , IwamotoT , ArchibaldDG , et al. Long‐term weight effects of aripiprazole versus olanzapine. Proceedings of the 156th Annual Meeting of the American Psychiatric Association; 2003 May 17‐22; San Francisco, California, USA. 2003. McQuadeRD , KujawaM , SahaAR , IngenitoGG , AliMW , LuoX , et al. Aripiprazole for long‐term maintenance treatment of schizophrenia. Schizophrenia Research2003;60(1):295. McQuadeRD , StockE , MarcusR , JodyD , GharbiaNA , VanveggelS , et al. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double‐blind study. Journal of Clinical Psychiatry2004;65(Suppl 18):47‐56. [MEDLINE: 15600384] McQuadeRD , StockE , MarcusR , JodyD , GharbiaNA , VanveggelS , et al. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double‐blind study. Journal of Clinical Psychiatry2004;65(Suppl 18):47‐56. MeyerJM , RosenblattLC , KimE , BakerRA , WhiteheadR . The moderating impact of ethnicity on metabolic outcomes during treatment with olanzapine and aripiprazole in patients with schizophrenia. Journal of Clinical Psychiatry2009;70(3):318‐25. [MEDLINE: 19192469] ">McQuade 2004</a>; <a href="./references#CD006569-bbs2-0082" title="PotkinSG , KujawaM , CarsonWH , SahaAR , AliM , IngenitoG . Aripiprazole and risperidone versus placebo in schizophrenia and schizoaffective disorder. Schizophrenia Research2003;60:300. PotkinSG , SahaAR , KujawaMJ , CarsonWH , AliM , StockE , et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Archives of General Psychiatry2003;60(7):681‐90. ">Potkin 2003</a>); in <a href="./references#CD006569-bbs2-0076" title="Abou GharbiaN , McQuadeR , JodyD , KujawaM , CarsonW , IwamotoT , et al. Comparative study of the long‐term effects of aripiprazole and olanzapine treatment on body weight. Proceedings of the Thematic Conference of the World Psychiatric Association on &quot;Treatments in Psychiatry: An Update&quot;; 2004 Nov 10‐13; Florence, Italy. 2004. BlondeL , RayS , Corey‐LislePK , CisloPR , L'ItalienG . The risk of new‐onset type 2 diabetes and coronary heart disease in chronic schizophrenic patients treated with aripiprazole and olanzapine. Journal of the European College of Neuropsychopharmacology2004;14(Suppl 3):S275. JodyD , McQuadeRD , KujawaM , CarsonW , IwamotoT , ArchibaldD , et al. Long‐term weight effects of aripiprazole versus olanzapine. Schizophrenia Research2004;67(1):187. McQuadeRD , JodyD , KujawaMJ , CarsonWH , IwamotoT , ArchibaldDG , et al. Long‐term weight effects of aripiprazole versus olanzapine. Proceedings of the 156th Annual Meeting of the American Psychiatric Association; 2003 May 17‐22; San Francisco, California, USA. 2003. McQuadeRD , KujawaM , SahaAR , IngenitoGG , AliMW , LuoX , et al. Aripiprazole for long‐term maintenance treatment of schizophrenia. Schizophrenia Research2003;60(1):295. McQuadeRD , StockE , MarcusR , JodyD , GharbiaNA , VanveggelS , et al. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double‐blind study. Journal of Clinical Psychiatry2004;65(Suppl 18):47‐56. [MEDLINE: 15600384] McQuadeRD , StockE , MarcusR , JodyD , GharbiaNA , VanveggelS , et al. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double‐blind study. Journal of Clinical Psychiatry2004;65(Suppl 18):47‐56. MeyerJM , RosenblattLC , KimE , BakerRA , WhiteheadR . The moderating impact of ethnicity on metabolic outcomes during treatment with olanzapine and aripiprazole in patients with schizophrenia. Journal of Clinical Psychiatry2009;70(3):318‐25. [MEDLINE: 19192469] ">McQuade 2004</a> it was as high as 72%. Overall attrition was about 35% to 40%. Last observation carried forward (LOCF) method to account for participants leaving the study early was used in studies that made clear attrition numbers, which we now know to be a far from ideal assumption (<a href="./references#CD006569-bbs2-0311" title="LeuchtS , EngelRR , BaumlJ , DavisJM . Is the superior efficacy of new generation antipsychotics an artifact of LOCF?. Schizophrenia Bulletin2007;33(1):183‐91. [PUBMED: 16905632] ">Leucht 2007</a>). Only <a href="./references#CD006569-bbs2-0076" title="Abou GharbiaN , McQuadeR , JodyD , KujawaM , CarsonW , IwamotoT , et al. Comparative study of the long‐term effects of aripiprazole and olanzapine treatment on body weight. Proceedings of the Thematic Conference of the World Psychiatric Association on &quot;Treatments in Psychiatry: An Update&quot;; 2004 Nov 10‐13; Florence, Italy. 2004. BlondeL , RayS , Corey‐LislePK , CisloPR , L'ItalienG . The risk of new‐onset type 2 diabetes and coronary heart disease in chronic schizophrenic patients treated with aripiprazole and olanzapine. Journal of the European College of Neuropsychopharmacology2004;14(Suppl 3):S275. JodyD , McQuadeRD , KujawaM , CarsonW , IwamotoT , ArchibaldD , et al. Long‐term weight effects of aripiprazole versus olanzapine. Schizophrenia Research2004;67(1):187. McQuadeRD , JodyD , KujawaMJ , CarsonWH , IwamotoT , ArchibaldDG , et al. Long‐term weight effects of aripiprazole versus olanzapine. Proceedings of the 156th Annual Meeting of the American Psychiatric Association; 2003 May 17‐22; San Francisco, California, USA. 2003. McQuadeRD , KujawaM , SahaAR , IngenitoGG , AliMW , LuoX , et al. Aripiprazole for long‐term maintenance treatment of schizophrenia. Schizophrenia Research2003;60(1):295. McQuadeRD , StockE , MarcusR , JodyD , GharbiaNA , VanveggelS , et al. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double‐blind study. Journal of Clinical Psychiatry2004;65(Suppl 18):47‐56. [MEDLINE: 15600384] McQuadeRD , StockE , MarcusR , JodyD , GharbiaNA , VanveggelS , et al. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double‐blind study. Journal of Clinical Psychiatry2004;65(Suppl 18):47‐56. MeyerJM , RosenblattLC , KimE , BakerRA , WhiteheadR . The moderating impact of ethnicity on metabolic outcomes during treatment with olanzapine and aripiprazole in patients with schizophrenia. Journal of Clinical Psychiatry2009;70(3):318‐25. [MEDLINE: 19192469] ">McQuade 2004</a>, however, analysed the study completers in a secondary analysis assuming that a participant who left the study prematurely would not have had a change of condition if he/she had stayed in the study. This assumption can also be misleading. The majority of new data from Chinese studies states no incomplete data ‐ therefore, this domain is largely rated across studies as a 'low' risk of bias. Twenty‐eight studies did not mention or make explicit any participants lost through attrition, and so were rated as an 'unclear' risk of bias. </p> </section> <section id="CD006569-sec-0133"> <h4 class="title">Selective reporting</h4> <p>In terms of selective reporting there was a high risk of bias in the majority of included studies. Overall, only 13 studies rated as a 'low' risk of bias, and only one rated as 'unclear', meaning that the remainder of the 174 included studies (160) were rated at a 'high' risk of bias with not all recorded outcomes reported. Six studies reported only adverse events that occurred in at least 5% to 10% of participants (<a href="./references#CD006569-bbs2-0005" title="ChanHY , LinWW , LinSK , HwangTJ , SuTP , ChiangSC , et al. Efficacy and safety of aripiprazole in the acute treatment of schizophrenia in Chinese patients with risperidone as an active control: A randomized trial. Journal of Clinical Psychiatry2007;68(1):29‐36. HwangTJ , ChanHY , LinWW , LinSK , HwuHG , ChengMY , et al. Aripiprazole versus risperidone in the treatment of acutely relapsed patients with schizophrenia in Taiwan: a randomized controlled trial. Journal of the European College of Neuropsychopharmacology2005;14(Suppl 3):S497. ">Chan 2007</a>; <a href="./references#CD006569-bbs2-0025" title="BMS . A multicenter, double‐blind, randomized, comparative study of aripiprazole and olanzapine in the treatment of patients with acute schizophrenia. Clinical Study Report CN1380032005. ">Fleischhacker 2008</a>; <a href="./references#CD006569-bbs2-0038" title="Ascher‐SvanumH , StenslandMD , PengX , FariesDE , StaufferVL , OsuntokunOO , et al. Cost‐effectiveness of olanzapine vs. aripiprazole in the treatment of schizophrenia. Current Medical Research and Opinion2011;27(1):115‐22. KaneJM , OsuntokunO , KryzhanovskayaLA , XuW , StaufferV , WatsonSB . A 28‐week, randomized, double‐blind study of olanzapine versus aripiprazole in the treatment of schizophrenia. Biological Psychiatry2008;63(7 Suppl):289S. KaneJM , OsuntokunO , KryzhanovskayaLA , XuW , StaufferV , WatsonSB . A 28‐week, randomized, double‐blind study of olanzapine versus aripiprazole in the treatment of schizophrenia. Proceedings of the 63rd Annual Convention of the Society of Biological Psychiatry. 2008. KaneJM , OsuntokunO , KryzhanovskayaLA , XuW , StaufferVL , WatsonSB , et al. A 28‐week, randomized, double‐blind study of olanzapine versus aripiprazole in the treatment of schizophrenia. Journal of Clinical Psychiatry2009;70(4):572‐81. [MEDLINE: 19323965] OsuntokunO , KaneJM , KryzhanovskayaLA , XuW , StaufferV , WatsonSB . A 28‐week, randomized, double‐blind study of olanzapine versus aripiprazole in the treatment of schizophrenia. International Journal of Neuropsychopharmacology2008;11(Suppl 1):153. WatsonSB , KaneJM , OsuntokunO , KryzhanovskayaLA , XuW , StaufferV . A 28‐week, randomized, double‐blind study of olanzapine versus aripiprazole in the treatment of schizophrenia. Proceedings of the 161st Annual Meeting of the American Psychiatric Association; 2008 May 3‐8; Washington DC, USA. 2008. ">Kane 2009</a>; <a href="./references#CD006569-bbs2-0082" title="PotkinSG , KujawaM , CarsonWH , SahaAR , AliM , IngenitoG . Aripiprazole and risperidone versus placebo in schizophrenia and schizoaffective disorder. Schizophrenia Research2003;60:300. PotkinSG , SahaAR , KujawaMJ , CarsonWH , AliM , StockE , et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Archives of General Psychiatry2003;60(7):681‐90. ">Potkin 2003</a>; <a href="./references#CD006569-bbs2-0173" title="Pfizer . A study comparing the efficacy and safety of ziprasidone and aripiprazole for the treatment of schizophrenia or schizoaffective disorder in hospitalized patients. http://www.clinicaltrials.gov2008. ZimbroffD , WarringtonL , LoebelA , YangR , SiuC . Comparison of ziprasidone and aripiprazole in acutely ill patients with schizophrenia or schizoaffective disorder: A randomized, double‐blind, 4‐week study. International Clinical Psychopharmacology2007;22(6):363‐70. [MEDLINE: 17917555] ">Zimbroff 2007</a>). By this procedure rare, but important adverse events, can be missed. <a href="./references#CD006569-bbs2-0041" title="EliLilly , Company . Olanzapine versus aripiprazole in the treatment of acutely ill patients with schizophrenia. Eli Lilly and Company Clinical Trial Registry2004. KinonBJ , StaufferVL , Kollack‐WalkerS , ChenL , SniadeckiJ . Olanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophrenia. Journal of Clinical Psychopharmacology2008;28(6):601‐7. [MEDLINE: 19011427] StaufferV , KinonB , Kollack‐WalkerS , ChenL , SniadeckiJ . Olanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophrenia. Proceedings of the 161st Annual Meeting of the American Psychiatric Association; 2008 May 3‐8; Washington DC, USA. 2008. ">Kinon 2004</a> reported adverse effects that occurred in at least 1% of patients. <a href="./references#CD006569-bbs2-0076" title="Abou GharbiaN , McQuadeR , JodyD , KujawaM , CarsonW , IwamotoT , et al. Comparative study of the long‐term effects of aripiprazole and olanzapine treatment on body weight. Proceedings of the Thematic Conference of the World Psychiatric Association on &quot;Treatments in Psychiatry: An Update&quot;; 2004 Nov 10‐13; Florence, Italy. 2004. BlondeL , RayS , Corey‐LislePK , CisloPR , L'ItalienG . The risk of new‐onset type 2 diabetes and coronary heart disease in chronic schizophrenic patients treated with aripiprazole and olanzapine. Journal of the European College of Neuropsychopharmacology2004;14(Suppl 3):S275. JodyD , McQuadeRD , KujawaM , CarsonW , IwamotoT , ArchibaldD , et al. Long‐term weight effects of aripiprazole versus olanzapine. Schizophrenia Research2004;67(1):187. McQuadeRD , JodyD , KujawaMJ , CarsonWH , IwamotoT , ArchibaldDG , et al. Long‐term weight effects of aripiprazole versus olanzapine. Proceedings of the 156th Annual Meeting of the American Psychiatric Association; 2003 May 17‐22; San Francisco, California, USA. 2003. McQuadeRD , KujawaM , SahaAR , IngenitoGG , AliMW , LuoX , et al. Aripiprazole for long‐term maintenance treatment of schizophrenia. Schizophrenia Research2003;60(1):295. McQuadeRD , StockE , MarcusR , JodyD , GharbiaNA , VanveggelS , et al. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double‐blind study. Journal of Clinical Psychiatry2004;65(Suppl 18):47‐56. [MEDLINE: 15600384] McQuadeRD , StockE , MarcusR , JodyD , GharbiaNA , VanveggelS , et al. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double‐blind study. Journal of Clinical Psychiatry2004;65(Suppl 18):47‐56. MeyerJM , RosenblattLC , KimE , BakerRA , WhiteheadR . The moderating impact of ethnicity on metabolic outcomes during treatment with olanzapine and aripiprazole in patients with schizophrenia. Journal of Clinical Psychiatry2009;70(3):318‐25. [MEDLINE: 19192469] ">McQuade 2004</a> did not report on the PANSS positive sub score despite having recorded it. See funnel plots for the primary outcome of no clinically significant response (<a href="#CD006569-fig-0006">Figure 6</a>; <a href="#CD006569-fig-0007">Figure 7</a>; <a href="#CD006569-fig-0008">Figure 8</a>; <a href="#CD006569-fig-0009">Figure 9</a>), where distrubution of studies is relatively symmetrical, except for comparison 5.1 (<a href="#CD006569-fig-0009">Figure 9</a>), perhaps owing to less included studies. </p> <div class="figure" id="CD006569-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 COMPARISON 1. ARIPIPRAZOLE versus CLOZAPINE, outcome: 1.1 Global state: 1. No clinically significant response (as defined by the original studies)." data-id="CD006569-fig-0006" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 COMPARISON 1. ARIPIPRAZOLE versus CLOZAPINE, outcome: 1.1 Global state: 1. No clinically significant response (as defined by the original studies). </p> </div> </div> </div> <div class="figure" id="CD006569-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 2 COMPARISON 2. ARIPIPRAZOLE versus QUETIAPINE, outcome: 2.1 Global state: 1.No clinically significant response (as defined by original studies)." data-id="CD006569-fig-0007" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-AFig-FIG07.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 2 COMPARISON 2. ARIPIPRAZOLE versus QUETIAPINE, outcome: 2.1 Global state: 1.No clinically significant response (as defined by original studies). </p> </div> </div> </div> <div class="figure" id="CD006569-fig-0008"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 8</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 3 COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE, outcome: 3.1 Global state: 1. No clinically significant response (as defined by the original studies)." data-id="CD006569-fig-0008" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-AFig-FIG08.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 3 COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE, outcome: 3.1 Global state: 1. No clinically significant response (as defined by the original studies). </p> </div> </div> </div> <div class="figure" id="CD006569-fig-0009"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 9</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 5 COMPARISON 5. ARIPIPRAZOLE versus OLANZAPINE, outcome: 5.1 Global state: 1.No clinically significant response (as defined by the original studies)." data-id="CD006569-fig-0009" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-AFig-FIG09.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 5 COMPARISON 5. ARIPIPRAZOLE versus OLANZAPINE, outcome: 5.1 Global state: 1.No clinically significant response (as defined by the original studies). </p> </div> </div> </div> </section> <section id="CD006569-sec-0134"> <h4 class="title">Other potential sources of bias</h4> <p>Many included studies were sponsored by the manufacturer of aripiprazole or the comparator drug. There is evidence that pharmaceutical companies may be selective in reporting the benefits and disadvantages of their own compounds (<a href="./references#CD006569-bbs2-0299" title="HeresS , DavisJ , MainoK , JetzingerE , KisslingW , LeuchtS . Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine. American Journal of Psychiatry2006;163:185‐94. ">Heres 2006</a>). </p> </section> </section> <section id="CD006569-sec-0135"> <h3 class="title" id="CD006569-sec-0135">Effects of interventions</h3> <p>See: <a href="./full#CD006569-tbl-0001"><b>Summary of findings for the main comparison</b> COMPARISON 1. ARIPIPRAZOLE versus CLOZAPINE for schizophrenia</a>; <a href="./full#CD006569-tbl-0002"><b>Summary of findings 2</b> COMPARISON 2. ARIPIPRAZOLE versus QUETIAPINE for schizophrenia</a>; <a href="./full#CD006569-tbl-0003"><b>Summary of findings 3</b> COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE for schizophrenia</a>; <a href="./full#CD006569-tbl-0004"><b>Summary of findings 4</b> COMPARISON 4. ARIPIPRAZOLE versus ZIPRASIDONE for schizophrenia</a>; <a href="./full#CD006569-tbl-0005"><b>Summary of findings 5</b> COMPARISON 5. ARIPIPRAZOLE versus OLANZAPINE for schizophrenia</a> </p> <p>We used risk ratios (RR) for dichotomous data and mean differences (MD) for continuous data, with their respective 95% confidence intervals (CIs) throughout. </p> <section id="CD006569-sec-0136"> <h4 class="title">COMPARISON 1: ARIPIPRAZOLE versus CLOZAPINE</h4> <section id="CD006569-sec-0137"> <h5 class="title">1.1 Global state: 1. No clinically significant response (as defined by the original studies) </h5> <p>Data demonstrate there was no difference between groups (29 RCTs, n = 2132, RR 1.05 CI 0.87 to 1.27, <a href="./references#CD006569-fig-0010" title="">Analysis 1.1</a>). </p> </section> <section id="CD006569-sec-0138"> <h5 class="title">1.2 Mental state: 1. Specific ‐ binary outcomes</h5> <section id="CD006569-sec-0139"> <h6 class="title">1.2.1 Anxiety and agitation</h6> <p>In the short term, there was significant favour (P = 0.01) for clozapine with higher levels of anxiety seen in participants receiving aripiprazole (11 RCTs, n = 732, RR 2.62 CI 1.21 to 5.70), however, with a slight degree of heterogeneity (ChI<sup>2</sup> = 13.34; df = 10; P = 0.21; I<sup>2</sup> = 25%). Data demonstrate no difference between groups at medium term (1 RCT, n = 90). Data for levels of agitation at short term demonstrated no difference between groups (1 RCT, n = 60, <a href="./references#CD006569-fig-0011" title="">Analysis 1.2</a>). </p> </section> </section> <section id="CD006569-sec-0140"> <h5 class="title">1.3 Mental state: 2. Average endpoint scores of various scales (short term, up to 12 weeks, high = poor) </h5> <p>Data for all scales demonstrated no significant difference, including the BPRS (5 RCTs, n = 426); PANSS (23 RCTs, n = 1638), however with considerable heterogeneity present (ChI<sup>2</sup> = 61.84; df = 22; P = 0.0; I<sup>2</sup> = 64%); and SANS (1 RCT, n = 50, <a href="./references#CD006569-fig-0012" title="">Analysis 1.3</a>). </p> </section> <section id="CD006569-sec-0141"> <h5 class="title">1.4 Mental state: 3. Average endpoint scores of various scales (medium term, 12 to 26 weeks, high = poor) </h5> <p>When using PANSS, data from 3 RCTs significantly favoured (P = 0.0004) aripiprazole (n = 236, MD ‐5.41 CI ‐8.42 to ‐2.41, <a href="./references#CD006569-fig-0013" title="">Analysis 1.4</a>). </p> </section> <section id="CD006569-sec-0142"> <h5 class="title">1.5 Mental state: 4. Average endpoint scores of various scales (skewed)</h5> <p>All data for this outcome are skewed and are best inspected by viewing <a href="./references#CD006569-fig-0014" title="">Analysis 1.5</a>. </p> </section> <section id="CD006569-sec-0143"> <h5 class="title">1.6 Mental state: 5. Specific ‐ average endpoint positive score (PANSS, high = poor)</h5> <p>Overall, there was no difference between groups at both short and medium term (22 RCTs, n = 1523, <a href="./references#CD006569-fig-0015" title="">Analysis 1.6</a>), however there was considerable heterogeneity present (ChI<sup>2</sup> = 74.67; df = 21; P = 0.00001; I<sup>2</sup> = 72%). </p> <p>By short term, data indicate no significant difference between groups (19 RCTs, n = 1287), however. considerable heterogeneity was present (ChI<sup>2</sup> = 66.47; df = 18; P = 0.00001; I<sup>2</sup> = 73%). Again, by the medium term, data indicate no significant difference between groups (3 RCTs, n = 236), however there was considerable heterogeneity present (ChI<sup>2</sup> = 5.87; df = 2; P = 0.05; I<sup>2</sup> = 66%). </p> </section> <section id="CD006569-sec-0144"> <h5 class="title">1.7 Mental state: 6. Specific ‐ average endpoint negative score (PANSS, high = poor)</h5> <p>Overall, there was no significant difference between aripiprazole between short term and medium term (23 RCTs, n = 1640), however considerable heterogeneity was present (ChI<sup>2</sup> = 114.66; df = 22; P = 0.0001; I<sup>2</sup> = 81%). </p> <p>Short‐term data indicate no significant difference between groups (20 RCTs, n = 1404), however there was considerable heterogeneity present (ChI<sup>2</sup> = 51.61; df = 19; P = 0.0001; I<sup>2</sup> = 63%). Medium‐term data significantly favoured aripiprazole (3 RCTs, n = 236, MD ‐3.24 CI ‐5.82 to ‐0.67, <a href="./references#CD006569-fig-0016" title="">Analysis 1.7</a>), however with considerable heterogeneity (ChI<sup>2</sup> = 15.99; df = 2; P = 0.0003; I<sup>2</sup> = 87%) </p> </section> <section id="CD006569-sec-0145"> <h5 class="title">1.8 Mental state: 7. Specific ‐ average endpoint general psychopathological score (PANSS, high = poor ) </h5> <p>Overall, data indicate no significant difference between groups (19 RCTs, n = 1330, <a href="./references#CD006569-fig-0017" title="">Analysis 1.8</a>). Data indicate a significant difference (P = 0.02) favouring aripiprazole at medium term (3 RCTs, n = 236 MD ‐1.89 CI ‐3.45 to ‐0.34). </p> </section> <section id="CD006569-sec-0146"> <h5 class="title">1.9 Mental state: 8. Specific ‐ average total score decreased rate (PANSS, low = poor)</h5> <section id="CD006569-sec-0147"> <h6 class="title">1.9.1 By up to 12 weeks</h6> <p>Data in one small study indicate no significant difference between groups (1 RCT, n = 118, <a href="./references#CD006569-fig-0018" title="">Analysis 1.9</a>). </p> </section> </section> <section id="CD006569-sec-0148"> <h5 class="title">1.10 Mental state: 9. Specific ‐ average positive score decreased rate (PANSS, low = poor) </h5> <p>Short‐term data in one small study indicate no significant difference between groups (1 RCT, n = 118, <a href="./references#CD006569-fig-0019" title="">Analysis 1.10</a>). </p> </section> <section id="CD006569-sec-0149"> <h5 class="title">1.11 Leaving the study early</h5> <p>Data demonstrate no significant difference between groups when leaving the study for any reasons (3 RCTs, n = 240, <a href="./references#CD006569-fig-0020" title="">Analysis 1.11</a>). This was also the case for adverse events (3 RCTs, n = 212) and due to 'economic issues' (1 RCT, n = 120). </p> </section> <section id="CD006569-sec-0150"> <h5 class="title">1.12 Quality of life: 1a. Average scores (short term, up to 12 weeks, WHO‐QOL‐100, low = poor) </h5> <p>Data demonstrate statistical significance (P = 0.0001) in favour of aripiprazole in two small RCTs (n = 132, MD 2.59 CI 1.43 to 3.74, <a href="./references#CD006569-fig-0021" title="">Analysis 1.12</a>). On the physical health component, data demonstrate statistical significance (P = 0.01) in favour of aripiprazole in two small RCTs (n = 132, MD 7.73 CI 1.51 to 13.94), however with considerable heterogeneity present (ChI<sup>2</sup> = 6.04; df = 1; P = 0.014; I<sup>2</sup> = 83%). Again, mental health component data demonstrate statistical significance (P = 0.0001) in favour of aripiprazole in two small RCTs (n = 132, MD 9.21 CI 4.74 to 13.68), however there was considerable heterogeneity present (ChI<sup>2</sup> = 2.31; df = 1; P = 0.13; I<sup>2</sup> = 57%). Data from one small RCT demonstrate statistical significance (P = 0.00001) in favour of aripiprazole for the spiritual support component (1 RCT, n = 72, MD 6.61 CI 4.25 to 8.97), and for external environment (P = 0.0001) (3 RCTs, n = 248, MD 13.82 CI 8.69 to 18.94) again with considerable heterogeneity present (ChI<sup>2</sup> = 7.63; df = 2; P = 0.02; I<sup>2</sup> = 74%).<br/> Data demonstrate no statistical significance for social function (2 RCTs, n = 132) again with considerable heterogeneity present (ChI<sup>2</sup> = 23.23; df = 1; P = 0.00001; I<sup>2</sup> = 96%) or independence (1 RCT, n = 72). </p> </section> <section id="CD006569-sec-0151"> <h5 class="title">1.13 Quality of life: 1b. Average scores (medium term, 12 to 24 weeks, WHO‐QOL‐100, low = poor) </h5> <p>The endpoint score demonstrated statistical significance (P = 0.00001) in favour of aripiprazole (2 RCTs, n = 176, MD 2.75 CI 1.98 to 3.53, <a href="./references#CD006569-fig-0022" title="">Analysis 1.13</a>). Data demonstrate statistical significance in the physical health component (P = 0.04) in favour of aripiprazole (3 RCTs, n = 256, MD 4.89 CI 0.22 to 9.56), however with considerable heterogeneity present (ChI<sup>2</sup> = 33.90; df = 2; P = 0.00001; I<sup>2</sup> = 94%). Mental health data demonstrate statistical significance (P = 0.00001) in favour of aripiprazole (3 RCTs, n = 256, MD 7.39 CI 5.26 to 9.53), again with considerable heterogeneity present (ChI<sup>2</sup> = 2.6; df = 2; P = 0.27; I<sup>2</sup> = 23%). This was also the case for social function with significant favour (P = 0.0008) of aripiprazole (3 RCTs, n = 256, MD 6.68 CI 2.79 to 10.56), again with considerable heterogeneity present (ChI<sup>2</sup> = 13.19; df = 2; P = 0.001; I<sup>2</sup> = 85%). Data in two small studies demonstrate statistical significance (P = 0.00001) in favour of aripiprazole for the independence component (2 RCTs, n = 176, MD 6.71 CI 4.76 to 8.66). Data demonstrate no significant difference between groups for material life (1 RCT, n = 80) and spiritual support (2 RCTs, n = 176). </p> </section> <section id="CD006569-sec-0152"> <h5 class="title">1.14 Quality of life: 2. Average endpoint general quality of life score (GQOLI ‐ 74, low = poor) </h5> <p>Physical health data from one small RCT demonstrate statistical significance (P = 0.01) in favour of aripiprazole ( n = 120, MD 7.70 CI 2.95 to 12.45, <a href="./references#CD006569-fig-0023" title="">Analysis 1.14</a>). Data for social function from one small RCT demonstrate statistical significance (P = 0.0002) in favour of aripiprazole (n = 120, MD 6.60 CI 3.15 to 10.05). Data from one small RCT demonstrate statistical significance (P = 0.0002) in favour of aripiprazole for environmental area (n = 90, MD 11.50 CI 5.55 to 17.45) and independence (P = 0.0003) in favour of aripiprazole (n = 90, MD 6.16 CI 2.84 to 9.48). No significant difference was found for: total GQOLI score (1 RCT, n = 114); mental health data (1 RCT, n = 120); and material life (1 RCT, n = 120) </p> </section> <section id="CD006569-sec-0153"> <h5 class="title">1.15 Adverse effects:1. At least one adverse effect, non‐specific</h5> <p>Data demonstrate statistical significance (P = 0.02) in favour of aripiprazole, with more people receiving clozapine experiencing at least one adverse effect (7 RCTs, n = 574, RR 0.67 CI 0.48 to 0.95, <a href="./references#CD006569-fig-0024" title="">Analysis 1.15</a>), however with considerable heterogeneity present (ChI<sup>2</sup> = 18.17; df = 7; P = 0.01; I<sup>2</sup> = 61%). There was no significant difference between groups in the short term for: epilepsy (1 RCT, n = 60); abnormal liver function (5 RCTs, n = 364); stuffy nose (3 RCTs, n = 258); sweating (1 RCT, n = 74); urinary retention (2 RCTs, n = 132); and urinary incontinence (2 RCTs, n = 120). </p> </section> <section id="CD006569-sec-0154"> <h5 class="title">1.16 Adverse effects: 2. Cardiac effects</h5> <p>Overall, less cardiac effects were seen in people receiving aripiprazole compared with clozapine. </p> <p>Significant results were found in the short term for abnormal ECG (P = 0.00001), with less occurrences found in people receiving aripiprazole (12 RCTs, n = 921, RR 0.38 CI 0.29 to 0.51, <a href="./references#CD006569-fig-0025" title="">Analysis 1.16</a>). Data were also significantly in favour of aripiprazole (P = 0.0003) for short‐term general adverse cardiac events (1 RCT, n = 62, RR 0.32 CI 0.17 to 0.60). QTc prolongation was significantly in favour (P = 0.001) of aripiprazole in both the short (4 RCTs, n = 334, RR 0.16 CI 0.05 to 0.49) and medium (P = 0.03) term (1 RCT, n = 90, RR 0.05 CI 0.00 to 0.79), as well as tachycardia (P = 0.00001) in the short term (15 RCTs, n = 1104, RR 0.29 CI 0.22 to 0.38). There was no significant difference between groups for a short‐term decrease in blood pressure (3 RCTs, n = 194); and medium‐term tachycardia (1 RCT, n = 60). </p> </section> <section id="CD006569-sec-0155"> <h5 class="title">1.17 Adverse effects: 3. Central/peripheral nervous system</h5> <p>Data showing a decrease in activity from one small RCT demonstrate statistical significance (P = 0.0002) in favour of aripiprazole at short term (n = 120, RR 0.21 CI 0.10 to 0.48, <a href="./references#CD006569-fig-0026" title="">Analysis 1.17</a>). This was also the case for blurred vision (P = 0.003) (6 RCTs, n = 472, RR 0.29 CI 0.12 to 0.66) with slight heterogeneity present (ChI<sup>2</sup> = 9.11; df = 5; P = 0.105; I<sup>2</sup> = 45%). Dizziness was also seen significantly more at short term (P = 0.05) in people receiving clozapine (9 RCTs, n = 698, RR 0.60 CI 0.36 to 1.00). Data from one small RCT for general vegetative nervous system adverse reaction demonstrate statistical significance (P = 0.01) in favour of aripiprazole (n = 62, RR 0.48 CI 0.27 to 0.84) by short term. Other short‐term CNS adverse effects that were significantly in favour of aripiprazole include; hyper‐salivation (P = 0.00001) (16 RCTs, n = 1074, RR 0.06 CI 0.03 to 0.10); memory decline (P = 0.04) (1 RCT n = 80, RR 0.13 CI 0.02 to 0.95); sedation (P = 0.02) (n = 80, RR 0.03 CI 0.00 to 0.52); and somnolence (P = 0.00001) (21 RCTs, n = 1492, RR 0.15 CI 0.09 to 0.24), with slight heterogeneity present (ChI<sup>2</sup> = 35.6; df = 20; P = 0.02; I<sup>2</sup> = 44%). </p> <p>Data significantly favoured clozapine at medium term for: headache (P = 0.03) (16 RCTs, n = 1102, RR 2.28 CI 1.07 to 4.86), however with considerable heterogeneity present (ChI<sup>2</sup> = 45.69; df = 15; P = 0.0001; I<sup>2</sup> = 67%); and insomnia (P = 0.00001) (14 RCTs, n = 990, RR 5.62 CI 2.90 to 10.91). </p> <p>There was no difference between groups in the short term for: increase in activity (1 RCT, n = 48); fatigue (4 RCTs, n = 300); general CNS adverse reaction (1 RCT, n = 62); irritability (2 RCTs, n = 120); as well as insomnia at medium term (1 RCT, n = 90); and headache at medium term (1 RCT, n = 90). </p> </section> <section id="CD006569-sec-0156"> <h5 class="title">1.18 Adverse effects: 4. Extrapyramidal effects</h5> <p>No significant difference was found between groups at short term for the following outcomes: general EPS (8 RCTs, n = 520); tardive dyskinesia (1 RCT, n = 72). For medium‐term outcomes, the following demonstrated no significant difference: akathisia (1 RCT, n = 80); dystonia (1 RCT, n = 80); spasmodic torticollis (1 RCT, n = 80); and tremor (1 RCT, n = 80, <a href="./references#CD006569-fig-0027" title="">Analysis 1.18</a>). </p> <p>The only homogenous data that demonstrate statistical significance (P = 0.01) was in favour of clozapine for the outcome of dystonia at short term (5 RCTs, n = 374, RR 3.24 CI 1.29 to 8.12). All other data either presented no significant difference between groups, or no difference with varying degrees of heterogeneity. The latter include short‐term data for akathisia, with no significant difference between groups (13 RCTs, n = 916, RR 1.21 CI 0.54 to 2.68) with considerable heterogeneity present (ChI<sup>2</sup> = 25.43; df = 12; P = 0.01; I<sup>2</sup> = 53%). Data for tremor at short term demonstrated no significant difference between groups (6 RCTs, n = 460, RR 1.99 CI 0.72 to 5.48) with slight heterogeneity present (ChI<sup>2</sup> = 7.17; df = 5; P = 0.208; I<sup>2</sup> = 30%). This was the same for use of antiparkinson medication in the short term (2 RCTs, n = 140, RR 2.84 CI 0.07 to 117.07) with considerable heterogeneity present (ChI<sup>2</sup> = 6.94; df = 1; P = 0.008; I<sup>2</sup> = 86%). </p> </section> <section id="CD006569-sec-0157"> <h5 class="title">1.19 Adverse effects: 5. Gastrointestinal</h5> <p>No significant difference was found in the short term for: general gastrointestinal adverse reaction (2 RCTs, n = 130); and indigestion (1 RCT, n = 60). Data for dry mouth at short term also demonstrated no significant difference between groups (4 RCTs, n = 268, RR 0.64 CI 0.08 to 5.38) with substantial heterogeneity present (ChI<sup>2</sup> = 13.3; df = 3; P = 0.004; I<sup>2</sup> = 77%). This was also true for nausea/vomiting (10 RCTs, n = 790, RR 1.55 CI 0.71 to 3.38) again with heterogeneity present (ChI<sup>2</sup> = 17.01; df = 9; P = 0.05; I<sup>2</sup> = 47%, <a href="./references#CD006569-fig-0029" title="">Analysis 1.20</a>). </p> <p>Data were significantly in favour of clozapine for abdominal discomfort or pain at short term (P = 0.03) (2 RCTs. n = 132, RR 10.21 CI 1.32 to 79.12). Short‐term data for constipation demonstrate statistical significance (P = 0.00001) in favour of aripiprazole (19 RCTs, n = 1390, RR 0.15 CI 0.08 to 0.31) with substantial heterogeneity present (ChI<sup>2</sup> = 74.05; df = 18; P = 0.0; I<sup>2</sup> = 76%). Remaing data for medium‐term outcomes were in favour of aripiprazole, with significantly less instances of constipation (P = 0.007) (1 RCT, n = 90, RR 0.02 CI 0.00 to 0.36) and hyper‐salivation (P = 0.005) (1 RCT, n = 90, RR 0.02 CI 0.00 to 0.29). </p> </section> <section id="CD006569-sec-0158"> <h5 class="title">1.20 Adverse effects: 6. Haematological</h5> <p>All data for this outcome were homogenous and statistically significant in favour of aripiprazole, including abnormal blood routine in the short term (P = 0.007) (5 RCTs, n = 368, RR 0.16 CI 0.04 to 0.60, <a href="./references#CD006569-fig-0028" title="">Analysis 1.19</a>); and leucopenia in the short term (P = 0.002) (10 RCTs, n = 726, RR 0.21 CI 0.08 to 0.56). Abnormal blood routine in the medium term also demonstrates statistical significance (P = 0.008) in favour of aripiprazole (2 RCTs, n = 152, RR 0.32 CI 0.14 to 0.75). </p> </section> <section id="CD006569-sec-0159"> <h5 class="title">1.21 Adverse effects: 7. Hormonal (short term, up to 12 weeks)</h5> <p>Data for lactation or menstrual changes demonstrate statistical significance (P = 0.003) in favour of aripiprazole (3 RCTs, n = 214, RR 0.11 CI 0.03 to 0.47, <a href="./references#CD006569-fig-0030" title="">Analysis 1.21</a>). </p> </section> <section id="CD006569-sec-0160"> <h5 class="title">1.22 Adverse effects: 8a. Metabolic ‐ binary measures</h5> <section id="CD006569-sec-0161"> <h6 class="title">1.22.1 Blood glucose ‐ increased (short term, up to 12 weeks)</h6> <p>Data demonstrate statistical significance (P = 0.0002) in favour of aripiprazole (5 RCTs, n = 410, RR 0.12 CI 0.04 to 0.37, <a href="./references#CD006569-fig-0031" title="">Analysis 1.22</a>). </p> </section> <section id="CD006569-sec-0162"> <h6 class="title">1.22.2 C‐peptide (short term, up to 12 weeks)</h6> <p>Data from one small RCT demonstrate statistical significance (P = 0.01) in favour of aripiprazole (1 RCT, n = 60, RR 0.03 CI 0.00 to 0.45). </p> </section> <section id="CD006569-sec-0163"> <h6 class="title">1.22.3 Decrease appetite (short term, up to 12 weeks)</h6> <p>Data demonstrate statistical significance (P = 0.01) in favour of aripiprazole (2 RCTs, n = 130, RR 0.07 CI 0.01 to 0.54). </p> </section> <section id="CD006569-sec-0164"> <h6 class="title">1.22.4 Postural hypotension (short term, up to 12 weeks)</h6> <p>Data demonstrate statistical significance (P = 0.001) in favour of aripiprazole (5 RCTs, n = 344, RR 0.16 CI 0.07 to 0.39). </p> </section> <section id="CD006569-sec-0165"> <h6 class="title">1.22.5 PRL‐ increase (short term, up to 12 weeks)</h6> <p>Data from one small RCT demonstrate statistical significance (P = 0.04) in favour of aripiprazole (1 RCT, n = 48, RR 0.05 CI 0.00 to 0.82). </p> </section> <section id="CD006569-sec-0166"> <h6 class="title">1.22.6 Weight gain (short term, up to 12 weeks)</h6> <p>Data demonstrate statistical significance (P = 0.00001) in favour of aripiprazole (18 RCTs, n = 1318, RR 0.13 CI 0.08 to 0.22). </p> </section> <section id="CD006569-sec-0167"> <h6 class="title">1.22.7 Blood glucose ‐ increased (medium term, 12 to 24 weeks)</h6> <p>Data demonstrate no significant difference between groups (1 RCT, n = 90).</p> </section> <section id="CD006569-sec-0168"> <h6 class="title">1.22.8 Decreased appetite (medium term, 12 to 24 weeks)</h6> <p>Data from one small RCT demonstrate statistical significance (P = 0.05) in favour of aripiprazole (n = 90, RR 0.06 CI 0.00 to 0.99). </p> </section> <section id="CD006569-sec-0169"> <h6 class="title">1.22.9 Weight gain (medium term, 12 to 24 weeks)</h6> <p>Data from one small RCT demonstrate statistical significance (P = 0.009) in favour of aripiprazole (n = 90, RR 0.02 CI 0.00 to 0.39, <a href="./references#CD006569-fig-0031" title="">Analysis 1.22</a>). </p> </section> </section> <section id="CD006569-sec-0170"> <h5 class="title">1.23 Adverse effects: 8b. Metabolic ‐ continuous measures</h5> <section id="CD006569-sec-0171"> <h6 class="title">1.23.1 Blood glucose ‐ FPG in HbA1c normal group (in mmol/L</h6> <p>Data demonstrate no significant difference between groups (1 RCT, n = 36).</p> </section> <section id="CD006569-sec-0172"> <h6 class="title">1.23.2 Blood glucose ‐ FPG in HbA1c abnormal group (in mmol/L)</h6> <p>Data demonstrate no significant difference between groups (1 RCT, n = 19).</p> </section> <section id="CD006569-sec-0173"> <h6 class="title">1.23.3 Blood glucose ‐ PBG in HbA1c normal group (in mmol/L)</h6> <p>Data demonstrate no significant difference between groups (1 RCT, n = 36).</p> </section> <section id="CD006569-sec-0174"> <h6 class="title">1.23.4 Blood glucose ‐ PBG in HbA1c abnormal group (in mmol/L)</h6> <p>Data from one small RCT demonstrate statistical significance (P = 0.00001) in favour of aripiprazole (1 RCT, n = 19, MD ‐1.90 CI ‐2.63 to ‐1.17). </p> </section> <section id="CD006569-sec-0175"> <h6 class="title">1.23.5 Blood glucose ‐ FPG average endpoint (in mmol/L)</h6> <p>Data demonstrate statistical significance (P = 0.0009) in favour of aripiprazole (2 RCTs, n = 134, MD ‐0.52 CI ‐0.83 to ‐0.22). </p> </section> <section id="CD006569-sec-0176"> <h6 class="title">1.23.6 Blood glucose ‐ C‐peptide average endpoint (in mg/dlmmol/L)</h6> <p>Data from one small RCT demonstrate statistical significance (P = 0.05) in favour of aripiprazole (1 RCT, n = 60, MD ‐0.72 CI ‐1.45 to 0.01). </p> </section> <section id="CD006569-sec-0177"> <h6 class="title">1.23.7 Weight gain ‐ average endpoint level (in kg)</h6> <p>Data demonstrate no significant difference between groups (1 RCT, n = 74, <a href="./references#CD006569-fig-0032" title="">Analysis 1.23</a>). </p> </section> </section> <section id="CD006569-sec-0178"> <h5 class="title">1.24 Cost‐effectiveness analysis (skewed)</h5> <p>All data for this outcome are skewed and are best inspected by viewing <a href="./references#CD006569-fig-0033" title="">Analysis 1.24</a>. </p> </section> </section> <section id="CD006569-sec-0179"> <h4 class="title">COMPARISON 2: ARIPIPRAZOLE versus QUETIAPINE</h4> <section id="CD006569-sec-0180"> <h5 class="title">2.1 Global state: 1. No clinically significant response (as defined by original studies)</h5> <p>Data demonstrate no significant difference between groups (12 RCTs, n = 991, <a href="./references#CD006569-fig-0034" title="">Analysis 2.1</a>). </p> </section> <section id="CD006569-sec-0181"> <h5 class="title">2.2 Global state: 2 a. Average endpoint total score (short term, up to 12 weeks, high = poor) </h5> <p>Data for the CGI demonstrate no significant difference between groups (1 RCT, n = 80, <a href="./references#CD006569-fig-0035" title="">Analysis 2.2</a>). This was also the case for PANSS (10 RCTs, n = 831), however with considerable heterogeneity present (ChI<sup>2</sup> = 21.14; df = 9; P = 0.012; I<sup>2</sup> = 57%). Data from the BPRS from one small RCT demonstrate statistical significance (P = 0.007) in favour of aripiprazole (1 RCT, n = 80, MD ‐2.63 CI ‐4.55 to ‐0.71). </p> </section> <section id="CD006569-sec-0182"> <h5 class="title">2.3 Global state: 2b. Average endpoint scale score (medium term, 12 to 24 weeks, high = poor) </h5> <p>Data for PANSS demonstrate no significant difference between groups (1 RCT, n = 100, <a href="./references#CD006569-fig-0036" title="">Analysis 2.3</a>). </p> </section> <section id="CD006569-sec-0183"> <h5 class="title">2.4 Global state: 3. Average endpoint SI score (CGI, high = poor)</h5> <section id="CD006569-sec-0184"> <h6 class="title">2.4.1 Up to 12 weeks ‐ short term</h6> <p>Data demonstrate no significant difference between groups (1 RCT, n = 108, <a href="./references#CD006569-fig-0037" title="">Analysis 2.4</a>). </p> </section> </section> <section id="CD006569-sec-0185"> <h5 class="title">2.5 Mental state: 2a. Specific ‐ binary outcomes</h5> <p>There was no significant difference between groups in the short term for: agitation (5 RCTs, n = 423); anxiety (2 RCTs, n = 168); and depression (1 RCT, n = 108, <a href="./references#CD006569-fig-0038" title="">Analysis 2.5</a>). This was also the case for agitation at medium term (1 RCT, n = 100). </p> </section> <section id="CD006569-sec-0186"> <h5 class="title">2.6 Mental state: 3. Specific ‐ average endpoint positive score (PANSS, high = poor)</h5> <section id="CD006569-sec-0187"> <h6 class="title">2.6.1 By up to 12 weeks ‐ short term</h6> <p>Short‐term data demonstrate no significant difference between groups (7 RCTs, n = 583, <a href="./references#CD006569-fig-0039" title="">Analysis 2.6</a>) with substantial heterogeneity present (ChI<sup>2</sup> = 20.25; df = 6; P = 0.002; I<sup>2</sup> = 70%). Medium term data, again, demonstrate no significant difference between groups (1 RCT, n = 100). </p> </section> </section> <section id="CD006569-sec-0188"> <h5 class="title">2.7 Mental state: 4. Specific ‐ average endpoint negative score (PANSS, high = poor)</h5> <section id="CD006569-sec-0189"> <h6 class="title">2.7.1 Up to 12 weeks ‐ short term</h6> <p>Short‐term data demonstrate no significant difference between groups using PANSS negative score (6 RCTs, n = 443, <a href="./references#CD006569-fig-0040" title="">Analysis 2.7</a>); this is also the case for medium‐term data (1 RCT, n = 100). </p> </section> </section> <section id="CD006569-sec-0190"> <h5 class="title">2.8 Mental state: 5. Specific ‐ average endpoint general pathological score (PANSS, high = poor ) </h5> <section id="CD006569-sec-0191"> <h6 class="title">2.8.1 Up to 12 weeks ‐ short term</h6> <p>Short‐term data for PANSS pathological score demonstrate no significant difference between groups (10 RCTs, n = 831, <a href="./references#CD006569-fig-0041" title="">Analysis 2.8</a>) with substantial heterogeneity present (ChI<sup>2</sup> = 83.29; df = 9; P = 0.00001; I<sup>2</sup> = 89%). Medium‐term data also demonstrate no significant difference between groups (1 RCT, n = 100). </p> </section> </section> <section id="CD006569-sec-0192"> <h5 class="title">2.9 Mental state: 6. Average scores of various scales (skewed)</h5> <p>All data for the various scales are skewed and are best inspected by viewing <a href="./references#CD006569-fig-0042" title="">Analysis 2.9</a> </p> </section> <section id="CD006569-sec-0193"> <h5 class="title">2.10 Leaving the study early</h5> <p>All data for leaving the study early showed no significant difference between groups: any reason (2 RCTs, n = 168); because of no effect (1 RCT, n = 108); early discharge (1 RCT, n = 60); early treatment termination (2 RCTs, n = 168); violation of test scheme (1 RCT, n = 108); and withdrawal of informed consent (1 RCT, n = 108, <a href="./references#CD006569-fig-0043" title="">Analysis 2.10</a>). </p> </section> <section id="CD006569-sec-0194"> <h5 class="title">2.11 Quality of life: Average score (medium term, 12 to 24 weeks, WHO‐QOL‐100, low = poor) </h5> <p>The majority of data from a single study are significantly in favour of aripiprazole for a better outcome using this scale, including; total score (P = 0.0001) (1 RCT, n = 100, MD 2.60 CI 1.31 to 3.89); physical health (P = 0.00001) (1 RCT, n = 100, MD 6.00 CI 4.38 to 7.62); mental health (P = 0.00001) (1 RCT, n = 100, MD 9.10 CI 5.92 to 12.28); social function (P = 0.00001) (1 RCT, n = 100, MD 5.60 CI 3.33 to 7.87); environmental area (P = 0.0001) (1 RCT, n = 100, MD 11.50 CI 5.86 to 17.14); and independence (P = 0.0001) (1 RCT, n = 100, MD 6.20 CI 3.05 to 9.35, <a href="./references#CD006569-fig-0044" title="">Analysis 2.11</a>). Data for spiritual pillar demonstrate no significant difference between groups (1 RCT, n = 100). </p> </section> <section id="CD006569-sec-0195"> <h5 class="title">2.12 Adverse effects: 1. At least one adverse effect</h5> <p>For non‐specific adverse effects, data demonstrate no significant difference between groups (3 RCTs, n = 258). All other data also demonstrated no significant difference, including: abnormal urinary test results (1 RCT, n = 108); abnormal liver function (8 RCTs, n = 658); stuffy nose (2 RCTs, n = 188); sweating (1 RCT, n = 70); urine routine abnormal (1 RCT, n = 80, <a href="./references#CD006569-fig-0045" title="">Analysis 2.12</a>). </p> </section> <section id="CD006569-sec-0196"> <h5 class="title">2.13 Adverse effects: 2. Cardiac effects (short term, up to 12 weeks)</h5> <p>Data for tachycardia demonstrate statistical significance (P = 0.003) in favour of aripiprazole (8 RCTs, n = 643, RR 0.35 CI 0.18 to 0.69). All other data demonstrate no significant difference between groups: abnormal ECG (6 RCTs, n = 528); decrease in blood pressure (4 RCTs, n = 348); and QTc prolongation (3 RCTs, n = 225, <a href="./references#CD006569-fig-0046" title="">Analysis 2.13</a>). </p> </section> <section id="CD006569-sec-0197"> <h5 class="title">2.14 Adverse effects: 3a. Central nervous system</h5> <p>No significant difference was found between groups in the short term for the following outcomes: blurred vision (6 RCTs, n = 521); dizziness (8 RCTs, n = 671); headache (5 RCTs, n = 436) with substantial heterogeneity present (ChI<sup>2</sup> = 13.42; df = 4; P = 0.009; I<sup>2</sup> = 70%); and insomnia (7 RCTs, n = 591). There was no difference at medium term for: dizziness (1 RCT, n = 100); insomnia (1 RCT, n = 100); or somnolence (1 RCT, n = 100, <a href="./references#CD006569-fig-0047" title="">Analysis 2.14</a>). </p> <p>Data at short term for somnolence demonstrate statistical significance (P = 0.01) in favour of aripiprazole (9 RCTs, n = 731, RR 0.34 CI 0.15 to 0.77) with heterogeneity present (ChI<sup>2</sup> = 18.37; df = 8; P = 0.019; I<sup>2</sup> = 56%). Medium‐term data for headache demonstrate statistical significance (P = 0.03) in favour of quetiapine (1 RCT, n = 100, RR 9.00 CI 1.18 to 48.42). </p> </section> <section id="CD006569-sec-0198"> <h5 class="title">2.15 Adverse effects: 4. Various extrapyramidal symptoms (short term, up to 12 weeks)</h5> <p>All data demonstrated no significant difference between groups for akathisia (7 RCTs, n = 571, <a href="./references#CD006569-fig-0048" title="">Analysis 2.15</a>); dystonia (2 RCTs, n = 145); general EPS (4 RCTs, n = 348); and tremor (4 RCTs, n = 343). </p> </section> <section id="CD006569-sec-0199"> <h5 class="title">2.16 Adverse effects: 5. Gastrointestinal</h5> <p>Data were significantly in favour of aripiprazole in the shot term from constipation (P = 0.005) (7 RCTs, n = 591, RR 0.38 CI 0.19 to 0.75, <a href="./references#CD006569-fig-0049" title="">Analysis 2.16</a>); dry mouth (P = 0.0007) (7 RCTs, n = 611, RR 0.23 CI 0.10 to 0.53); and in the medium term for dry mouth (P = 0.009) (1 RCT, n = 100, RR 0.11 CI 0.01 to 0.84). Data were significantly in favour of quetiapine in the short term for: nausea/ vomiting (P = 0.004) (7 RCTs, n = 611, RR 2.68 CI 1.36 to 5.26).There was no significant difference at medium term for nausea/vomiting (1 RCT, n = 100). </p> </section> <section id="CD006569-sec-0200"> <h5 class="title">2.17 Adverse effects: 6. Haematological</h5> <p>Data demonstrate no significant difference in the short term for abnormal blood routine (1 RCT, n = 85, <a href="./references#CD006569-fig-0050" title="">Analysis 2.17</a>) and leucopenia (2 RCTs, n = 140). </p> </section> <section id="CD006569-sec-0201"> <h5 class="title">2.18 Adverse effects: 7. Hormonal ‐ binary measures</h5> <section id="CD006569-sec-0202"> <h6 class="title">2.18.1 Menstrual disorder (short term, up to 12 weeks)</h6> <p>There was no significant difference between groups for menstrual disorder at both short term (6 RCTs, n = 518) and medium term (1 RCT, n = 100, <a href="./references#CD006569-fig-0051" title="">Analysis 2.18</a>). </p> </section> </section> <section id="CD006569-sec-0203"> <h5 class="title">2.19 Adverse effects: 8a. Metabolic ‐ binary measures</h5> <p>At short term, there was no significant difference between groups for a decrease in appetite (4 RCTs, n = 328) and lactation (5 RCTs, n = 383). Medium data were also not significant for weight gain (1 RCT, n = 100). Data were significantly in favour of aripiprazole in the short term for weight gain (P = 0.01) (10 RCTs, n = 823, RR 0.45 CI 0.24 to 0.85) and at medium term for decreased appetite (P = 0.05) (1 RCT, n = 100, RR 0.13 CI 0.02 to 0.96, <a href="./references#CD006569-fig-0052" title="">Analysis 2.19</a>). </p> </section> <section id="CD006569-sec-0204"> <h5 class="title">2.20 Adverse effects: 8b.Metabolic ‐ continuous measure</h5> <p>Data from one small RCT demonstrate statistical significance (P = 0.03) in favour of aripiprazole for cholesterol TC average endpoint level (in mmol/L) (1 RCT, n = 180, MD ‐0.19 CI ‐0.36 to ‐0.02, <a href="./references#CD006569-fig-0053" title="">Analysis 2.20</a>). However, all other data demonstrated no significant difference between groups. </p> </section> </section> <section id="CD006569-sec-0205"> <h4 class="title">COMPARISON 3: ARIPIPRAZOLE versus RISPERIDONE</h4> <section id="CD006569-sec-0206"> <h5 class="title">3.1 Global state: 1.No clinically significant response (as defined by the original studies) </h5> <p>Data are equivocal at short term, demonstrating no significant difference between groups (80 RCTs, n = 6381, RR 1.08 CI 0.96 to 1.21, <a href="./references#CD006569-fig-0054" title="">Analysis 3.1</a>). </p> </section> <section id="CD006569-sec-0207"> <h5 class="title">3.2 Global state: 2. Average endpoint total score (short term, up to 12 weeks, CGI, high = poor) </h5> <p>Data demonstrate statistical significance (P = 0.006) in favour of risperidone (2 RCTs, n = 196, MD 0.35 CI 0.09 to 0.61, <a href="./references#CD006569-fig-0055" title="">Analysis 3.2</a>). </p> </section> <section id="CD006569-sec-0208"> <h5 class="title">3.3 Global state: 3.Average CGI subscale scores (short term, up to 12 weeks, high = poor) </h5> <p>CGI‐EI data demonstrate statistical significance (P = 0.006) in favour of risperidone (1 RCT, n = 120, MD 0.50 CI 0.14 to 0.86, <a href="./references#CD006569-fig-0056" title="">Analysis 3.3</a>), and CGI‐SI data demonstrate statistical significance (P = 0.006) in favour of risperidone (1 RCT, n = 120, MD 0.40 CI 0.12 to 0.68). </p> </section> <section id="CD006569-sec-0209"> <h5 class="title">3.4 Global state average endpoint of various scales (skewed)</h5> <p>All data are skewed and are best inspected by viewing <a href="./references#CD006569-fig-0057" title="">Analysis 3.4</a>. </p> </section> <section id="CD006569-sec-0210"> <h5 class="title">3.5 Mental state: 1. Specific ‐ binary outcomes (short term, up to 12 weeks)</h5> <p>Data for anxiety demonstrate statistical significance (P = 0.01) in favour of risperidone (9 RCTs, n = 744, RR 1.81 CI 1.12 to 2.94, <a href="./references#CD006569-fig-0058" title="">Analysis 3.5</a>); however all other data are equivocal, demonstrating no difference between groups, including for agitation/excitement (26 RCTs, n = 2038) and irritability (1 RCT, n = 100). </p> </section> <section id="CD006569-sec-0211"> <h5 class="title">3.6 Mental state: 2a. Average endpoint scale score (short term, up to 12 weeks, high = poor) </h5> <p>Data at short term for BPRS demonstrate statistical significance (P = 0.004) in favour of aripiprazole (5 RCTs, n = 570, MD ‐1.33 CI ‐2.24 to ‐0.42, <a href="./references#CD006569-fig-0059" title="">Analysis 3.6</a>), as were data for PANSS short term which showed a risk reduction by 0.8 on the PANSS scale favouring aripiprazole group (77 RCTs, n = 5733, MD ‐0.80 95% CI ‐1.58 to ‐0.02, <a href="./references#CD006569-fig-0059" title="">Analysis 3.6</a>). However, all other data show no significant difference between groups: PANSS medium term (1 RCT, n = 50) and SANS medium term (1 RCT, n = 50). </p> </section> <section id="CD006569-sec-0212"> <h5 class="title">3.7 Mental state: 3. Specific ‐ average endpoint positive score (PANSS, high = poor)</h5> <p>Data are equivocal at both short and medium term, demonstrating no significant difference between groups (40 RCTs, n = 3205, MD 0.02 CI ‐0.37 to 0.41, <a href="./references#CD006569-fig-0060" title="">Analysis 3.7</a>). </p> </section> <section id="CD006569-sec-0213"> <h5 class="title">3.8 Mental state: 4. Specific ‐ average endpoint negative score (PANSS, high = poor)</h5> <p>Data demonstrate statistical significance (P = 0.001) in favour of aripiprazole at short term (37 RCTs, n = 2976, MD ‐0.64 CI ‐1.04 to ‐0.25, <a href="./references#CD006569-fig-0061" title="">Analysis 3.8</a>). </p> </section> <section id="CD006569-sec-0214"> <h5 class="title">3.9 Mental state: 5. Specific ‐ average endpoint general psychopathological score (PANSS, high = poor) </h5> <p>Data are equivocal at both short and medium term, demonstrating no significant difference between groups (58 RCTs, n = 4243, MD ‐0.25 CI ‐0.71 to 0.20, <a href="./references#CD006569-fig-0062" title="">Analysis 3.9</a>). </p> </section> <section id="CD006569-sec-0215"> <h5 class="title">3.10 Mental state: 6. PANSS average score decreased rate (short term, up to 12 weeks, low = poor) </h5> <p>Data for total scale score decreased rate demonstrate statistical significance (P = 0.03) in favour of aripiprazole (3 RCTs, n = 219, MD 3.06 CI 0.24 to 5.87, <a href="./references#CD006569-fig-0063" title="">Analysis 3.10</a>). All other data demonstrate no significant difference between groups. </p> </section> <section id="CD006569-sec-0216"> <h5 class="title">3.11 Mental state: 7. BPRS total score decreased rate (short term, up to 12 weeks, high = poor) </h5> <p>Data demonstrate no significant difference between groups (2 RCTs, n = 132, MD ‐2.97 CI ‐6.61 to 0.67, <a href="./references#CD006569-fig-0064" title="">Analysis 3.11</a>). </p> </section> <section id="CD006569-sec-0217"> <h5 class="title">3.12 Mental state: 8. General ‐ average total score (PANSS, high = poor)</h5> <p>Data from two RCTs demonstrate no significant difference between groups at short term (2 RCTs, n = 372, MD 1.50 CI ‐2.96 to 5.96, <a href="./references#CD006569-fig-0065" title="">Analysis 3.12</a>). </p> </section> <section id="CD006569-sec-0218"> <h5 class="title">3.13 Mental state: 9. Average scores of various scale (skewed)</h5> <p>All data for this outcome are skewed, and are best inspected by viewing <a href="./references#CD006569-fig-0066" title="">Analysis 3.13</a>. </p> </section> <section id="CD006569-sec-0219"> <h5 class="title">3.14 Leaving the study early</h5> <p>All data for leaving the study early demonstrate no significant difference between groups, including leaving for any reason (12 RCTs, n = 1239, <a href="./references#CD006569-fig-0067" title="">Analysis 3.14</a>); progressive disease (2 RCTs, n = 188); incomplete data (1 RCT, n = 180); adverse effects (9 RCTs, n = 1272); and no effect of study drug (5 RCTs, n = 681). </p> </section> <section id="CD006569-sec-0220"> <h5 class="title">3.15 Adverse effects: 1. At least one adverse effect, non‐specific</h5> <p>With more non‐specific adverse effects seen with people receiving risperidone, data demonstrate statistical significance (P = 0.0002) in favour of aripiprazole (28 RCTs, n = 2361, RR 0.81 CI 0.73 to 0.91, <a href="./references#CD006569-fig-0068" title="">Analysis 3.15</a>). Generally, data demonstrated no significant difference between groups, including hyper‐salivation (7 RCTs, n = 554), and sweating (4 RCTs, n = 278).<br/> <br/> Data demonstrate statistical significance (P = 0.003) in favour of aripiprazole for abnormal liver function (29 RCTs, n = 2300, RR 0.63 CI 0.46 to 0.86) and sexual desire change (P = 0.0001) (8 RCTs, n = 614, RR 0.11 CI 0.04 to 0.30). </p> </section> <section id="CD006569-sec-0221"> <h5 class="title">3.16 Adverse effects: 2a.Cardiac effects (short term, up to 12 weeks)</h5> <p>Data for tachycardia demonstrate statistical significance (P = 0.02) in favour of aripiprazole (49 RCTs, n = 3835, RR 0.76 CI 0.61 to 0.96, <a href="./references#CD006569-fig-0069" title="">Analysis 3.16</a>). All other data are equivocal, demonstrating no significant difference between groups. </p> </section> <section id="CD006569-sec-0222"> <h5 class="title">3.17 Adverse effects: 2b. Cardiac ‐ QTc change from baseline (in ms)</h5> <p>Data demonstrate statistical significance (P = 0.005) in favour of aripiprazole (2 RCTs, n = 383, MD ‐7.19 CI ‐12.19 to ‐2.19, <a href="./references#CD006569-fig-0070" title="">Analysis 3.17</a>). </p> </section> <section id="CD006569-sec-0223"> <h5 class="title">3.18 Adverse effects: 3. Central nervous system (short term, up to 12 weeks)</h5> <p>The majority of data are equivocal, demonstrating no difference between groups. Data for headache demonstrate statistical significance (P = 0.01) in favour of risperidone (20 RCTs, n = 1505, RR 1.91 CI 1.31 to 2.78, <a href="./references#CD006569-fig-0071" title="">Analysis 3.18</a>). Data from one small RCT demonstrate statistical significance (P = 0.04) in favour of aripiprazole for decrease in memory, with higher instances seen in people receiving risperidone (1 RCT, n = 60, RR 0.22 CI 0.05 to 0.94). </p> </section> <section id="CD006569-sec-0224"> <h5 class="title">3.19 Adverse effects: 3a. Endocrine ‐ Prolactin ‐ average change (ng/mL)</h5> <p>Data demonstrate statistical significance (P = 0.00001) in favour of aripiprazole (2 RCTs, n = 383, MD ‐54.71 CI ‐60.06 to ‐49.36, <a href="./references#CD006569-fig-0072" title="">Analysis 3.19</a>). </p> </section> <section id="CD006569-sec-0225"> <h5 class="title">3.20 Adverse effects: 3b. Endocrine ‐ Prolactin ‐ associated</h5> <p>Data from one small RCT demonstrate statistical significance (P = 0.00001) in favour of aripiprazole for abnormally high prolactin value (1 RCT, n = 301, RR 0.04 CI 0.02 to 0.08, <a href="./references#CD006569-fig-0073" title="">Analysis 3.20</a>). Data demonstrate no significant difference between groups for dysmenorrhoea (1 RCT, n = 91). </p> </section> <section id="CD006569-sec-0226"> <h5 class="title">3.21 Adverse effects:4.Various extrapyramidal symptoms (short term, up to 12 weeks)</h5> <section id="CD006569-sec-0227"> <h6 class="title">3.21.1 Akathisia</h6> <p>Data demonstrate statistical significance of aripiprazole for: akathisia (P = 0.00001) (42 RCTs, n = 3501, RR 0.60 CI 0.48 to 0.74, <a href="./references#CD006569-fig-0074" title="">Analysis 3.21</a>); tremor (P = 0.00001) (36 RCTs, n = 2799, RR 0.35 CI 0.27 to 0.45); dystonia (P = 0.00001) (32 RCTs, n = 2640, RR 0.35 CI 0.25 to 0.49); and EPS (P = 0.00001) (31 RCTs, n = 2605, RR 0.39 CI 0.31 to 0.50) with slight heterogeneity present (ChI<sup>2</sup> = 53.91; df = 30; P = 0.005; I<sup>2</sup> = 44%). All other data demonstrate no difference between groups for parkinsonism (1 RCT, n = 301); use of antiparkinson medication (1 RCT, n = 83); tremor (2 RCTs, n = 391). </p> </section> </section> <section id="CD006569-sec-0228"> <h5 class="title">3.22 Adverse effects: 4b. Extrapyramidal ‐ average score</h5> <section id="CD006569-sec-0229"> <h6 class="title">3.22.1 Abnormal Involuntary Movement Scale (high = poor)</h6> <p>Data demonstrate no significant difference between groups (2 RCTs, n = 383, MD ‐0.25 CI ‐1.24 to 0.75, <a href="./references#CD006569-fig-0075" title="">Analysis 3.22</a>) with considerable heterogeneity present (ChI<sup>2</sup> = 3.09; df = 1; P = 0.079; I<sup>2</sup> = 68%). </p> </section> <section id="CD006569-sec-0230"> <h6 class="title">3.22.2 Barnes Akathisia Scale (high = poor)</h6> <p>Data demonstrate no significant difference between groups (2 RCTs, n = 383, MD ‐0.11 CI ‐0.49 to 0.27) with slight heterogeneity present (ChI<sup>2</sup> = 1.98; df = 1; P = 0.16; I<sup>2</sup> = 49%). </p> </section> <section id="CD006569-sec-0231"> <h6 class="title">3.22.3 Simpson‐Angus Scale (high = poor)</h6> <p>Data demonstrate no significant difference between groups (2 RCTs, n = 383, MD ‐0.70 CI ‐2.22 to 0.82) with substantial heterogeneity present (ChI<sup>2</sup> = 5.11; df = 1; P = 0.024; I<sup>2</sup> = 80%). </p> </section> </section> <section id="CD006569-sec-0232"> <h5 class="title">3.23 Adverse effects: 5. Gastrointestinal</h5> <p>Data for constipation (27 RCTs, n = 2067) and dry mouth (33 RCTs, n = 2658) are equivocal, demonstrating no significant difference between groups (<a href="./references#CD006569-fig-0076" title="">Analysis 3.23</a>). For nausea and vomiting data demonstrate statistical significance (P = 0.00001) in favour of risperidone (28 RCTs, n = 2180, RR 1.84 CI 1.31 to 2.56). </p> </section> <section id="CD006569-sec-0233"> <h5 class="title">3.24 Adverse effects: 6. Haematological</h5> <p>All data demonstrate no difference between groups for abnormal blood routine (6 RCTs, n = 515, <a href="./references#CD006569-fig-0077" title="">Analysis 3.24</a>); leucopenia (1 RCT, n = 60) and abnormal blood lipids (1 RCT, n = 80). </p> </section> <section id="CD006569-sec-0234"> <h5 class="title">3.25 Adverse effects: 7a. Metabolic ‐ binary measures (short term, up to 12 weeks)</h5> <section id="CD006569-sec-0235"> <h6 class="title">3.25.1 Appetite ‐ decrease</h6> <p>Data demonstrate statistical significance (P = 0.05) in favour of aripiprazole (2 RCTs, n = 204, RR 0.26 CI 0.07 to 1.03, <a href="./references#CD006569-fig-0078" title="">Analysis 3.25</a>). </p> </section> <section id="CD006569-sec-0236"> <h6 class="title">3.25.2 Blood glucose‐ increase</h6> <p>Data demonstrate statistical significance (P = 0.02) in favour of aripiprazole (5 RCTs, n = 358, RR 0.28 CI 0.09 to 0.82). </p> </section> <section id="CD006569-sec-0237"> <h6 class="title">3.25.3 Endocrine disorder</h6> <p>Data demonstrate statistical significance (P = 0.00001) in favour of aripiprazole (9 RCTs, n = 642, RR 0.07 CI 0.03 to 0.17). </p> </section> <section id="CD006569-sec-0238"> <h6 class="title">3.25.4 Lactation</h6> <p>Data demonstrate statistical significance (P = 0.01) in favour of aripiprazole (3 RCTs, n = 216, RR 0.11 CI 0.02 to 0.60). </p> </section> <section id="CD006569-sec-0239"> <h6 class="title">3.25.5 Menstrual disorder/lactation</h6> <p>Data demonstrate statistical significance (P = 0.00001) in favour of aripiprazole (29 RCTs, n = 2278, RR 0.10 CI 0.06 to 0.16). </p> </section> <section id="CD006569-sec-0240"> <h6 class="title">3.25.6 Menstrual disorder or sexual function change</h6> <p>Data demonstrate no significant difference between groups (1 RCT, n = 68).</p> </section> <section id="CD006569-sec-0241"> <h6 class="title">3.25.7 Menstrual disorder</h6> <p>Data demonstrate statistical significance (P = 0.00001) in favour of aripiprazole (9 RCTs, n = 655, RR 0.13 CI 0.06 to 0.27). </p> </section> <section id="CD006569-sec-0242"> <h6 class="title">3.25.8 Skin symptoms</h6> <p>Data demonstrate statistical significance (P = 0.02) in favour of aripiprazole (9 RCTs, n = 778, RR 0.32 CI 0.12 to 0.86). </p> </section> <section id="CD006569-sec-0243"> <h6 class="title">3.25.9 PRL‐increase</h6> <p>Data demonstrate statistical significance (P = 0.002) in favour of aripiprazole (3 RCTs, n = 184, RR 0.07 CI 0.01 to 0.38). </p> </section> <section id="CD006569-sec-0244"> <h6 class="title">3.25.10 Obesity</h6> <p>Data demonstrate no significant difference between groups (1 RCT, n = 72).</p> </section> <section id="CD006569-sec-0245"> <h6 class="title">3.25.11 Vaginal bleeding</h6> <p>Data demonstrate no significant difference between groups (1 RCT, n = 72).</p> </section> <section id="CD006569-sec-0246"> <h6 class="title">3.25.12 Weight gain</h6> <p>Data demonstrate statistical significance (P = 0.00001) in favour of aripiprazole (58 RCTs, n = 4623, RR 0.22 CI 0.17 to 0.29). </p> </section> <section id="CD006569-sec-0247"> <h6 class="title">3.25.13 Weight loss</h6> <p>Data demonstrate no significant difference between groups (1 RCT, n = 101)</p> </section> </section> <section id="CD006569-sec-0248"> <h5 class="title">3.26 Adverse effects: 7b. Metabolic ‐ continuous measures</h5> <section id="CD006569-sec-0249"> <h6 class="title">3.26.1 Endpoint average weight (in kg)</h6> <p>Data demonstrate statistical significance (P = 0.02) in favour of aripiprazole (5 RCTs, n = 465, MD ‐2.30 CI ‐4.17 to ‐0.44, <a href="./references#CD006569-fig-0079" title="">Analysis 3.26</a>), however with substantial heterogeneity present (ChI<sup>2</sup> = 37.17; df = 4; P = 0.0; I<sup>2</sup> = 89%). </p> </section> <section id="CD006569-sec-0250"> <h6 class="title">3.26.2 Weight change from baseline (in kg)</h6> <p>Data from one small RCT demonstrate statistical significance (P = 0.00001) in favour of aripiprazole (1 RCT, n = 100, MD ‐1.50 CI ‐1.84 to ‐1.16). </p> </section> <section id="CD006569-sec-0251"> <h6 class="title">3.26.3 Average endpoint BMI of male participants (in kg/m2)</h6> <p>Data from one small RCT demonstrate statistical significance (P = 0.003) in favour of aripiprazole (1 RCT, n = 60, MD ‐2.46 CI ‐4.08 to ‐0.84). </p> </section> <section id="CD006569-sec-0252"> <h6 class="title">3.26.4 Average endpoint BMI of female participants (in kg/m2)</h6> <p>Data demonstrate no significant difference between groups (2 RCTs, n = 124, MD ‐1.47 CI ‐3.55 to 0.60) with substantial heterogeneity between groups (ChI<sup>2</sup> = 4.32; df = 1; P = 0.038; I<sup>2</sup> = 77%). </p> </section> <section id="CD006569-sec-0253"> <h6 class="title">3.26.5 Average endpoint blood glucose of female participants (in mmol/L)</h6> <p>Data demonstrate statistical significance (P = 0.00001) in favour of risperidone (1 RCT, n = 60). </p> </section> <section id="CD006569-sec-0254"> <h6 class="title">3.26.6 Average endpoint blood glucose of male participants (in mmol/L)</h6> <p>Data demonstrate no significant difference between groups (1 RCT, n = 60).</p> </section> <section id="CD006569-sec-0255"> <h6 class="title">3.26.7 Average endpoint blood glucose FBG (in mg/dL)</h6> <p>Data demonstrate no significant difference between groups (1 RCT, n = 60).</p> </section> <section id="CD006569-sec-0256"> <h6 class="title">3.26.8 Average endpoint cholesterol ‐ TC of female participants (in mmol/L)</h6> <p>Data from one small RCT demonstrate statistical significance (P = 0.03) in favour of aripiprazole (1 RCT, n = 60, MD ‐0.51 CI ‐0.96 to ‐0.06). </p> </section> <section id="CD006569-sec-0257"> <h6 class="title">3.26.9 Average endpoint cholesterol ‐ TC of male participants (in mmol/L)</h6> <p>Data from one small RCT demonstrate statistical significance (P = 0.05) in favour of aripiprazole (1 RCT, n = 60, MD ‐0.48 CI ‐0.96 to 0.00). </p> </section> <section id="CD006569-sec-0258"> <h6 class="title">3.26.10 Average endpoint cholesterol ‐ TC level (in mmol/L)</h6> <p>Data demonstrate no significant difference between groups (2 RCTs, n = 240).</p> </section> <section id="CD006569-sec-0259"> <h6 class="title">3.26.11 Average endpoint cholesterol ‐ TG level (in mmol/L)</h6> <p>Data demonstrate no significant difference between groups (1 RCT, n = 60).</p> </section> <section id="CD006569-sec-0260"> <h6 class="title">3.26.12 Average endpoint cholesterol ‐ LDL level (in mmol/L)</h6> <p>Data demonstrate no significant difference between groups (2 RCTs, n = 240).</p> </section> <section id="CD006569-sec-0261"> <h6 class="title">3.26.13 Average endpoint waistline (in cm)</h6> <p>Data from one small RCT demonstrate statistical significance (P = 0.003) in favour of aripiprazole (1 RCT, n = 180, MD ‐3.30 CI ‐5.47 to ‐1.13). </p> </section> </section> <section id="CD006569-sec-0262"> <h5 class="title">3.27. Adverse effect: 7c. Metabolic ‐ continuous measures</h5> <p>Data from one small RCT demonstrate statistical significance (P = 0.01) in favour of aripiprazole for change in cholesterol from baseline (1 RCT, n = 83, MD ‐22.30 CI ‐39.69 to ‐4.91, <a href="./references#CD006569-fig-0080" title="">Analysis 3.27</a>). Remaining data demonstrate no significant difference between groups. </p> </section> <section id="CD006569-sec-0263"> <h5 class="title">3.28 Adverse effect: 8. required additional drug combination</h5> <section id="CD006569-sec-0264"> <h6 class="title">3.28.1 Benzodiazepines</h6> <p>Data demonstrate no significant difference between groups (2 RCTs, n = 138, RR 1.07 CI 0.73 to 1.58, <a href="./references#CD006569-fig-0081" title="">Analysis 3.28</a>). </p> </section> <section id="CD006569-sec-0265"> <h6 class="title">3.28.2 Benzhexol</h6> <p>Data from one small RCT demonstrate statistical significance (P = 0.04) in favour of aripiprazole (1 RCT, n = 69, RR 0.34 CI 0.12 to 0.93). </p> </section> <section id="CD006569-sec-0266"> <h6 class="title">3.28.3 Benzhexol/propranolol</h6> <p>Data demonstrate no significant difference between groups (1 RCT, n = 69, RR 1.11 CI 0.45 to 2.72). </p> </section> </section> <section id="CD006569-sec-0267"> <h5 class="title">3.29 Adverse effects: 9.TESS score (short term, up to 12 weeks, high = poor)</h5> <p>Data demonstrate statistical significance (P = 0.006) in favour of aripiprazole (4 RCTs, n = 250, MD ‐1.34 CI ‐2.3 to ‐0.39, <a href="./references#CD006569-fig-0082" title="">Analysis 3.29</a>), however with substantial heterogeneity present (ChI<sup>2</sup> = 48.54; df = 3; P = 0.00001; I<sup>2</sup> = 94%). </p> </section> <section id="CD006569-sec-0268"> <h5 class="title">3.30 Adverse effects: 10. TESS score (skewed)</h5> <p>All data for this outcome are skewed and are best inspected by viewing <a href="./references#CD006569-fig-0083" title="">Analysis 3.30</a>. </p> </section> <section id="CD006569-sec-0269"> <h5 class="title">3.31 Adverse effects: 11. weight gain (skewed)</h5> <p>All data for this outcome are skewed and are best inspected by viewing <a href="./references#CD006569-fig-0084" title="">Analysis 3.31</a>. </p> </section> <section id="CD006569-sec-0270"> <h5 class="title">3.32 Cognitive functioning: 1. Specific ‐ average endpoint total score</h5> <section id="CD006569-sec-0271"> <h6 class="title">3.32.1 Short term, up to 12 weeks, WMS, low = poor</h6> <p>Data demonstrate no significant difference between groups for both WMS (1 RCT, n = 72, <a href="./references#CD006569-fig-0085" title="">Analysis 3.32</a>) and WAIS‐RC (1 RCT, n = 72). </p> </section> </section> <section id="CD006569-sec-0272"> <h5 class="title">3.33 Cost‐effectiveness analysis (skewed)</h5> <p>All data for this outcome are skewed and are best viewed by inspecting <a href="./references#CD006569-fig-0086" title="">Analysis 3.33</a>. </p> </section> </section> <section id="CD006569-sec-0273"> <h4 class="title">COMPARISON 4: ARIPIPRAZOLE versus ZIPRASIDONE</h4> <section id="CD006569-sec-0274"> <h5 class="title">4.1 Global state: 1. No clinically significant response (as defined by the original studies) </h5> <p>Short term data demonstrate no significant difference between groups (6 RCTs, n = 442, RR 0.97 CI 0.62 to 1.52, <a href="./references#CD006569-fig-0087" title="">Analysis 4.1</a>). </p> </section> <section id="CD006569-sec-0275"> <h5 class="title">4.2 Global state: 2. Average endpoint CGI‐GI score (short term, up to 12 weeks, high = poor) </h5> <p>Data from one small RCT demonstrate statistical significance (P = 0.001) in favour of aripiprazole (1 RCT, n = 86, MD ‐3.93 CI ‐6.32 to ‐1.54, <a href="./references#CD006569-fig-0088" title="">Analysis 4.2</a>). </p> </section> <section id="CD006569-sec-0276"> <h5 class="title">4.3 Global state: 3. Average change score (CGI‐S, decline = best)</h5> <p>Data demonstrate no significant difference between groups (1 RCT, n = 247, MD ‐0.03 CI ‐0.28 to 0.22, <a href="./references#CD006569-fig-0089" title="">Analysis 4.3</a>). </p> </section> <section id="CD006569-sec-0277"> <h5 class="title">4.4 Mental state: 1. Average endpoint total score (short term, up to 12 weeks, high = poor) </h5> <p>PANSS data demonstrate no significant difference between groups (7 RCTs, n = 689, <a href="./references#CD006569-fig-0090" title="">Analysis 4.4</a>), neither do BPRS data (1 RCT, n = 247). However, SANS data demonstrate statistical significance (P = 0.02) in favour of aripiprazole (3 RCTs, n = 238, MD ‐1.39 CI ‐2.56 to ‐0.22). </p> </section> <section id="CD006569-sec-0278"> <h5 class="title">4.5 Mental state: 2. Specific ‐ binary outcomes (up to 12 weeks ‐ short term)</h5> <p>There was no significant difference between groups for anxiety (1 RCT, n = 86) or agitation (2 RCTs, n = 150, <a href="./references#CD006569-fig-0091" title="">Analysis 4.5</a>). </p> </section> <section id="CD006569-sec-0279"> <h5 class="title">4.6 Mental state: 3. Specific ‐ average endpoint PANSS subscale scores (short term, high = poor) </h5> <p>There was no significant difference between groups for positive symptom score (2 RCTs, n = 146); negative symptom scores (4 RCTs, n = 272); and general pathology scores (5 RCTs, n = 382, <a href="./references#CD006569-fig-0092" title="">Analysis 4.6</a>.) </p> </section> <section id="CD006569-sec-0280"> <h5 class="title">4.7 Mental state: 4. Average endpoint scores of various scales (skewed)</h5> <p>All data for this outcome are skewed and are best inspected by viewing <a href="./references#CD006569-fig-0093" title="">Analysis 4.7</a>. </p> </section> <section id="CD006569-sec-0281"> <h5 class="title">4.8 Leaving the study early</h5> <p>All data for leaving study early were equivocal, demonstrating no significant difference between groups (<a href="./references#CD006569-fig-0094" title="">Analysis 4.8</a>). </p> </section> <section id="CD006569-sec-0282"> <h5 class="title">4.9 Adverse effects:1.At least one adverse effect, non‐specific</h5> <p>Data demonstrate statistical significance (P = 0.0001) in favour of ziprasidone for sexual function change (2 RCTs, n = 172, RR 8.00 CI 2.96 to 21.65, <a href="./references#CD006569-fig-0095" title="">Analysis 4.9</a>); all other data for adverse effects were equivocal. </p> </section> <section id="CD006569-sec-0283"> <h5 class="title">4.10 Adverse effects: 2.Cardiac effects (short term, up to 12 weeks)</h5> <p>All data for cardiac effects are equivocal and demonstrate no difference between groups (<a href="./references#CD006569-fig-0096" title="">Analysis 4.10</a>). </p> </section> <section id="CD006569-sec-0284"> <h5 class="title">4.11 Adverse effects: 3. Central/ peripheral nervous system</h5> <p>Data for dizziness demonstrate statistical significance (P = 0.002) in favour of ziprasidone (5 RCTs, n = 376, RR 3.24 CI 1.57 to 6.70, <a href="./references#CD006569-fig-0097" title="">Analysis 4.11</a>), as well as data for insomnia (P = 0.02) (5 RCTs, n = 382, RR 2.93 CI 1.17 to 7.30), however with slight heterogeneity present (ChI<sup>2</sup> = 7.38; df = 4; P = 0.117; I<sup>2</sup> = 46%). All other data are equivocal, demonstrating no significant difference between groups, including for headache (2 RCTs, n = 150); blurred vision (1 RCT, n = 84) and somnolence (4 RCTs, n = 296). </p> </section> <section id="CD006569-sec-0285"> <h5 class="title">4.12 Adverse effects: 4. Various extrapyramidal symptoms (short term, up to 12 weeks)</h5> <p>All data were equivocal, demonstrating no difference between groups (<a href="./references#CD006569-fig-0098" title="">Analysis 4.12</a>), including dystonia (1 RCT, n = 84); tremor (2 RCTs, n = 152) and use of anti‐Parkinson drugs (2 RCTs, n = 140) with substantial heterogeneity present (ChI<sup>2</sup> = 6.94; df = 1; P = 0.008; I<sup>2</sup> = 86%). </p> </section> <section id="CD006569-sec-0286"> <h5 class="title">4.13 Adverse effects: 5. Gastrointestinal (short term, up to 12 weeks)</h5> <p>Again, all data were equivocal, demonstrating no difference between groups (<a href="./references#CD006569-fig-0099" title="">Analysis 4.13</a>), including: constipation (3 RCTs, n = 230); dry mouth (4 RCTs, n = 296); hyper‐salivation (1 RCT, n = 86) and nausea/vomiting (6 RCTs, n = 442). </p> </section> <section id="CD006569-sec-0287"> <h5 class="title">4.14 Adverse effects: 6. Haematological</h5> <p>Data for leucopenia demonstrate no significant difference between groups (2 RCTs, n = 140, <a href="./references#CD006569-fig-0100" title="">Analysis 4.14</a>). </p> </section> <section id="CD006569-sec-0288"> <h5 class="title">4.15 Adverse effects: 7. Hormonal</h5> <p>Data for menstrual disorder demonstrate no significant difference between groups (6 RCTs, n = 538, <a href="./references#CD006569-fig-0101" title="">Analysis 4.15</a>). </p> </section> <section id="CD006569-sec-0289"> <h5 class="title">4.16 Adverse effects: 8a. Metabolic ‐ binary measures</h5> <p>All data were equivocal, demonstrating no difference between groups, including appetite decrease (2 RCTs, n = 152, <a href="./references#CD006569-fig-0102" title="">Analysis 4.16</a>)) with substantial heterogeneity present (ChI<sup>2</sup> = 4.04; df = 1; P = 0.045; I<sup>2</sup> = 75%); abnormal blood routine (1 RCT, n = 85); lactation (1 RCT, n = 66); and weight gain (3 RCTs, n = 232). </p> </section> <section id="CD006569-sec-0290"> <h5 class="title">4.17 Adverse effects: 8b. Metabolic ‐ continuous measures</h5> <p>Most data were equivocal, demonstrating no difference between groups; however, data for HDL demonstrate statistical significance (P = 0.04) in favour of aripiprazole (1 RCT, n = 180, MD 0.10 CI 0.01 to 0.19) and data for waistline average endpoint level (in cm) demonstrate statistical significance (P = 0.0004) in favour of aripiprazole (1 RCT, n = 180, MD ‐3.40 CI ‐5.29 to ‐1.51 <a href="./references#CD006569-fig-0103" title="">Analysis 4.17</a>). </p> </section> </section> <section id="CD006569-sec-0291"> <h4 class="title">COMPARISON 5: ARIPIPRAZOLE versus OLANZAPINE</h4> <section id="CD006569-sec-0292"> <h5 class="title">5.1 Global state: 1. No clinically significant response (as defined by the original studies) </h5> <p>Data are equivocal at short term (10 RCTs, n = 1422) and medium term (1 RCT, n = 317), demonstrating no significant difference between groups (<a href="./references#CD006569-fig-0104" title="">Analysis 5.1</a>). </p> </section> <section id="CD006569-sec-0293"> <h5 class="title">5.2 Global state: 2. Not responded (decline in PANSS of 30% or more)</h5> <section id="CD006569-sec-0294"> <h6 class="title">5.2.1 By up to 12 weeks (short term)</h6> <p>Data from one small RCT demonstrate statistical significance (P = 0.04) in favour of olanzapine at short term (1 RCT, n = 566, RR 1.16 CI 1.01 to 1.34, <a href="./references#CD006569-fig-0105" title="">Analysis 5.2</a>) and long term (P = 0.05) (1 RCT, n = 566, RR 1.13 CI 1.0 to 1.27). </p> </section> </section> <section id="CD006569-sec-0295"> <h5 class="title">5.3 Global state: 3. Remission not achieved (as defined in the study)</h5> <p>Data demonstrate no significant difference between groups at short term (1 RCT, n = 566, <a href="./references#CD006569-fig-0106" title="">Analysis 5.3</a>). Data from one small RCT demonstrate statistical significance (P = 0.00001) in favour of olanzapine by long term (1 RCT, n = 566, RR 1.38 CI 1.23 to 1.56). </p> </section> <section id="CD006569-sec-0296"> <h5 class="title">5.4 Global state: 4. Average endpoint EI score (CGI, high = poor)</h5> <p>Data demonstrate no significant difference between groups at short term (2 RCTs, n = 180, <a href="./references#CD006569-fig-0107" title="">Analysis 5.4</a>). </p> </section> <section id="CD006569-sec-0297"> <h5 class="title">5.5 Global state: 5. Average endpoint CGI score decreased rate (short term, low = poor) </h5> <p>Data demonstrate no significant difference between groups (1 RCT, n = 60, <a href="./references#CD006569-fig-0108" title="">Analysis 5.5</a>). </p> </section> <section id="CD006569-sec-0298"> <h5 class="title">5.6 Global state: 6. Average change score (CGI‐S, decline = best)</h5> <p>Data demonstrate no significant difference between groups at long term (1 RCT, n = 566, <a href="./references#CD006569-fig-0109" title="">Analysis 5.6</a>). </p> </section> <section id="CD006569-sec-0299"> <h5 class="title">5.7 Global state: 7. Improvement (CGI‐I, high = poor)</h5> <p>Data demonstrate no significant difference between groups (1 RCT, n = 566, <a href="./references#CD006569-fig-0110" title="">Analysis 5.7</a>). </p> </section> <section id="CD006569-sec-0300"> <h5 class="title">5.8 Mental state: 1. General ‐ average total score (PANSS, high = poor)</h5> <p>Data are equivocal, demonstrating no significant difference between groups at short term (11 RCTs, n = 1500, <a href="./references#CD006569-fig-0111" title="">Analysis 5.8</a>) and medium term (2 RCTs, n = 139). Data from one small RCT demonstrate statistical significance (P = 0.04) in favour of olanzapine (1 RCT, n = 566, MD 4.20 CI 0.10 to 8.3) in the long term. </p> </section> <section id="CD006569-sec-0301"> <h5 class="title">5.9 Mental state: 2. Average endpoint scale score (SANS, high = poor)</h5> <p>Data demonstrate no significant difference between groups at short term (1 RCT, n = 89, <a href="./references#CD006569-fig-0112" title="">Analysis 5.9</a>) and long term (1 RCT, n = 48). </p> </section> <section id="CD006569-sec-0302"> <h5 class="title">5.10 Mental state: 3. average endpoint score (PANSS, skewed)</h5> <p>All data for this outcome are skewed and are best inspected by viewing <a href="./references#CD006569-fig-0113" title="">Analysis 5.10</a>. </p> </section> <section id="CD006569-sec-0303"> <h5 class="title">5.11 Mental state: 4. Specific ‐ average endpoint positive score (PANSS, high = poor)</h5> <p>Overall, data from all time frames demonstrate statistical significance (P = 0.01) in favour of olanzapine (7 RCTs, n = 1043, MD 0.71 CI 0.17 to 1.26, <a href="./references#CD006569-fig-0114" title="">Analysis 5.11</a>). Data are equivocal at short term, demonstrating no significant difference between groups (5 RCTs, n = 429) with slight heterogeneity between groups (ChI<sup>2</sup> = 6.26; df = 4; P = 0.181; I<sup>2</sup> = 36%). Data demonstrate no significant difference at medium term (1 RCT, n = 48) or long term (1 RCT, n = 566). </p> </section> <section id="CD006569-sec-0304"> <h5 class="title">5.12 Mental state: 5. Specific ‐ average endpoint negative subscale score (PANSS, high = poor) </h5> <p>At both short and medium term, data demonstrate no significant difference between group (6 RCTs, n = 967, <a href="./references#CD006569-fig-0115" title="">Analysis 5.12</a>). </p> </section> <section id="CD006569-sec-0305"> <h5 class="title">5.13 Mental state: 6. Specific ‐ average endpoint general pathological score (PANSS, high = poor) </h5> <p>At both short and medium term, data demonstrate no significant difference between groups (8 RCTs, n = 642, <a href="./references#CD006569-fig-0116" title="">Analysis 5.13</a>). </p> </section> <section id="CD006569-sec-0306"> <h5 class="title">5.14 Mental state: 7. Specific ‐ binary outcomes</h5> <section id="CD006569-sec-0307"> <h6 class="title">5.14.1 Anxiety ‐ labelled as" adverse effect"</h6> <p>Data demonstrate no significant difference between groups for anxiety (2 RCTs, n = 778, <a href="./references#CD006569-fig-0117" title="">Analysis 5.14</a>) or exacerbation of schizophrenia (2 RCTs, n = 778). Data from one small RCT demonstrate statistical significance (P = 0.04) in favour of aripiprazole for depression (1 RCT, n = 566, RR 0.27 CI 0.08 to 0.95). </p> </section> </section> <section id="CD006569-sec-0308"> <h5 class="title">5.15 Mental state: 8. Average various scale scores decreased rate (skewed)</h5> <p>All data for this outcome are skewed and are best inspected by viewing <a href="./references#CD006569-fig-0118" title="">Analysis 5.15</a>. </p> </section> <section id="CD006569-sec-0309"> <h5 class="title">5.16 Adverse effects: 1. At least one adverse effect</h5> <p>For non‐specific adverse effects, data demonstrate no significant difference between groups (1 RCT, n = 75, <a href="./references#CD006569-fig-0119" title="">Analysis 5.16</a>). For endocrine dyscrasia, data from one small RCT demonstrate statistical significance (P = 0.01) in favour of aripiprazole (1 RCT, n = 80, RR 0.08 CI 0.01 to 0.61); and for high prolactin level (P = 0.001) (1 RCT, n = 317, RR 0.27 CI 0.12 to 0.60). Remaining data are equivocal and demonstrate no difference between groups, including skin reaction (1 RCT, n = 89); and liver function abnormality  (5 RCTs, n = 348). </p> </section> <section id="CD006569-sec-0310"> <h5 class="title">5.17 Adverse effects: 2. Cardiac effects</h5> <p>All data are equivocal and demonstrate no difference between groups for abnormal ECG (2 RCTs, n = 121); decrease in blood pressure (1 RCT, n = 89); QTc prolongation (3 RCTs, n = 618) and tachycardia (5 RCTs, n = 339). </p> </section> <section id="CD006569-sec-0311"> <h5 class="title">5.18 Adverse effects: 3a. Cardiac ‐ QTc change from baseline (in ms)</h5> <p>Data from one RCT demonstrate no significant difference between groups (1 RCT, n = 317, <a href="./references#CD006569-fig-0121" title="">Analysis 5.18</a>). </p> </section> <section id="CD006569-sec-0312"> <h5 class="title">5.19 Adverse effects: 3b. Central/ peripheral nervous system</h5> <p>Data from two RCTs demonstrate statistical significance (P = 0.0001) in favour of aripiprazole for levels of sedation (2 RCTs, n = 883, RR 0.37 CI 0.23 to 0.60) and data from one small RCT demonstrate statistical significance (P = 0.05) in favour of aripiprazole for headache/dizziness (1 RCT, n = 89, RR 0.29 CI 0.09 to 1.00, <a href="./references#CD006569-fig-0072" title="">Analysis 3.19</a>). All other data are equivocal and demonstrate no difference between groups, including dizziness (6 RCTs, n = 1057); blurred vision (1 RCT, n = 75); fatigue (3 RCTs, n = 721) and insomnia (7 RCTs, n = 1141), however with considerable heterogeneity present (ChI<sup>2</sup> = 13.87; df = 6; P = 0.031; I<sup>2</sup> = 57%). </p> </section> <section id="CD006569-sec-0313"> <h5 class="title">5.20 Adverse effects: 4. Endocrine ‐ Prolactin ‐ average increase</h5> <p>Data from one small RCT demonstrate statistical significance (P = 0.0001) in favour of aripiprazole (1 RCT, n = 566, MD ‐8.89 CI ‐12.96 to ‐4.82, <a href="./references#CD006569-fig-0123" title="">Analysis 5.20</a>). </p> </section> <section id="CD006569-sec-0314"> <h5 class="title">5.21 Adverse effects: 5. Extrapyramidal ‐ various</h5> <p>All data are equivocal and demonstrate no difference between groups, including: tremor (1 RCT, n = 61); EPS (4 RCTs, n = 667); and parkinsonism (3 RCTs, n = 618). Data for akathisia are equivocal, demonstrating no significant difference between groups (6 RCTs, n = 1320, <a href="./references#CD006569-fig-0124" title="">Analysis 5.21</a>), however with considerable heterogeneity present (ChI<sup>2</sup> = 19.45; df = 6; P = 0.003; I<sup>2</sup> = 69%). </p> </section> <section id="CD006569-sec-0315"> <h5 class="title">5.22 Adverse effects: 6. Gastrointestinal</h5> <p>Data from one small RCT demonstrate statistical significance (P = 0.03) in favour of aripiprazole for abdominal pain (1 RCT, n = 566, RR 2.96 CI 1.09 to 8.03). All remaining data are equivocal and demonstrate no significant difference between groups, including: dry mouth (5 RCTs, n = 854); constipation (6 RCTs, n = 443) and nausea/vomiting (6 RCTs, n = 948, <a href="./references#CD006569-fig-0125" title="">Analysis 5.22</a>). </p> </section> <section id="CD006569-sec-0316"> <h5 class="title">5.23 Adverse effects: 7. Hormonal</h5> <section id="CD006569-sec-0317"> <h6 class="title">5.23.1 Menstrual changes</h6> <p>Data are equivocal and demonstrate no significant difference between groups (3 RCTs, n = 198, <a href="./references#CD006569-fig-0126" title="">Analysis 5.23</a>). </p> </section> </section> <section id="CD006569-sec-0318"> <h5 class="title">5.24 Adverse effects: 8a. Metabolic ‐ binary measures</h5> <p>Data demonstrate statistical significance (P = 0.001) in favour of aripiprazole for blood glucose increase (3 RCTs, n = 227, RR 0.12 CI 0.03 to 0.44); for abnormally high cholesterol level (P = 0.0001) (1 RCT, n = 223, RR 0.32 CI 0.19 to 0.54, <a href="./references#CD006569-fig-0127" title="">Analysis 5.24</a>); and weight gain (P = 0.00001) (9 RCTs, n = 1538, RR 0.25 CI 0.15 to 0.43). All remaining data demonstrate no significant difference between groups for appetite increase (2 RCTs, n = 655); lactation (1 RCT, n = 60) and PRL increase (1 RCT, n = 89). </p> </section> <section id="CD006569-sec-0319"> <h5 class="title">5.25 Adverse effects: 8b. Metabolic ‐ continuous measures (high = poor)</h5> <section id="CD006569-sec-0320"> <h6 class="title">5.25.1 Weight ‐ average endpoint level (in kg)</h6> <p>Data demonstrate statistical significance (P = 0.00001) in favour of aripiprazole (3 RCTs, n = 242, MD ‐7.43 CI ‐9.21 to ‐5.65, <a href="./references#CD006569-fig-0128" title="">Analysis 5.25</a>). </p> </section> <section id="CD006569-sec-0321"> <h6 class="title">5.25.2 Weight gain ‐ change from baseline (in kg)</h6> <p>Data demonstrate no significant difference between groups (2 RCTs, n = 656), however with substantial heterogeneity present (ChI<sup>2</sup> = 6.31; df = 1; P = 0.012; I<sup>2</sup> = 84%). </p> </section> <section id="CD006569-sec-0322"> <h6 class="title">5.25.3 Cholesterol ‐ change from baseline (in mg/dL)</h6> <p>Data demonstrate statistical significance (P = 0.00001) in favour of aripiprazole (2 RCTs, n = 789, MD ‐15.37 CI ‐21.62 to ‐9.11). </p> </section> <section id="CD006569-sec-0323"> <h6 class="title">5.25.4 Cholesterol ‐ TC average endpoint level (in mmol/L)</h6> <p>Data demonstrate statistical significance (P = 0.00001) in favour of aripiprazole (2 RCTs, n = 182, MD ‐1.00 CI ‐1.44 to ‐0.56). </p> </section> <section id="CD006569-sec-0324"> <h6 class="title">5.25.5 Cholesterol ‐ TG average endpoint level (in mmol/L</h6> <p>Data from one small RCT demonstrate statistical significance (P = 0.00001) in favour of aripiprazole (1 RCT, n = 102, MD ‐1.00 CI ‐1.31 to ‐0.69). </p> </section> <section id="CD006569-sec-0325"> <h6 class="title">5.25.6 Blood glucose ‐ PBG average endpoint level (in mg/dL)</h6> <p>Data from one small RCT demonstrate statistical significance (P = 0.00001) in favour of aripiprazole (1 RCT, n = 60, MD ‐0.95 CI ‐1.27 to ‐0.63). </p> </section> <section id="CD006569-sec-0326"> <h6 class="title">5.25.7 Glucose ‐ change from baseline (in mg/dl)</h6> <p>Data demonstrate no significant difference between groups (2 RCTs, n = 883).</p> </section> </section> <section id="CD006569-sec-0327"> <h5 class="title">5.26 Adverse effects: average endpoint scale scores (TESS, skewed)</h5> <p>All data for this outcome are skewed and are best inspected by viewing <a href="./references#CD006569-fig-0129" title="">Analysis 5.26</a>. </p> </section> <section id="CD006569-sec-0328"> <h5 class="title">5.27 Leaving the study early</h5> <p>Data for leaving for any reason from one small RCT demonstrate statistical significance (P = 0.002) in favour of olanzapine (9 RCTs, n = 2331, RR 1.15 CI 1.05 to 1.25, <a href="./references#CD006569-fig-0130" title="">Analysis 5.27</a>); statistical significance was also found in inefficacy (P = 0.003) in favour of olanzapine (4 RCTs, n = 1352, RR 1.81 CI 1.23 to 2.67). Remaining reasons for leaving the study early demonstrated no significant difference between groups, including adverse event (4 RCTs, n = 1352); early discharge (1 RCT, n = 60); medication non‐compliance (1 RCT, n = 255); and death (1 RCT, n = 214). </p> </section> <section id="CD006569-sec-0329"> <h5 class="title">5.28 Quality of life: 1. Average endpoint general quality of life score (GQOLI‐74, low = poor) </h5> <p>All data are equivocal and demonstrate no difference between groups (<a href="./references#CD006569-fig-0131" title="">Analysis 5.28</a>). </p> </section> </section> <section id="CD006569-sec-0330"> <h4 class="title">COMPARISON 6: ARIPIPRAZOLE versus OLANZAPINE (acutely agitated people ‐ all data by five days) </h4> <p>One study was included in this category.</p> <section id="CD006569-sec-0331"> <h5 class="title">6.1 Global state</h5> <p>An improvement was defined as reduction in the Brief Psychiatric Rating Scale (BPRS). There was no significant difference in the two groups (n = 471, MD ‐0.18, CI ‐0.79 to 0.43, <a href="./references#CD006569-fig-0132" title="">Analysis 6.1</a>). </p> </section> <section id="CD006569-sec-0332"> <h5 class="title">6.2 Mental state</h5> <p>There was no significant difference reported in participants on aripiprazole and olanzapine in agitation level (defined as at least  40% reduction in PANSS‐EC (n = 604, RR 0.92, CI 0.76 to 1.12). No significant difference was noted in agitation (n = 578, RR 0.25, CI 0.05 to 1.17); anxiety (n = 604, RR 0.93, CI 0.40 to 2.17) and exacerbation of schizophrenia (n = 604, RR 5.13, CI 0.25 to 106.49, <a href="./references#CD006569-fig-0133" title="">Analysis 6.2</a>). All such outcomes were labelled as “adverse effects” in the published report. </p> </section> <section id="CD006569-sec-0333"> <h5 class="title">6.3 Leaving the study early</h5> <p>Both groups were similar in the number of participants leaving the study early due to adverse effects (n = 604, RR 0.68 CI 0.12 to 4.07, <a href="./references#CD006569-fig-0134" title="">Analysis 6.3</a>). </p> </section> <section id="CD006569-sec-0334"> <h5 class="title">6.4 Adverse effects</h5> <section id="CD006569-sec-0335"> <h6 class="title">6.4.1 Central nervous system</h6> <p>No significant difference was reported between administering aripiprazole or olanzapine in acutely agitated patients with regards to CNS side effects of dizziness (n = 578, RR 0.29, CI 0.06 to 1.36); sedation (n = 578, RR 0.71, CI 0.23 to 2.22); insomnia (n = 604, RR 1.60, CI 0.87 to 2.94) and somnolence (n = 578, RR 0.14, CI 0.02 to 1.15). Participants on aripiprazole reported more headaches (n = 578, RR 2.43, CI 1.02 to 5.77) and lethargy (n = 578, RR 1.33, CI 0.30 to 5.90, <a href="./references#CD006569-fig-0135" title="">Analysis 6.4</a>). </p> </section> <section id="CD006569-sec-0336"> <h6 class="title">6.4.2 Endocrine system ‐ increase in average levels of prolactin</h6> <p>People allocated aripiprazole reported significantly lower (P = 0.00001) prolactin level increase compared with participants given olanzapine (n = 604, MD ‐15.76, CI ‐19.18 to ‐12.34, <a href="./references#CD006569-fig-0136" title="">Analysis 6.5</a>). </p> </section> <section id="CD006569-sec-0337"> <h6 class="title">6.4.3 Extrapyramidal side effects</h6> <p>Participants in both groups experienced similar rates of akathisia (n = 604, RR 1.43, CI 0.79 to 2.56) and parkinsonian symptoms (n = 604, 1 RCT, RR 1.71 CI 0.41 to 7.10, <a href="./references#CD006569-fig-0137" title="">Analysis 6.6</a>). </p> </section> <section id="CD006569-sec-0338"> <h6 class="title">6.4.4 Extrapyramidal symptoms</h6> <p>Extrapyramidal symptoms were also reported by using scales where higher score represents a poor outcome. There was no significant difference between groups when assessed using Barnes Akathisia scale (n = 604, MD 0.07, CI ‐0.24 to 0.38) or Simpson Angus scale (n = 604, MD ‐0.05, CI ‐0.13 to 0.03, <a href="./references#CD006569-fig-0138" title="">Analysis 6.7</a>). </p> </section> <section id="CD006569-sec-0339"> <h6 class="title">6.4.5 Gastrointestinal side effects</h6> <p>Both groups reported similar occurrence of dry mouth (n = 578, RR 1.00, CI 0.20 to 4.91) and twice the number of participants on olanzapine reported nausea/dyspepsia (n = 578, RR 0.50, CI 0.09 to 2.71, <a href="./references#CD006569-fig-0139" title="">Analysis 6.8</a>). </p> </section> <section id="CD006569-sec-0340"> <h6 class="title">6.4.6 Metabolic side effects‐ increase in triglyceride levels</h6> <p>These results favoured patients on aripiprazole significantly (P = 0.00001) (n = 604, MD ‐35.62, CI ‐49.25 to ‐21.99, <a href="./references#CD006569-fig-0140" title="">Analysis 6.9</a>). </p> </section> </section> </section> <section id="CD006569-sec-0341"> <h4 class="title">COMPARISON 7. ARIPIPRAZOLE versus OTHER ANTIPSYCHOTIC DRUGS</h4> <p>We used data from three studies for this comparison. In all three studies aripiprazole was compared with any one of several new generation antipsychotic drugs. </p> <section id="CD006569-sec-0342"> <h5 class="title">7.1 Global state: 1. No change as defined by the original study (measured by IAQ)</h5> <p><a href="./references#CD006569-bbs2-0040" title="BeuzenJN , L'ItalienG , HanssensL , MarcusRN , McQuadeRD , CarsonWH . Changes in prolactin levels and arizona sexual experience scale (ASEX) scores among patients switched from risperidone to aripiprazole in the schizophrenia trial of aripiprazole (STAR) study. Schizophrenia Bulletin2007;33(2):421‐2. BlondeL , KanHJ , GuttermanEM , L'ItalienGJ , KimMS , HanssensL , et al. Predicted risk of diabetes and coronary heart disease in patients with schizophrenia: aripiprazole versus standard of care. Journal of Clinical Psychiatry2008;69(5):741‐8. [MEDLINE: 18435564] HanssensL , L'ItalienG , MarcusRN , McQuadeRD , CarsonWH , BeuzenJN . Reasons for switching from previous therapy and preference of medication in the large, randomized, naturalistic schizophrenia trial of aripiprazole (STAR). Schizophrenia Bulletin2007;33(2):432. HanssensL , L’ ItalienG , McQuadeR , IwamotoT , PansM . Evaluation of quality of life in community‐treated schizophrenic patients: a naturalistic, open‐label study comparing aripiprazole to standard‐of‐care (Schizophrenia Trial of aripiprazole: STAR study). European Psychiatry2006;21(Suppl 1):S99. KerwinR , MilletB , HermanE , BankiCM , LublinH , PansM , et al. A multi centre, randomized, naturalistic, open‐label study between aripiprazole and standard of care in the management of community‐treated schizophrenic patients Schizophrenia Trial of aripiprazole: (STAR) study. European Psychiatry2007;22(7):433‐43. [MEDLINE: 17555947] KerwinR , MilletB , HermanE , BankiCM , LublinH , PansM , et al. A multi centre, randomized, naturalistic, open‐label study between aripiprazole and standard of care in the management of community‐treated schizophrenic patients. Schizophrenic Trial of aripiprazole: (STAR) study. Wiadomosci Psychiatryczne2008;11(2):105‐19. KingD , KnappM , ThomasP , RazzoukD , LozeJY , KanHJ , et al. Cost‐effectiveness analysis of aripiprazole vs standard‐of‐care in the management of community‐treated patients with schizophrenia: Star study. Current Medical Research and Opinion2011;27(2):365‐74. KolotkinRL , Corey‐LislePK , CrosbyRD , KanHJ , McQuadeRD . Changes in weight and weight‐related quality of life in a multi centre, randomized trial of aripiprazole versus standard of care. European Psychiatry2008;23(8):561‐6. [MEDLINE: 18374544] L'ItalienG , HanssensL , KanHJ , BakerRA , MarcusRN , McQuadeRD , et al. Metabolic effects of aripiprazole versus olanzapine, quetiapine, or risperidone (the STAR trial). Schizophrenia Bulletin2007;33(2):439. L'ItalienGJ , BlondeL , HanssensL , McQuadeR . Prevalence of diabetes/cardiovascular risk factors among schizophrenia patients treated with atypical antipsychotics in a multicenter, randomized, naturalistic, open‐label study (Schizophrenia Trial of aripiprazole: STAR study). Diabetes2006;55(Suppl 1):A538. L'ltalienGJ , HanssensL , MarcusRN , McQuadeRD . Evidence of antipsychotic treatment selection based on metabolic risk factors among community‐based schizophrenia patients (The STAR Trial). Proceedings of the 160th Annual Meeting of the American Psychiatric Association; 2007 May 19‐24; San Diego, CA2007. MilletB . A multicenter, randomized, naturalistic, open‐label study between aripiprazole and standard of care in the management of community‐treated schizophrenic patients (Schizophrenia Trial of aripiprazole ‐ STAR). http://www.clinicaltrials.gov2005. TaylorD , HanssensL , LozeJ‐Y , PansM , L'ItalienG , MarcusRN . Preference of medicine and patient‐reported quality of life in community‐treated schizophrenic patients receiving aripiprazole vs standard of care: results from the STAR study. European Psychiatry2008;23(5):336‐43. ">Kerwin 2007</a> showed an improvement in global state in energy (n = 523, 1 RCT, RR 0.69 CI 0.56 to 0.84); mood (n = 523, 1 RCT, RR 0.77 CI 0.65 to 0.92); negative symptoms (n = 523, 1 RCT, RR 0.82 CI 0.68 to 0.99); somnolence (n = 523, 1 RCT, RR 0.80 CI 0.69 to 0.93) and weight gain (n = 523, 1 RCT, RR 0.84 CI 0.76 to 0.94) when aripiprazole was used but no significant difference was noted in cognition (n = 523, 1 RCT, <a href="./references#CD006569-fig-0141" title="">Analysis 7.1</a>). </p> </section> <section id="CD006569-sec-0343"> <h5 class="title">7.2 Global state: 2. Change in sexual dysfunction (measured by ASEX)</h5> <p>No significant difference was seen in the two groups (n = 85, 1 RCT, <a href="./references#CD006569-fig-0142" title="">Analysis 7.2</a>). </p> </section> <section id="CD006569-sec-0344"> <h5 class="title">7.3 Mental state: 1. Binary outcomes</h5> <p>No significant difference was noted in anxiety (n = 1361, 2 RCTs); "schizophrenia" (n = 548, 1 RCT) and psychotic disorder (n = 2881, 3 RCTs). Participants on aripiprazole experienced slightly less agitation (n = 548, 1 RCT, RR 2.64 CI 0.96 to 7.23, <a href="./references#CD006569-fig-0143" title="">Analysis 7.3</a>). </p> </section> <section id="CD006569-sec-0345"> <h5 class="title">7.4 Medication preference (study medication worse than or equal to previous medication)</h5> <p>People reported aripiprazole being better in the short term (n = 446, 1 RCT, RR 0.67 CI 0.49 to 0.91) and medium term (n = 330, 1 RCT, RR 0.39 CI 0.25 to 0.61). Carers, however, reported no difference in the two groups both in the short (n = 121, 1 RCT) and medium term (n = 80, 1 RCT, <a href="./references#CD006569-fig-0144" title="">Analysis 7.4</a>) </p> </section> <section id="CD006569-sec-0346"> <h5 class="title">7.5 Quality of life: 1. Unsatisfactory response (Health dimension scale)</h5> <p>Fewer participants reported an unsatisfactory response on the health dimension scale when using aripiprazole (n = 329, 1 RCT, RR 0.29 CI 0.13 to 0.66, <a href="./references#CD006569-fig-0145" title="">Analysis 7.5</a>). </p> </section> <section id="CD006569-sec-0347"> <h5 class="title">7.6 Quality of life: 2. Average change in Quality of Life score (high is better)</h5> <p>The results favoured other antipsychotics (n = 326, 1 RCT, MD 6.20 CI 3.08 to 9.32, <a href="./references#CD006569-fig-0146" title="">Analysis 7.6</a>). </p> </section> <section id="CD006569-sec-0348"> <h5 class="title">7.7 Quality of life: 3. Average EQ‐5D utility score (high is better)</h5> <p>No significant difference was noted in the two groups (n = 329, 1 RCT, <a href="./references#CD006569-fig-0147" title="">Analysis 7.7</a>). </p> </section> <section id="CD006569-sec-0349"> <h5 class="title">7.8 Quality of life: 4a. Weight‐related score ‐ no meaningful change (measured by Impact of Weight on Quality of Life (IWQoL‐Lite)) </h5> <p>No significant difference was noted in the two groups when weight was measured in binary scale (n = 327, 1 RCT, <a href="./references#CD006569-fig-0148" title="">Analysis 7.8</a>). </p> </section> <section id="CD006569-sec-0350"> <h5 class="title">7.9 Quality of life: 4b. Weight‐related score (measured by Impact of Weight on Quality of Life (IWQoL‐Lite)) </h5> <p>No significant difference was noted in the two groups for average change in weight in the short term (n = 443, 1 RCT) and medium term (n = 328, 1 RCT, <a href="./references#CD006569-fig-0149" title="">Analysis 7.9</a>). </p> </section> <section id="CD006569-sec-0351"> <h5 class="title">7.10 Leaving the study early</h5> <p>No significant difference was noted in the participants who left the study early in the three groups for any reason (n = 2908, 3 RCTs, RR 0.97 CI 0.78 to 1.19); administrative reasons (n = 833, 1 RCT, RR 0.80 CI 0.00 to 1.84); death (n = 555, 1 RCT, RR 0.48 CI 0.04 to 5.23); inefficacy (n = 2908, 3 RCTs, RR 0.94 CI 0.45 to 1.96); lost to follow‐up (n = 1388, 2 RCTs, RR 0.85 CI 0.34 to 2.13); no longer meets criteria (n = 1388, 2 RCTs, RR 0.65 CI 0.16 to 2.63); other (n = 1388, 2 RCTs, RR 0.62 CI 0.10 to 3.80); compliance issues (n = 1388, 2 RCTs, RR 1.10 CI 0.53 to 2.32) and pregnancy (n = 555, 1 RCT, RR 0.95 CI 0.14 to 6.73). More participants in the aripiprazole group left due to adverse events (n = 2908, 3 RCTs, RR 1.40 CI 1.11 to 1.76). Fewer participants in the aripiprazole group withdrew from the study (n = 2908, 3 RCTs, RR 0.48 CI 0.36 to 0.66, <a href="./references#CD006569-fig-0150" title="">Analysis 7.10</a>). </p> </section> <section id="CD006569-sec-0352"> <h5 class="title">7.11 Adverse effects ‐ 1. At least one side effect</h5> <p>Participants taking other antipsychotics reported this slightly more (n = 2333, 2 RCTs, RR 1.14 CI 1.05 to 1.23, <a href="./references#CD006569-fig-0151" title="">Analysis 7.11</a>). </p> </section> <section id="CD006569-sec-0353"> <h5 class="title">7.12 Adverse effects ‐ 2. Central nervous system</h5> <p>No significant difference was noted in sleep disorder (n = 813, 1 RCT, RR 1.79 CI 0.78 to 4.10) and fatigue (n = 548, 1 RCT, RR 0.59 CI 0.27 to 1.28). A larger number of participants on aripiprazole reported insomnia (n = 2881, 3 RCTs, RR 2.09 CI 1.65 to 2.66) and headache (n = 2881, 3 RCTs, RR 1.47 CI 1.09 to 1.99). Fewer participants on aripiprazole reported somnolence (n = 2881, 3 RCTs, RR 0.52 CI 0.39 to 0.71, <a href="./references#CD006569-fig-0152" title="">Analysis 7.12</a>). </p> </section> <section id="CD006569-sec-0354"> <h5 class="title">7.13 Adverse effects ‐ 3a. Endocrine system ‐ increase in prolactin level</h5> <p>Significantly fewer participants on aripiprazole reported an increased prolactin level (n = 548, 1 RCT, RR 0.31 CI 0.23 to 0.41, <a href="./references#CD006569-fig-0153" title="">Analysis 7.13</a>). </p> </section> <section id="CD006569-sec-0355"> <h5 class="title">7.14 Adverse effects ‐ 3b. Endocrine system ‐ change in prolactin level from baseline</h5> <p>The results favoured aripiprazole (n = 94, 1 RCT, MD ‐8.60 CI ‐19.14 to 1.94, <a href="./references#CD006569-fig-0154" title="">Analysis 7.14</a>). </p> </section> <section id="CD006569-sec-0356"> <h5 class="title">7.15 Adverse effects ‐ 4. Extrapyramidal symptoms (EPS)</h5> <p>The results did not favour any of the comparison groups with a large confidence interval (n = 2881, 3 RCTs, RR 1.02 CI 0.09 to 11.09, <a href="./references#CD006569-fig-0155" title="">Analysis 7.15</a>) and prohibitively high heterogeneity (97%). It is unclear why <a href="./references#CD006569-bbs2-0097" title="RieraL , HuR , StockE , NyilasM , TorbeynsA , BorianF , et al. Broad effectiveness trial with aripiprazole. Schizophrenia Research2004;67(1):157. TandonR , MarcusRN , StockEG , RieraLC , KosticD , PansM , et al. A prospective, multicenter, randomized, parallel‐group, open‐label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad Effectiveness Trial With aripiprazole (BETA). Schizophrenia Research2006;84(1):77‐89. ">Tandon 2006</a> causes this and removal of this study results in homogeneity being restored. </p> </section> <section id="CD006569-sec-0357"> <h5 class="title">7.16 Adverse effects ‐ 5. Gastrointestinal</h5> <p>A significantly larger number of people given aripiprazole reported symptoms of nausea (n = 2881, 3 RCTs, RR 3.13 CI 2.12 to 4.61, <a href="./references#CD006569-fig-0156" title="">Analysis 7.16</a>). </p> </section> <section id="CD006569-sec-0358"> <h5 class="title">7.17 Adverse effects ‐ 6a. Metabolic ‐ binary measures</h5> <p>Significantly fewer people allocated aripiprazole reported 7% or more weight gain in the medium term (n = 330, 1 RCT, RR 0.35 CI 0.19 to 0.64); average weight gain (n = 548, 1 RCT, RR 0.11 CI 0.03 to 0.37); total cholesterol increase (n = 269, 1 RCT, RR 0.75 CI 0.62 to 0.91) and low‐density lipoprotein (LDL) increase (n = 268, 1 RCT, RR 0.65 CI 0.51 to 0.84). We found no significant difference in either group in high‐density lipoprotein (HDL) increase (n = 269, 1 RCT, RR 0.87 CI 0.61 to 1.22); triglyceride increase (n = 267, 1 RCT, RR O.80 CI 0.64 to 1.00) and increase in fasting glucose (n = 236, 1 RCT, RR 0.95 CI 0.62 to1.47). A greater number of people given aripiprazole reported 7% or more of weight loss in the medium term (n = 330, 1 RCT, RR 1.75 CI 0.97 to 3.19, <a href="./references#CD006569-fig-0157" title="">Analysis 7.17</a>). </p> </section> <section id="CD006569-sec-0359"> <h5 class="title">7.18 Adverse effects ‐ 6b. Metabolic ‐ continuous measures</h5> <p>Aripiprazole was favoured for no risk of weight gain (n = 537, 1 RCT, MD ‐2.70 CI ‐3.68 to ‐1.72); weight change from baseline (n = 441, 1 RCT, MD short term ‐2.48 CI ‐3.30 to ‐1.66; n = 327, 1 RCT, MD medium term ‐3.74 CI ‐4.65 to ‐2.83); and change in fasting cholesterol (n = 262, 1 RCT, MD ‐9.70 CI ‐16.07 to ‐3.33). There was no difference reported in change in fasting glucose (n = 229, 1 RCT, MD ‐1.90 CI ‐5.78 to 1.98, <a href="./references#CD006569-fig-0158" title="">Analysis 7.18</a>). </p> </section> </section> <section id="CD006569-sec-0360"> <h4 class="title">8. SENSITIVITY ANALYSIS</h4> <p>We planned to undertake a sensitivity analysis for the primary outcomes of interest of (i) no clinically important response (as defined by each study); (ii) general functioning; and (iii) clinically important specific adverse effects. No study, however, reported data for the outcome of general functioning. For sensitivity analysis of 'comparator dose', we tested outcome of (i) no clinically important response (as defined by each study); and (ii) general mental state. </p> <section id="CD006569-sec-0361"> <h5 class="title">8.1 Implication of randomisation</h5> <section id="CD006569-sec-0362"> <h6 class="title">8.1.1 Aripiprazole versus Clozapine</h6> <section id="CD006569-sec-0363"> <p><b>8.1.1.1 Global state: no clinically significant response (as defined by the individual studies)</b></p> <p>There remained no significant differences between groups after removing studies from meta‐analysis that only implied randomisation (n = 322, 4 RCTs, RR 1.04 CI 0.76 to 1.44). </p> </section> <section id="CD006569-sec-0364"> <p><b>8.1.1.2 Adverse effects ‐ clinically important specific adverse effects</b></p> <p>Few studies provided data at medium term for any clinically important adverse effects; for EPS effects, only one study (<a href="./references#CD006569-bbs2-0045" title="LiM , WuN , LiY‐F . Comparative study of influence of aripiprazole on life quality in schizophrenic patients. Chinese Journal of Health Psychology2007;15(10):956‐7.[MEDLINE:]. ">Li 2007</a>) provided relevant data. This study only implied randomisation, therefore after removing this study from data and analysis, there were no data left to compare. However, at short term, there remained no significant differences between groups after removing studies from meta‐analysis that only implied randomisation for the outcome of 'general EPS' (n = 60, 1 RCT, RR 1.50 CI 0.27 to 8.34). When implied randomised studies were removed from the outcome of akathisia, there was significantly greater instances (P = 0.002) in people receiving aripiprazole (n = 180, 2 RCTs, RR 4.99 CI 1.78 to 14.00). </p> </section> </section> <section id="CD006569-sec-0365"> <h6 class="title">8.1.2 Aripiprazole versus Quetiapine</h6> <section id="CD006569-sec-0366"> <p><b>8.1.2.1 Global state: no clinically significant response (as defined by the individual studies)</b></p> <p>There remained no significant differences between groups after removing studies from meta‐analysis that only implied randomisation (n = 108, 1 RCT, RR 1.00 CI 0.26 to 3.79). </p> </section> <section id="CD006569-sec-0367"> <p><b>8.1.2.2 Adverse effects ‐ clinically important specific adverse effects</b></p> <p>All adverse data reported are for the short term; there remained no significant differences between groups after removing studies from meta‐analysis that only implied randomisation for the outcome of akathisia (n = 108, 1 RCT, RR 2.00 CI 0.19 to 21.41). This was also the case for tremor (n = 108, 1 RCT, RR 0.33 CI 0.01 to 8.01). Remaining studies in other outcomes of dystonia and general EPS were all implied as randomised; therefore, the removal of these studies left us with no data to compare. </p> </section> </section> <section id="CD006569-sec-0368"> <h6 class="title">8.1.3 Aripiprazole versus Risperidone</h6> <section id="CD006569-sec-0369"> <p><b>8.1.3.1 Global state: no clinically significant response (as defined by the individual studies)</b></p> <p>There remained no significant differences between groups after removing studies from meta‐analysis that only implied randomisation (n = 703, 7 RCTs, RR 1.29 CI 0.87 to 1.92). </p> </section> <section id="CD006569-sec-0370"> <p><b>8.1.3.2 Adverse effects ‐ clinically important specific adverse effects</b></p> <p>All adverse data reported are for the short term; data were no longer statistically significant in favour of aripiprazole for akathisia after removing studies from the meta‐analysis that only implied randomisation (n = 293, 4 RCTs, RR 0.93 CI 0.45 to 1.90), this was also the case for tremor (n = 210, 3 RCTs, RR 0.61 CI 0.30 to 1.23). Data were still statistically significant (P = 0.003, albeit slightly lower in the level of significance) in favour of aripiprazole for the outcome of dystonia after the removal of implied randomised studies from meta‐analysis (n = 210, 3 RCTs, RR 0.17 CI 0.05 to 0.56), as well as for general EPS (n = 367, 4 RCTs, RR 0.53 CI 0.35 to 0.80). All data for tremor and parkinsonism were from implied randomised studies, which left no data to compare after removal. </p> </section> </section> <section id="CD006569-sec-0371"> <h6 class="title">8.1.4 Aripiprazole versus Ziprasidone</h6> <section id="CD006569-sec-0372"> <p><b>8.1.4.1 Global state: no clinically important response (as defined by the individual studies)</b></p> <p>All studies reporting this outcome were implied as randomised; therefore, there were no data left to compare once they were removed from the meta‐analysis. </p> </section> <section id="CD006569-sec-0373"> <p><b>8.1.4.2 Adverse effects ‐ clinically important specific adverse effects</b></p> <p>All adverse data reported are for the short term; data remained equivocal for akathisia after removing implied randomised studies (n = 253, 1 RCT, RR 1.26 CI 0.48 to 3.27). Data for all other various EPS outcomes, including dystonia, tremor, use of antiparkinson medication and general EPS effects, were reported by implied randomised studies, leaving no data to compare once removed from analysis. </p> </section> </section> <section id="CD006569-sec-0374"> <h6 class="title">8.1.5 Aripiprazole versus Olanzapine</h6> <section id="CD006569-sec-0375"> <p><b>8.1.5.1 Global state: no clinically significant response (as defined by the individual studies)</b></p> <p>There remained no significant differences between groups after removing studies from meta‐analysis that only implied randomisation (n = 778, 2 RCTs, RR 1.00 CI 0.82 to 1.23). </p> </section> <section id="CD006569-sec-0376"> <p><b>8.1.5.2 Adverse effects ‐ clinically important specific adverse effects</b></p> <p>Data proved statistically significant (P = 0.05) in favour of olanzapine for akathisia after removing implied randomised studies from meta‐analysis (n = 75, 1 RCT, RR 16.68 CI 1.01 to 276.65), while data for remaining extrapyramidal effects (tremor, EPS, parkinsonism) were from implied randomised studies, leaving no data to compare. </p> </section> </section> <section id="CD006569-sec-0377"> <h6 class="title">8.1.6 Aripiprazole versus Olanzapine (acutely agitated)</h6> <p>The one study included in this comparison only implied randomisation, therefore there were no data left to compare. </p> </section> <section id="CD006569-sec-0378"> <h6 class="title">8.1.7 Aripiprazole versus Other antipsychotic drugs</h6> <section id="CD006569-sec-0379"> <p><b>8.1.7.1 Global state: no clinically significant response (as defined by the individual studies)</b></p> <p>The one study included in this outcome only implied randomisation, therefore there were no data left to compare. </p> </section> <section id="CD006569-sec-0380"> <p><b>8.1.7.2 Adverse effects ‐ clinically important specific adverse effects</b></p> <p>For the outcome of akathisia, after removing the two studies that implied randomisation, only one study (with higher methodological quality) was left to compare (<a href="./references#CD006569-bbs2-0097" title="RieraL , HuR , StockE , NyilasM , TorbeynsA , BorianF , et al. Broad effectiveness trial with aripiprazole. Schizophrenia Research2004;67(1):157. TandonR , MarcusRN , StockEG , RieraLC , KosticD , PansM , et al. A prospective, multicenter, randomized, parallel‐group, open‐label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad Effectiveness Trial With aripiprazole (BETA). Schizophrenia Research2006;84(1):77‐89. ">Tandon 2006</a>), which eliminated the heterogeneity present and found statistical significance (P = 0.00001) in favour of aripiprazole over other antipsychotic drugs (n = 1520, 1 RCT, RR 0.17 CI 0.12 to 0.22). </p> </section> </section> </section> <section id="CD006569-sec-0381"> <h5 class="title">8.2 Assumptions for lost binary data</h5> <section id="CD006569-sec-0382"> <h6 class="title">8.2.1 Aripiprazole versus Clozapine</h6> <p>Only one study for this comparison did not report all data. <a href="./references#CD006569-bbs2-0144" title="YuC‐X , JiD‐C , YuanH . The study of clinical efficacy of aripiprazole in the treatment for refractory schizophrenia [阿立哌唑治疗难治性精神分裂症的疗效观察]. Shandong Jingshen Yixue2006;19(4):263‐5. ">Yu 2006</a> reported the loss of n = 5 participants; however it was not clear to which group these participants belonged. </p> </section> <section id="CD006569-sec-0383"> <h6 class="title">8.2.2 Aripiprazole versus Quetiapine</h6> <p>No included studies reported losses for this comparison.</p> </section> <section id="CD006569-sec-0384"> <h6 class="title">8.2.3 Aripiprazole versus Risperidone</h6> <section id="CD006569-sec-0385"> <p><b>8.2.3.1 Global state: no clinically significant response (as defined by the individual studies)</b></p> <p>There remained no difference in the estimate of effect when completer‐only data were pooled at short term (79 RCTs, n = 6245, RR 1.12 CI 0.98 to 1.28). </p> </section> </section> <section id="CD006569-sec-0386"> <h6 class="title">8.2.4 Aripiprazole versus Ziprasidone</h6> <p>No included studies reported losses for this comparison.</p> </section> <section id="CD006569-sec-0387"> <h6 class="title">8.2.5 Aripiprazole versus Olanzapine</h6> <section id="CD006569-sec-0388"> <p><b>8.2.5.1 Global state: no clinically significant response (as defined by the individual studies</b></p> <p>There remained no difference in the estimate of effect when completer‐only data were pooled in the short and medium term combined (11 RCTs, n = 1558, RR 1.04 CI 0.93 to 1.16). </p> </section> </section> <section id="CD006569-sec-0389"> <h6 class="title">8.2.6 Aripiprazole versus Olanzapine (acutely agitated)</h6> <p>The one study included in this comparison did not report losses for this comparison.</p> </section> <section id="CD006569-sec-0390"> <h6 class="title">8.2.7 Aripiprazole versus Other antipsychotic drugs</h6> <p>No included studies reported losses for this comparison.</p> </section> </section> <section id="CD006569-sec-0391"> <h5 class="title">8.3 Risk of bias</h5> <section id="CD006569-sec-0392"> <h6 class="title">8.3.1 Aripiprazole versus Clozapine</h6> <section id="CD006569-sec-0393"> <p><b>8.3.1.1 Global state: no clinically significant response (as defined by the individual studies)</b></p> <p>There remained no significant differences between groups after removing studies from meta‐analysis that rated as a 'high' risk on one or more of the risk of bias domains (n = 90, 1 RCT, RR 0.91 CI 0.32 to 2.62). </p> </section> <section id="CD006569-sec-0394"> <p><b>8.3.1.2 General functioning: no clinically important change in general functioning</b></p> <p>No included study reported this outcome.</p> </section> <section id="CD006569-sec-0395"> <p><b>8.3.1.3 Adverse effects ‐ clinically important specific adverse effects</b></p> <p>For extrapyramidal effects, all studies rated as a 'high' risk on one or more of the risk of bias domains, leaving no data to compare for this outcome. </p> </section> </section> <section id="CD006569-sec-0396"> <h6 class="title">8.3.2 Aripiprazole versus Quetiapine</h6> <section id="CD006569-sec-0397"> <p><b>8.3.2.1 Global state: no clinically significant response (as defined by the individual studies)</b></p> <p>All studies rated as a 'high' risk on one or more of the risk of bias domains, leaving no data to compare for this outcome. </p> </section> <section id="CD006569-sec-0398"> <p><b>8.3.2.2 General functioning: no clinically important change in general functioning</b></p> <p>No included study reported this outcome.</p> </section> <section id="CD006569-sec-0399"> <p><b>8.3.2.3 Adverse effects ‐ clinically important specific adverse effects</b></p> <p>All studies rated as a 'high' risk on one or more of the risk of bias domains, leaving no data to compare for this outcome. </p> </section> </section> <section id="CD006569-sec-0400"> <h6 class="title">8.3.3 Aripiprazole versus Risperidone</h6> <section id="CD006569-sec-0401"> <p><b>8.3.3.1 Global state: no clinically significant response (as defined by the individual studies)</b></p> <p>There remained no significant differences between groups after removing studies from meta‐analysis that rated as a 'high' risk on one or more of the risk of bias domains (n = 465, 6 RCTs, RR 1.27 CI 0.69 to 2.31). </p> </section> <section id="CD006569-sec-0402"> <p><b>8.3.3.2 General functioning: no clinically important change in general functioning</b></p> <p>No included study reported this outcome.</p> </section> <section id="CD006569-sec-0403"> <p><b>8.3.3.3 Adverse effects ‐ clinically important specific adverse effects</b></p> <p>All adverse data reported are for the short term; data were no longer statistically significant in favour of aripiprazole for akathisia after removing studies that rated as a 'high' risk on one or more of the risk of bias domains (n = 161, 2 RCTs, RR 0.59 CI 0.14 to 2.55), this was also the case for tremor (n = 161, 2 RCTs, RR 0.20 CI 0.04 to 1.14), and dystonia (n = 161, 2 RCTs, RR 0.17 CI 0.59 to 4.21). However, data were still statistically significant (P = 0.0001) in favour of aripiprazole for general EPS (n = 284, 4 RCTs, RR 0.29 CI 0.16 to 0.51). All data for tremor and parkinsonism were rated as 'high' risk on one or more of the risk of bias domains, which left no data to compare after removal. </p> </section> </section> <section id="CD006569-sec-0404"> <h6 class="title">8.3.4 Aripiprazole versus Ziprasidone</h6> <p>All studies providing data for all primary outcomes rated as a 'high' risk on one or more of the risk of bias domains, leaving no data to compare for this outcome in a sensitivity analysis. </p> </section> <section id="CD006569-sec-0405"> <h6 class="title">8.3.5 Aripiprazole versus Olanzapine</h6> <p>All studies providing data for all primary outcomes rated as a 'high' risk on one or more of the risk of bias domains, leaving no data to compare for this outcome in a sensitivity analysis. </p> </section> <section id="CD006569-sec-0406"> <h6 class="title">8.3.6 Aripiprazole versus Olanzapine (acutely agitated)</h6> <p>The one study included in this comparison rated as a 'high' risk on one or more of the risk of bias domains, therefore there were no data left to compare. </p> </section> <section id="CD006569-sec-0407"> <h6 class="title">8.3.7 Aripiprazole versus Other antipsychotic drugs</h6> <p>Again, all studies providing data for all primary outcomes rated as a 'high' risk on one or more of the risk of bias domains, leaving no data to compare for this outcome in a sensitivity analysis. </p> </section> </section> <section id="CD006569-sec-0408"> <h5 class="title">8.4 Imputed values</h5> <p>No values were imputed for intra‐class correlation coefficients (ICC), since we included no cluster randomised trials in meta‐analysis. </p> </section> <section id="CD006569-sec-0409"> <h5 class="title">8.5 Skewed data</h5> <p>All skewed data have been presented separately in tables within data and analyses, therefore a sensitivity analysis was not possible via meta‐analysis. </p> </section> <section id="CD006569-sec-0410"> <h5 class="title">8.6 Comparator dose</h5> <p>Not all studies reported mean doses and standard deviations; therefore, this sensitivity analysis has been undertaken with the dose values made available, taking predominantly ranges into account. </p> <section id="CD006569-sec-0411"> <h6 class="title">8.6.1 Aripiprazole versus Clozapine</h6> <section id="CD006569-sec-0412"> <p><b>8.6.1.1 Global state: no clinically significant response (as defined by the individual studies)</b></p> <p>There remained no significant difference between groups when removing two studies (<a href="./references#CD006569-bbs2-0045" title="LiM , WuN , LiY‐F . Comparative study of influence of aripiprazole on life quality in schizophrenic patients. Chinese Journal of Health Psychology2007;15(10):956‐7.[MEDLINE:]. ">Li 2007</a>; <a href="./references#CD006569-bbs2-0146" title="YuL , LiB . A control study of aripirazole and clozapine in the treatment of first‐episode schizophrenia [阿立哌唑与氯氮平治疗首发精神分裂症对照研究]. Journal of Clinical Psychosomatic Diseases [临床心身疾病杂志]2007;13(2):115‐6. ">Yu 2007</a>) that compared doses of aripiprazole that exceeded BNF recommendations to lower doses of clozapine (27 RCTs, n = 1978, RR 1.08 CI 0.88 to 1.32). </p> </section> <section id="CD006569-sec-0413"> <p><b>8.6.1.2 General mental state (BPRS/ PANSS)</b></p> <p>At short term, none of the five studies rating mental state using the BPRS (endpoint scores) used inappropriate comparator doses, therefore there were no differences between results. Using the PANSS at short term, after removing the two studies (<a href="./references#CD006569-bbs2-0045" title="LiM , WuN , LiY‐F . Comparative study of influence of aripiprazole on life quality in schizophrenic patients. Chinese Journal of Health Psychology2007;15(10):956‐7.[MEDLINE:]. ">Li 2007</a>; <a href="./references#CD006569-bbs2-0146" title="YuL , LiB . A control study of aripirazole and clozapine in the treatment of first‐episode schizophrenia [阿立哌唑与氯氮平治疗首发精神分裂症对照研究]. Journal of Clinical Psychosomatic Diseases [临床心身疾病杂志]2007;13(2):115‐6. ">Yu 2007</a>) that compared doses of aripiprazole that exceeded BNF recommendations to lower doses of clozapine, there was still no significant difference between groups, (23 RCTs, n = 1484, MD 0.55 CI ‐0.53 to 1.63), however the degree of heterogeneity was reduced from I<sup>2</sup> = 64% (P = 0.0001) to I<sup>2</sup> = 44% (P = 0.02). At medium term, three studies provided data using PANSS used comparisons within the recommended doses. </p> </section> </section> <section id="CD006569-sec-0414"> <h6 class="title">8.6.2 Aripiprazole versus Quetiapine</h6> <section id="CD006569-sec-0415"> <p><b>8.6.2.1 Global state: no clinically significant response (as defined by the individual studies)</b></p> <p>Three studies exceeded recommended doses of clozapine, each employing a maximum dose of 800 mg daily (<a href="./references#CD006569-bbs2-0010" title="陈红英 , 张郦 , 付迎春 , 季海峰 , 费玥 , 黄雅南 . Aripiprazole and quetiapine in the treatment of schizophrenia] Google Translate [阿立哌唑和喹硫平治疗精神分裂症的对照研究]. Shandong Archives of Psychiatry [山东精神医学]2009;22(1):53‐4. ">Chen 2009</a>; <a href="./references#CD006569-bbs2-0047" title="李美花 , 吕伟 , 邢秀娟 . Aripiprazole and quetiapine in the treatment of schizophrenia [阿立哌唑和喹硫平治疗精神分裂症的对照研究]. 中国医师进修杂志2007;30(11A):49‐50. ">Li 2007b</a>; <a href="./references#CD006569-bbs2-0069" title="LuoX , AnB‐F . Comparison of quetiapine and aripiprazole in the treatment of first episode schizophrenia [奎硫平与阿立哌唑治疗首发精神分裂症对照研究]. Linchuang Jingshen Yixue Zazhi [临床精神医学杂志]2008;18(3):191‐2. ">Luo 2008</a>). There was no difference in the estimate of the effect when these studies were excluded from meta‐analysis (9 RCTs, n = 801, RR 0.91 CI 0.59 to 1.14) </p> </section> <section id="CD006569-sec-0416"> <p><b>8.6.2.2 General mental state (BPRS/ PANSS)</b></p> <p>No studies provided data for general average endpoint scores using either the BPRS or PANSS. </p> </section> </section> <section id="CD006569-sec-0417"> <h6 class="title">8.6.3 Aripiprazole versus Risperidone</h6> <p>The majority of studies used a range with a maximum of 6 mg daily risperidone, which exceeds the 4 mg BNF recommendation. </p> <section id="CD006569-sec-0418"> <p><b>8.6.3.1 Global state: no clinically significant response (as defined by the individual studies)</b></p> <p>After excluding 70 studies with a range of 1 to 6 mg risperidone, there remained no difference between groups (9 RCTs, n = 727, RR 1.14 CI 0.76 to 1.71). </p> </section> <section id="CD006569-sec-0419"> <p><b>8.6.3.2 General mental state (BPRS/ PANSS)</b></p> <p>For average endpoint mental state in the short term using BPRS, after excluding four of the five studies providing data, there was no longer significant favour for aripiprazole, instead showing no difference between groups (1 RCT, n = 68, MD 2.30 CI ‐1.17 to 5.77) and removing all heterogeneity. For PANSS in the short term, after removing 69 studies that used a higher than recommended dose of risperidone, results still demonstrated no difference (8 RCTs, n = 659, MD ‐0.50 CI ‐2.09 to 1.09s), however all heterogeneity was removed. </p> </section> </section> <section id="CD006569-sec-0420"> <h6 class="title">8.6.4 Aripiprazole versus Ziprasidone</h6> <p>None of the included studies for the outcomes of interest used inappropriate comparator doses; therefore, there were no studies to exclude. </p> </section> <section id="CD006569-sec-0421"> <h6 class="title">8.6.5 Aripiprazole versus Olanzapine</h6> <p>None of the included studies for the outcomes of interest used inappropriate comparator doses; therefore, there were no studies to exclude. </p> </section> <section id="CD006569-sec-0422"> <h6 class="title">8.6.6 Aripiprazole versus Olanzapine (acutely agitated)</h6> <p>The one study included in this comparison did not use any inappropriate comparator doses, therefore there was no difference in results. </p> </section> <section id="CD006569-sec-0423"> <h6 class="title">8.6.7 Aripiprazole versus Other antipsychotic drugs</h6> <p>Of the three studies included in this outcome, <a href="./references#CD006569-bbs2-0040" title="BeuzenJN , L'ItalienG , HanssensL , MarcusRN , McQuadeRD , CarsonWH . Changes in prolactin levels and arizona sexual experience scale (ASEX) scores among patients switched from risperidone to aripiprazole in the schizophrenia trial of aripiprazole (STAR) study. Schizophrenia Bulletin2007;33(2):421‐2. BlondeL , KanHJ , GuttermanEM , L'ItalienGJ , KimMS , HanssensL , et al. Predicted risk of diabetes and coronary heart disease in patients with schizophrenia: aripiprazole versus standard of care. Journal of Clinical Psychiatry2008;69(5):741‐8. [MEDLINE: 18435564] HanssensL , L'ItalienG , MarcusRN , McQuadeRD , CarsonWH , BeuzenJN . Reasons for switching from previous therapy and preference of medication in the large, randomized, naturalistic schizophrenia trial of aripiprazole (STAR). Schizophrenia Bulletin2007;33(2):432. HanssensL , L’ ItalienG , McQuadeR , IwamotoT , PansM . Evaluation of quality of life in community‐treated schizophrenic patients: a naturalistic, open‐label study comparing aripiprazole to standard‐of‐care (Schizophrenia Trial of aripiprazole: STAR study). European Psychiatry2006;21(Suppl 1):S99. KerwinR , MilletB , HermanE , BankiCM , LublinH , PansM , et al. A multi centre, randomized, naturalistic, open‐label study between aripiprazole and standard of care in the management of community‐treated schizophrenic patients Schizophrenia Trial of aripiprazole: (STAR) study. European Psychiatry2007;22(7):433‐43. [MEDLINE: 17555947] KerwinR , MilletB , HermanE , BankiCM , LublinH , PansM , et al. A multi centre, randomized, naturalistic, open‐label study between aripiprazole and standard of care in the management of community‐treated schizophrenic patients. Schizophrenic Trial of aripiprazole: (STAR) study. Wiadomosci Psychiatryczne2008;11(2):105‐19. KingD , KnappM , ThomasP , RazzoukD , LozeJY , KanHJ , et al. Cost‐effectiveness analysis of aripiprazole vs standard‐of‐care in the management of community‐treated patients with schizophrenia: Star study. Current Medical Research and Opinion2011;27(2):365‐74. KolotkinRL , Corey‐LislePK , CrosbyRD , KanHJ , McQuadeRD . Changes in weight and weight‐related quality of life in a multi centre, randomized trial of aripiprazole versus standard of care. European Psychiatry2008;23(8):561‐6. [MEDLINE: 18374544] L'ItalienG , HanssensL , KanHJ , BakerRA , MarcusRN , McQuadeRD , et al. Metabolic effects of aripiprazole versus olanzapine, quetiapine, or risperidone (the STAR trial). Schizophrenia Bulletin2007;33(2):439. L'ItalienGJ , BlondeL , HanssensL , McQuadeR . Prevalence of diabetes/cardiovascular risk factors among schizophrenia patients treated with atypical antipsychotics in a multicenter, randomized, naturalistic, open‐label study (Schizophrenia Trial of aripiprazole: STAR study). Diabetes2006;55(Suppl 1):A538. L'ltalienGJ , HanssensL , MarcusRN , McQuadeRD . Evidence of antipsychotic treatment selection based on metabolic risk factors among community‐based schizophrenia patients (The STAR Trial). Proceedings of the 160th Annual Meeting of the American Psychiatric Association; 2007 May 19‐24; San Diego, CA2007. MilletB . A multicenter, randomized, naturalistic, open‐label study between aripiprazole and standard of care in the management of community‐treated schizophrenic patients (Schizophrenia Trial of aripiprazole ‐ STAR). http://www.clinicaltrials.gov2005. TaylorD , HanssensL , LozeJ‐Y , PansM , L'ItalienG , MarcusRN . Preference of medicine and patient‐reported quality of life in community‐treated schizophrenic patients receiving aripiprazole vs standard of care: results from the STAR study. European Psychiatry2008;23(5):336‐43. ">Kerwin 2007</a> used higher than recommended doses of risperidone and quetiapine; however, this study did not provide data for the outcomes of interest, therefore there were no difference between results. </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD006569-sec-0424" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD006569-sec-0424"></div> <p>Many trials were sponsored by the manufacturers of aripiprazole or the comparator agent manufacturers. In a blinded analysis of abstracts it has been shown that pharmaceutical companies emphasize positive aspects of their compounds (<a href="./references#CD006569-bbs2-0299" title="HeresS , DavisJ , MainoK , JetzingerE , KisslingW , LeuchtS . Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine. American Journal of Psychiatry2006;163:185‐94. ">Heres 2006</a>). Every result, without exception, therefore, must be viewed with this in mind. </p> <section id="CD006569-sec-0425"> <h3 class="title" id="CD006569-sec-0425">Summary of main results</h3> <section id="CD006569-sec-0426"> <h4 class="title">1. COMPARISON 1. ARIPIPRAZOLE versus CLOZAPINE</h4> <p>Thirty‐nine studies fell into this category, please see <a href="./full#CD006569-tbl-0001">summary of findings Table for the main comparison</a>. Data are generally of poor quality and we found no data on indices including service use or global functioning. Overall, inclusion of new Chinese studies gave us much more data for this comparison. Quality of life outcomes, more often than not, significantly favoured use of aripiprazole over clozapine. However, there was no difference between the use of either drug for the primary outcome of clinically significant response in global state. Largely, people were at significantly less risk of adverse effects when receiving aripiprazole (<a href="./references#CD006569-fig-0024" title="">Analysis 1.15</a>; <a href="./references#CD006569-fig-0025" title="">Analysis 1.16</a>), but greater risk of central nervous system (CNS) adverse effects such as headache and insomnia than people receiving clozapine (<a href="./references#CD006569-fig-0026" title="">Analysis 1.17</a>), Extrapyramidal effects (EPS) were largely equivocal between groups. Data were heterogeneous as regards EPS, which may well be attributable to the differing doses employed between studies ‐ as some used low doses (between 5 to 20 mg aripiprazole versus 5 to 500 mg clozapine) of either drugs, and some used slightly higher (10 to 30 mg aripiprazole versus 50 to 270 mg clozapine). Evidence from 11 studies (n = 732) does suggest that people receiving aripiprazole had a greater risk of experiencing anxiety in the short term (<a href="./references#CD006569-fig-0011" title="">Analysis 1.2</a>). </p> </section> <section id="CD006569-sec-0427"> <h4 class="title">2. COMPARISON 2. ARIPIPRAZOLE versus QUETIAPINE</h4> <p>Fifteen studies provided data for this comparison, please see <a href="./full#CD006569-tbl-0002">summary of findings Table 2</a>; again, the inclusion of new Chinese studies gave us data for this comparison, which was lacking in the previous version of this review. The quality of the data were generally 'low' to 'very low', due to poor outcome reporting and methodological quality. There were, again, no data for service use; only one study reported data using any quality of life scale, which significantly favoured use of aripiprazole in six out of the seven components measured. Further larger scale, high‐quality trials are needed in order to reach any confident conclusions for this outcome. The evidence from 12 included studies (n = 991) suggest no significant difference between the two drugs in terms of clinically significant response. Adverse effect data do suggest a greater risk of tachycardia in people receiving quetiapine (<a href="./references#CD006569-fig-0046" title="">Analysis 2.13</a>), as well as dry mouth, constipation (<a href="./references#CD006569-fig-0049" title="">Analysis 2.16</a>) and weight gain (<a href="./references#CD006569-fig-0052" title="">Analysis 2.19</a>). However, nausea and vomiting was more common in people receiving aripiprazole (<a href="./references#CD006569-fig-0049" title="">Analysis 2.16</a>). </p> </section> <section id="CD006569-sec-0428"> <h4 class="title">3. COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE</h4> <p>Eighty studies (n = 6381) report data for the primary outcome of clinically significant response for this important comparison. Risperidone, now off‐licence, is inexpensive and widely accessible; aripiprazole is not. Data are, again, of limited quality (randomisation and concealment methods being unclear, <a href="./full#CD006569-tbl-0003">summary of findings Table 3</a>), however, this current update search has provided data that were lacking in the previous version of this review, including global functioning, and economic analyses; however, service use data are still missing. The majority of reported data are short term; adverse effects were selectively reported and studies were often sponsored by pharmaceutical companies. </p> <p>For global outcomes there were no convincing differences between the two drugs (<a href="./references#CD006569-fig-0054" title="">Analysis 3.1</a>, <a href="./references#CD006569-fig-0055" title="">Analysis 3.2</a>, <a href="./references#CD006569-fig-0056" title="">Analysis 3.3</a>, <a href="./references#CD006569-fig-0057" title="">Analysis 3.4</a>). Binary mental state data were largely equivocal, with the exception of anxiety, which was significantly higher in people receiving aripiprazole (<a href="./references#CD006569-fig-0058" title="">Analysis 3.5</a>). Scale data for mental state favoured aripiprazole using the BPRS and PANSS average endpoint negative score (<a href="./references#CD006569-fig-0059" title="">Analysis 3.6</a>; <a href="./references#CD006569-fig-0061" title="">Analysis 3.8</a>). As regards adverse effects, the only convincing data were for tachycardia (<a href="./references#CD006569-fig-0069" title="">Analysis 3.16</a>) and abnormal liver function (<a href="./references#CD006569-fig-0068" title="">Analysis 3.15</a>) in risperidone. Risperidone also carried greater risk of metabolic adverse effects (<a href="./references#CD006569-fig-0078" title="">Analysis 3.25</a>) including weight gain, menstrual disorder and lactation. General EPS, akathisia, tremor and dystonia were all significantly higher in people receiving risperidone than aripiprazole (<a href="./references#CD006569-fig-0074" title="">Analysis 3.21</a>). Again, headache (<a href="./references#CD006569-fig-0071" title="">Analysis 3.18</a>), and nausea and vomiting were significantly more prominent in people receiving aripiprazole (<a href="./references#CD006569-fig-0076" title="">Analysis 3.23</a>). Both drugs may cause movement disorders and about one third of people allocated aripiprazole used antiparkinsonian drugs (<a href="./references#CD006569-fig-0074" title="">Analysis 3.21</a>). </p> </section> <section id="CD006569-sec-0429"> <h4 class="title">4. COMPARISON 4. ARIPIPRAZOLE versus ZIPRASIDONE</h4> <p>The addition of new Chinese studies gave us an additional 15 studies to add to the previous one in this comparison. Ziprasidone is a major competitor of aripiprazole but data are of limited quality (<a href="./full#CD006569-tbl-0004">summary of findings Table 4</a>), and there are still no data for service use. Data are all short term (four weeks). </p> <p>There really does seem to be very little suggestion of differences in global state, attrition (about one third of people left in a matter of a few weeks) and mental state; however, there was greater improvement noted using SANS in people receiving aripiprazole in three RCTs (n = 238). </p> <p>As regards adverse effects, there were largely no clear differences between groups; however, people receiving aripiprazole were significantly more likely to show signs of dizziness and insomnia (<a href="./references#CD006569-fig-0097" title="">Analysis 4.11</a>) as well as weight gain (<a href="./references#CD006569-fig-0102" title="">Analysis 4.16</a>). There is a need for better trials providing clear information for all interested in the care of people with schizophrenia who have access to these drugs. </p> </section> <section id="CD006569-sec-0430"> <h4 class="title">5. COMPARISON 5. ARIPIPRAZOLE versus OLANZAPINE</h4> <p>Nineteen studies reported data for this comparison, see <a href="./full#CD006569-tbl-0005">summary of findings Table 5</a>. Data are generally of poor quality and we found no data on indices including service use or global functioning. The inclusion of new Chinese studies gave data for quality of life outcomes (one RCT), which were lacking in the previous version of this review. The studies, although randomised and blinded, lack clarity on how both were carried out. Some studies were sponsored by pharmaceutical companies and adverse effects were seemingly selectively reported. </p> <p>Even with the addition of new studies, global state outcomes show no clear differences between the drugs and the various measures of mental state did not clearly point to an advantage of one drug over another. The only significant findings from PANSS showed greater improvement in positive symptoms over each short, medium and long term combined (<a href="./references#CD006569-fig-0114" title="">Analysis 5.11</a>). Approaching 50% of people left these studies for any reason (<a href="./references#CD006569-fig-0130" title="">Analysis 5.27</a>) which may be a reflection of study design. </p> <p>Regarding adverse effects, extrapyramidal side effects did not appear to be  a major problem. Weight gain appears to be olanzapine’s major shortcoming when compared with aripiprazole (<a href="./references#CD006569-fig-0127" title="">Analysis 5.24</a>). This is important as there were significantly smaller mean increase of cholesterol levels from baseline in the aripiprazole group than in people allocated olanzapine (<a href="./references#CD006569-fig-0128" title="">Analysis 5.25</a>). Few people like gain weight or to be exposed to risks resulting from higher cholesterol levels. Olanzapine seemed to have a higher sedative effect on people in two randomised trials (<a href="./references#CD006569-fig-0122" title="">Analysis 5.19</a>). </p> </section> <section id="CD006569-sec-0431"> <h4 class="title">6. COMPARISON 6. ARIPIPRAZOLE versus OLANZAPINE (in acutely agitated patients)</h4> <p>These results were based on a single five‐day trial but with nearly 500 participants. This comparison was included to comply with the protocol of this review but, in retrospect, we feel would be best in a separate review and are pleased to see that this is underway (<a href="./references#CD006569-bbs2-0324" title="PagadalaB , Jayaram MaheshB , MitraL . Aripiprazole for psychosis‐induced aggression or agitation. Cochrane Database of Systematic Reviews2009, Issue 4. [DOI: 10.1002/14651858.CD008074] ">Pagadala 2009</a>). Overall, the results suggest that the two drugs may be of some use in the acute situation but data are few, not of high quality, undertaken by those with a pecuniary interest in the findings, and do not have a comparison group of other more widely used treatments for acute agitation thought due to serious mental illness. </p> <p>Very few (0.83%) participants left the study early with numbers being similar in both groups. This very low figure may reflect the coercive nature of the treatment and that people were not free to leave. This is an observation and is not meant as criticism as this too may reflect real‐world practice. </p> </section> <section id="CD006569-sec-0432"> <h4 class="title">7. COMPARISON 7. ARIPIPRAZOLE versus OTHER ANTIPSYCHOTIC DRUGS</h4> <p>The studies were randomised but no concealment methods were clarified. We do think the comparison of aripiprazole with any one of several new generation antipsychotic drugs is practical and reflects real‐world practice. One of the studies reported quality of life measures, which we feel gives a fresh dimension to the comparison. Although some attempts were made to incorporate clinically important issues, the overall quality of evidence remains low. </p> <p>Many general measures did improve with aripiprazole although there was not any difference for sexual dysfunction. Several measures of mental state did not improve although evidence of limited quality did show some advantage of aripiprazole for negative symptoms. This latter finding is important and should be replicated in a study independent of industry conflicts of interest. </p> <p>We are not sure why people with schizophrenia reported aripiprazole being preferred when their carers did not (<a href="./references#CD006569-fig-0144" title="">Analysis 7.4</a>). This could be a chance finding. Despite this expression of preference, about one third of participants left the trial early. Perhaps this is reflective of a vote of lack of confidence for the trial design rather than the drug itself. </p> <p>It is good that quality of life is now recorded as a matter of routine in these studies but not good that it is measured by many scales that are problematic to interpret. Partly as a result of this, we are unsure of the effects of aripiprazole on quality of life compared with several of its competitors. </p> <p>Aripiprazole is not free of adverse effects but there may be slightly less overall than with the other drugs. Nausea may be a problem (<a href="./references#CD006569-fig-0156" title="">Analysis 7.16</a>) but weight gain less problematic than other drugs. </p> </section> </section> <section id="CD006569-sec-0433"> <h3 class="title" id="CD006569-sec-0433">Overall completeness and applicability of evidence</h3> <section id="CD006569-sec-0434"> <h4 class="title">1. Completeness</h4> <p>Randomised evidence is available for only five out of eight possible comparisons of aripiprazole with other second generation antipsychotic drugs, although three studies compared aripiprazole with other atypical antipsychotics grouped together. Overall, evidence is incomplete. We do not have any good data on the implications of the use of aripiprazole on use of services from trials and we do think that 'admission' is a key outcome for people with schizophrenia. There are also very few economic data, which could be most important in this area. </p> </section> <section id="CD006569-sec-0435"> <h4 class="title">2. Applicability</h4> <p>In terms of applicability, we highlight that most included studies were 'efficacy' studies. Large and simple, pragmatic, real‐world effectiveness studies are not available, greatly limiting external validity (<a href="./references#CD006569-bbs2-0331" title="ThorpeKE , ZwarensteinM , OxmanAD , TreweekS , FurbergCD , AltmanDG , et al. A pragmatic‐explanatory continuum indicator summary (PRECIS): a tool to help trial designers. Journal of Clinical Epidemiology2009;62(5):464‐75. [PUBMED: 19348971] ">Thorpe 2009</a>). </p> </section> </section> <section id="CD006569-sec-0436"> <h3 class="title" id="CD006569-sec-0436">Quality of the evidence</h3> <p>All studies were randomised and double blind or open label, but details were rarely presented. It is therefore unclear whether randomisation and blinding, where mentioned, were really appropriately done. The high number of participants leaving studies early (between 30% to 40% overall) must call into question the credibility of the findings (<a href="./references#CD006569-bbs2-0336" title="XiaJ , AdamsCE , BhagatN , BhagatV , BhoopathiP , El‐SayehH , et al. The Leeds Outcomes Stakeholders Survey (LOSS) study. Proceedings of the 15th Cochrane Colloquium, Sao Paulo, 23‐27 October 2007. 2007. ">Xia 2007</a>) because, once a person is lost to follow‐up outcomes become a matter of assumption. Three long‐term studies were available but in a chronic, often life‐long, disorder such as schizophrenia it is important that many more participants are followed up for longer. Overall, we considered the quality of evidence to be 'medium' at best with a moderate risk of bias. </p> </section> <section id="CD006569-sec-0437"> <h3 class="title" id="CD006569-sec-0437">Potential biases in the review process</h3> <p>It is possible that some important information may have been excluded during the review process due to human error or information not being available. New data from 162 Chinese studies that were previously awaiting assessment did not substantially change the findings of the first review, however they have given us more comparisons and increased precision whilst not clearly effecting overall quality of data. </p> </section> <section id="CD006569-sec-0438"> <h3 class="title" id="CD006569-sec-0438">Agreements and disagreements with other studies or reviews</h3> <p>An earlier Cochrane review compared aripiprazole with any other antipsychotic drugs (<a href="./references#CD006569-bbs2-0291" title="El‐SayehHG , MorgantiC . Aripiprazole for schizophrenia. Cochrane Database of Systematic Reviews2006, Issue 2. [DOI: 10.1002/14651858.CD004578.pub3] ">EL‐Sayeh 2006</a>). In this past review authors combined olanzapine and risperidone as one group of 'atypical antipsychotic' drugs. A subsequent review comparing aripiprazole with other atypical antipsychotics was also published (<a href="./references#CD006569-bbs2-0339" title="KomossaK , Rummel‐KlugeC , SchmidF , HungerH , SchwarzS , El‐SayehHG , et al. Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews2009, Issue 4. [DOI: 10.1002/14651858.CD006569.pub3; PUBMED: 19821375] ">Komossa 2009</a>) where the authors concluded that aripiprazole was not much different from other second generation antipsychotic drugs. This current update again concludes that aripiprazole was similar to other atypical antipsychotic drugs but we have found some evidence of it being better tolerated than its competitors. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD006569-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram: original search" data-id="CD006569-fig-0001" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram: original search</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/full#CD006569-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram: update 2011" data-id="CD006569-fig-0002" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Study flow diagram: update 2011</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/full#CD006569-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram: update 2012" data-id="CD006569-fig-0003" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Study flow diagram: update 2012</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/full#CD006569-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD006569-fig-0004" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/full#CD006569-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD006569-fig-0005" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/full#CD006569-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 COMPARISON 1. ARIPIPRAZOLE versus CLOZAPINE, outcome: 1.1 Global state: 1. No clinically significant response (as defined by the original studies)." data-id="CD006569-fig-0006" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 COMPARISON 1. ARIPIPRAZOLE versus CLOZAPINE, outcome: 1.1 Global state: 1. No clinically significant response (as defined by the original studies). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/full#CD006569-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-AFig-FIG07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-AFig-FIG07.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 2 COMPARISON 2. ARIPIPRAZOLE versus QUETIAPINE, outcome: 2.1 Global state: 1.No clinically significant response (as defined by original studies)." data-id="CD006569-fig-0007" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-AFig-FIG07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Funnel plot of comparison: 2 COMPARISON 2. ARIPIPRAZOLE versus QUETIAPINE, outcome: 2.1 Global state: 1.No clinically significant response (as defined by original studies). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/full#CD006569-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-AFig-FIG07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-AFig-FIG08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-AFig-FIG08.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 3 COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE, outcome: 3.1 Global state: 1. No clinically significant response (as defined by the original studies)." data-id="CD006569-fig-0008" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-AFig-FIG08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 8</div> <div class="figure-caption"> <p>Funnel plot of comparison: 3 COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE, outcome: 3.1 Global state: 1. No clinically significant response (as defined by the original studies). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/full#CD006569-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-AFig-FIG08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-AFig-FIG09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-AFig-FIG09.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 5 COMPARISON 5. ARIPIPRAZOLE versus OLANZAPINE, outcome: 5.1 Global state: 1.No clinically significant response (as defined by the original studies)." data-id="CD006569-fig-0009" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-AFig-FIG09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 9</div> <div class="figure-caption"> <p>Funnel plot of comparison: 5 COMPARISON 5. ARIPIPRAZOLE versus OLANZAPINE, outcome: 5.1 Global state: 1.No clinically significant response (as defined by the original studies). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/full#CD006569-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-AFig-FIG09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 COMPARISON 1. ARIPIPRAZOLE versus CLOZAPINE, Outcome 1 Global state: 1. No clinically significant response (as defined by the original studies)." data-id="CD006569-fig-0010" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 COMPARISON 1. ARIPIPRAZOLE versus CLOZAPINE, Outcome 1 Global state: 1. No clinically significant response (as defined by the original studies). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 COMPARISON 1. ARIPIPRAZOLE versus CLOZAPINE, Outcome 2 Mental state: 1. Specific ‐ binary outcomes." data-id="CD006569-fig-0011" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 COMPARISON 1. ARIPIPRAZOLE versus CLOZAPINE, Outcome 2 Mental state: 1. Specific ‐ binary outcomes. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 COMPARISON 1. ARIPIPRAZOLE versus CLOZAPINE, Outcome 3 Mental state: 2. Average endpoint scores of various scales (short term, up to 12 weeks, high=poor)." data-id="CD006569-fig-0012" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 COMPARISON 1. ARIPIPRAZOLE versus CLOZAPINE, Outcome 3 Mental state: 2. Average endpoint scores of various scales (short term, up to 12 weeks, high=poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 COMPARISON 1. ARIPIPRAZOLE versus CLOZAPINE, Outcome 4 Mental state: 3. Average endpoint scores of various scales (medium term, 12 to 26 weeks, high=poor)." data-id="CD006569-fig-0013" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 COMPARISON 1. ARIPIPRAZOLE versus CLOZAPINE, Outcome 4 Mental state: 3. Average endpoint scores of various scales (medium term, 12 to 26 weeks, high=poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0014"> <p> <div class="table" id="CD006569-tblf-0001"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Notes</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>BPRS</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Xiao 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15.33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Xiao 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clozapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15.91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>PANSS</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Jiang 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>53.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Jiang 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clozapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>PANSS negative symptom subscale score</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Jiang 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Jiang 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clozapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Liu 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Liu 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clozapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Xiao 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Xiao 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clozapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 COMPARISON 1. ARIPIPRAZOLE versus CLOZAPINE, Outcome 5 Mental state: 4. Average endpoint scores of various scales (skewed data, high=poor). </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0014">Navigate to figure in review</a></div> </div> <div class="figure" id="CD006569-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 COMPARISON 1. ARIPIPRAZOLE versus CLOZAPINE, Outcome 6 Mental state: 5. Specific ‐ average endpoint positive score (PANSS, high=poor)." data-id="CD006569-fig-0015" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 COMPARISON 1. ARIPIPRAZOLE versus CLOZAPINE, Outcome 6 Mental state: 5. Specific ‐ average endpoint positive score (PANSS, high=poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 COMPARISON 1. ARIPIPRAZOLE versus CLOZAPINE, Outcome 7 Mental state: 6. Specific ‐ average endpoint negative score (PANSS, high=poor)." data-id="CD006569-fig-0016" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 COMPARISON 1. ARIPIPRAZOLE versus CLOZAPINE, Outcome 7 Mental state: 6. Specific ‐ average endpoint negative score (PANSS, high=poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 COMPARISON 1. ARIPIPRAZOLE versus CLOZAPINE, Outcome 8 Mental state: 7. Specific ‐ average endpoint general psychopathological score (PANSS, high=poor )." data-id="CD006569-fig-0017" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 COMPARISON 1. ARIPIPRAZOLE versus CLOZAPINE, Outcome 8 Mental state: 7. Specific ‐ average endpoint general psychopathological score (PANSS, high=poor ). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 COMPARISON 1. ARIPIPRAZOLE versus CLOZAPINE, Outcome 9 Mental state: 8. Specific ‐ average total score decreased rate (PANSS, low=poor)." data-id="CD006569-fig-0018" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 COMPARISON 1. ARIPIPRAZOLE versus CLOZAPINE, Outcome 9 Mental state: 8. Specific ‐ average total score decreased rate (PANSS, low=poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 COMPARISON 1. ARIPIPRAZOLE versus CLOZAPINE, Outcome 10 Mental state: 9. Specific ‐ average positive score decreased rate (PANSS, low=poor)." data-id="CD006569-fig-0019" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 COMPARISON 1. ARIPIPRAZOLE versus CLOZAPINE, Outcome 10 Mental state: 9. Specific ‐ average positive score decreased rate (PANSS, low=poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 COMPARISON 1. ARIPIPRAZOLE versus CLOZAPINE, Outcome 11 Leaving the study early." data-id="CD006569-fig-0020" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 COMPARISON 1. ARIPIPRAZOLE versus CLOZAPINE, Outcome 11 Leaving the study early. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 COMPARISON 1. ARIPIPRAZOLE versus CLOZAPINE, Outcome 12 Quality of life: 1a. Average scores (short term, up to 12 weeks, WHO‐QOL‐100, low=poor)." data-id="CD006569-fig-0021" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 COMPARISON 1. ARIPIPRAZOLE versus CLOZAPINE, Outcome 12 Quality of life: 1a. Average scores (short term, up to 12 weeks, WHO‐QOL‐100, low=poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-001-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 COMPARISON 1. ARIPIPRAZOLE versus CLOZAPINE, Outcome 13 Quality of life: 1b. Average scores (medium term, 12 to 24 weeks, WHO‐QOL‐100, low=poor)." data-id="CD006569-fig-0022" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 COMPARISON 1. ARIPIPRAZOLE versus CLOZAPINE, Outcome 13 Quality of life: 1b. Average scores (medium term, 12 to 24 weeks, WHO‐QOL‐100, low=poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-001-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-001-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 COMPARISON 1. ARIPIPRAZOLE versus CLOZAPINE, Outcome 14 Quality of life: 2. Average endpoint general quality of life score (GQOLI ‐ 74, low=poor)." data-id="CD006569-fig-0023" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-001-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1 COMPARISON 1. ARIPIPRAZOLE versus CLOZAPINE, Outcome 14 Quality of life: 2. Average endpoint general quality of life score (GQOLI ‐ 74, low=poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-001-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-001-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-001-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 COMPARISON 1. ARIPIPRAZOLE versus CLOZAPINE, Outcome 15 Adverse effects: 1. At least one adverse effect." data-id="CD006569-fig-0024" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-001-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1 COMPARISON 1. ARIPIPRAZOLE versus CLOZAPINE, Outcome 15 Adverse effects: 1. At least one adverse effect. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-001-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-001-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-001-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 COMPARISON 1. ARIPIPRAZOLE versus CLOZAPINE, Outcome 16 Adverse effects: 2. Cardiac effects." data-id="CD006569-fig-0025" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-001-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1 COMPARISON 1. ARIPIPRAZOLE versus CLOZAPINE, Outcome 16 Adverse effects: 2. Cardiac effects. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-001-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-001-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-001-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 COMPARISON 1. ARIPIPRAZOLE versus CLOZAPINE, Outcome 17 Adverse effects: 3. Central / peripheral nervous system." data-id="CD006569-fig-0026" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-001-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1 COMPARISON 1. ARIPIPRAZOLE versus CLOZAPINE, Outcome 17 Adverse effects: 3. Central / peripheral nervous system. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-001-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-001-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-001-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 COMPARISON 1. ARIPIPRAZOLE versus CLOZAPINE, Outcome 18 Adverse effects: 4. Extrapyramidal effects." data-id="CD006569-fig-0027" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-001-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.18</div> <div class="figure-caption"> <p>Comparison 1 COMPARISON 1. ARIPIPRAZOLE versus CLOZAPINE, Outcome 18 Adverse effects: 4. Extrapyramidal effects. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-001-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-001-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-001-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 COMPARISON 1. ARIPIPRAZOLE versus CLOZAPINE, Outcome 19 Adverse effects: 6. Haematological." data-id="CD006569-fig-0028" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-001-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.19</div> <div class="figure-caption"> <p>Comparison 1 COMPARISON 1. ARIPIPRAZOLE versus CLOZAPINE, Outcome 19 Adverse effects: 6. Haematological. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-001-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-001-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-001-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 COMPARISON 1. ARIPIPRAZOLE versus CLOZAPINE, Outcome 20 Adverse effects: 5. Gastrointestinal." data-id="CD006569-fig-0029" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-001-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.20</div> <div class="figure-caption"> <p>Comparison 1 COMPARISON 1. ARIPIPRAZOLE versus CLOZAPINE, Outcome 20 Adverse effects: 5. Gastrointestinal. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-001-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-001-21" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-001-21.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 COMPARISON 1. ARIPIPRAZOLE versus CLOZAPINE, Outcome 21 Adverse effects: 7. Hormonal." data-id="CD006569-fig-0030" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-001-21.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.21</div> <div class="figure-caption"> <p>Comparison 1 COMPARISON 1. ARIPIPRAZOLE versus CLOZAPINE, Outcome 21 Adverse effects: 7. Hormonal. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-001-21.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-001-22" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-001-22.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 COMPARISON 1. ARIPIPRAZOLE versus CLOZAPINE, Outcome 22 Adverse effects: 8a. Metabolic ‐ binary measures." data-id="CD006569-fig-0031" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-001-22.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.22</div> <div class="figure-caption"> <p>Comparison 1 COMPARISON 1. ARIPIPRAZOLE versus CLOZAPINE, Outcome 22 Adverse effects: 8a. Metabolic ‐ binary measures. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-001-22.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-001-23" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-001-23.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 COMPARISON 1. ARIPIPRAZOLE versus CLOZAPINE, Outcome 23 Adverse effects: 8b. Metabolic ‐ continuous measures (short term, up to 12 weeks, high=poor)." data-id="CD006569-fig-0032" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-001-23.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.23</div> <div class="figure-caption"> <p>Comparison 1 COMPARISON 1. ARIPIPRAZOLE versus CLOZAPINE, Outcome 23 Adverse effects: 8b. Metabolic ‐ continuous measures (short term, up to 12 weeks, high=poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-001-23.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0033"> <p> <div class="table" id="CD006569-tblf-0002"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Note</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Cost of hospitalisation (in RMB)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Liu 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3413.66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1815.05</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Liu 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clozapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4582.00</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3372.42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Cost of drug (in RMB)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Liu 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>418.13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>326.43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Liu 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clozapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>210.39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>300.32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Length of hospitalisation (day)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Liu 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33.19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16.71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Liu 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clozapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49.50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30.83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.24</div> <div class="figure-caption"> <p>Comparison 1 COMPARISON 1. ARIPIPRAZOLE versus CLOZAPINE, Outcome 24 Cost effectiveness analysis (high=poor, data skewed). </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0033">Navigate to figure in review</a></div> </div> <div class="figure" id="CD006569-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-002-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 COMPARISON 2. ARIPIPRAZOLE versus QUETIAPINE, Outcome 1 Global state: 1.No clinically significant response (as defined by original studies)." data-id="CD006569-fig-0034" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 COMPARISON 2. ARIPIPRAZOLE versus QUETIAPINE, Outcome 1 Global state: 1.No clinically significant response (as defined by original studies). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 COMPARISON 2. ARIPIPRAZOLE versus QUETIAPINE, Outcome 2 Global state: 2a. Average endpoint total score (short term, up to 12 weeks, high=poor)." data-id="CD006569-fig-0035" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 COMPARISON 2. ARIPIPRAZOLE versus QUETIAPINE, Outcome 2 Global state: 2a. Average endpoint total score (short term, up to 12 weeks, high=poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 COMPARISON 2. ARIPIPRAZOLE versus QUETIAPINE, Outcome 3 Global state: 2b. Average endpoint scale score (medium term, 12 to 24 weeks, high=poor)." data-id="CD006569-fig-0036" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 COMPARISON 2. ARIPIPRAZOLE versus QUETIAPINE, Outcome 3 Global state: 2b. Average endpoint scale score (medium term, 12 to 24 weeks, high=poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 COMPARISON 2. ARIPIPRAZOLE versus QUETIAPINE, Outcome 4 Global state: 3. Average endpoint SI score (CGI, high=poor)." data-id="CD006569-fig-0037" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 COMPARISON 2. ARIPIPRAZOLE versus QUETIAPINE, Outcome 4 Global state: 3. Average endpoint SI score (CGI, high=poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 COMPARISON 2. ARIPIPRAZOLE versus QUETIAPINE, Outcome 5 Mental state: 2a. Specific ‐ binary outcomes." data-id="CD006569-fig-0038" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 COMPARISON 2. ARIPIPRAZOLE versus QUETIAPINE, Outcome 5 Mental state: 2a. Specific ‐ binary outcomes. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 COMPARISON 2. ARIPIPRAZOLE versus QUETIAPINE, Outcome 6 Mental state: 3. Specific ‐ average endpoint positive score (PANSS, high=poor)." data-id="CD006569-fig-0039" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 COMPARISON 2. ARIPIPRAZOLE versus QUETIAPINE, Outcome 6 Mental state: 3. Specific ‐ average endpoint positive score (PANSS, high=poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 COMPARISON 2. ARIPIPRAZOLE versus QUETIAPINE, Outcome 7 Mental state: 4. Specific ‐ average endpoint negative score (PANSS, high=poor)." data-id="CD006569-fig-0040" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 COMPARISON 2. ARIPIPRAZOLE versus QUETIAPINE, Outcome 7 Mental state: 4. Specific ‐ average endpoint negative score (PANSS, high=poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-002-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-002-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 COMPARISON 2. ARIPIPRAZOLE versus QUETIAPINE, Outcome 8 Mental state: 5. Specific ‐ average endpoint general pathological score (PANSS, high=poor )." data-id="CD006569-fig-0041" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-002-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2 COMPARISON 2. ARIPIPRAZOLE versus QUETIAPINE, Outcome 8 Mental state: 5. Specific ‐ average endpoint general pathological score (PANSS, high=poor ). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-002-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0042"> <p> <div class="table" id="CD006569-tblf-0003"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Note</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>BPRS endpoint scale score</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zhu 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zhu 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quetiapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>PANSS general pathology subscale score</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zhu 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zhu 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quetiapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>PANSS negative subscale score</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dai 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dai 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quetiapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7. 6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ge 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ge 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quetiapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15.12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wei 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wei 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quetiapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zhu 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zhu 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quetiapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>PANSS positive subscale score</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chen 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chen 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quetiapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dai 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dai 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quetiapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wei 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 .4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wei 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quetiapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zhu 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zhu 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quetiapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>PANSS total endpoint scale score</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zhu 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zhu 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quetiapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2 COMPARISON 2. ARIPIPRAZOLE versus QUETIAPINE, Outcome 9 Mental state: 6. average scores of various scales (high=poor, skewed data). </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0042">Navigate to figure in review</a></div> </div> <div class="figure" id="CD006569-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-002-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-002-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 COMPARISON 2. ARIPIPRAZOLE versus QUETIAPINE, Outcome 10 Leaving the study early." data-id="CD006569-fig-0043" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-002-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2 COMPARISON 2. ARIPIPRAZOLE versus QUETIAPINE, Outcome 10 Leaving the study early. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-002-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-002-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-002-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 COMPARISON 2. ARIPIPRAZOLE versus QUETIAPINE, Outcome 11 Quality of life: Average score (medium term, 12 to 24 weeks, WHO‐QOL‐100, low=poor)." data-id="CD006569-fig-0044" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-002-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.11</div> <div class="figure-caption"> <p>Comparison 2 COMPARISON 2. ARIPIPRAZOLE versus QUETIAPINE, Outcome 11 Quality of life: Average score (medium term, 12 to 24 weeks, WHO‐QOL‐100, low=poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-002-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-002-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-002-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 COMPARISON 2. ARIPIPRAZOLE versus QUETIAPINE, Outcome 12 Adverse effects:1. At least one adverse effect." data-id="CD006569-fig-0045" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-002-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.12</div> <div class="figure-caption"> <p>Comparison 2 COMPARISON 2. ARIPIPRAZOLE versus QUETIAPINE, Outcome 12 Adverse effects:1. At least one adverse effect. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-002-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-002-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-002-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 COMPARISON 2. ARIPIPRAZOLE versus QUETIAPINE, Outcome 13 Adverse effects: 2. Cardiac effects (short term, up to 12 weeks)." data-id="CD006569-fig-0046" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-002-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.13</div> <div class="figure-caption"> <p>Comparison 2 COMPARISON 2. ARIPIPRAZOLE versus QUETIAPINE, Outcome 13 Adverse effects: 2. Cardiac effects (short term, up to 12 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-002-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-002-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-002-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 COMPARISON 2. ARIPIPRAZOLE versus QUETIAPINE, Outcome 14 Adverse effects: 3. Central / peripheral nervous system." data-id="CD006569-fig-0047" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-002-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.14</div> <div class="figure-caption"> <p>Comparison 2 COMPARISON 2. ARIPIPRAZOLE versus QUETIAPINE, Outcome 14 Adverse effects: 3. Central / peripheral nervous system. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-002-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-002-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-002-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 COMPARISON 2. ARIPIPRAZOLE versus QUETIAPINE, Outcome 15 Adverse effects: 4. Extrapyramidal symptoms ‐ various (short term, up to 12 weeks)." data-id="CD006569-fig-0048" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-002-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.15</div> <div class="figure-caption"> <p>Comparison 2 COMPARISON 2. ARIPIPRAZOLE versus QUETIAPINE, Outcome 15 Adverse effects: 4. Extrapyramidal symptoms ‐ various (short term, up to 12 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-002-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-002-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-002-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 COMPARISON 2. ARIPIPRAZOLE versus QUETIAPINE, Outcome 16 Adverse effects: 5. Gastrointestinal." data-id="CD006569-fig-0049" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-002-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.16</div> <div class="figure-caption"> <p>Comparison 2 COMPARISON 2. ARIPIPRAZOLE versus QUETIAPINE, Outcome 16 Adverse effects: 5. Gastrointestinal. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-002-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-002-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-002-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 COMPARISON 2. ARIPIPRAZOLE versus QUETIAPINE, Outcome 17 Adverse effects: 6. Haematological." data-id="CD006569-fig-0050" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-002-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.17</div> <div class="figure-caption"> <p>Comparison 2 COMPARISON 2. ARIPIPRAZOLE versus QUETIAPINE, Outcome 17 Adverse effects: 6. Haematological. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-002-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-002-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-002-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 COMPARISON 2. ARIPIPRAZOLE versus QUETIAPINE, Outcome 18 Adverse events: 7. Hormonal." data-id="CD006569-fig-0051" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-002-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.18</div> <div class="figure-caption"> <p>Comparison 2 COMPARISON 2. ARIPIPRAZOLE versus QUETIAPINE, Outcome 18 Adverse events: 7. Hormonal. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-002-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-002-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-002-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 COMPARISON 2. ARIPIPRAZOLE versus QUETIAPINE, Outcome 19 Adverse effects: 8a. Metabolic ‐ binary measures." data-id="CD006569-fig-0052" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-002-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.19</div> <div class="figure-caption"> <p>Comparison 2 COMPARISON 2. ARIPIPRAZOLE versus QUETIAPINE, Outcome 19 Adverse effects: 8a. Metabolic ‐ binary measures. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-002-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-002-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-002-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 COMPARISON 2. ARIPIPRAZOLE versus QUETIAPINE, Outcome 20 Adverse effects: 8b. Metabolic ‐ continuous measure." data-id="CD006569-fig-0053" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-002-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.20</div> <div class="figure-caption"> <p>Comparison 2 COMPARISON 2. ARIPIPRAZOLE versus QUETIAPINE, Outcome 20 Adverse effects: 8b. Metabolic ‐ continuous measure. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-002-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-003-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE, Outcome 1 Global state: 1. No clinically significant response (as defined by the original studies)." data-id="CD006569-fig-0054" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE, Outcome 1 Global state: 1. No clinically significant response (as defined by the original studies). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE, Outcome 2 Global state: 2. Average endpoint total score(short term, up to 12 weeks, CGI, high=poor)." data-id="CD006569-fig-0055" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE, Outcome 2 Global state: 2. Average endpoint total score(short term, up to 12 weeks, CGI, high=poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE, Outcome 3 Global state: 3. Average CGI subscale scores (short term, up to 12 weeks, high=poor)." data-id="CD006569-fig-0056" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE, Outcome 3 Global state: 3. Average CGI subscale scores (short term, up to 12 weeks, high=poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0057"> <p> <div class="table" id="CD006569-tblf-0004"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Note</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>CGI‐GI</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chen 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chen 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>CGI‐SI</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chen 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chen 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yang 2008a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yang 2008a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>CGI</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Feng 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.05</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Feng 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zhang 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zhang 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE, Outcome 4 Global state: 4. average endpoint data of various scales (high=poor, data skewed). </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0057">Navigate to figure in review</a></div> </div> <div class="figure" id="CD006569-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE, Outcome 5 Mental state: 1. Specific ‐ binary outcomes (short term, up to 12 weeks)." data-id="CD006569-fig-0058" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE, Outcome 5 Mental state: 1. Specific ‐ binary outcomes (short term, up to 12 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-003-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-003-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE, Outcome 6 Mental state: 2. Average endpoint scale score." data-id="CD006569-fig-0059" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-003-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3 COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE, Outcome 6 Mental state: 2. Average endpoint scale score. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-003-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0060"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-003-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-003-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE, Outcome 7 Mental state: 3. Specific ‐ average endpoint positive score (PANSS, high=poor)." data-id="CD006569-fig-0060" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-003-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3 COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE, Outcome 7 Mental state: 3. Specific ‐ average endpoint positive score (PANSS, high=poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0060">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-003-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0061"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-003-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-003-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE, Outcome 8 Mental state: 4. Specific ‐ average endpoint negative score (PANSS, high=poor)." data-id="CD006569-fig-0061" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-003-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3 COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE, Outcome 8 Mental state: 4. Specific ‐ average endpoint negative score (PANSS, high=poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0061">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-003-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0062"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-003-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-003-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE, Outcome 9 Mental state: 5. Specific ‐ average endpoint general psychopathological score (PANSS, high=poor )." data-id="CD006569-fig-0062" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-003-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.9</div> <div class="figure-caption"> <p>Comparison 3 COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE, Outcome 9 Mental state: 5. Specific ‐ average endpoint general psychopathological score (PANSS, high=poor ). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0062">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-003-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0063"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-003-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-003-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE, Outcome 10 Mental state: 6. PANSS average score decreased rate (short term, up to 12 weeks, low=poor)." data-id="CD006569-fig-0063" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-003-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.10</div> <div class="figure-caption"> <p>Comparison 3 COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE, Outcome 10 Mental state: 6. PANSS average score decreased rate (short term, up to 12 weeks, low=poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0063">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-003-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0064"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-003-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-003-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE, Outcome 11 Mental state: 7. BPRS total score decreased rate (short term, up to 12 weeks, high=poor)." data-id="CD006569-fig-0064" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-003-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.11</div> <div class="figure-caption"> <p>Comparison 3 COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE, Outcome 11 Mental state: 7. BPRS total score decreased rate (short term, up to 12 weeks, high=poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0064">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-003-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0065"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-003-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-003-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE, Outcome 12 Mental state: 8. General ‐ average total score (PANSS, high=poor)." data-id="CD006569-fig-0065" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-003-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.12</div> <div class="figure-caption"> <p>Comparison 3 COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE, Outcome 12 Mental state: 8. General ‐ average total score (PANSS, high=poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0065">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-003-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0066"> <p> <div class="table" id="CD006569-tblf-0005"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Note</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>SANS endpoint scale score</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tong 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10. 6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14. 4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tong 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14. 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20. 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>PANSS general pathology subscale score</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chang 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18.65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chang 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19.15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Xie 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19. 24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12. 18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Xie 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19. 36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10. 71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>PANSS negative symptom subscale score</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chang 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.04</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chang 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.08</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CuiMeng 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9. 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8. 7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CuiMeng 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ziprasidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12. 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8. 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Deng 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14.89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Deng 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.01</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.362</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Guo 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Guo 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ji 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ji 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15.19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Li 2007d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Li 2007d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Li 2009b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Li 2009b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Li X 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Li X 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Liu 2006a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Liu 2006a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lv 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11. 5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3. 8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lv 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12. 5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6. 8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mai 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12. 9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7. 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mai 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13. 9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6. 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pan 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pan 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Shan 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Shan 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Song 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Song 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Su 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11. 4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7. 6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Su 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12. 6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6. 7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tang 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tang 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tang 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tang 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tu 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tu 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wen 2009a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14.89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wen 2009a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.02</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Xie 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11. 95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5. 69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Xie 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12. 32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6. 17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Xie 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Xie 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yang 2008b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yang 2008b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ye 2005a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11. 8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4. 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ye 2005a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12. 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8. 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zhang 2008b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zhang 2008b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zhi 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zhi 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zhou 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10. 8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5. 5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zhou 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11. 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5. 7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zhu 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zhu 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>PANSS positive symptom subscale score</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chang 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16.82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chang 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17.64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chen 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chen 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fan 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fan 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Feng 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.04</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Feng 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hu 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hu 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Li 2007a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.02</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Li 2007a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Li 2007d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Li 2007d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Li X 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Li X 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lian 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lian 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Liu 2006a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Liu 2006a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Liu 2008c</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9. 59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3. 17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Liu 2008c</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10. 29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5. 47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mu 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10. 95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5. 07</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mu 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11. 50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6. 02</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Song 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Song 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Su 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10. 8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7. 5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Su 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12. 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6. 8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tang 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tang 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tang 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tang 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tang 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tang 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wang 2007e</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wang 2007e</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Xie 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17. 21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10. 97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Xie 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17. 33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11. 82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Xie 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Xie 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yang 2008b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yang 2008b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yu 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yu 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zhang 2007a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zhang 2007a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zhang 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zhang 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zhang 2008b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zhang 2008b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zhi 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zhi 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.13</div> <div class="figure-caption"> <p>Comparison 3 COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE, Outcome 13 Mental state: 9. average scores of various scale (high=poor, skewed data). </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0066">Navigate to figure in review</a></div> </div> <div class="figure" id="CD006569-fig-0067"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-003-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-003-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE, Outcome 14 Leaving the study early." data-id="CD006569-fig-0067" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-003-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.14</div> <div class="figure-caption"> <p>Comparison 3 COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE, Outcome 14 Leaving the study early. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0067">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-003-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0068"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-003-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-003-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE, Outcome 15 Adverse effects: 1. At least one adverse effect, non‐specific." data-id="CD006569-fig-0068" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-003-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.15</div> <div class="figure-caption"> <p>Comparison 3 COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE, Outcome 15 Adverse effects: 1. At least one adverse effect, non‐specific. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0068">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-003-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0069"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-003-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-003-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE, Outcome 16 Adverse effects: 2a.Cardiac effects (short term, up to 12 weeks)." data-id="CD006569-fig-0069" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-003-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.16</div> <div class="figure-caption"> <p>Comparison 3 COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE, Outcome 16 Adverse effects: 2a.Cardiac effects (short term, up to 12 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0069">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-003-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0070"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-003-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-003-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE, Outcome 17 Adverse effects: 2b. Cardiac ‐ QTc change from baseline (in ms)." data-id="CD006569-fig-0070" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-003-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.17</div> <div class="figure-caption"> <p>Comparison 3 COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE, Outcome 17 Adverse effects: 2b. Cardiac ‐ QTc change from baseline (in ms). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0070">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-003-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0071"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-003-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-003-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE, Outcome 18 Adverse effects: 3. Central / peripheral nervous system (short term, up to 12 weeks)." data-id="CD006569-fig-0071" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-003-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.18</div> <div class="figure-caption"> <p>Comparison 3 COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE, Outcome 18 Adverse effects: 3. Central / peripheral nervous system (short term, up to 12 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0071">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-003-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0072"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-003-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-003-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE, Outcome 19 Adverse effects: 3a. Endocrine ‐ Prolactin ‐ average change (ng/ml)." data-id="CD006569-fig-0072" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-003-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.19</div> <div class="figure-caption"> <p>Comparison 3 COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE, Outcome 19 Adverse effects: 3a. Endocrine ‐ Prolactin ‐ average change (ng/ml). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0072">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-003-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0073"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-003-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-003-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE, Outcome 20 Adverse effects: 3b. Endocrine ‐ Prolactin‐associated." data-id="CD006569-fig-0073" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-003-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.20</div> <div class="figure-caption"> <p>Comparison 3 COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE, Outcome 20 Adverse effects: 3b. Endocrine ‐ Prolactin‐associated. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0073">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-003-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0074"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-003-21" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-003-21.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE, Outcome 21 Adverse effects: 4. Various extrapyramidal symptoms (short term, up to 12 weeks)." data-id="CD006569-fig-0074" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-003-21.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.21</div> <div class="figure-caption"> <p>Comparison 3 COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE, Outcome 21 Adverse effects: 4. Various extrapyramidal symptoms (short term, up to 12 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0074">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-003-21.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0075"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-003-22" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-003-22.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE, Outcome 22 Adverse effects: 4b. Extrapyramidal ‐ average score." data-id="CD006569-fig-0075" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-003-22.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.22</div> <div class="figure-caption"> <p>Comparison 3 COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE, Outcome 22 Adverse effects: 4b. Extrapyramidal ‐ average score. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0075">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-003-22.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0076"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-003-23" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-003-23.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE, Outcome 23 Adverse effects: 5. Gastrointestinal." data-id="CD006569-fig-0076" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-003-23.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.23</div> <div class="figure-caption"> <p>Comparison 3 COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE, Outcome 23 Adverse effects: 5. Gastrointestinal. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0076">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-003-23.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0077"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-003-24" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-003-24.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE, Outcome 24 Adverse effects: 6. Haematological." data-id="CD006569-fig-0077" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-003-24.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.24</div> <div class="figure-caption"> <p>Comparison 3 COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE, Outcome 24 Adverse effects: 6. Haematological. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0077">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-003-24.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0078"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-003-25" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-003-25.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE, Outcome 25 Adverse effects: 7a. Metabolic ‐ binary measures (short term, up to 12 weeks)." data-id="CD006569-fig-0078" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-003-25.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.25</div> <div class="figure-caption"> <p>Comparison 3 COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE, Outcome 25 Adverse effects: 7a. Metabolic ‐ binary measures (short term, up to 12 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0078">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-003-25.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0079"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-003-26" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-003-26.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE, Outcome 26 Adverse effects: 7b. Metabolic ‐ continuous measures (high=poor )." data-id="CD006569-fig-0079" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-003-26.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.26</div> <div class="figure-caption"> <p>Comparison 3 COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE, Outcome 26 Adverse effects: 7b. Metabolic ‐ continuous measures (high=poor ). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0079">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-003-26.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0080"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-003-27" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-003-27.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE, Outcome 27 Adverse effect : 7c. Metabolic ‐ continuous measures." data-id="CD006569-fig-0080" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-003-27.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.27</div> <div class="figure-caption"> <p>Comparison 3 COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE, Outcome 27 Adverse effect : 7c. Metabolic ‐ continuous measures. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0080">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-003-27.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0081"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-003-28" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-003-28.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE, Outcome 28 Adverse effect: 8. required additional drug combination." data-id="CD006569-fig-0081" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-003-28.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.28</div> <div class="figure-caption"> <p>Comparison 3 COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE, Outcome 28 Adverse effect: 8. required additional drug combination. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0081">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-003-28.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0082"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-003-29" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-003-29.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE, Outcome 29 Adverse effects: 9. TESS score (short term, up to 12 weeks, high=poor)." data-id="CD006569-fig-0082" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-003-29.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.29</div> <div class="figure-caption"> <p>Comparison 3 COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE, Outcome 29 Adverse effects: 9. TESS score (short term, up to 12 weeks, high=poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0082">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-003-29.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0083"> <p> <div class="table" id="CD006569-tblf-0006"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Note</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chen 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chen 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CuiMeng 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CuiMeng 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mu 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.08</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mu 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3. 62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Qu 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Qu 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yan 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yan 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zhang 2010a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zhang 2010a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zhou 2007b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zhou 2007b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.30</div> <div class="figure-caption"> <p>Comparison 3 COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE, Outcome 30 Adverse effects: 10. TESS score (short term, up to 12 weeks, high=poor, data skewed). </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0083">Navigate to figure in review</a></div> </div> <div class="figure" id="CD006569-fig-0084"> <p> <div class="table" id="CD006569-tblf-0007"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Heading 1</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Heading 2</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Heading 3</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Heading 4</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Heading 5</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chen 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chen 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tao 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.06</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tao 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wang 2007e</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wang 2007e</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.31</div> <div class="figure-caption"> <p>Comparison 3 COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE, Outcome 31 Adverse effects: 11. weight gain (in KG, high=poor, data skewed). </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0084">Navigate to figure in review</a></div> </div> <div class="figure" id="CD006569-fig-0085"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-003-32" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-003-32.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE, Outcome 32 Cognitive functioning: 1. Specific ‐ average endpoint total score." data-id="CD006569-fig-0085" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-003-32.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.32</div> <div class="figure-caption"> <p>Comparison 3 COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE, Outcome 32 Cognitive functioning: 1. Specific ‐ average endpoint total score. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0085">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-003-32.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0086"> <p> <div class="table" id="CD006569-tblf-0008"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Note</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Cost of hospitalisation (in RMB)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Liu 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3413.66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1815.05</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Liu 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4551.41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3024.38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Cost of drug (in RMB)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Liu 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>418.13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>326.43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Liu 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>685.00</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>493.02</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Length of hospitalisation (day)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Liu 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33.19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16.71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Liu 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risperidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50.84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40.85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.33</div> <div class="figure-caption"> <p>Comparison 3 COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE, Outcome 33 Cost effectiveness analysis (high=poor, data skewed). </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0086">Navigate to figure in review</a></div> </div> <div class="figure" id="CD006569-fig-0087"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 COMPARISON 4. ARIPIPRAZOLE versus ZIPRASIDONE, Outcome 1 Global state: 1. No clinically significant response (as defined by the original studies)." data-id="CD006569-fig-0087" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 COMPARISON 4. ARIPIPRAZOLE versus ZIPRASIDONE, Outcome 1 Global state: 1. No clinically significant response (as defined by the original studies). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0087">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0088"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 COMPARISON 4. ARIPIPRAZOLE versus ZIPRASIDONE, Outcome 2 Global state: 2. Average endpoint CGI‐GI score (short term, up to 12 weeks, high=poor)." data-id="CD006569-fig-0088" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 COMPARISON 4. ARIPIPRAZOLE versus ZIPRASIDONE, Outcome 2 Global state: 2. Average endpoint CGI‐GI score (short term, up to 12 weeks, high=poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0088">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0089"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 COMPARISON 4. ARIPIPRAZOLE versus ZIPRASIDONE, Outcome 3 Global state: 3. Average change score (CGI‐S, decline=good)." data-id="CD006569-fig-0089" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 COMPARISON 4. ARIPIPRAZOLE versus ZIPRASIDONE, Outcome 3 Global state: 3. Average change score (CGI‐S, decline=good). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0089">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0090"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-004-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-004-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 COMPARISON 4. ARIPIPRAZOLE versus ZIPRASIDONE, Outcome 4 Mental state: 1. Average endpoint total score (short term, up to 12 weeks, high=poor)." data-id="CD006569-fig-0090" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-004-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4 COMPARISON 4. ARIPIPRAZOLE versus ZIPRASIDONE, Outcome 4 Mental state: 1. Average endpoint total score (short term, up to 12 weeks, high=poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0090">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-004-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0091"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-004-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-004-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 COMPARISON 4. ARIPIPRAZOLE versus ZIPRASIDONE, Outcome 5 Mental state: 2. Specific ‐ binary outcomes (up to 12 weeks ‐ short term)." data-id="CD006569-fig-0091" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-004-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4 COMPARISON 4. ARIPIPRAZOLE versus ZIPRASIDONE, Outcome 5 Mental state: 2. Specific ‐ binary outcomes (up to 12 weeks ‐ short term). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0091">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-004-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0092"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-004-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-004-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 COMPARISON 4. ARIPIPRAZOLE versus ZIPRASIDONE, Outcome 6 Mental state: 3. Specific ‐ average endpoint PANSS subscale scores (short term, high=poor)." data-id="CD006569-fig-0092" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-004-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4 COMPARISON 4. ARIPIPRAZOLE versus ZIPRASIDONE, Outcome 6 Mental state: 3. Specific ‐ average endpoint PANSS subscale scores (short term, high=poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0092">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-004-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0093"> <p> <div class="table" id="CD006569-tblf-0009"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Note</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>PANSS negative symptom subscale score</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cheng 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14.56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cheng 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ziprasidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>PANSS positive symptom subscale score</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Liu 2008a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14.21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Liu 2008a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ziprasidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wang 2008c</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wang 2008c</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ziprasidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14.56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yang 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yang 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ziprasidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.7</div> <div class="figure-caption"> <p>Comparison 4 COMPARISON 4. ARIPIPRAZOLE versus ZIPRASIDONE, Outcome 7 Mental state: endpoint scores of various scales (high=poor, data skewed). </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0093">Navigate to figure in review</a></div> </div> <div class="figure" id="CD006569-fig-0094"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-004-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-004-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 COMPARISON 4. ARIPIPRAZOLE versus ZIPRASIDONE, Outcome 8 Leaving the study early." data-id="CD006569-fig-0094" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-004-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.8</div> <div class="figure-caption"> <p>Comparison 4 COMPARISON 4. ARIPIPRAZOLE versus ZIPRASIDONE, Outcome 8 Leaving the study early. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0094">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-004-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0095"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-004-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-004-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 COMPARISON 4. ARIPIPRAZOLE versus ZIPRASIDONE, Outcome 9 Adverse effects: 1. At least one adverse effect, non‐specific." data-id="CD006569-fig-0095" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-004-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.9</div> <div class="figure-caption"> <p>Comparison 4 COMPARISON 4. ARIPIPRAZOLE versus ZIPRASIDONE, Outcome 9 Adverse effects: 1. At least one adverse effect, non‐specific. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0095">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-004-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0096"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-004-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-004-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 COMPARISON 4. ARIPIPRAZOLE versus ZIPRASIDONE, Outcome 10 Adverse effects: 2. Cardiac effects (short term, up to 12 weeks)." data-id="CD006569-fig-0096" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-004-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.10</div> <div class="figure-caption"> <p>Comparison 4 COMPARISON 4. ARIPIPRAZOLE versus ZIPRASIDONE, Outcome 10 Adverse effects: 2. Cardiac effects (short term, up to 12 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0096">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-004-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0097"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-004-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-004-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 COMPARISON 4. ARIPIPRAZOLE versus ZIPRASIDONE, Outcome 11 Adverse effects: 3. Central / peripheral nervous system (short term, up to 12 weeks)." data-id="CD006569-fig-0097" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-004-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.11</div> <div class="figure-caption"> <p>Comparison 4 COMPARISON 4. ARIPIPRAZOLE versus ZIPRASIDONE, Outcome 11 Adverse effects: 3. Central / peripheral nervous system (short term, up to 12 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0097">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-004-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0098"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-004-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-004-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 COMPARISON 4. ARIPIPRAZOLE versus ZIPRASIDONE, Outcome 12 Adverse effects: 4. Various extrapyramidal symptoms (short term, up to 12 weeks)." data-id="CD006569-fig-0098" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-004-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.12</div> <div class="figure-caption"> <p>Comparison 4 COMPARISON 4. ARIPIPRAZOLE versus ZIPRASIDONE, Outcome 12 Adverse effects: 4. Various extrapyramidal symptoms (short term, up to 12 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0098">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-004-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0099"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-004-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-004-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 COMPARISON 4. ARIPIPRAZOLE versus ZIPRASIDONE, Outcome 13 Adverse effects: 5. Gastrointestinal (short term, up to 12 weeks)." data-id="CD006569-fig-0099" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-004-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.13</div> <div class="figure-caption"> <p>Comparison 4 COMPARISON 4. ARIPIPRAZOLE versus ZIPRASIDONE, Outcome 13 Adverse effects: 5. Gastrointestinal (short term, up to 12 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0099">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-004-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0100"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-004-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-004-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 COMPARISON 4. ARIPIPRAZOLE versus ZIPRASIDONE, Outcome 14 Adverse effects: 6. Haematological." data-id="CD006569-fig-0100" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-004-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.14</div> <div class="figure-caption"> <p>Comparison 4 COMPARISON 4. ARIPIPRAZOLE versus ZIPRASIDONE, Outcome 14 Adverse effects: 6. Haematological. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0100">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-004-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0101"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-004-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-004-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 COMPARISON 4. ARIPIPRAZOLE versus ZIPRASIDONE, Outcome 15 Adverse effects: 7. Hormonal." data-id="CD006569-fig-0101" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-004-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.15</div> <div class="figure-caption"> <p>Comparison 4 COMPARISON 4. ARIPIPRAZOLE versus ZIPRASIDONE, Outcome 15 Adverse effects: 7. Hormonal. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0101">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-004-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0102"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-004-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-004-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 COMPARISON 4. ARIPIPRAZOLE versus ZIPRASIDONE, Outcome 16 Adverse effects: 8a. Metabolic ‐ binary measures." data-id="CD006569-fig-0102" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-004-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.16</div> <div class="figure-caption"> <p>Comparison 4 COMPARISON 4. ARIPIPRAZOLE versus ZIPRASIDONE, Outcome 16 Adverse effects: 8a. Metabolic ‐ binary measures. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0102">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-004-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0103"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-004-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-004-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 COMPARISON 4. ARIPIPRAZOLE versus ZIPRASIDONE, Outcome 17 Adverse effects: 8b. Metabolic ‐ continuous measures." data-id="CD006569-fig-0103" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-004-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.17</div> <div class="figure-caption"> <p>Comparison 4 COMPARISON 4. ARIPIPRAZOLE versus ZIPRASIDONE, Outcome 17 Adverse effects: 8b. Metabolic ‐ continuous measures. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0103">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-004-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0104"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-005-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 COMPARISON 5. ARIPIPRAZOLE versus OLANZAPINE, Outcome 1 Global state: 1.No clinically significant response (as defined by the original studies)." data-id="CD006569-fig-0104" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 COMPARISON 5. ARIPIPRAZOLE versus OLANZAPINE, Outcome 1 Global state: 1.No clinically significant response (as defined by the original studies). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0104">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0105"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-005-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-005-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 COMPARISON 5. ARIPIPRAZOLE versus OLANZAPINE, Outcome 2 Global state: 2. Not responded (decline in PANSS of 30% or more)." data-id="CD006569-fig-0105" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-005-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 COMPARISON 5. ARIPIPRAZOLE versus OLANZAPINE, Outcome 2 Global state: 2. Not responded (decline in PANSS of 30% or more). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0105">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-005-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0106"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-005-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-005-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 COMPARISON 5. ARIPIPRAZOLE versus OLANZAPINE, Outcome 3 Global state: 3. Remission not achieved (as defined in the study)." data-id="CD006569-fig-0106" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-005-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5 COMPARISON 5. ARIPIPRAZOLE versus OLANZAPINE, Outcome 3 Global state: 3. Remission not achieved (as defined in the study). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0106">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-005-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0107"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-005-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-005-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 COMPARISON 5. ARIPIPRAZOLE versus OLANZAPINE, Outcome 4 Global state: 4. Average endpoint EI score (CGI, high=poor)." data-id="CD006569-fig-0107" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-005-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5 COMPARISON 5. ARIPIPRAZOLE versus OLANZAPINE, Outcome 4 Global state: 4. Average endpoint EI score (CGI, high=poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0107">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-005-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0108"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-005-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-005-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 COMPARISON 5. ARIPIPRAZOLE versus OLANZAPINE, Outcome 5 Global state: 5. Average endpoint CGI score decreased rate (short term, low=poor)." data-id="CD006569-fig-0108" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-005-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5 COMPARISON 5. ARIPIPRAZOLE versus OLANZAPINE, Outcome 5 Global state: 5. Average endpoint CGI score decreased rate (short term, low=poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0108">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-005-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0109"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-005-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-005-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 COMPARISON 5. ARIPIPRAZOLE versus OLANZAPINE, Outcome 6 Global state: 6. Average change score (CGI‐S, decline=best)." data-id="CD006569-fig-0109" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-005-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.6</div> <div class="figure-caption"> <p>Comparison 5 COMPARISON 5. ARIPIPRAZOLE versus OLANZAPINE, Outcome 6 Global state: 6. Average change score (CGI‐S, decline=best). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0109">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-005-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0110"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-005-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-005-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 COMPARISON 5. ARIPIPRAZOLE versus OLANZAPINE, Outcome 7 Global state: 7. Improvement (CGI‐I, high=poor)." data-id="CD006569-fig-0110" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-005-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.7</div> <div class="figure-caption"> <p>Comparison 5 COMPARISON 5. ARIPIPRAZOLE versus OLANZAPINE, Outcome 7 Global state: 7. Improvement (CGI‐I, high=poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0110">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-005-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0111"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-005-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-005-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 COMPARISON 5. ARIPIPRAZOLE versus OLANZAPINE, Outcome 8 Mental state: 1. Average endpoint scale score (PANSS, high=poor)." data-id="CD006569-fig-0111" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-005-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.8</div> <div class="figure-caption"> <p>Comparison 5 COMPARISON 5. ARIPIPRAZOLE versus OLANZAPINE, Outcome 8 Mental state: 1. Average endpoint scale score (PANSS, high=poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0111">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-005-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0112"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-005-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-005-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 COMPARISON 5. ARIPIPRAZOLE versus OLANZAPINE, Outcome 9 Mental state: 2. Average endpoint scale score (SANS, high=poor)." data-id="CD006569-fig-0112" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-005-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.9</div> <div class="figure-caption"> <p>Comparison 5 COMPARISON 5. ARIPIPRAZOLE versus OLANZAPINE, Outcome 9 Mental state: 2. Average endpoint scale score (SANS, high=poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0112">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-005-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0113"> <p> <div class="table" id="CD006569-tblf-0010"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Note</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>PANSS total</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bai 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.07</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bai 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Olanzapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>PANSS negative symptom subscale score</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Han 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Han 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ziprasidone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>PANSS positive symptom subscale score</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Han 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Han 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.10</div> <div class="figure-caption"> <p>Comparison 5 COMPARISON 5. ARIPIPRAZOLE versus OLANZAPINE, Outcome 10 Mental state: 3. average endpoint score (PANSS, high=poor, data skewed). </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0113">Navigate to figure in review</a></div> </div> <div class="figure" id="CD006569-fig-0114"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-005-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-005-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 COMPARISON 5. ARIPIPRAZOLE versus OLANZAPINE, Outcome 11 Mental state: 4. Specific ‐ average endpoint positive score (PANSS, high=poor)." data-id="CD006569-fig-0114" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-005-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.11</div> <div class="figure-caption"> <p>Comparison 5 COMPARISON 5. ARIPIPRAZOLE versus OLANZAPINE, Outcome 11 Mental state: 4. Specific ‐ average endpoint positive score (PANSS, high=poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0114">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-005-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0115"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-005-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-005-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 COMPARISON 5. ARIPIPRAZOLE versus OLANZAPINE, Outcome 12 Mental state: 5. Specific ‐ average endpoint negative subscale score (PANSS, high=poor)." data-id="CD006569-fig-0115" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-005-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.12</div> <div class="figure-caption"> <p>Comparison 5 COMPARISON 5. ARIPIPRAZOLE versus OLANZAPINE, Outcome 12 Mental state: 5. Specific ‐ average endpoint negative subscale score (PANSS, high=poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0115">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-005-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0116"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-005-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-005-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 COMPARISON 5. ARIPIPRAZOLE versus OLANZAPINE, Outcome 13 Mental state: 6. Specific ‐ average endpoint general pathological score (PANSS, high=poor )." data-id="CD006569-fig-0116" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-005-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.13</div> <div class="figure-caption"> <p>Comparison 5 COMPARISON 5. ARIPIPRAZOLE versus OLANZAPINE, Outcome 13 Mental state: 6. Specific ‐ average endpoint general pathological score (PANSS, high=poor ). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0116">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-005-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0117"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-005-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-005-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 COMPARISON 5. ARIPIPRAZOLE versus OLANZAPINE, Outcome 14 Mental state: 7. Specific ‐ binary outcomes." data-id="CD006569-fig-0117" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-005-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.14</div> <div class="figure-caption"> <p>Comparison 5 COMPARISON 5. ARIPIPRAZOLE versus OLANZAPINE, Outcome 14 Mental state: 7. Specific ‐ binary outcomes. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0117">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-005-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0118"> <p> <div class="table" id="CD006569-tblf-0011"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Heading 1</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Heading 2</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Heading 3</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Heading 4</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Heading 5</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>PANSS positive symptom subscale</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ye 2005a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>PANSS negative symptom subscale</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ye 2005a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>PANSS general pathology subscale</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ye 2005a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>BPRS total</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ye 2005a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>PANSS total</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ye 2005a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.15</div> <div class="figure-caption"> <p>Comparison 5 COMPARISON 5. ARIPIPRAZOLE versus OLANZAPINE, Outcome 15 Mental state: 8. Various scale scores decreased rate (low=poor, data skewed). </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0118">Navigate to figure in review</a></div> </div> <div class="figure" id="CD006569-fig-0119"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-005-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-005-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 COMPARISON 5. ARIPIPRAZOLE versus OLANZAPINE, Outcome 16 Adverse effects: 1. At least one adverse effect." data-id="CD006569-fig-0119" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-005-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.16</div> <div class="figure-caption"> <p>Comparison 5 COMPARISON 5. ARIPIPRAZOLE versus OLANZAPINE, Outcome 16 Adverse effects: 1. At least one adverse effect. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0119">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-005-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0120"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-005-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-005-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 COMPARISON 5. ARIPIPRAZOLE versus OLANZAPINE, Outcome 17 Adverse effects: 2. Cardiac effects." data-id="CD006569-fig-0120" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-005-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.17</div> <div class="figure-caption"> <p>Comparison 5 COMPARISON 5. ARIPIPRAZOLE versus OLANZAPINE, Outcome 17 Adverse effects: 2. Cardiac effects. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0120">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-005-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0121"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-005-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-005-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 COMPARISON 5. ARIPIPRAZOLE versus OLANZAPINE, Outcome 18 Adverse effects: 3a. Cardiac ‐ QTc change from baseline (in ms)." data-id="CD006569-fig-0121" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-005-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.18</div> <div class="figure-caption"> <p>Comparison 5 COMPARISON 5. ARIPIPRAZOLE versus OLANZAPINE, Outcome 18 Adverse effects: 3a. Cardiac ‐ QTc change from baseline (in ms). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0121">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-005-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0122"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-005-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-005-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 COMPARISON 5. ARIPIPRAZOLE versus OLANZAPINE, Outcome 19 Adverse effects: 3b. Central / peripheral nervous system." data-id="CD006569-fig-0122" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-005-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.19</div> <div class="figure-caption"> <p>Comparison 5 COMPARISON 5. ARIPIPRAZOLE versus OLANZAPINE, Outcome 19 Adverse effects: 3b. Central / peripheral nervous system. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0122">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-005-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0123"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-005-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-005-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 COMPARISON 5. ARIPIPRAZOLE versus OLANZAPINE, Outcome 20 Adverse effects: 4. Endocrine ‐ Prolactin ‐ average increase." data-id="CD006569-fig-0123" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-005-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.20</div> <div class="figure-caption"> <p>Comparison 5 COMPARISON 5. ARIPIPRAZOLE versus OLANZAPINE, Outcome 20 Adverse effects: 4. Endocrine ‐ Prolactin ‐ average increase. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0123">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-005-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0124"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-005-21" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-005-21.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 COMPARISON 5. ARIPIPRAZOLE versus OLANZAPINE, Outcome 21 Adverse effects: 5. Extrapyramidal ‐ various." data-id="CD006569-fig-0124" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-005-21.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.21</div> <div class="figure-caption"> <p>Comparison 5 COMPARISON 5. ARIPIPRAZOLE versus OLANZAPINE, Outcome 21 Adverse effects: 5. Extrapyramidal ‐ various. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0124">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-005-21.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0125"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-005-22" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-005-22.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 COMPARISON 5. ARIPIPRAZOLE versus OLANZAPINE, Outcome 22 Adverse effects: 6. Gastrointestinal." data-id="CD006569-fig-0125" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-005-22.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.22</div> <div class="figure-caption"> <p>Comparison 5 COMPARISON 5. ARIPIPRAZOLE versus OLANZAPINE, Outcome 22 Adverse effects: 6. Gastrointestinal. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0125">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-005-22.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0126"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-005-23" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-005-23.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 COMPARISON 5. ARIPIPRAZOLE versus OLANZAPINE, Outcome 23 Adverse effects: 7. Hormonal." data-id="CD006569-fig-0126" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-005-23.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.23</div> <div class="figure-caption"> <p>Comparison 5 COMPARISON 5. ARIPIPRAZOLE versus OLANZAPINE, Outcome 23 Adverse effects: 7. Hormonal. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0126">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-005-23.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0127"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-005-24" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-005-24.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 COMPARISON 5. ARIPIPRAZOLE versus OLANZAPINE, Outcome 24 Adverse effects: 8a. Metabolic ‐ binary measures." data-id="CD006569-fig-0127" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-005-24.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.24</div> <div class="figure-caption"> <p>Comparison 5 COMPARISON 5. ARIPIPRAZOLE versus OLANZAPINE, Outcome 24 Adverse effects: 8a. Metabolic ‐ binary measures. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0127">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-005-24.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0128"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-005-25" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-005-25.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 COMPARISON 5. ARIPIPRAZOLE versus OLANZAPINE, Outcome 25 Adverse effects: 8b. Metabolic ‐ continuous measures (high=poor)." data-id="CD006569-fig-0128" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-005-25.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.25</div> <div class="figure-caption"> <p>Comparison 5 COMPARISON 5. ARIPIPRAZOLE versus OLANZAPINE, Outcome 25 Adverse effects: 8b. Metabolic ‐ continuous measures (high=poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0128">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-005-25.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0129"> <p> <div class="table" id="CD006569-tblf-0012"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Note</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zhang 2006a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.03</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zhang 2006a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Olanzapine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.26</div> <div class="figure-caption"> <p>Comparison 5 COMPARISON 5. ARIPIPRAZOLE versus OLANZAPINE, Outcome 26 Adverse effects: 9. Average endpoint scale score (TESS, high=poor, data skewed). </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0129">Navigate to figure in review</a></div> </div> <div class="figure" id="CD006569-fig-0130"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-005-27" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-005-27.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 COMPARISON 5. ARIPIPRAZOLE versus OLANZAPINE, Outcome 27 Leaving the study early." data-id="CD006569-fig-0130" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-005-27.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.27</div> <div class="figure-caption"> <p>Comparison 5 COMPARISON 5. ARIPIPRAZOLE versus OLANZAPINE, Outcome 27 Leaving the study early. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0130">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-005-27.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0131"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-005-28" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-005-28.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 COMPARISON 5. ARIPIPRAZOLE versus OLANZAPINE, Outcome 28 Quality of life: 1. Average endpoint general quality of life score (GQOLI‐74, low=poor)." data-id="CD006569-fig-0131" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-005-28.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.28</div> <div class="figure-caption"> <p>Comparison 5 COMPARISON 5. ARIPIPRAZOLE versus OLANZAPINE, Outcome 28 Quality of life: 1. Average endpoint general quality of life score (GQOLI‐74, low=poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0131">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-005-28.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0132"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-006-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-006-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 COMPARISON 6. ARIPIPRAZOLE versus OLANZAPINE (acutely agitated people ‐ all data by 5 days), Outcome 1 Global state: Average improvement (BPRS, high=good)." data-id="CD006569-fig-0132" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-006-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 COMPARISON 6. ARIPIPRAZOLE versus OLANZAPINE (acutely agitated people ‐ all data by 5 days), Outcome 1 Global state: Average improvement (BPRS, high=good). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0132">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-006-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0133"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-006-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-006-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 COMPARISON 6. ARIPIPRAZOLE versus OLANZAPINE (acutely agitated people ‐ all data by 5 days), Outcome 2 Mental state: Specific ‐ binary outcomes." data-id="CD006569-fig-0133" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-006-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6 COMPARISON 6. ARIPIPRAZOLE versus OLANZAPINE (acutely agitated people ‐ all data by 5 days), Outcome 2 Mental state: Specific ‐ binary outcomes. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0133">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-006-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0134"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-006-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-006-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 COMPARISON 6. ARIPIPRAZOLE versus OLANZAPINE (acutely agitated people ‐ all data by 5 days), Outcome 3 Leaving the study early." data-id="CD006569-fig-0134" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-006-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6 COMPARISON 6. ARIPIPRAZOLE versus OLANZAPINE (acutely agitated people ‐ all data by 5 days), Outcome 3 Leaving the study early. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0134">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-006-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0135"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-006-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-006-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 COMPARISON 6. ARIPIPRAZOLE versus OLANZAPINE (acutely agitated people ‐ all data by 5 days), Outcome 4 Adverse effects: 1. Central nervous system." data-id="CD006569-fig-0135" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-006-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.4</div> <div class="figure-caption"> <p>Comparison 6 COMPARISON 6. ARIPIPRAZOLE versus OLANZAPINE (acutely agitated people ‐ all data by 5 days), Outcome 4 Adverse effects: 1. Central nervous system. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0135">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-006-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0136"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-006-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-006-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 COMPARISON 6. ARIPIPRAZOLE versus OLANZAPINE (acutely agitated people ‐ all data by 5 days), Outcome 5 Adverse effects: 2. Endocrine ‐ Prolactin ‐ average increase." data-id="CD006569-fig-0136" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-006-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.5</div> <div class="figure-caption"> <p>Comparison 6 COMPARISON 6. ARIPIPRAZOLE versus OLANZAPINE (acutely agitated people ‐ all data by 5 days), Outcome 5 Adverse effects: 2. Endocrine ‐ Prolactin ‐ average increase. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0136">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-006-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0137"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-006-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-006-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 COMPARISON 6. ARIPIPRAZOLE versus OLANZAPINE (acutely agitated people ‐ all data by 5 days), Outcome 6 Adverse effects: 3a. Extrapyramidal ‐ various." data-id="CD006569-fig-0137" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-006-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.6</div> <div class="figure-caption"> <p>Comparison 6 COMPARISON 6. ARIPIPRAZOLE versus OLANZAPINE (acutely agitated people ‐ all data by 5 days), Outcome 6 Adverse effects: 3a. Extrapyramidal ‐ various. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0137">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-006-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0138"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-006-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-006-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 COMPARISON 6. ARIPIPRAZOLE versus OLANZAPINE (acutely agitated people ‐ all data by 5 days), Outcome 7 Adverse effects: 3b. Extrapyramidal ‐ average score." data-id="CD006569-fig-0138" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-006-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.7</div> <div class="figure-caption"> <p>Comparison 6 COMPARISON 6. ARIPIPRAZOLE versus OLANZAPINE (acutely agitated people ‐ all data by 5 days), Outcome 7 Adverse effects: 3b. Extrapyramidal ‐ average score. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0138">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-006-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0139"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-006-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-006-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 COMPARISON 6. ARIPIPRAZOLE versus OLANZAPINE (acutely agitated people ‐ all data by 5 days), Outcome 8 Adverse effects: 4. Gastrointestinal." data-id="CD006569-fig-0139" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-006-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.8</div> <div class="figure-caption"> <p>Comparison 6 COMPARISON 6. ARIPIPRAZOLE versus OLANZAPINE (acutely agitated people ‐ all data by 5 days), Outcome 8 Adverse effects: 4. Gastrointestinal. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0139">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-006-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0140"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-006-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-006-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 COMPARISON 6. ARIPIPRAZOLE versus OLANZAPINE (acutely agitated people ‐ all data by 5 days), Outcome 9 Adverse effects: 5. Metabolic ‐ continuous measures." data-id="CD006569-fig-0140" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-006-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.9</div> <div class="figure-caption"> <p>Comparison 6 COMPARISON 6. ARIPIPRAZOLE versus OLANZAPINE (acutely agitated people ‐ all data by 5 days), Outcome 9 Adverse effects: 5. Metabolic ‐ continuous measures. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0140">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-006-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0141"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-007-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-007-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 COMPARISON 7. ARIPIPRAZOLE versus OTHER ANTIPSYCHOTIC DRUGS, Outcome 1 Global state: 1. No change (as defined in the study, measured by IAQ)." data-id="CD006569-fig-0141" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-007-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7 COMPARISON 7. ARIPIPRAZOLE versus OTHER ANTIPSYCHOTIC DRUGS, Outcome 1 Global state: 1. No change (as defined in the study, measured by IAQ). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0141">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-007-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0142"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-007-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-007-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 COMPARISON 7. ARIPIPRAZOLE versus OTHER ANTIPSYCHOTIC DRUGS, Outcome 2 Global state: 2. Change in sexual dysfunction (ASEX)." data-id="CD006569-fig-0142" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-007-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7 COMPARISON 7. ARIPIPRAZOLE versus OTHER ANTIPSYCHOTIC DRUGS, Outcome 2 Global state: 2. Change in sexual dysfunction (ASEX). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0142">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-007-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0143"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-007-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-007-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 COMPARISON 7. ARIPIPRAZOLE versus OTHER ANTIPSYCHOTIC DRUGS, Outcome 3 Mental state: Specific ‐ binary outcomes." data-id="CD006569-fig-0143" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-007-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.3</div> <div class="figure-caption"> <p>Comparison 7 COMPARISON 7. ARIPIPRAZOLE versus OTHER ANTIPSYCHOTIC DRUGS, Outcome 3 Mental state: Specific ‐ binary outcomes. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0143">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-007-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0144"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-007-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-007-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 COMPARISON 7. ARIPIPRAZOLE versus OTHER ANTIPSYCHOTIC DRUGS, Outcome 4 Preference: Study medication worse than or equal to previous medication." data-id="CD006569-fig-0144" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-007-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.4</div> <div class="figure-caption"> <p>Comparison 7 COMPARISON 7. ARIPIPRAZOLE versus OTHER ANTIPSYCHOTIC DRUGS, Outcome 4 Preference: Study medication worse than or equal to previous medication. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0144">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-007-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0145"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-007-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-007-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 COMPARISON 7. ARIPIPRAZOLE versus OTHER ANTIPSYCHOTIC DRUGS, Outcome 5 Quality of life: 1. Unsatisfactory response on health dimension scale." data-id="CD006569-fig-0145" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-007-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.5</div> <div class="figure-caption"> <p>Comparison 7 COMPARISON 7. ARIPIPRAZOLE versus OTHER ANTIPSYCHOTIC DRUGS, Outcome 5 Quality of life: 1. Unsatisfactory response on health dimension scale. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0145">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-007-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0146"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-007-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-007-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 COMPARISON 7. ARIPIPRAZOLE versus OTHER ANTIPSYCHOTIC DRUGS, Outcome 6 Quality of life: 3. Average change score (QLS, high=better))." data-id="CD006569-fig-0146" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-007-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.6</div> <div class="figure-caption"> <p>Comparison 7 COMPARISON 7. ARIPIPRAZOLE versus OTHER ANTIPSYCHOTIC DRUGS, Outcome 6 Quality of life: 3. Average change score (QLS, high=better)). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0146">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-007-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0147"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-007-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-007-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 COMPARISON 7. ARIPIPRAZOLE versus OTHER ANTIPSYCHOTIC DRUGS, Outcome 7 Quality of life: 2. Average score (EQ‐5D utility score, high=better)." data-id="CD006569-fig-0147" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-007-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.7</div> <div class="figure-caption"> <p>Comparison 7 COMPARISON 7. ARIPIPRAZOLE versus OTHER ANTIPSYCHOTIC DRUGS, Outcome 7 Quality of life: 2. Average score (EQ‐5D utility score, high=better). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0147">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-007-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0148"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-007-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-007-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 COMPARISON 7. ARIPIPRAZOLE versus OTHER ANTIPSYCHOTIC DRUGS, Outcome 8 Quality of life: 4a. Weight related ‐ No meaningful change (IWQOL‐Lite)." data-id="CD006569-fig-0148" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-007-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.8</div> <div class="figure-caption"> <p>Comparison 7 COMPARISON 7. ARIPIPRAZOLE versus OTHER ANTIPSYCHOTIC DRUGS, Outcome 8 Quality of life: 4a. Weight related ‐ No meaningful change (IWQOL‐Lite). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0148">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-007-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0149"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-007-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-007-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 COMPARISON 7. ARIPIPRAZOLE versus OTHER ANTIPSYCHOTIC DRUGS, Outcome 9 Quality of life: 4b. Weight related ‐ average score (IWQOL‐Lite, high=better)." data-id="CD006569-fig-0149" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-007-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.9</div> <div class="figure-caption"> <p>Comparison 7 COMPARISON 7. ARIPIPRAZOLE versus OTHER ANTIPSYCHOTIC DRUGS, Outcome 9 Quality of life: 4b. Weight related ‐ average score (IWQOL‐Lite, high=better). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0149">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-007-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0150"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-007-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-007-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 COMPARISON 7. ARIPIPRAZOLE versus OTHER ANTIPSYCHOTIC DRUGS, Outcome 10 Leaving the study early." data-id="CD006569-fig-0150" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-007-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.10</div> <div class="figure-caption"> <p>Comparison 7 COMPARISON 7. ARIPIPRAZOLE versus OTHER ANTIPSYCHOTIC DRUGS, Outcome 10 Leaving the study early. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0150">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-007-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0151"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-007-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-007-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 COMPARISON 7. ARIPIPRAZOLE versus OTHER ANTIPSYCHOTIC DRUGS, Outcome 11 Adverse effects: 1. At least one adverse effect." data-id="CD006569-fig-0151" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-007-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.11</div> <div class="figure-caption"> <p>Comparison 7 COMPARISON 7. ARIPIPRAZOLE versus OTHER ANTIPSYCHOTIC DRUGS, Outcome 11 Adverse effects: 1. At least one adverse effect. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0151">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-007-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0152"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-007-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-007-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 COMPARISON 7. ARIPIPRAZOLE versus OTHER ANTIPSYCHOTIC DRUGS, Outcome 12 Adverse effects: 2. Central nervous system." data-id="CD006569-fig-0152" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-007-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.12</div> <div class="figure-caption"> <p>Comparison 7 COMPARISON 7. ARIPIPRAZOLE versus OTHER ANTIPSYCHOTIC DRUGS, Outcome 12 Adverse effects: 2. Central nervous system. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0152">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-007-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0153"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-007-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-007-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 COMPARISON 7. ARIPIPRAZOLE versus OTHER ANTIPSYCHOTIC DRUGS, Outcome 13 Adverse effects: 3a. Endocrine ‐ Prolactin ‐ increase in level." data-id="CD006569-fig-0153" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-007-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.13</div> <div class="figure-caption"> <p>Comparison 7 COMPARISON 7. ARIPIPRAZOLE versus OTHER ANTIPSYCHOTIC DRUGS, Outcome 13 Adverse effects: 3a. Endocrine ‐ Prolactin ‐ increase in level. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0153">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-007-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0154"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-007-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-007-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 COMPARISON 7. ARIPIPRAZOLE versus OTHER ANTIPSYCHOTIC DRUGS, Outcome 14 Adverse effects: 3b. Endocrine ‐ Prolactin ‐ Change in level." data-id="CD006569-fig-0154" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-007-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.14</div> <div class="figure-caption"> <p>Comparison 7 COMPARISON 7. ARIPIPRAZOLE versus OTHER ANTIPSYCHOTIC DRUGS, Outcome 14 Adverse effects: 3b. Endocrine ‐ Prolactin ‐ Change in level. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0154">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-007-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0155"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-007-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-007-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 COMPARISON 7. ARIPIPRAZOLE versus OTHER ANTIPSYCHOTIC DRUGS, Outcome 15 Adverse effects: 4. Extrapyramidal ‐ akathisia." data-id="CD006569-fig-0155" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-007-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.15</div> <div class="figure-caption"> <p>Comparison 7 COMPARISON 7. ARIPIPRAZOLE versus OTHER ANTIPSYCHOTIC DRUGS, Outcome 15 Adverse effects: 4. Extrapyramidal ‐ akathisia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0155">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-007-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0156"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-007-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-007-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 COMPARISON 7. ARIPIPRAZOLE versus OTHER ANTIPSYCHOTIC DRUGS, Outcome 16 Adverse effects: 5. Gastrointestinal." data-id="CD006569-fig-0156" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-007-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.16</div> <div class="figure-caption"> <p>Comparison 7 COMPARISON 7. ARIPIPRAZOLE versus OTHER ANTIPSYCHOTIC DRUGS, Outcome 16 Adverse effects: 5. Gastrointestinal. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0156">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-007-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0157"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-007-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-007-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 COMPARISON 7. ARIPIPRAZOLE versus OTHER ANTIPSYCHOTIC DRUGS, Outcome 17 Adverse effects: 6a. Metabolic‐ binary measures." data-id="CD006569-fig-0157" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-007-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.17</div> <div class="figure-caption"> <p>Comparison 7 COMPARISON 7. ARIPIPRAZOLE versus OTHER ANTIPSYCHOTIC DRUGS, Outcome 17 Adverse effects: 6a. Metabolic‐ binary measures. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0157">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-007-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006569-fig-0158"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/urn:x-wiley:14651858:media:CD006569:CD006569-CMP-007-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_t/tCD006569-CMP-007-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 COMPARISON 7. ARIPIPRAZOLE versus OTHER ANTIPSYCHOTIC DRUGS, Outcome 18 Adverse effects: 6b. Metabolic ‐ continuous measures." data-id="CD006569-fig-0158" src="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-007-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.18</div> <div class="figure-caption"> <p>Comparison 7 COMPARISON 7. ARIPIPRAZOLE versus OTHER ANTIPSYCHOTIC DRUGS, Outcome 18 Adverse effects: 6b. Metabolic ‐ continuous measures. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-fig-0158">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/media/CDSR/CD006569/image_n/nCD006569-CMP-007-18.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table data-id="CD006569-tbl-0006"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Titles for reviews suggested by excluded studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Suggested title/ongoing title</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Excluded study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Reference to relevant ongoing Cochrane title*</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Alpha‐receptor agonists for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006569-bbs2-0179" title="BergmanM , FriedmanJI , StawarzK , BowmanA , SieverL , CavagnaM , et al. A double blind placebo controlled study of guanfacine adjunctive treatment to atypical antipsychotics for cognitive dysfunction in schizophrenia. http://www.clinicaltrials.gov2007. ">Bergman 2007</a>   </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Currently no review.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Antidepressant augmentation of antipsychotic drugs for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006569-bbs2-0190" title="FawziM , FawziMJr . Aripiprazole, olanzapine and olanzapine‐clomipramine combination in schizophrenia with obsessive‐compulsive symptoms. World Psychiatry2009;8(Suppl 1):NRS5.4. ">Fawzi 2009</a>   </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006569-bbs2-0334" title="WhiteheadC , MossS , CardnoA , LewisG . Antidepressants for people with both schizophrenia and depression. Cochrane Database of Systematic Reviews2002, Issue 2. [DOI: 10.1002/14651858.CD002305; PUBMED: 12076447] ">Whitehead 2002</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole augmentation of other antipsychotics for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006569-bbs2-0180" title="Bristol‐MyersSquibb , Otsuka AmericaPharmaceutical . A multicenter, randomized, double‐blind, placebo‐controlled, 16 week study of aripiprazole used as dual therapy in the treatment of patients with chronic stable schizophrenia or schizoaffective disorder demonstrating an inadequate response to quetiapine or risperidone monotherapy. http://www.clinicaltrials.gov2006. ">Bristol‐Myers 2006</a>, <a href="./references#CD006569-bbs2-0231" title="ShimJC , KellyDL , JungDU , SeoYS , KimYH , ConleyRR . Adjunctive treatment with a dopamine partial agonist, aripiprazole for antipsychotic induced hyperprolactinemia. European Neuropsychopharmacology2006;16(Suppl 4):S405. ">Shim 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006569-bbs2-0314" title="MaayanN , Soares‐WeiserK , XiaJ , AdamsCE . Antipsychotic combinations for schizophrenia. Cochrane Database of Systematic Reviews2011, Issue 2. [DOI: 10.1002/14651858.CD009005] ">Maayan 2011</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole for people with metabolic syndrome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006569-bbs2-0188" title="ColomboGL , CaruggiM , DiMatteoS , RossiA . An economic evaluation of aripiprazole vs olanzapine adapted to the Italian setting using outcomes of metabolic syndrome and risk for diabetes in patients with schizophrenia. Neuropsychiatric Disease and Treatment2008;4(5):967‐76. ">Colombo 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006569-bbs2-0320" title="MukundanA , FaulknerG , CohnT , RemingtonG . Antipsychotic switching for people with schizophrenia who have neuroleptic‐induced weight or metabolic problems. Cochrane Database of Systematic Reviews2010, Issue 12. [DOI: 10.1002/14651858.CD006629.pub2; CD006629] ">Mukundan 2010</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole versus first generation antipsychotics for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006569-bbs2-0181" title="CarsonWH , KaneJM , AliM , DunbarGC , IngenitoG . Efficacy of aripiprazole in psychotic disorders: comparison with haloperidol and placebo. European Neuropsychopharmacology2000;10(Suppl 3):S309. ">Carson 2000</a>, <a href="./references#CD006569-bbs2-0221" title="MossnerR , SchuhmacherA , KuhnKU , CvetanovskaG , RujescuD , ZillP , et al. Functional serotonin 1A receptor variant influences treatment response to atypical antipsychotics in schizophrenia. Pharmacogenetics and Genomics2009;19(1):91‐4. [MEDLINE: 18849890] ">Mossner 2009</a>, <a href="./references#CD006569-bbs2-0235" title="TalbottS , BuckleyP , EudiconeJ , McQuadeR , Van‐TranQ . Akathisia in schizophrenia patients treated with aripiprazole, haloperidol, or olanzapine‐analyses of the first 12 weeks of three double‐blind, long‐term trials. Proceedings of the 11th International Congress on Schizophrenia Research; 2007 Mar 28‐Apr 1; Colorado Springs, Colorado, USA2007. ">Talbott 2007</a>, <a href="./references#CD006569-bbs2-0236" title="TaylorD . Haloperidol, olanzapine and risperidone reduce treatment failure compared to aripiprazole, quetiapine and ziprasidone in acute schizophrenia. Evidence‐Based Mental Health2007;10(3):76. [MEDLINE: 17652558] ">Taylor 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006569-bbs2-0279" title="BhattacharjeeJ , El‐Sayeh Hany GeorgeG . Aripiprazole versus typical antipsychotic drugs for schizophrenia. Cochrane Database of Systematic Reviews2008, Issue 3. [DOI: 10.1002/14651858.CD006617.pub3] ">Bhattacharjee 2008</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aripiprazole versus placebo for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006569-bbs2-0181" title="CarsonWH , KaneJM , AliM , DunbarGC , IngenitoG . Efficacy of aripiprazole in psychotic disorders: comparison with haloperidol and placebo. European Neuropsychopharmacology2000;10(Suppl 3):S309. ">Carson 2000</a>, <a href="./references#CD006569-bbs2-0196" title="HendersonDC , FanX , CopelandPM , BorbaCP , FreudenreichO , EvinsAE , et al. Aripiprazole added to overweight and obese olanzapine‐treated schizophrenia patients. Journal of Clinical Psychopharmacology2009;29(2):165‐9. RousselJJ , MachonDA , HendersonDC . A placebo‐controlled, cross‐over trial of aripiprazole added to obese olanzapine‐treated patients with schizophrenia. http://www.clinicaltrials.gov2006. ">Henderson 2009</a>, <a href="./references#CD006569-bbs2-0220" title="MortimerAMP . Aripiprazole is effective for relapse prevention in people with chronic stable schizophrenia. Evidence‐Based Mental Health2004;7(2):41. [MEDLINE: 15107337] ">Mortimer 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006569-bbs2-0278" title="Belgamwar RavindraB , El‐Sayeh Hany GeorgeG . Aripiprazole versus placebo for schizophrenia. Cochrane Database of Systematic Reviews2011, Issue 8. [DOI: 10.1002/14651858.CD006622.pub2] ">Belgamwar 2011</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Augmentation of clozapine for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006569-bbs2-0191" title="FleischhackerW , HeikkinenME , OlieJP , DewaeleP , McQuadeR , HennickenD , et al. Long‐term effect on weight of aripiprazole‐clozapine in schizophrenia patients with suboptimal response on clozapine. European Neuropsychopharmacology2008;18:S447. MarkovicO . A multicenter, comparative, randomized, double‐blind, placebo controlled study on the effect on weight of adjunctive treatment with aripiprazole in patients with schizophrenia. http://www.clinicaltrials.gov2006. ">Fleischhacker 2008a</a>, <a href="./references#CD006569-bbs2-0201" title="KimYS . A double‐blind randomized placebo controlled study of aripiprazole augmentation for clozapine‐treated patients with refractory schizophrenia. http://www.clinicaltrials.gov2006. ">Kim 2006</a>, <a href="./references#CD006569-bbs2-0216" title="MaQ , LianH‐T , LiL‐X . A study of aripiprazole combined with clozapine in refractory schizophrenia [阿 立 哌 唑 合 并 氯 氮 平 治 疗 难 治 性 精 神 分 裂 症]. Medical Journal of Chinese People's Health [中 国 民 康 医 学 ]2007;19(12):1046, 1048. ">Ma 2007</a>, <a href="./references#CD006569-bbs2-0219" title="MillarH , FelterC , LandsbergW . The effects of aripiprazole in combination with clozapine: patient functioning results from a double‐blind, 16‐week study in patients with schizophrenia (CN138‐170). Journal of Psychopharmacology2008;22(5):A17. ">Millar 2008</a>, <a href="./references#CD006569-bbs2-0222" title="NameyLB , HendersonDC . Aripiprazole for clozapine associated medical morbidity. http://www.clinicaltrials.gov2006. ">Namey 2006</a>, <a href="./references#CD006569-bbs2-0228" title="RemingtonG . Refractory schizophrenia: Adding aripiprazole to clozapine reduces negative but not overall symptoms. Evidence‐Based Mental Health2009;12(2):51. ">Remington 2009</a>     </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006569-bbs2-0285" title="CiprianiA , BosoM , BarbuiC . Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia. Cochrane Database of Systematic Reviews2009, Issue 3. [DOI: 10.1002/14651858.CD006324.pub2] ">Cipriani 2009</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Psychosocial intervention for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006569-bbs2-0177" title="Anon . Effectiveness of antipsychotic combination with psychosocial intervention on outcome of patients with schizophrenia. http://www.clinicaltrials.gov2008. ">Anon 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear which of the many reviews would be relevant.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Switching from other antipsychotics to aripiprazole for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006569-bbs2-0198" title="JanssenF . A comparative, randomized, open‐label, multicenter study on the efficacy and safety of switch treatment with aripiprazole in schizophrenic out‐patients who are experiencing insufficient efficacy with risperidone and/or safety and tolerability issues, while on risperidone. http://www.clinicaltrials.gov2005. ">Janssen 2005</a>, <a href="./references#CD006569-bbs2-0203" title="LanT , ChiuH , HuT , HuangH , WuB , TuanY . Prolactin level as an indicator to clinical psychopathological severity in aripiprazole treated schizophrenia. European Neuropsychopharmacology2008;18:S440. ">Lan 2008</a>, <a href="./references#CD006569-bbs2-0226" title="PaeCU , SerrettiA , ChiesaA , MandelliL , LeeC , KimJ , et al. Immediate versus gradual suspension of previous treatments during switch to aripiprazole: results of a randomized, open label study. European Neuropsychopharmacology2009;19(8):562‐70. ">Pae 2009a</a>, <a href="./references#CD006569-bbs2-0229" title="SchreinerA , DeArceR , EdingE , Marques‐TeixeiraJ , MilanovaV , RancansE , et al. Descriptive analyses of the aripiprazole arm in the risperidone long‐acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Proceedings of the 9th World Congress of Biological Psychiatry; 2009 Jun 28‐Jul 2; Paris, France. 2009. ">Schreiner 2009</a>, <a href="./references#CD006569-bbs2-0234" title="TakeuchiH , SuzukiT , UchidaH , NakajimaS , NomuraK , KikuchiT , et al. A randomized, open‐label comparison of 2 switching strategies to aripiprazole treatment in patients with schizophrenia: add‐on, wait, and tapering of previous antipsychotics versus add‐on and simultaneous tapering. Journal of Clinical Psychopharmacology2008;28(5):540‐3. ">Takeuchi 2008</a>   </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006569-bbs2-0320" title="MukundanA , FaulknerG , CohnT , RemingtonG . Antipsychotic switching for people with schizophrenia who have neuroleptic‐induced weight or metabolic problems. Cochrane Database of Systematic Reviews2010, Issue 12. [DOI: 10.1002/14651858.CD006629.pub2; CD006629] ">Mukundan 2010</a> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>* It is possible that these studies could also contribute to other titles not referenced in this column. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Titles for reviews suggested by excluded studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/full#CD006569-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD006569-tbl-0007"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Suggested design of future study</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Methods</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Allocation: randomised ‐ clearly described generation of sequence and concealment of allocation.<br/> Blindness: double ‐ described and tested.<br/> Duration: six months minimum. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diagnosis: schizophrenia (operational criteria).<br/> N = 2700.*<br/> Age: any.<br/> Gender: both.<br/> History: any. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1. Aripiprazole: dose ˜ 10‐30 mg/day. N = 300.<br/> 2. Amisulpride: dose ˜ 400‐800 mg/day. N = 300.<br/> 3. Clozapine: dose ˜ 300‐800 mg/day. N = 300.<br/> 4. Olanzapine: dose ˜ 10‐20 mg/day. N = 300.<br/> 5. Quetiapine: dose ˜300‐800 mg/day. N = 300.<br/> 6. Risperidone: dose ˜ 4‐8 mg/day. N = 300.<br/> 7. Sertindole: dose ˜ 12‐24 mg/day. N = 300.<br/> 8. Ziprasidone: dose ˜ 120‐160 mg/day. N = 300.<br/> 9. Zotepine: dose ˜ 100‐300 mg/day. N = 300. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Leaving study early (any reason, adverse events, inefficacy).<br/> Service outcomes: hospitalised, time in hospital, attending out patient clinics.<br/> Global impression: CGI**, relapse.<br/> Mental state: PANSS.<br/> Adverse events/effects: UKU, major adverse event/effect.<br/> Employment, living independently, family satisfaction, patient satisfaction. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="2"> <div class="table-footnote"> <p>* power calculation suggested 300/group would allow good chance of showing a 10% difference between groups for primary outcome.<br/> <br/> ** Primary outcome<br/> CGI: Clinical Global Impression Scale<br/> PANSS: Positive and Negative Syndrome Scale<br/> UKU: Udvalg for kliniske ndersogelser Side Effect Rating Scale ‐side effect rating scale </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Suggested design of future study</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/full#CD006569-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD006569-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">COMPARISON 1. ARIPIPRAZOLE versus CLOZAPINE for schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>COMPARISON 1. ARIPIPRAZOLE versus CLOZAPINE for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with schizophrenia<br/> <b>Settings:</b> inpatient and outpatient<br/> <b>Intervention:</b> COMPARISON 1. ARIPIPRAZOLE versus CLOZAPINE </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> COMPARISON 1. ARIPIPRAZOLE versus CLOZAPINE</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Global state: No clinically significant response</b> <br/> Follow‐up: up to 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Low<sup>1</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>RR 1.05</b> <br/> (0.87 to 1.27) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>2132<br/> (29 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"></td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>105 per 1000</b> <br/> (87 to 127) </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>150 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>157 per 1000</b> <br/> (131 to 190) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>200 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>210 per 1000</b> <br/> (174 to 254) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state: as measured by BPRS</b> <br/> BPRS (high score = poor) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean mental state: as measured by BPRS in the intervention groups was<br/> <b>0.22 lower</b> <br/> (1.44 lower to 1 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>426<br/> (5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,3,4,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Leaving the study early ‐ Any reason</b> <br/> Follow‐up: up to 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Low<sup>1</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>RR 1.41</b> <br/> (0.46 to 4.29) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>240<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> <br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>50 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>70 per 1000</b> <br/> (23 to 214) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>141 per 1000</b> <br/> (46 to 429) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life: as measured by WHO‐QOL‐100</b> <br/> WHO‐QOL‐100 (low score = poor)<br/> Follow‐up: up to 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean quality of life: as measured by WHO‐QOL‐100 in the intervention groups was<br/> <b>2.59 higher</b> <br/> (1.43 to 3.74 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>132<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Adverse effects: extrapyramidal effects</b> <br/> Follow‐up: up to 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Low<sup>1</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>RR 1.91</b> <br/> (0.75 to 4.85) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>520<br/> (8 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,3,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> <br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>50 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>96 per 1000</b> <br/> (38 to 242) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>191 per 1000</b> <br/> (75 to 485) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>General functioning</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study measured or reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Service use</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study measured or reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Risk: moderate risk approximately equates to that of the control group risk in the study population.<br/> <sup>2</sup> Risk of bias: rated 'serious' ‐ majority of the included studies had inadequate study design ‐ unclear randomisation, allocation concealment and blinding. Some also had selective reporting concerns.<br/> <sup>3</sup> Imprecision: rated 'serious' ‐ most of these included studies are of small samples with small effect size and wide confidence interval. The combined effect was not statistically significant.<br/> <sup>4</sup> Imprecision: rated 'serious' ‐ we were unable to obtain direct binary measure of mental state, thus used BPRS score as an indicator.<br/> <sup>5</sup> Publication bias: rated 'strongly suspected' ‐ only a small number of studies favouring intervention group were identified.<br/> <sup>6</sup> Indirectness: rated 'serious' ‐ we were unable to obtain direct binary measure of quality of life, thus employed WHO‐QOL‐100 rating score as an indicator. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">COMPARISON 1. ARIPIPRAZOLE versus CLOZAPINE for schizophrenia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/full#CD006569-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD006569-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">COMPARISON 2. ARIPIPRAZOLE versus QUETIAPINE for schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>COMPARISON 2. ARIPIPRAZOLE versus QUETIAPINE for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with schizophrenia<br/> <b>Settings:</b> inpatient and outpatient<br/> <b>Intervention:</b> COMPARISON 2. ARIPIPRAZOLE versus QUETIAPINE </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> COMPARISON 2. ARIPIPRAZOLE versus QUETIAPINE</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Global state: No clinically significant response (as defined by original studies)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Low<sup>1</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>RR 0.92</b> <br/> (0.64 to 1.32) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>991<br/> (12 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"></td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>50 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>46 per 1000</b> <br/> (32 to 66) </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>92 per 1000</b> <br/> (64 to 132) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>150 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>138 per 1000</b> <br/> (96 to 198) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state: as assessed by PANSS positive symptom scale score</b> <br/> PANSS positive symptom subscale (high score = poor)<br/> Follow‐up: up to 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean mental state: as assessed by PANSS positive symptom scale score in the intervention groups was<br/> <b>0.97 lower</b> <br/> (2.34 lower to 0.41 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>583<br/> (7 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>4,5,6,7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Leaving the study early</b> <br/> Follow‐up: up to 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Low<sup>1</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>RR 0.8</b> <br/> (0.22 to 2.87) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>168<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,8</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> <br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>50 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>40 per 1000</b> <br/> (11 to 143) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>80 per 1000</b> <br/> (22 to 287) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life: as measured by WHO‐QOL‐100</b> <br/> Follow‐up: up to 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean quality of life: as measured by WHO‐QOL‐100 in the intervention groups was<br/> <b>2.6 higher</b> <br/> (1.31 to 3.89 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>8,9,10,11</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Adverse effects: extrapyramidal symptoms</b> <br/> Follow‐up: up to 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Low<sup>1</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>RR 2.8</b> <br/> (0.64 to 12.31) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>348<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,7,12,13</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> <br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>50 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>140 per 1000</b> <br/> (32 to 616) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>280 per 1000</b> <br/> (64 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>General functioning</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study measured or reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Service use</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study measured or reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Risk: moderate risk approximately equates to that of the control group risk in the study population.<br/> <sup>2</sup> Risk of bias: rated 'serious' – majority of the included studies had inadequate study design ‐ unclear randomisation, allocation concealment and blinding. A large proportion of them also had selective reporting concerns.<br/> <sup>3</sup> Imprecision: rated 'serious' – most of these included studies are of small samples with small effect size and wide confidence interval. The 95% confidence interval of the combined estimated effect was not statistically significant.<br/> <sup>4</sup> Imprecision and risk of bias: rated 'serious' ‐ most of the studies included are of small sample size, the overall pooled estimate of effect is not significant.<br/> <sup>5</sup> Inconsistency: rated 'serious' ‐ unexplained heterogeneity is high (70%).<br/> <sup>6</sup> Indirectness: rated 'serious' ‐ we were unable to obtain direct binary measure of mental state, thus used the best approximate measure available as an indicator.<br/> <sup>7</sup> Publication bias: rated 'strongly suspected' ‐ only small number of studies were identified ‐ publication bias likely.<br/> <sup>8</sup> Imprecision and publication bias: rated 'serious' ‐ only small number of studies with poor methodological design favouring intervention group were identified ‐ publication bias likely<br/> <sup>9</sup> Risk of bias: rated 'serious' – the only included study has unclear study design (randomisation, allocation concealment, blinding were unclear) and concerns of selective reporting.<br/> <sup>10</sup> Indirectness: rated 'serious' ‐ we are unable to obtain a direct binary measure of quality of life, thus used the best available proximate measure of WHO‐QOL‐100 as an indicator.<br/> <sup>11</sup> Imprecision: rated 'very serious' ‐ only one study is available on this outcome. The sample size is small and the CI of effect estimate is wide.<br/> <sup>12</sup> Inconsistency: rated 'serious' ‐ unexplained heterogeneity is around 53%.<br/> <sup>13</sup> Imprecision: rated 'serious' ‐ overall event rate is small (&lt;300). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">COMPARISON 2. ARIPIPRAZOLE versus QUETIAPINE for schizophrenia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/full#CD006569-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD006569-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE for schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with schizophrenia<br/> <b>Settings:</b> inpatient and outpatient<br/> <b>Intervention:</b> COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Global state: No clinically significant response (as defined by the original studies)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Low<sup>1</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>RR 1.08</b> <br/> (0.96 to 1.21) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>6381<br/> (80 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"></td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>50 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>54 per 1000</b> <br/> (48 to 61) </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>108 per 1000</b> <br/> (96 to 121) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>150 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>162 per 1000</b> <br/> (144 to 182) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state: as measured by BPRS</b> <br/> BPRS (high score = poor)<br/> Follow‐up: up to 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean mental state: as measured by BPRS in the intervention groups was<br/> <b>1.33 lower</b> <br/> (2.24 to 0.42 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>570<br/> (5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>4,5,6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Leaving the study early</b> <br/> Follow‐up: up to 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Low<sup>1</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>RR 1.02</b> <br/> (0.79 to 1.32) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>1239<br/> (12 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>6,7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> <br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>102 per 1000</b> <br/> (79 to 132) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>150 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>153 per 1000</b> <br/> (119 to 198) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study measured or reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Adverse effects: extrapyramidal symptoms</b> <br/> Follow‐up: up to 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Low<sup>1</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>RR 0.39</b> <br/> (0.31 to 0.5) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>2605<br/> (31 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,8</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>39 per 1000</b> <br/> (31 to 50) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>300 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>117 per 1000</b> <br/> (93 to 150) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>400 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>156 per 1000</b> <br/> (124 to 200) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>General functioning</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study measured or reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Service use</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study measured or reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Risk: moderate risk approximately equates to that of the control group risk of the study population.<br/> <sup>2</sup> Risk of bias: rated 'serious' ‐ majority of the included studies had inadequate study design ‐ unclear randomisation, allocation concealment and blinding. A large proportion of them also had selective reporting concerns.<br/> <sup>3</sup> Imprecision: rated 'serious' ‐ 95% CI around the pool estimate of effect was not statistically significant.<br/> <sup>4</sup> Risk of bias: rated 'serious' ‐ only a small number of publications with poor methodological design favouring intervention group were identified ‐ publication bias likely.<br/> <sup>5</sup> Indirectness: rated 'serious' ‐ we were unable to find direct binary measure of mental state, thus used the best available data as an indicator.<br/> <sup>6</sup> Publication bias: rated 'strongly suspected' ‐ overall event number is small (&lt;300) and the pooled effect estimate is not statistically significant.<br/> <sup>7</sup> Imprecision: rated 'serious' ‐ overall event number is small (&lt;300).<br/> <sup>8</sup> Publication bias: rated 'strongly suspected' ‐ most of the studies identified were of poor methodological quality favouring intervention group ‐ publication bias likely. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE for schizophrenia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/full#CD006569-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD006569-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">COMPARISON 4. ARIPIPRAZOLE versus ZIPRASIDONE for schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>COMPARISON 4. ARIPIPRAZOLE versus ZIPRASIDONE for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with schizophrenia<br/> <b>Settings:</b> inpatient and outpatient<br/> <b>Intervention:</b> COMPARISON 4. ARIPIPRAZOLE versus ZIPRASIDONE </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> COMPARISON 4. ARIPIPRAZOLE versus ZIPRASIDONE</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Global state: No clinically significant response (as defined by the original studies)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Low<sup>1</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>RR 0.97</b> <br/> (0.62 to 1.52) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>442<br/> (6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"></td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>97 per 1000</b> <br/> (62 to 152) </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>150 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>146 per 1000</b> <br/> (93 to 228) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>200 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>194 per 1000</b> <br/> (124 to 304) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state: as measured with BPRS</b> <br/> BPRS (high score = poor)<br/> Follow‐up: up to 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean mental state: as measured with BPRS in the intervention groups was<br/> <b>2.2 lower</b> <br/> (4.97 lower to 0.57 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>247<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>5,6,7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Leaving the study early</b> <br/> Follow‐up: up to 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Low<sup>1</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>RR 0.94</b> <br/> (0.66 to 1.34) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>316<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>150 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>141 per 1000</b> <br/> (99 to 201) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>250 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>235 per 1000</b> <br/> (165 to 335) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>350 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>329 per 1000</b> <br/> (231 to 469) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study measured or reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Adverse effects: weight gain</b> <br/> Follow‐up: up to 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Low<sup>1</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>RR 4.01</b> <br/> (1.1 to 14.6) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>232<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,3,8</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> <br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>40 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>160 per 1000</b> <br/> (44 to 584) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>401 per 1000</b> <br/> (110 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>General functioning</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study measured or reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Service use</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study measured or reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Risk: moderate risk approximately equates to that of the control group risk in the study population.<br/> <sup>2</sup> Risk of bias: rated 'serious' ‐ majority of the included studies had inadequate study design ‐ unclear randomisation, allocation concealment and blinding. A large proportion of them also had selective reporting concerns.<br/> <sup>3</sup> Imprecision: rated 'serious' ‐ the total event number is small (&lt;300) and that the 95% CI of the pooled best estimate of effect is not statistically significant.<br/> <sup>4</sup> Publication bias: rated 'strongly suspected' ‐ only a small number of trials with small sample size were identified. It is likely that these trials with low methodological quality would have exaggerated intervention effect.<br/> <sup>5</sup> Risk of bias: rated 'serious' ‐ the only included study has serious concern with selective reporting and unclear allocation concealment and incomplete outcome.<br/> <sup>6</sup> Indirectness: rated 'serious' ‐ we were unable to find direct binary measure of mental state, thus used BPRS score as an indicator.<br/> <sup>7</sup> Imprecision: rated 'serious' ‐ only one study is identified, the estimate of effect is not statistically significant.<br/> <sup>8</sup> Publication bias: rated 'strongly suspected' ‐ only small number of trials with poor methodological quality were identified ‐ publication bias likely. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">COMPARISON 4. ARIPIPRAZOLE versus ZIPRASIDONE for schizophrenia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/full#CD006569-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD006569-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">COMPARISON 5. ARIPIPRAZOLE versus OLANZAPINE for schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>COMPARISON 5. ARIPIPRAZOLE versus OLANZAPINE for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with schizophrenia<br/> <b>Settings:</b> inpatient and outpatient<br/> <b>Intervention:</b> COMPARISON 5. ARIPIPRAZOLE versus OLANZAPINE </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> COMPARISON 5. ARIPIPRAZOLE versus OLANZAPINE</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Global state: No clinically significant response</b> <br/> Follow‐up: up to 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Low<sup>1</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>RR 1.06</b> <br/> (0.96 to 1.17) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>1739<br/> (11 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"></td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>200 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>212 per 1000</b> <br/> (192 to 234) </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>350 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>371 per 1000</b> <br/> (336 to 409) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>500 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>530 per 1000</b> <br/> (480 to 585) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state: as measured with PANSS</b> <br/> PANSS (high score = poor)<br/> Follow‐up: up to 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean mental state: as measured with PANSS in the intervention groups was<br/> <b>0.61 higher</b> <br/> (0.23 lower to 1.46 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1500<br/> (11 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,5,6,7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Leaving the study early</b> <br/> Follow‐up: up to 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Low<sup>1</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>RR 1.15</b> <br/> (1.05 to 1.25) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>2331<br/> (9 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>200 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>230 per 1000</b> <br/> (210 to 250) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>350 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>402 per 1000</b> <br/> (367 to 438) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>500 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>575 per 1000</b> <br/> (525 to 625) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life: as measured with GQOLI‐74</b> <br/> GQOLI‐74 (low score = poor) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean quality of life: as measured with gqoli‐74 in the intervention groups was<br/> <b>1.26 lower</b> <br/> (6.37 lower to 3.85 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>7,8,9,10</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Adverse effects: weight gain</b> <br/> Follow‐up: up to 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Low<sup>1</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>RR 0.25</b> <br/> (0.15 to 0.43) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>1538<br/> (9 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,3,7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>25 per 1000</b> <br/> (15 to 43) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>200 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>50 per 1000</b> <br/> (30 to 86) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>300 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>75 per 1000</b> <br/> (45 to 129) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>General functioning</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study measured or reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Service use</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study measured or reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Risk: moderate risk approximately equates to that of the control group risk of the study population.<br/> <sup>2</sup> Risk of bias: rated 'serious' ‐ majority of the included studies had inadequate study design ‐ unclear randomisation, allocation concealment and blinding. Some of them also had selective reporting concerns.<br/> <sup>3</sup> Imprecision: rated 'serious' ‐ total number of events is small (&lt;300) and that the 95% CI of pooled estimate of effect is not statistically significant.<br/> <sup>4</sup> Publication bias: rated 'strongly suspected' ‐ only small number of trials with small sample size were identified. It is likely that these small studies with poor methodological quality have negatively affected on the estimate of treatment effect.<br/> <sup>5</sup> Indirectness: rated 'serious' ‐ we are unable to find direct binary measure of mental state, thus used PANSS score as an indicator.<br/> <sup>6</sup> Imprecision: rated 'serious' ‐ the overall pooled estimate of effect was not statistically significant and with wide confidence interval.<br/> <sup>7</sup> Publication bias: rated 'strongly suspected' ‐ only a small number of studies with poor methodological deign were identified ‐ publication bias likely.<br/> <sup>8</sup> Risk of bias: rated 'serious' ‐ unclear randomisation, allocation concealment, blinding and serious concern with selective reporting.<br/> <sup>9</sup> Indirectness: rated 'serious' ‐ we are unable to find direct binary measure of quality of life, thus used GQOLI‐74 score as an indicator.<br/> <sup>10</sup> Imprecision: rated 'very serious' ‐ only one study with serious methodological concerns was identified and the estimate of effect is not significant. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">COMPARISON 5. ARIPIPRAZOLE versus OLANZAPINE for schizophrenia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/full#CD006569-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006569-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">COMPARISON 1. ARIPIPRAZOLE versus CLOZAPINE</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Global state: 1. No clinically significant response (as defined by the original studies) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2132</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.87, 1.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Mental state: 1. Specific ‐ binary outcomes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 anxiety (short term, up to 12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>732</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.62 [1.21, 5.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 anxiety (medium term, 12 to 26 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.04, 3.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 agitation (short term, up to 12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.87 [0.18, 19.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Mental state: 2. Average endpoint scores of various scales (short term, up to 12 weeks, high=poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 BPRS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>426</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.22 [‐1.44, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 PANSS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1638</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.10 [‐1.41, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 SANS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.27 [‐6.27, 1.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Mental state: 3. Average endpoint scores of various scales (medium term, 12 to 26 weeks, high=poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 PANSS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>236</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.41 [‐8.42, ‐2.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Mental state: 4. Average endpoint scores of various scales (skewed data, high=poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 BPRS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 PANSS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 PANSS negative symptom subscale score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Mental state: 5. Specific ‐ average endpoint positive score (PANSS, high=poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1523</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.27 [‐0.48, 1.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 by up to 12 weeks ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1287</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [‐0.50, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 from 12‐26 weeks ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>236</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.23 [‐1.79, 1.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Mental state: 6. Specific ‐ average endpoint negative score (PANSS, high=poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1640</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.61 [‐1.53, 0.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 up to 12 weeks ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1404</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.04 [‐0.79, 0.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 from 12‐26 weeks ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>236</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.24 [‐5.82, ‐0.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Mental state: 7. Specific ‐ average endpoint general psychopathological score (PANSS, high=poor ) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1330</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.27 [‐0.78, 0.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 up to 12 weeks ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1094</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.08 [‐0.62, 0.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 from 12‐26 weeks ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>236</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.89 [‐3.45, ‐0.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Mental state: 8. Specific ‐ average total score decreased rate (PANSS, low=poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 by up to 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>118</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.06 [‐0.03, 0.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Mental state: 9. Specific ‐ average positive score decreased rate (PANSS, low=poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 by up to 12 weeks ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>118</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.01 [‐0.10, 0.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Leaving the study early <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 Any reason</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>240</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.41 [0.46, 4.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 Adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>212</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.20, 2.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.3 Economic issues</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.0 [0.38, 10.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Quality of life: 1a. Average scores (short term, up to 12 weeks, WHO‐QOL‐100, low=poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 endpoint scale score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>132</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.59 [1.43, 3.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 physical health</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>132</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.73 [1.51, 13.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.3 mental health</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>132</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.21 [4.74, 13.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.4 social function</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>132</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.78 [‐0.98, 16.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.5 external environmental</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>248</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>13.82 [8.69, 18.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.6 independence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [‐1.62, 1.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.7 spiritual support</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.61 [4.25, 8.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Quality of life: 1b. Average scores (medium term, 12 to 24 weeks, WHO‐QOL‐100, low=poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 endpoint scale score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>176</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.75 [1.98, 3.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 physical health</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>256</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.89 [0.22, 9.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.3 mental health</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>256</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.39 [5.26, 9.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.4 social function</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>256</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.68 [2.79, 10.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.5 material life</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.80 [‐2.00, 2.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.6 independence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>176</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.71 [4.76, 8.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.7 spiritual support</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>176</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.31 [‐1.37, 0.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Quality of life: 2. Average endpoint general quality of life score (GQOLI ‐ 74, low=poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 Total score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.5 [‐3.40, 4.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2 Physical health</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.70 [2.95, 12.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.3 Mental health</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.70 [‐2.30, 7.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.4 Social function</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.60 [3.15, 10.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.5 Material life</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐5.30, 5.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.6 Environmental area (medium term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>11.5 [5.55, 17.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.7 Independence (medium term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.16 [2.84, 9.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Adverse effects: 1. At least one adverse effect <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1582</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.47, 0.81]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 Non‐specific</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>574</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.48, 0.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.2 epilepsy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 7.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.3 liver function abnormal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>364</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.16, 1.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.4 stuffy nose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>258</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.21, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.5 sweating</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [0.04, 3.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.6 urinary retention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>132</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.11, 9.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.7 urinary incontinence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.18 [0.02, 1.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Adverse effects: 2. Cardiac effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 abnormal ECG (short term, up to 12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>921</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.38 [0.29, 0.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.2 blood pressure‐ decrease (short term, up to 12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>194</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.23, 1.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.3 general adverse cardiac events (short term, up to 12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.17, 0.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.4 QTc prolongation (short term, up to 12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>334</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.16 [0.05, 0.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.5 tachycardia (short term, up to 12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [0.22, 0.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.6 QTc prolongation (medium term, 12 to 24 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.05 [0.00, 0.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.7 tachycardia (medium term, 12 to 24 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [0.01, 1.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Adverse effects: 3. Central / peripheral nervous system <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.1 activity‐ decrease (short term, up to 12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.21 [0.10, 0.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.2 activity‐ increase (short term, up to 12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.26 [0.22, 84.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.3 blurred vision (short term, up to 12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>472</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [0.12, 0.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.4 dizziness (short term, up to 12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>698</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.36, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.5 fatigue (short term, up to 12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.27, 1.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.6 general central nervous system adverse reaction (short term, up to 12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.0 [0.55, 7.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.7 general vegetative nervous system adverse reaction (short term, up to 12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.27, 0.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.8 headache (short term, up to 12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.28 [1.07, 4.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.9 hyper‐salivation (short term, up to 12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1074</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.06 [0.03, 0.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.10 insomnia (short term, up to 12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>990</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.62 [2.90, 10.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.11 irritability (short term, up to 12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.77 [0.82, 55.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.12 memory decline (short term, up to 12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [0.02, 0.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.13 sedation (short term, up to 12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [0.00, 0.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.14 somnolence (short term, up to 12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1492</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.15 [0.09, 0.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.15 insomnia (medium term, 12 to 24 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [0.13, 71.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.16 headache (medium term, 12 to 24 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.5 [0.10, 2.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Adverse effects: 4. Extrapyramidal effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.1 akathisia (short term, up to 12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>916</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.54, 2.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.2 dystonia (short term, up to 12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>374</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.24 [1.29, 8.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.3 general extrapyramidal symptoms (short term, up to 12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>520</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.91 [0.75, 4.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.4 tardive dyskinesia (short term, up to 12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.15, 6.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.5 tremor (short term, up to 12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>460</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.99 [0.72, 5.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.6 use of antiparkinson medication (short term, up to 12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.84 [0.07, 117.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.7 akathisia (medium term, 12 to 24 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.04, 3.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.8 dystonia (medium term, 12 to 24 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.5 [0.05, 5.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.9 spasmodic torticollis (medium term, 12 to 24 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 7.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.10 tremor (medium term, 12 to 24 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.15, 6.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 Adverse effects: 6. Haematological <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.1 abnormal blood routine (short term, up to 12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>368</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.16 [0.04, 0.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.2 leucopenia (short term, up to 12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>726</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.21 [0.08, 0.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.3 abnormal blood routine (medium term, 12 to 24 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>152</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.14, 0.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 Adverse effects: 5. Gastrointestinal <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.1 abdominal discomfort / pain (short term, up to 12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>132</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>10.21 [1.32, 79.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.2 constipation (short term, up to 12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1390</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.15 [0.08, 0.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.3 dry mouth (short term, up to 12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>268</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.08, 5.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.4 general gastrointestinal aderse reaction (short term, up to 12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.41, 3.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.5 indigestion (short term, up to 12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.04, 4.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.6 nausea / vomiting (short term, up to 12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>790</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.55 [0.71, 3.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.7 constipation (medium term, 12 to 24 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [0.00, 0.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.8 hyper‐salivation (medium term, 12 to 24 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [0.00, 0.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21 Adverse effects: 7. Hormonal <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.1 lactation/menstrual changes (short term, up to 12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>214</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [0.03, 0.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22 Adverse effects: 8a. Metabolic ‐ binary measures <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.1  blood glucose ‐ increased (short term, up to 12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>410</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.12 [0.04, 0.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.2  C‐peptide (short term, up to 12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [0.00, 0.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.3 decreased appetite (short term, up to 12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.07 [0.01, 0.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.4 postural hypotension (short term, up to 12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>344</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.16 [0.07, 0.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.5 PRL‐ increase (short term, up to 12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.05 [0.00, 0.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.6 weight gain (short term, up to 12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1318</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [0.08, 0.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.7 blood glucose ‐ increased (medium term, 12 to 24 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [0.00, 1.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.8 decreased appetite (medium term, 12 to 24 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.06 [0.00, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.9 weight gain (medium term, 12 to 24 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [0.00, 0.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23 Adverse effects: 8b. Metabolic ‐ continuous measures (short term, up to 12 weeks, high=poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.1 blood glucose ‐ FPG in HbA1c normal group (in mmol/l)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐0.39, 0.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.2 blood glucose ‐ FPG in HbA1c abnormal group (in mmol/l)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐0.61, 0.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.3 blood glucose ‐ PBG in HbA1c normal group (in mmol/l)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐0.66, 0.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.4 blood glucose ‐ PBG in HbA1c abnormal group (in mmol/l)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.90 [‐2.63, ‐1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.5 blood glucose ‐ FPG average endpoint (in mmol/l)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.52 [‐0.83, ‐0.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.6 blood glucose ‐ C‐peptide average endpoint (in mg/dlmmol/l)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.72 [‐1.45, 0.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.7 weight gain ‐ average endpoint level (in kg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.99 [‐5.56, 1.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">24 Cost effectiveness analysis (high=poor, data skewed) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.1 Cost of hospitalisation (in RMB)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.2 Cost of drug (in RMB)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.3 Length of hospitalisation (day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">COMPARISON 1. ARIPIPRAZOLE versus CLOZAPINE</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006569-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">COMPARISON 2. ARIPIPRAZOLE versus QUETIAPINE</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Global state: 1.No clinically significant response (as defined by original studies) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>991</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.64, 1.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Global state: 2a. Average endpoint total score (short term, up to 12 weeks, high=poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>991</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.00 [‐2.58, 0.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 CGI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐0.49, 0.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 PANSS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>831</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.88 [‐3.15, 1.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 BPRS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.63 [‐4.55, ‐0.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Global state: 2b. Average endpoint scale score (medium term, 12 to 24 weeks, high=poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 PANSS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.20 [‐5.67, 3.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Global state: 3. Average endpoint SI score (CGI, high=poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 up to 12 weeks ‐short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐0.41, 0.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Mental state: 2a. Specific ‐ binary outcomes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 agitation (short term, up to 12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>423</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.29 [0.27, 6.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 anxiety (short term, up to 12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>168</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.18 [0.51, 9.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 depression (short term, up to 12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 8.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4 agitation (medium term, 12 to 26 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 7.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Mental state: 3. Specific ‐ average endpoint positive score (PANSS, high=poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>683</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.83 [‐1.99, 0.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 by up to 12 weeks ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>583</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.97 [‐2.34, 0.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 from 12‐26 weeks ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.10 [‐1.32, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Mental state: 4. Specific ‐ average endpoint negative score (PANSS, high=poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>543</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.48 [‐1.17, 0.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 up to 12 weeks ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>443</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.68 [‐1.52, 0.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 from 12‐26 weeks ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐1.23, 1.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Mental state: 5. Specific ‐ average endpoint general pathological score (PANSS, high=poor ) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>931</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.69 [‐3.81, 0.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 up to 12 weeks ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>831</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.83 [‐4.19, 0.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 from 12‐26 weeks ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.40 [‐2.52, 1.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Mental state: 6. average scores of various scales (high=poor, skewed data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 BPRS endpoint scale score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 PANSS general pathology subscale score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3 PANSS negative subscale score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.4 PANSS positive subscale score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.5 PANSS total endpoint scale score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Leaving the study early <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 any reason</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>168</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.22, 2.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 no effect</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 8.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3 early discharge</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [0.13, 70.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.4 early treatment termination</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>168</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.35 [0.09, 19.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.5 violation of test scheme</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.0 [0.25, 101.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.6 withdrew informed consent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 8.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Quality of life: Average score (medium term, 12 to 24 weeks, WHO‐QOL‐100, low=poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 Total score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.60 [1.31, 3.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 Physical health</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.0 [4.38, 7.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.3 Mental health</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.10 [5.92, 12.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.4 Social function</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.60 [3.33, 7.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.5 Spiritual pillar</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐1.49, 1.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.6 Environmental area</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>11.5 [5.86, 17.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.7 Independence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.20 [3.05, 9.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Adverse effects:1. At least one adverse effect <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1362</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.66, 1.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 non‐specific</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>258</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.70, 1.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 abnormal urinary test result</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 8.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.3 liver function abnormal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>658</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.26, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.4 stuffy nose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>188</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [0.32, 28.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.5 sweating</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.07, 15.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.6 urine routine abnormal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 7.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Adverse effects: 2. Cardiac effects (short term, up to 12 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 abnormal ECG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>528</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.40, 2.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 blood pressure‐ decrease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>348</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.20, 1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.3 QTc prolongation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>225</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.08, 1.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.4 tachycardia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>643</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [0.18, 0.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Adverse effects: 3. Central / peripheral nervous system <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 blurred vision (short term, up to 12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>521</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.31, 2.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2 dizziness (short term, up to 12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>671</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.34, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.3 headache (short term, up to 12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>436</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.15 [0.52, 18.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.4 insomnia (short term, up to 12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>591</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.12 [0.88, 5.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.5 somnolence (short term, up to 12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>731</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.15, 0.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.6 dizziness (medium term, 12 to 24 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.31, 2.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.7 headache (medium term, 12 to 24 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.00 [1.18, 68.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.8 insomnia (medium term, 12 to 24 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.0 [0.19, 21.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.9 somnolence (medium term, 12 to 24 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.8 [0.34, 1.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Adverse effects: 4. Extrapyramidal symptoms ‐ various (short term, up to 12 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 akathisia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>571</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.49, 2.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.2 dystonia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.06, 3.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.3 general extrapyramidal symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>348</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.80 [0.64, 12.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.4 tremor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>343</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.09, 2.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Adverse effects: 5. Gastrointestinal <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 constipation (short term, up to 12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>591</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.38 [0.19, 0.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.2 dry mouth (short term, up to 12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>611</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.23 [0.10, 0.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.3 nausea / vomiting (short term, up to 12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>611</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.68 [1.36, 5.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.4 dry mouth (medium term, 12 to 24 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [0.01, 0.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.5 nausea / vomiting (medium term, 12 to 24 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.00 [0.89, 54.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Adverse effects: 6. Haematological <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.1 blood routine abnormal (short term, up to 12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [0.01, 7.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.2 leucopenia (short term, up to 12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.07, 15.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Adverse events: 7. Hormonal <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.1 menstrual disorder (short term, up to 12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>518</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.20, 1.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.2 menstrual disorder (medium term, 12 to 24 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.5 [0.05, 5.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 Adverse effects: 8a. Metabolic ‐ binary measures <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.1 decreased appetite (short term, up to 12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>328</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.28 [0.06, 1.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.2 lactation (short term, up to 12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>383</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.17, 1.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.3 weight gain (short term, up to 12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>823</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.45 [0.24, 0.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.4 decreased appetite (medium term, 12 to 24 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [0.02, 0.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.5 lactation (medium term, 12 to 24 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.6 weight gain (medium term, 12 to 24 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.5 [0.05, 5.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 Adverse effects: 8b. Metabolic ‐ continuous measure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.1 cholesterol ‐ TC average endpoint level (in mmol/L, high=poor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.19 [‐0.36, ‐0.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.2 cholesterol‐TG average endpoint level (in mmol/L, high=poor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.04 [‐0.21, 0.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.3 cholesterol ‐ LDL average endpoint level (in mmol/L, high=poor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.12 [‐0.26, 0.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.4 waistline‐ average endpoint level (in cm, high=poor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.80 [‐3.88, 0.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.5 weight‐ average endpoint level (in Kg, high=poor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [‐1.30, 3.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.6 cholesterol ‐ HDL average endpoint (in mmol/L, low=poor))</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.02 [‐0.11, 0.07]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">COMPARISON 2. ARIPIPRAZOLE versus QUETIAPINE</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006569-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Global state: 1. No clinically significant response (as defined by the original studies) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 by up to 12 weeks ‐‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6381</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.96, 1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Global state: 2. Average endpoint total score(short term, up to 12 weeks, CGI, high=poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>196</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [0.09, 0.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Global state: 3. Average CGI subscale scores (short term, up to 12 weeks, high=poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>240</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.22, 0.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 CGI‐EI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.5 [0.14, 0.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 CGI‐SI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [0.12, 0.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Global state: 4. average endpoint data of various scales (high=poor, data skewed) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 CGI‐GI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 CGI‐SI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 CGI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Mental state: 1. Specific ‐ binary outcomes (short term, up to 12 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 anxiety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>744</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.81 [1.12, 2.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 agitation/excitement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2038</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.26 [0.86, 1.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 irritability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.06, 15.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Mental state: 2. Average endpoint scale score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 BPRS (short term, up to 12 weeks, high=poor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>570</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.33 [‐2.24, ‐0.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 PANSS (short term, up to 12 weeks, high=poor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5733</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.80 [‐1.58, ‐0.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 PANSS (medium term, 12 to 24 weeks, high=poor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.15 [‐8.03, 7.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4 SANS (medium term, 12 to 24 weeks, high=poor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.55 [‐3.72, 2.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Mental state: 3. Specific ‐ average endpoint positive score (PANSS, high=poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3205</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.37, 0.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 short term (up to 12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3155</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [‐0.38, 0.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 medium term (12‐26 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.21 [‐2.38, 1.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Mental state: 4. Specific ‐ average endpoint negative score (PANSS, high=poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 short term (up to 12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2976</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.64 [‐1.04, ‐0.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Mental state: 5. Specific ‐ average endpoint general psychopathological score (PANSS, high=poor ) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4243</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.25 [‐0.71, 0.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 by up to 12 weeks ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4193</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.27 [‐0.74, 0.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 12‐ 26 weeks ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.52 [‐2.66, 5.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Mental state: 6. PANSS average score decreased rate (short term, up to 12 weeks, low=poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 total scale score decreased rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>219</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.06 [0.24, 5.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 negative symptom subscale score decreased rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>216</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.02 [‐0.11, 0.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3 positive symptom subscale score decreased rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>216</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.01 [‐0.10, 0.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.4 general pathology subscale score decreased rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.38 [‐0.33, 5.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Mental state: 7. BPRS total score decreased rate (short term, up to 12 weeks, high=poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>132</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.97 [‐6.61, 0.67]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Mental state: 8. General ‐ average total score (PANSS, high=poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 up to 12 weeks (short‐term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>372</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.5 [‐2.96, 5.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Mental state: 9. average scores of various scale (high=poor, skewed data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 SANS endpoint scale score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 PANSS general pathology subscale score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.3 PANSS negative symptom subscale score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.4 PANSS positive symptom subscale score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Leaving the study early <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 Any reason</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1239</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.79, 1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2 Progressive disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>188</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.14, 5.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.3 Not insisting follow up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.48 [0.49, 4.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.4 Termination treatment early</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [0.13, 71.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.5 Violation of study scheme</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>152</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.32 [0.30, 5.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.6 Incomplete data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.0 [0.24, 102.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.7 Adverse effect</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1272</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.64, 2.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.8 Economic issue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.11, 9.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.9 No effect</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>681</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.49, 2.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Adverse effects: 1. At least one adverse effect, non‐specific <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 non‐specific</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2361</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.73, 0.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.2 liver function abnormal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.46, 0.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.3 hyper‐salivation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>554</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.22, 1.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.4 myalgia/ostealgia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.95 [0.51, 7.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.5 renal function abnormal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.6 sexual desire change</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>614</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [0.04, 0.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.7 sweating‐ increase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>278</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.16, 2.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.8 stuffy nose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>165</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.90 [0.44, 34.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Adverse effects: 2a.Cardiac effects (short term, up to 12 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 abnormal ECG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1032</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.41, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.2 blood pressure decline or rise</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>363</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.54 [0.46, 5.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.3 blood pressure‐ increase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.06, 15.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.4 blood pressure‐ decrease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>504</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.45, 2.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.5 EEG abnormal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.12, 3.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.6 postural hypotension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>399</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.46, 1.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.7 QTc prolongation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>649</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.37 [0.13, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.8 tachycardia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3835</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.61, 0.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Adverse effects: 2b. Cardiac ‐ QTc change from baseline (in ms) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>383</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐7.19 [‐12.19, ‐2.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Adverse effects: 3. Central / peripheral nervous system (short term, up to 12 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.1 acute onset of schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.33 [0.49, 3.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.2 dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1896</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.72, 1.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.3 blurred vision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3272</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.70, 1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.4 fatigue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>369</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.29, 1.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.5 headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1505</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.91 [1.31, 2.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.6 headache/dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1486</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.29 [0.93, 1.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.7 insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4209</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.98, 1.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.8 memory decrease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.22 [0.05, 0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.9 sedation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>170</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.04, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.10 sleep disorder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>152</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.39, 1.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.11 somnolence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2779</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.74, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 Adverse effects: 3a. Endocrine ‐ Prolactin ‐ average change (ng/ml) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>383</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐54.71 [‐60.06, ‐49.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 Adverse effects: 3b. Endocrine ‐ Prolactin‐associated <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.1 abnormally high prolactin value</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>301</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.04 [0.02, 0.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.2 dysmenorrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.17 [0.17, 59.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21 Adverse effects: 4. Various extrapyramidal symptoms (short term, up to 12 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.1 akathisia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3501</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.48, 0.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.2 tremor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2799</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [0.27, 0.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.3 dystonia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2640</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [0.25, 0.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.4 parkinsonism</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>301</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.39 [0.43, 128.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.5 use of antiparkinson medication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.32, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.6 extrapyramidal symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2605</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.39 [0.31, 0.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.7 torsion spasm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.04, 7.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.8 tremor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>391</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.07, 21.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.9 increase activities</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.0 [0.25, 100.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22 Adverse effects: 4b. Extrapyramidal ‐ average score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.1 Abnormal Involuntary Movement Scale (high=poor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>383</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.25 [‐1.24, 0.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.2 Barnes Akathisia Scale (high=poor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>383</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.11 [‐0.49, 0.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.3 Simpson‐Angus Scale (high=poor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>383</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.70 [‐2.22, 0.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23 Adverse effects: 5. Gastrointestinal <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.1 constipation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2067</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.52, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.2 dry mouth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2658</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [0.86, 1.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.3 gastrointestinal reaction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.01 [0.76, 5.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.4 nausea / vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.84 [1.31, 2.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">24 Adverse effects: 6. Haematological <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.1 blood routine abnormal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>515</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.45 [0.20, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.2 leucopenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 7.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.3 blood lipid abnormal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.0 [0.19, 21.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">25 Adverse effects: 7a. Metabolic ‐ binary measures (short term, up to 12 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.1 appetite‐ decrease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>204</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.26 [0.07, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.2 blood glucose‐ increase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>358</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.28 [0.09, 0.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.3 endocrine disorder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>642</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.07 [0.03, 0.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.4 lactation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>216</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [0.02, 0.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.5 menstrual disorder/lactation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2278</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [0.06, 0.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.6 menstrual disorder or sexual function change</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.07 [0.00, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.7 menstrual disorder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>655</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [0.06, 0.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.8 skin symptom</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>778</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.12, 0.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.9 PRL‐increase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>184</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.07 [0.01, 0.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.10 obesity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.14, 6.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.11 vaginal bleeding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.84 [0.12, 67.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.12 weight gain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4623</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.22 [0.17, 0.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.13 weight loss</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.94 [0.12, 70.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">26 Adverse effects: 7b. Metabolic ‐ continuous measures (high=poor ) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.1 endpoint average weight (in kg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>465</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.30 [‐4.17, ‐0.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.2 weight change from baseline (in kg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.50 [‐1.84, ‐1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.3 average endpoint BMI of male (in kg/m2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.46 [‐4.08, ‐0.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.4 average endpoint BMI of female (in kg/m2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>124</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.47 [‐3.55, 0.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.5 average endpoint blood glucose of female (in mmol/L)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.29 [3.97, 4.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.6 average endpoint blood glucose of male (in mmol/L)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.28 [‐0.04, 0.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.7 average endpoint blood glucose FBG (in mg/dl)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.08 [‐0.37, 0.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.8 average endpoint cholesterol ‐ TC of female (in mmol/L)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.51 [‐0.96, ‐0.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.9 average endpoint cholesterol ‐ TC of male (in mmol/L)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.48 [‐0.96, ‐0.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.10 average endpoint cholesterol ‐ TC level (in mmol/L)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>240</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.02 [‐0.19, 0.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.11 average endpoint cholesterol‐TG level (in mmol/L)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.07 [‐0.21, 0.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.12 average endpoint cholesterol ‐ LDL level (in mmol/L)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>240</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.07 [‐0.11, 0.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.13 average endpoint waistline (in cm)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.30 [‐5.47, ‐1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">27 Adverse effect : 7c. Metabolic ‐ continuous measures <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>789</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.01 [‐0.22, 0.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.1 average endpoint cholesterol‐ HDL level (in mmol/L)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>240</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.06 [‐0.03, 0.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.2 cholesterol ‐ change from baseline (in mg/dl)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐22.3 [‐39.69, ‐4.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.3 glucose ‐ change from baseline (in mg/dl)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.8 [‐6.10, 19.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.4 weight gain ‐ change from baseline (in kg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>383</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.54 [‐1.24, 0.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">28 Adverse effect: 8. required additional drug combination <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>28.1 benzodiazepines</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>138</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.73, 1.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>28.2 benzhexol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.12, 0.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>28.3 benzhexol/propranolol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.45, 2.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">29 Adverse effects: 9. TESS score (short term, up to 12 weeks, high=poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>250</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.34 [‐2.30, ‐0.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">30 Adverse effects: 10. TESS score (short term, up to 12 weeks, high=poor, data skewed) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">31 Adverse effects: 11. weight gain (in KG, high=poor, data skewed) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">32 Cognitive functioning: 1. Specific ‐ average endpoint total score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>32.1 (short term, up to 12 weeks, WMS, low= poor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.56 [‐7.95, 4.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>32.2 (short term, up to 12 weeks, WAIS‐RC, low=poor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.57 [‐8.92, 5.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">33 Cost effectiveness analysis (high=poor, data skewed) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>33.1 Cost of hospitalisation (in RMB)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>33.2 Cost of drug (in RMB)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>33.3 Length of hospitalisation (day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">COMPARISON 3. ARIPIPRAZOLE versus RISPERIDONE</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006569-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">COMPARISON 4. ARIPIPRAZOLE versus ZIPRASIDONE</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Global state: 1. No clinically significant response (as defined by the original studies) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 up to 12 weeks ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>442</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.62, 1.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Global state: 2. Average endpoint CGI‐GI score (short term, up to 12 weeks, high=poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Global state: 3. Average change score (CGI‐S, decline=good) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Mental state: 1. Average endpoint total score (short term, up to 12 weeks, high=poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 PANSS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>689</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.74 [‐3.68, 0.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 SANS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>238</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.39 [‐2.56, ‐0.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 BPRS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>247</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.20 [‐4.97, 0.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Mental state: 2. Specific ‐ binary outcomes (up to 12 weeks ‐ short term) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 anxiety ‐ labelled as "adverse effect"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [0.64, 14.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 agitation ‐ labelled as "adverse effect"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.11, 9.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Mental state: 3. Specific ‐ average endpoint PANSS subscale scores (short term, high=poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 positive symptom scores</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.16 [‐1.36, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 negative symptom scores</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>272</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.31 [‐1.23, 0.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 general pathology scores</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>382</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.35 [‐1.73, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Mental state: endpoint scores of various scales (high=poor, data skewed) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 PANSS negative symptom subscale score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 PANSS positive symptom subscale score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Leaving the study early <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 any reason</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>316</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.66, 1.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>256</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.14, 1.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 defaulted</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>256</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.58, 1.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.4 inefficacy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>256</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.48 [0.54, 4.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.5 other/withdrew</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>256</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.25, 3.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Adverse effects: 1. At least one adverse effect, non‐specific <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 non‐specific</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>126</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.85, 1.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 endocrine disorder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3 liver function abnormal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [0.13, 71.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.4 respiratory tract infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>253</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.09, 1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.5 sexual function change</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>172</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.00 [2.96, 21.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.6 skin rash</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 7.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.7 stuffy nose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.06, 15.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.8 sweating</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.07, 15.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.9 urine routine abnormal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 7.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Adverse effects: 2. Cardiac effects (short term, up to 12 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 abnormal ECG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>296</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.22, 1.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 QTc prolongation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.42 [0.06, 2.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3 tachycardia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>230</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.43, 3.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.4 blood pressure‐ decrease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.92 [0.44, 34.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Adverse effects: 3. Central / peripheral nervous system (short term, up to 12 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 blurred vision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.0 [0.90, 54.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>376</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.24 [1.57, 6.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.3 headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.92 [0.96, 25.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.4 insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>382</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.93 [1.17, 7.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.5 somnolence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>296</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.45 [0.62, 3.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Adverse effects: 4. Various extrapyramidal symptoms (short term, up to 12 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 akathisia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>423</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.25, 2.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 activity‐decrease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [0.13, 71.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.3 dystonia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.07 [0.00, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.4 general extrapyramidal symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.37, 1.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.5 tremor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>152</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [0.32, 28.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.6 spasmodic torticollis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 7.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.7 use of antiparkinson medication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.84 [0.07, 117.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Adverse effects: 5. Gastrointestinal (short term, up to 12 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 appetite‐decrease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.0 [0.39, 10.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 constipation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>230</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.13, 2.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.3 dry mouth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>296</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.10, 2.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.4 hyper‐salivation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.0 [0.19, 21.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.5 nausea / vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>442</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.53 [0.91, 7.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Adverse effects: 6. Haematological <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 leucopenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.07, 15.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Adverse effects: 7. Hormonal <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 menstrual disorder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>538</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.28, 1.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Adverse effects: 8a. Metabolic ‐ binary measures <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 appetite‐decrease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>152</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.04, 7.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.2 blood routine abnormal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [0.01, 7.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.3 lactation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [0.13, 71.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.4 weight gain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>232</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.01 [1.10, 14.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Adverse effects: 8b. Metabolic ‐ continuous measures <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.1 cholesterol ‐ TG average endpoint level (in mmol/L, high= poor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.04 [‐0.21, 0.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.2 cholesterol ‐ TC average endpoint level (in mmol/L, high= poor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐0.17, 0.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.3 cholesterol ‐ LDL average endpoint level (in mmol/L, high= poor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [‐0.04, 0.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.4 HDL (low=poor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [0.01, 0.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.5 waistline‐ average endpoint level (in cm, high= poor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.40 [‐5.29, ‐1.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.6 weight‐ average endpoint level (in kg, high= poor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.5 [‐5.06, 0.06]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">COMPARISON 4. ARIPIPRAZOLE versus ZIPRASIDONE</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006569-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">COMPARISON 5. ARIPIPRAZOLE versus OLANZAPINE</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Global state: 1.No clinically significant response (as defined by the original studies) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1739</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.96, 1.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 up to 12 weeks‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1422</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.86, 1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 from 12 to 26 weeks (medium‐term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>317</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.95, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Global state: 2. Not responded (decline in PANSS of 30% or more) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 by up to 12 weeks (short‐term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>566</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [1.01, 1.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 more than 26 weeks (long‐term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>566</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [1.00, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Global state: 3. Remission not achieved (as defined in the study) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 by up to 12 weeks (short‐term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>566</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.91, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 more than 26 weeks (long‐term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>566</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.38 [1.23, 1.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Global state: 4. Average endpoint EI score (CGI, high=poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 up to 12 weeks ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐0.16, 0.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Global state: 5. Average endpoint CGI score decreased rate (short term, low=poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Global state: 6. Average change score (CGI‐S, decline=best) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 more than 26 weeks (long‐term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>566</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐0.12, 0.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Global state: 7. Improvement (CGI‐I, high=poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>566</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐0.12, 0.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Mental state: 1. Average endpoint scale score (PANSS, high=poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 up to 12 weeks ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1500</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [‐0.23, 1.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 12‐ 26 weeks ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>139</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [‐5.26, 6.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 more than 26 weeks (long‐term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>566</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.20 [0.10, 8.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Mental state: 2. Average endpoint scale score (SANS, high=poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>137</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.04 [‐2.04, 1.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 up to 12 weeks ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.04 [‐2.52, 2.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 more than 26 weeks ‐ long term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.03 [‐3.45, 3.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Mental state: 3. average endpoint score (PANSS, high=poor, data skewed) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 PANSS total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 PANSS negative symptom subscale score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3 PANSS positive symptom subscale score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Mental state: 4. Specific ‐ average endpoint positive score (PANSS, high=poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1043</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.17, 1.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 by up to 12 weeks ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>429</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [‐0.16, 1.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 12‐ 26 weeks ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [‐1.54, 2.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.3 more than 26 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>566</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [‐0.03, 1.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Mental state: 5. Specific ‐ average endpoint negative subscale score (PANSS, high=poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>967</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.42 [‐0.25, 1.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 up to 12 weeks ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>401</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.16 [‐0.59, 0.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 more than 26 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>566</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [‐0.07, 2.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Mental state: 6. Specific ‐ average endpoint general pathological score (PANSS, high=poor ) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>642</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.80 [‐2.24, 0.64]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 up to 12 weeks ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>594</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.94 [‐2.49, 0.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 12‐ 26 weeks ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [‐3.08, 4.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Mental state: 7. Specific ‐ binary outcomes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 anxiety ‐ labelled as"adverse effect"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>778</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.79, 1.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2 depression ‐ labelled as"adverse effect"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>566</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.27 [0.08, 0.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.3 exacerbation of schizophrenia ‐ labelled as"adverse effect"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>778</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.50, 1.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Mental state: 8. Various scale scores decreased rate (low=poor, data skewed) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 PANSS positive symptom subscale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.2 PANSS negative symptom subscale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.3 PANSS general pathology subscale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.4 BPRS total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.5 PANSS total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Adverse effects: 1. At least one adverse effect <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 non‐specific</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.69, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.2 endocrine dyscrasia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [0.01, 0.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.3 high prolactin level</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>317</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.27 [0.12, 0.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.4 liver function abnormal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>348</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.20, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.5 skin adverse reaction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.63 [0.41, 6.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.6 sweating‐ increase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>138</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [0.32, 28.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.7 flu syndrome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>212</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.16, 1.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.8 respiratory infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>212</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.54 [0.50, 4.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Adverse effects: 2. Cardiac effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.1 abnormal ECG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.15, 6.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.2 blood pressure‐ decrease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 7.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.3 QTc prolongation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>618</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [0.11, 1.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.4 tachycardia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>339</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.39, 2.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Adverse effects: 3a. Cardiac ‐ QTc change from baseline (in ms) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>317</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.70 [‐9.51, 2.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 Adverse effects: 3b. Central / peripheral nervous system <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.1 dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1057</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.62, 1.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.2 blurred vision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [0.01, 2.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.3 headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>991</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.03 [0.82, 5.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.4 fatigue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>721</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.21, 1.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.5 insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1141</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.81 [0.95, 3.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.6 somnolence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.42, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.7 headache/dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [0.09, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.8 sedation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>883</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.37 [0.23, 0.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.9 nervousness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>212</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.32 [0.42, 4.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.10 CNS stimulation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>212</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.21, 2.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 Adverse effects: 4. Endocrine ‐ Prolactin ‐ average increase <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>566</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐8.89 [‐12.96, ‐4.82]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21 Adverse effects: 5. Extrapyramidal ‐ various <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.1 Akathisia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1320</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.56 [0.67, 3.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.2 Tremor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.23 [0.95, 55.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.3 Extrapyramidal symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>667</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.62, 1.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.4 Parkinsonism</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>618</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.46, 1.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22 Adverse effects: 6. Gastrointestinal <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.1 nausea / vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>948</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.34 [0.80, 2.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.2 constipation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>443</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.21, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.3 dry mouth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>854</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.38, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.4 abdominal pain ‐ upper</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>566</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.96 [1.09, 8.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23 Adverse effects: 7. Hormonal <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.1 menstrual changes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>198</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.04, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">24 Adverse effects: 8a. Metabolic ‐ binary measures <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.1 appetite‐ increase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>655</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.06, 2.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.2  blood glucose ‐ increase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>227</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.12 [0.03, 0.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.3 cholesterol ‐ abnormally high cholesterol value</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>223</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.19, 0.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.4 lactation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 7.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.5 PRL‐ increase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [0.01, 1.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.6 weight gain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1538</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.25 [0.15, 0.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">25 Adverse effects: 8b. Metabolic ‐ continuous measures (high=poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.1 weight ‐ average endpoint level (in kg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>242</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐7.43 [‐9.21, ‐5.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.2 weight gain ‐ change from baseline (in kg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>656</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.03 [‐7.35, 1.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.3 cholesterol ‐ change from baseline (in mg/dl)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>789</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐15.37 [‐21.62, ‐9.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.4 cholesterol ‐ TC average endpoint level (in mmol/L)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>182</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.00 [‐1.44, ‐0.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.5 cholesterol ‐ TG average endpoint level (in mmol/L)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.0 [‐1.31, ‐0.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.6 blood glucose ‐ PBG average endpoint level (in mg/dl)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.95 [‐1.27, ‐0.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.7 glucose ‐ change from baseline (in mg/dl)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>883</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.39 [‐7.98, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">26 Adverse effects: 9. Average endpoint scale score (TESS, high=poor, data skewed) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">27 Leaving the study early <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.1 Any reason</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2331</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [1.05, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.2 Economic issues</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [0.13, 71.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.3 Early discharge</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [0.13, 70.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.4 Refusing therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 7.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.5 adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1352</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [0.92, 1.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.6 inefficacy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1352</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.81 [1.23, 2.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.7 lost to follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>821</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.46, 1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.8 medication noncompliance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>255</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.23 [0.71, 7.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.9 others</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>780</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.21 [0.77, 6.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.10 patient decision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1035</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.60, 1.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.11 protocol entry or interim criteria not met</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>566</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.02, 1.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.12 protocol violation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>821</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.42, 1.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.13 sponsor decision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>566</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 8.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.14 death</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>214</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [0.01, 8.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">28 Quality of life: 1. Average endpoint general quality of life score (GQOLI‐74, low=poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>28.1 Total score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.26 [‐6.37, 3.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>28.2 Physical health</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.19 [‐4.72, 4.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>28.3 Mental health</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.46 [‐8.20, 3.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>28.4 Social function</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [‐3.41, 5.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>28.5 Material life</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.77 [‐4.62, 3.08]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">COMPARISON 5. ARIPIPRAZOLE versus OLANZAPINE</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006569-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">COMPARISON 6. ARIPIPRAZOLE versus OLANZAPINE (acutely agitated people ‐ all data by 5 days)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Global state: Average improvement (BPRS, high=good) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>471</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.18 [‐0.79, 0.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Mental state: Specific ‐ binary outcomes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 agitation ‐ no change ‐ (change defined as ≥ 40%reduction in PANSS‐EC)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>604</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.76, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 agitation ‐ labelled as"adverse effect"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>578</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.25 [0.05, 1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 anxiety ‐ labelled as"adverse effect"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>604</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.40, 2.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 exacerbation of schizophrenia ‐ labelled as"adverse effect"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>604</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.13 [0.25, 106.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Leaving the study early <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>604</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.12, 4.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Adverse effects: 1. Central nervous system <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>578</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [0.06, 1.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>578</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.43 [1.02, 5.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 lethargy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>578</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.33 [0.30, 5.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 sedation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>578</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.23, 2.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5 sleep ‐ insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>604</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.60 [0.87, 2.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6 somnolence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>578</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [0.02, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Adverse effects: 2. Endocrine ‐ Prolactin ‐ average increase <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>604</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐15.76 [‐19.18, ‐12.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Adverse effects: 3a. Extrapyramidal ‐ various <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 akathisia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>604</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.43 [0.79, 2.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 parkinsonism</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>604</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.71 [0.41, 7.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Adverse effects: 3b. Extrapyramidal ‐ average score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Barnes Akathesia Scale (high=poor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>604</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.07 [‐0.24, 0.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Simpson‐Angus Scale (high=poor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>604</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.05 [‐0.13, 0.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Adverse effects: 4. Gastrointestinal <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 nausea / dyspepsia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>578</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.5 [0.09, 2.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 salivation ‐ dry mouth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>578</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.20, 4.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Adverse effects: 5. Metabolic ‐ continuous measures <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 triglycerides ‐ fasting, increase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>604</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐35.62 [‐49.25, ‐21.99]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">COMPARISON 6. ARIPIPRAZOLE versus OLANZAPINE (acutely agitated people ‐ all data by 5 days)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006569-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">COMPARISON 7. ARIPIPRAZOLE versus OTHER ANTIPSYCHOTIC DRUGS</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Global state: 1. No change (as defined in the study, measured by IAQ) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 cognition</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>523</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.82, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 energy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>523</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.56, 0.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 mood</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>523</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.65, 0.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 negative symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>523</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.68, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5 somnolence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>523</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.69, 0.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6 weight gain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>523</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.76, 0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Global state: 2. Change in sexual dysfunction (ASEX) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.43 [‐2.97, 0.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Mental state: Specific ‐ binary outcomes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5338</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [0.96, 1.51]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Anxiety ‐ labelled as"adverse effects"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1361</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.33 [0.94, 1.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Agitation ‐ labelled as"adverse effects"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>548</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.64 [0.96, 7.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Schizophrenia ‐ labelled as"adverse effects"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>548</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.49, 1.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 Psychotic disorder ‐ labelled as"adverse effects"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2881</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.73, 1.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Preference: Study medication worse than or equal to previous medication <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 patient ‐ by up to 12 weeks (short‐term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>446</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.49, 0.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 care giver ‐ by up to 12 weeks (short‐term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.52, 1.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 patient ‐ from 12 to 26 weeks (medium‐term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>330</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.39 [0.25, 0.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 care giver ‐ from 12 to 26 weeks (medium‐term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.15, 1.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Quality of life: 1. Unsatisfactory response on health dimension scale <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>329</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [0.13, 0.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Quality of life: 3. Average change score (QLS, high=better)) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>326</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.20 [3.08, 9.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Quality of life: 2. Average score (EQ‐5D utility score, high=better) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>329</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.04, 0.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Quality of life: 4a. Weight related ‐ No meaningful change (IWQOL‐Lite) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>327</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.83, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Quality of life: 4b. Weight related ‐ average score (IWQOL‐Lite, high=better) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 short‐term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>443</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [‐1.84, 4.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 medium‐term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>328</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.50 [1.04, 3.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Leaving the study early <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 any reason</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2908</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.78, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 administrative reasons</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>833</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [0.00, 1.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3 adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2908</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [1.11, 1.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.4 death</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>555</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.04, 5.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.5 inefficacy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2908</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.45, 1.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.6 lost to follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1388</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.34, 2.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.7 no longer meets criteria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1388</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.16, 2.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.8 other</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1388</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.10, 3.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.9 poor/non compliance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1388</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.53, 2.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.10 pregnancy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>555</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.14, 6.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.11 withdrew</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2908</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.36, 0.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Adverse effects: 1. At least one adverse effect <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2333</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [1.05, 1.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Adverse effects: 2. Central nervous system <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11524</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.29 [1.12, 1.49]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 sleep disorder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>813</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.79 [0.78, 4.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2881</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.09 [1.65, 2.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.3 somnolence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2881</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.39, 0.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.4 headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2881</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.47 [1.09, 1.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.5 fatigue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>548</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.27, 1.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.6 Lightheadedness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1520</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.59, 1.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Adverse effects: 3a. Endocrine ‐ Prolactin ‐ increase in level <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>548</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [0.23, 0.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Adverse effects: 3b. Endocrine ‐ Prolactin ‐ Change in level <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐8.60 [‐19.14, 1.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Adverse effects: 4. Extrapyramidal ‐ akathisia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 homogeneous data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1361</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.77 [1.28, 5.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.2 outlying study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1520</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.17 [0.12, 0.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Adverse effects: 5. Gastrointestinal <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2881</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.13 [2.12, 4.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2881</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.13 [2.12, 4.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Adverse effects: 6a. Metabolic‐ binary measures <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2517</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.65, 0.82]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.1 weight gain (7% or more of total body weight at 26 weeks ‐ medium‐term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>330</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [0.19, 0.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.2 weight loss (7% or more of total body weight at 26 weeks ‐ medium‐term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>330</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.75 [0.97, 3.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.3 average weight gain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>548</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [0.03, 0.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.4 total cholesterol increase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>269</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.62, 0.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.5 LDL increase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>268</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.51, 0.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.6 HDL increase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>269</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.61, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.7 triglyceride increase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>267</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.64, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.8 fasting glucose (increase)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>236</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.62, 1.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Adverse effects: 6b. Metabolic ‐ continuous measures <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1796</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.97 [‐3.48, ‐2.46]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.1 weight change (no risk)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>537</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.7 [‐3.68, ‐1.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.2 % weight change from baseline‐ up to 12 weeks (short‐term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>441</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.48 [‐3.30, ‐1.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.3 % weight change from baseline ‐ from 12 to 26 weeks (medium‐term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>327</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.74 [‐4.65, ‐2.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.4 no change in fasting total cholesterol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>262</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐9.70 [‐16.07, ‐3.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.5 no change in fasting total glucose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>229</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.9 [‐5.78, 1.98]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">COMPARISON 7. ARIPIPRAZOLE versus OTHER ANTIPSYCHOTIC DRUGS</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006569.pub5/references#CD006569-tbl-0014">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD006569.pub5&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD006569-note-0004">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD006569-note-0016">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD006569-note-0003">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD006569-note-0001">Hrvatski</a> </li> <li class="section-language"> <a class="" href="pl#CD006569-note-0002">Polski</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006569\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006569\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006569\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006569\x2epub5"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006569\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006569\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006569\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006569\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006569\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006569\x2epub5"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006569\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006569\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006569\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006569\x2epub5"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006569\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006569\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006569\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006569\x2epub5"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=IYhCEbRn&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006569.pub5&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD006569.pub5';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD006569.pub5/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD006569.pub5/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006569.pub5%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740715136195"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD006569.pub5/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740715136199"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD006569.pub5/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d7fac68a41bde',t:'MTc0MDcxNTEzNi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 